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Abstract 
The ghrelin receptor (GRLN-R) was cloned in 1996 after the discovery that a series of 
synthetic growth hormone-releasing compounds (the growth hormone secretagogues) acted 
through a receptor distinct from the growth hormone-releasing hormone receptor. In 1999 
the endogenous ligand of the receptor, ghrelin, was discovered. As well as stimulating 
growth hormone release, ghrelin has been shown to be involved in many other processes 
such as appetite stimulation and the regulation of energy homeostasis, making the 
ghrelin/GRLN-R system an attractive pharmaceutical target for the treatment of disorders 
such as growth hormone deficiency, cachexia and obesity. The GRLN-R displays a high 
level of ligand-independent (constitutive) activity and has been suggested to couple to 
Gαq/11, Gαi/o, Gαs and Gα12/13 G protein pathways, although little is known about the 
signalling of ghrelin and the growth hormone secretagogues in all but the Gαq/11 pathway. 
Two of the growth hormone secretagogues, GHRP-6 and L-692,429, have been described 
as ‘ago-allosteric modulators’ of the GRLN-R as, when co-administered with ghrelin, 
GHRP-6 and L-692,429 were reported to act both as co-agonists (increasing the efficacy of 
the ghrelin response) and as negative or positive (respectively) regulators of the potency of 
ghrelin. This study sought to investigate the pharmacology of the GRLN-R through the 
Gαi/o pathway. 
[35S]GTPγS binding assays were used to measure activation of the Gαi/o pathway, 
demonstrating that GHRP-6, L-692,585 (a commercially available analogue of L-692,429) 
and a third growth hormone secretagogues, MK-677, acted with higher efficacy than 
ghrelin. At least in the system tested, upon co-administration with ghrelin each of the 
growth hormone secretagogues acted in a simple competitive fashion with ghrelin. 
Radioligand binding experiments showed that the dissociation kinetics of [His[125I]]-
ghrelin from the GRLN-R were not altered by co-administration of the growth hormone 
secretagogues. Fitting data to a modified operational model of allosterism demonstrated 
that GHRP-6, L-692,585 and MK-677 were not ago-allosteric modulators of the GRLN-R 
but simple orthosteric agonists. 
In order to further examine the receptor-specific effects of ghrelin and the growth hormone 
secretagogues, a Flp-In™ T-REx™ HEK293 cell line expressing the GRLN-R was 
constructed. [35S]GTPγS binding assays confirmed that the GRLN-R was constitutively 
active through both the Gαq/11 and Gαi/o pathways, demonstrated by an increase in 
[35S]GTPγS loading upon receptor expression which could be reduced by the 
  3 
administration of the GRLN-R inverse agonist SPA. Upon expression of the GRLN-R a 
considerable level of cell detachment was observed with the remaining cells appearing 
rounded compared to parental HEK293 cells, an affect that appeared to be mediated by the 
constitutive activity of the receptor.  
In contrast to the [35S]GTPγS assays used to measure activation of Gαi/o, [35S]GTPγS assays 
with a Gαq-immunoprecipitation step demonstrated that the growth hormone secretagogues 
acted with equal efficacies to that of ghrelin, demonstrating functional selectivity at the 
GRLN-R. Intact cell assays were also used to measure Gαq/11 and Gαi/o responses, however, 
a Gαi/o-mediated response could not be measured in cAMP accumulation assays, suggesting 
that the GRLN-R could signal via activation of Gαo but not Gαi1-3. Although the activation 
of the Gαs pathway by the GRLN-R remains controversial, in this study ghrelin and the 
growth secretagogues could evoke a Gαs-mediated cAMP response (although L-692,585 
acted with a lower efficacy than ghrelin). 
Finally, two naturally occurring missense mutations of the GRLN-R (A204E in the second 
extracellular loop and I134T in the third transmembrane helix) were analysed to investigate 
whether these mutations led to retention of the receptor within the endoplasmic reticulum 
and to investigate whether the mutations affected the ability of the GRLN-R to signal to 
the growth hormone secretagogues. The A204E mutation caused partial retention of the 
GRLN-R within the endoplasmic reticulum, whilst receptor that was transported to the 
plasma membrane did not display any measurable constitutive activity. In contrast, the 
I134T mutation did not alter receptor localisation, nor did it have any effect on the 
constitutive or ligand-induced activation of the GRLN-R, however, it appeared to lower the 
efficacy of the inverse agonist SPA.
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1 Introduction 
1.1 Introduction to ghrelin and the ghrelin receptor 
In 1981 the ability of two enkephalin analogues, met-enkephalin and leu-enkephalin, to 
stimulate growth hormone (GH) release in primary cultures of rat pituitary cells was 
described (Momany et al., 1981). Seven years later Bowers and colleagues described the 
first synthetic GH–releasing hormone peptide (GHRP-6) displaying in vivo GH-releasing 
activity; both in human and animal models (Bowers et al., 1984). In an attempt to increase 
bioavailability the structure of GHRP-6 was used as a template in the development of a 
series of synthetic ligands, termed the ‘growth hormone secretagogues’ (GHs; in which 
GHRP-6 is usually included), including the benzolactams L-692,429 (Smith et al., 1993) 
and L-692,585 (Jacks et al., 1994) and the spiroperidine MK-677 (Patchett et al., 1995) 
(Table 1-1 lists some of the growth hormone secretagogues). 
Around the same time as the studies by Bowers and colleagues, a naturally occurring 
hypothalamic hormone, growth hormone-releasing hormone (GHRH), was discovered 
(Rivier et al., 1982; Guillemin et al., 1982). However, it was clear that the growth hormone 
secretagogues were mediating their GH-releasing effects through a distinct pathway from 
the GHRH (Smith et al., 1996). For example, [35S]-MK-677 binding was competitively 
inhibited by L-692,429 but not by GHRH (Pong et al., 1996).  
In 1996 the receptor for the growth hormone secretagogues was cloned and named the 
‘growth hormone secretagogues receptor’ (GHs-R) (Howard et al., 1996). The GHs-R was 
shown to belong to the G protein coupled receptor (GPCR) superfamily, a family of 
receptors characterised by the presence of 7 transmembrane (TM) spanning alpha helical 
domains separated by 3 intracellular loops and 3 extracellular loops. The GHs-R gene is 
located at the chromosomal location of 3q26.2 and consists of a single intron of around 2 
kb that divides the open reading frame into two exons, one encoding TM I-V of the GHs-R 
and the other encoding TM VI-VII (McKee et al., 1997). Two types of cDNA arise from 
the gene by alternative mRNA processing; the cDNA for the full length GHs-R (GHs-R1a; 
366 amino acids in length) and cDNA for GHs-R1b, a truncated receptor (289 amino acids 
in length), which, as the intron is not removed (probably due to the use of an alternative 
splice site and an alternative polyadenylation site), encodes a receptor containing TMI-V 
fused to a short conserved reading frame of 24 amino acids followed by a translational stop 
codon (Howard et al., 1996; McKee et al., 1997). GHs-R1b has been shown to be unable to 
bind MK-677 and GHRP-6  (Howard et al., 1996).
  20  
Table 1-1 – Ligands acting at the growth hormone secretagogues receptor  
Agonists (‘the growth hormone 
secretagogues’) 
Company 
(where 
appropriate) 
Ligand type Reference 
Met-enkephalin   Peptide Momany et al., 
1981 
Leu-enkephalin  Peptide Momany et al., 
1981 
GHRP-6  Peptide Bowers et al., 
1984 
GHRP-1   Peptide Bower, 1993 
GHRP-2  Peptide Bowers, 1993 
Examorelin/hexarelin Mediolanum 
Farmaceutici 
Peptide Deghenghi et 
al., 1994 
L-692,429 Merck Benzolactam Cheng et al., 
1993 
L-692,585 Merck Benzolactam Jacks et al., 
1994 
MK-677 Merck Spiropiperidine Patchett et al., 
1995 
SM-130686 (partial agonist) Sumitomo 
Pharmaceuticals 
Oxindole 
derivative 
Nagamine et 
al., 2006 
Antagonists    
BIM-28163 (also binds to somatostatin 
receptors) 
 Only detail given 
is that BIM-28163 
is a ghrelin 
analogue 
Halem et al., 
2004 
YIL-781 Bayer 
Healthcare 
Quinazolinone 
derivative 
Esler et al., 
2007 
Inverse agonists    
[D-lys3]-GHRP-6, originally classed as 
an antagonist by Cheng et al. (1993) 
Merck Peptide Chan et al., 
2004 
[D-Arg1, D-Phe5,D-Trp7,9, Leu11]-
substance P, originally classed as an 
antagonist by Cheng et al. (1997) 
Merck Peptide Holst et al., 
2003 
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Interestingly cloning of GHs-R1a from other species has demonstrated that the sequence of 
the GHs-R1a is highly conserved, with mouse, ferret, pig, rabbit and rat cDNA showing 
over 90 % sequence homology to the human receptor. 
The GHs-R1a remained an orphan receptor (i.e. the endogenous ligand remained 
unknown) for a further three years until Kojima and colleagues isolated a peptide from rat 
stomach extract that could activate the GHs-R1a, a peptide which they called ghrelin 
(‘ghre’ from the Proto-Indo-European root of the word ‘grow’) (Kojima et al., 1999). This 
led to the suggestion that the GHs-R1a should be renamed the ghrelin receptor (GRLN-R) 
(Davenport et al., 2005). 
The human ghrelin gene is located at a chromosomal location of 3q25-56 and comprises 
five exons and three introns (Soares and Leite-Moreira, 2008). This encodes mRNA for 
pre-pro-ghrelin, a 117-amino acid ghrelin precursor (Kojima et al., 1999). Pre-pro-ghrelin 
contains a 23 amino acid signal peptide and a 94 amino acid peptide pro-ghrelin (Soares 
and Leite-Moreira, 2008). Pro-ghrelin consists of the 28 amino acid long mature ghrelin 
(see Figure 1-1) plus a 66 amino acid ‘tail’ (Kojima et al., 1999; Jeffery et al., 2005) and is 
cleaved by pro-hormone convertase 1/3 to generate mature ghrelin (Zhu et al., 2006). Like 
the GRLN-R, ghrelin appears to be highly conserved across multiple species, with human 
and rat pre-pro-ghrelin showing 82.9 % sequence homology, with only two amino acids 
replaced in the 28-amino acid ghrelin segment (Kojima et al., 1999).  
Interestingly ghrelin undergoes a unique modification at serine 3 where the residue is 
octanylated (the hydrogen atom is replaced by a C7H15CO moiety; see Figure 1-1) (Kojima 
et al., 1999), a modification that appears to be essential for the activity of ghrelin as 
removal of the octanoyl group decreases the potency of ghrelin by more than 2300-fold 
(Matsumoto et al., 2001). In 2008 the acyltransferase responsible for the octanylation of 
ghrelin was identified and named ghrelin O-Acyltransferase (GOAT) (Yang et al., 2008), a 
member of the membrane bound O-Acyltransferase family that attach fatty acids to lipids 
and proteins (Hofmann, 2000). GOAT appears to be located in the endoplasmic reticulum 
(in stomach and pancreas of humans; Gutierrez et al., 2008) where it acts to octanylate pro-
ghrelin before pro-ghrelin is transported to the Golgi and cleaved to form mature ghrelin 
(Yang et al., 2008). Interestingly, although ghrelin is a peptide ligand, there is some 
evidence to suggest that ghrelin can cross the blood-brain barrier via a saturatable 
transporter system (Banks et al., 2002). 
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Figure 1-1 - The structure of ghrelin, GHRP-6, L-692,585, MK-677 and SPA. A. Pre-pro-ghrelin 
comprises of a 23 amino acid signal peptide and pro-ghrelin. Pro-ghrelin is cleaved by pro-
hormone convertase 1/3 to form mature ghrelin (which undergoes octanylation at the third residue, 
S), whilst processing of the 3’ extremity results in the formation of obestatin (adapted from De 
Vriese and Delporte, 2008). B. The structure of the growth hormone secretagogues GHRP-6, L-
692,585, MK-677 and the inverse agonist SPA (adapted from Moulin et al., 2007). A basic amine 
group is conserved across GRLN-R ligands and is required for their bioactivity. 
B 
A 
Kirstie Ann Bennett, 2009  Chapter 1, 23  
Alternative splicing of pre-pro-ghrelin results in the formation of the biologically active 
peptide des-Gln14-ghrelin, which is also octanylated at serine 3 but lacks a glutamic acid 
residue in position 14 (Kojima et al., 1999). Des-Gln14-ghrelin appears to possess the same 
hormonal activities as ghrelin (Hosoda et al., 2000). Processing of the 66 amino acid tail of 
pro-ghrelin results in the formation of obestatin (Soares & Leite-Moreira, 2008) – a ligand 
proposed to be the endogenous ligand for a receptor related to the GRLN-R, GPR39 
(Zhang et al., 2005; Zhang et al., 2008) although this needs further confirmation as there 
are now reports that obestatin does not activate GPR39 (Holst et al., 2007; Chartrel et al., 
2007).  
Interestingly, the GRLN-R can signal in the absence of ghrelin and the growth horomone 
secretagogues i.e. the receptor exhibits a high level of constitutive (ligand-independent) 
activity, which has been shown to be a key requirement for constitutive (ligand-
independent) receptor internalisation (Holliday et al., 2007). Depending on the system 
used, the constitutive activity of the GRLN-R has been recorded to be up to 50 % of the 
maximum activity measured in the presence of ghrelin (Holst et al., 2003). This ligand-
independent activity was shown to be reduced by administration of a substance P analogue 
(SPA) (Holst et al., 2003); thus demonstrating that SPA acts as an inverse agonist, 
favouring the formation of an inactive receptor state. Intriguingly, the constitutive activity 
of the GRLN-R appears to be important in vivo as naturally occurring point mutations of 
the GRLN-R which ablate the constitutive activity of the receptor, whilst preserving the 
reponse to ghrelin, are associated with the development of obesity and short stature (Pantel 
et al., 2006; Wang et al., 2004).  
The GRLN-R has become an attractive therapeutic target not only due to its effects on 
growth hormone release (per mol, ghrelin is more potent at stimulating GH release than 
GHRH; Gil-Campos et al., 2006) but also because ghrelin and the GRLN-R have been 
demonstrated to possess a wide-range of other central and peripheral actions, ranging from 
modulating appetite and energy homeostasis to opposing inflammation of the 
cardiovascular system (van der Lely et al., 2004).  
The aim of this chapter is to provide background on the distribution and biological effects 
of ghrelin and the GRLN-R, before focusing on the structure and signalling mechanisms of 
the GRLN-R. 
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1.2 Ghrelin tissue distribution 
The main source of endogenous ghrelin appears to be from X/A-like cells in the oxyntic 
mucosa of the stomach (Date et al., 2000). However it is clear that there are other sources 
of ghrelin as plasma ghrelin levels increase after a total gastrectomy (Hosoda et al., 2003) 
suggesting that other tissues can compensate for the loss of ghrelin production (Moller et 
al., 2003). Indeed ghrelin mRNA has also been detected in the pancreas (Date et al., 
2002b), placenta (Gualillo et al., 2001), the adrenal glands, oesophagus, adipocytes, gall 
bladder, muscle, myocardium, ovary, prostate, skin, spleen, liver, thyroid gland, blood 
vessels (Gnanapavan et al., 2002), T-lymphocytes, B-lymphocytes and neutrophils (Hattori 
et al., 2001). However the levels of ghrelin expression in these tissues is relatively low 
compared to that of the stomach (van der Lely et al., 2004).  
Ghrelin has been detected in the brain (e.g. the pituitary; Korbonits et al., 2001) using 
mRNA amplification and immunofluorescence histochemistry (Hou et al., 2006). However 
GOAT, which is responsible for the octanylation of ghrelin, is not expressed in mouse 
brain, therefore casting doubts on whether brain cells produce biologically active ghrelin 
(Yang et al., 2008). 
1.3 GRLN-R tissue distribution 
In contrast to ghrelin, levels of GRLN-R are highest in the central nervous system. GRLN-
R mRNA expression has been recorded in the hypothalamus (especially the arcuate 
nucleus) and pituitary gland with GRLN-R expression also reported in other brain areas 
such as the hippocampus, pars compacta of the substantia nigra, the ventral tegmental 
area, and in the dorsal and medial raphe nuclei (van der Lely et al., 2004). In addition 
much lower levels of mRNA expression (than seen in the pituitary) are detected in 
peripheral organs and tissues, such as: the thyroid gland, pancreas, spleen, myocardium 
and adrenal glands (Gnanapavan et al., 2002). Specific binding of [125I]-ghrelin to the 
GRLN-R has also been detected in the aorta, pulmonary arteries, saphenous veins, and the 
arcuate arteries of the kidney (Katugampola et al., 2001).  
Interestingly although GHs-R1b does not signal to ghrelin (Leung et al., 2007) or the 
growth hormone secretagogues (Howard et al., 1996) the receptor is much more widely 
expressed than the GRLN-R; being detected in the skin, myocardium, pituitary, thyroid, 
pancreas, ileum, colon, liver, breast, spleen, duodenum, placenta, lung, adrenal glands, 
buccal mucosa, the stomach (fundus and antrum), lymph node, gall bladder, atrium, 
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lymphocytes, kidney, bladder, prostate, fallopian tubes, vein, muscle, ovaries, testes, fat, 
oesophagus and jejunum (Gnanapavan et al., 2002).  
A study by Gnanapavan et al. (2002) revealed that GHs-R1b mRNA copy number varied 
depending on the tissue measured, from an mRNA copy number (per total µg tissue) of 1 
in jejunum to 107 in skin. GRLN-R mRNA copy number (per total µg tissue) varied from 
103 in adrenal glands to 105 in the pituitary. In some tissues, such as the myocardium, 
GHs-R1b mRNA copy number was greater than GRLN-R mRNA copy number (GRLN-R 
mRNA copy number = 103; whilst GHs-R1b copy number = 107) (Gnanapavan et al., 
2002). 
1.4 Biological actions of the GHs-R1b 
The exact function of the GHs-R1b remains unknown. In HEK293 cells transfected to 
express the GHs-R1b, the receptor was detected predominantly expressed in the nucleus of 
the cells but some receptor was also detected at the cell surface (Leung et al., 2007). There 
is some evidence that GHs-R1b inhibits growth hormone secretagogues-mediated calcium 
mobilisation in HEK293 cells transfected to express the seabream GRLN-R (Chan and 
Cheng, 2004). Meanwhile, another report has suggested that the receptor might act as a 
dominant negative mutant of the GRLN-R (Leung et al., 2007; this finding is further 
discussed in section 1.9.2). 
1.5 Biological actions of ghrelin, the growth hormone 
secretagogues and the GRLN-R 
The two most studied actions of ghrelin and the GRLN-R are in modulating GH release 
and in the regulation of appetite and energy homeostasis.  
1.5.1 GH release 
GH is released by somatotroph cells in the anterior pituitary gland in response to hormones 
produced from the hypothalamus, such as GHRH and somatostatin. Multiple studies have 
demonstrated that ghrelin and the growth hormone secretagogues can stimulate GH release 
from somatotrophs in vitro (Kojima et al., 1999; Sartor et al., 1985; Bowers et al., 1991). 
In vivo, administration of the growth hormone secretagogues has been demonstrated to 
have a synergistic effect on GH-release mediated by the GHRH (Bowers et al., 1991; Wu 
et al., 1994). In contrast to GHRH, which increases GH release in vivo, somatostatin acts to 
inhibit GH secretion (Brazeau et al., 1973). There is evidence to suggest that, in addition to 
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increasing GH release, the growth hormone secretagogues may also act to antagonise the 
inhibitory effect of somatostatin on GH release, by counteracting its hyperpolarising effect 
on somatotroph cell membranes (Goth et al., 1992). 
As well as acting on the anterior pituitary there is evidence to suggest that ghrelin and the 
growth hormone secretagogues act directly at the hypothalamus. For example, GH-
releasing activity of the growth hormone secretagogues is greater in hypothalamic-pituitary 
preparations than in pituitary preparations (Mazza et al., 1989) whilst GH release is 
reduced, but not completely abolished, in animals with lesions of the pituitary stalk 
(Fletcher et al., 1994; Hickey et al., 1996). Indeed it is evident that an intact GHRH system 
is required for the effects of ghrelin and the growth hormone secretagogues in vivo. For 
example, GH release pulsatility and responsiveness are decreased by the administration of 
antibodies against GHRH in rats (Pandya et al., 1998). In humans GH response to the 
growth hormone secretagogues is inhibited in subjects with deficiencies in the GHRH 
receptor (Maheshwari et al., 1999).  
The main target of ghrelin action in the hypothalamus is the arcuate nucleus of the 
hypothalamus where it may bind and activate the GRLN-R, here ghrelin and the growth 
hormone secretagogues act to increase the electrical activity and c-fos expression (a marker 
of neuronal activity) in a subpopulation of cells, of which some are GHRH neurones 
(Dickson et al., 1995a; Dickson et al., 1995b). Activation of GHRH producing neurones in 
the arcuate nucleus amplifies the effect of GHRH in somatotrophs (Lengyel, 2006). 
Interestingly, a recent study has shown that GHRH can act as an agonist of the GRLN-R, 
binding to an area on the receptor distinct from the ghrelin binding pocket where is acts to 
increase the binding capacity or the potency of ghrelin in the pathways tested (i.e. it acts as 
an allosteric modulator; see section 1.10.6) (Casanueva et al., 2008). Thus GHRH could 
potentially act on the GRLN-R to further increase GH release in vivo. 
1.5.2 Appetite and energy homeostasis 
Evidence for the role of ghrelin in appetite regulation was first obtained by Arvat and 
colleagues whose studies on the effect of ghrelin in human volunteers showed that, when 
injected with ghrelin, along with a prompt, marked increase in GH release, three out of the 
four healthy participants also reported the feeling of hunger (Arvat et al., 2000). In 2000-
01 further reports were published demonstrating that ghrelin was involved in the 
hypothalamic regulation of energy homeostasis (Wren et al., 2000; Wren et al., 2001; 
Nakazato et al., 2001). For example, exogenous ghrelin was found to increase adiposity in 
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rodents by stimulating an acute increase in food intake as well as reducing fat utilisation 
(Nazazato et al., 2001; Wren et al., 2000; Tschop et al., 2000; Shitani et al., 2001; Asakawa 
et al., 2001). This effect appeared to be mediated by the GRLN-R as 
intracerebroventricular injections of ghrelin strongly stimulated feeding in rats in a dose-
dependent manner, causing an increase in body weight gain, an effect that was suppressed 
by an antagonist/inverse agonist of the GRLN-R ([D-lys3]-GHRP-6; Cheng et al., 1989) 
(Nakazato et al., 2001).  
Further studies have demonstrated that plasma ghrelin levels are dependent on food-intake, 
with ghrelin levels rising before a meal and declining sharply after eating, suggesting that 
ghrelin plays a major role in meal initiation (Cummings et al., 2001). After a meal the 
depth and duration of ghrelin suppression is related to the energy intake (Callahan et al., 
2004). Ghrelin has also been shown to stimulate gastric acid secretion and motility in rats 
(Masuda et al., 2000) and circulating ghrelin levels are correlated with gastric emptying 
time in humans (Tschop et al., 2001). Factors that promote ghrelin secretion include 
fasting, hypoglycaemia and the hormone leptin whilst the main inhibiting factors are food 
intake, hyperglycaemia and obesity (Cummings et al., 2001; Tschop et al., 2001; Toshinai 
et al., 2001; Shiiya et al., 2002). Interestingly during prolonged fasting an eight-fold 
increase in expression of the GRLN-R in the hypothalamus has been measured (Kim et al., 
2003). Together these studies demonstrate that ghrelin is involved in appetite stimulation. 
The cellular mechanism underlying the orexigenic effect of ghrelin has been clarified. 
Ghrelin travels in the bloodstream to the arcuate nuclues of the hypothalamus (Hewson and 
Dickson, 2000). Here the major target for ghrelin appears to be the appetite-stimulating 
neuropeptide Y- (NPY) and agouti-related protein- (AGRP) containing neurones which 
increase their firing rate in response to ghrelin (Cowley et al., 2003). The appetite-
supressing pro-opiomelanocortin- (POMC) and cocaine- and amphetamine-regulated 
transcript- (CART) containing neurones do not possess GRLN-Rs however, projections 
from the NPY/AGRP-containing neurones terminate on POMC/CART-containing 
neurones which are indirectly inhibited by ghrelin by the release of the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA) (Cowley et al., 2003). Other peripheral 
hormones that are involved in appetite and energy regulation include leptin, insulin and 
PYY3-36  which all act to decrease food intake (Schwartz et al., 2000). Thus on NPY/AGRP 
containing neurones ghrelin and the GRLN-R provide the only hormonal appetite-
stimulatory input to counterbalance the inhibitory signals (Schwartz et al., 2000; Holst and 
Schwartz, 2004).  
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Following food ingestion signals from the gastrointestinal tract are conveyed to the nucleus 
solitary tract in the brain stem through afferent vagal nerves and other sympathetic nervous 
system afferents (Gil-Campos et al., 2006). In addition to ghrelin travelling in the 
bloodstream, it appears that an intact vagus nerve is required for exogenous ghrelin to 
stimulate appetite in both man and rodents (Date et al., 2002a; le Roux et al., 2005) 
suggesting that a neuronal pathway (involving the vagal nerves) is an alternative and 
important mechanism for ghrelin signalling. As GRLN-R are also found near the nucleus 
solitary tract (such as in the dorsal vagus complex; Date et al., 2002a) several sites other 
than the hypothalamus may be important in regulating ghrelin-induced appetite (Holst and 
Schwartz, 2004). Indeed recently the area postrema was shown to be excited by stimulation 
with ghrelin in a concentration-dependent manner, thus ghrelin may partially regulate 
appetite regulation via the area postrema (Fry and Ferguson, 2008).   
Interestingly, ghrelin levels are low in obese and high in lean individuals, suggesting that 
ghrelin is not only important for the acute regulation of food intake but also plays an 
important role in the regulation of long term energy homeostasis (Cummings et al., 2005). 
Ghrelin levels increase in response to weight-loss resulting from, for example, low-energy 
diets, cancer cachexia and anorexia (Cummings et al., 2005; Horvath et al., 2001; Tolle et 
al., 2003; Soriano-Guillen et al., 2004); suggesting that it signals the need to conserve 
energy. Indeed plasma ghrelin concentration rises rapidly after fasting in normal weight 
animals but is delayed in fatty Zucker rats suggesting that short-term energy storage is 
modified by an excess energy deposit (Ariyasu et al., 2002). Intraperitoneal injection of 
ghrelin in mice was shown to decrease energy expenditure (Asakawa et al., 2001); in rats 
and mice ghrelin was shown to reduce fat catabolism and lipolysis (Tschop et al., 2000; 
Muccioli et al., 2004) (although this may be via a non-GRLN-R mediated mechanism as 
GRLN-R has not been detected in adipose tissue) and chronic central administration of 
ghrelin in rats has been suggested to decrease adipocyte apoptosis (Kim et al., 2004a).  
1.5.3 Other ghrelin/GRLN-R effects 
As well as the effects of ghrelin and the GRLN-R on GH release and appetite/energy 
homeostasis there has been a wealth of studies linking ghrelin and the GRLN-R to a 
number of other functions such as regulation of sleep, bone formation and gonadotroph 
secretion; these studies are summarised in Table 1-2. The distribution of the GRLN-R 
supports the idea that ghrelin has functions in addition to regulation of GH release and 
appetite regulation/energy homeostasis. 
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1.5.4 Existence of receptors for ghrelin/the growth hormone 
secretagogues other than the GRLN-R 
There is increasing evidence to suggest that the GRLN-R is not the sole receptor for 
ghrelin and/or the growth hormone secretagogues. For example, 1 µM ghrelin (a 
concentration of ghrelin which has been shown to be maximally effective at stimulating 
human GRLN-R-mediated inositol phosphate accumulation in HEK293 cells; Holst et al., 
2005) exerts a cardioprotective effect in H9c2 cardiomyocytes, cells that do not express the 
GRLN-R (Baldanzi et al., 2002). Meanwhile, in CALU-1 lung carcinoma cells, DNA 
synthesis and proliferation was inhibited by peptidyl growth hormone secretagogues (at a 
concentration of 1 nM to 1 µM) but not by ghrelin or the non-peptidyl growth hormone 
secretagogues (Ghe et al., 2002). Interestingly in the heart a binding site for peptidyl 
growth hormone secretagogues has been identified as CD36 (Kim et al., 2005), a multi-
functional class B scavenger receptor (also known as glycoprotein IV) which has been 
implicated in multiple physiological functions (e.g. cellular adhesion and fatty acid 
transportation) and pathological functions related to macrophage foam cell formation and 
pathogenesis of atherosclerosis (Bodart et al., 2002). Thus the reported effects of ghrelin 
and the growth hormone secretagogues in some cases may be mediated through a distinct 
GRLN-R subtype or by a completely different receptor.  
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Table 1-2 - Reported effects of ghrelin, the growth hormone secretagogues and the GRLN-R 
both in vivo and in vitro.
 
 
Effects  Details Reference(s) 
Ghrelin defends 
against depressive-
like symptoms of 
chronic stress 
Ghrelin administered in a rodent model of depression 
produced anxiolytic and anti-depressive-like responses 
in elevated maze and forced swim tests. GRLN-R-null 
mice showed deleterious effects of chronic defeat.  
Lutter et al., 2008 
Ghrelin controls 
hippocampal spine 
synapse density and 
memory 
performance 
Circulating ghrelin enters hippocampus, binding to 
neurones of hippocampal formation where it promotes 
dendritic spine synapse formation and generation of 
long term potentiation, paralleled by enhanced spatial 
learning and memory. Disrupting ghrelin gene in mice 
impairs performance in behavioural memory testing, an 
effect reversible by ghrelin administration. 
Diano et al., 2006 
Ghrelin influences 
gonadotroph 
secretion 
In rats intracerebroventricular injection of ghrelin 
decreases frequency of pulsatile luteinising hormone 
secretion, probably reflecting a modulation of the 
activity of the gonadotrophin releasing hormone pulse 
generator. 
Furuta et al., 
2001; 
Fernandez-
Fernandez et al., 
2004 
Constitutive activity 
of the GRLN-R 
attenuates apoptosis 
Cadmium-induced activation of caspase-3 (a protease 
involved in apoptosis) is attenuated in HEK293 cells 
expressing the seabream GRLN-R but not in wild-type 
HEK293 cells. GRLN-R ligands have no effect on 
caspase-3 activation. 
Lau et al., 2009 
MK-677 increases 
rapid eye movement 
(REM) sleep 
In humans MK-677 was shown to increase REM sleep 
both in healthy young adults as well as in elderly 
subjects.     
Copinschi et al., 
1997 
Ghrelin has diverse 
cardiovascular 
effects 
In vitro ghrelin inhibits apoptosis of cardiomyocytes. 
Ghrelin may also oppose inflammation of the 
cardiovascular system as it inhibits NF-κB activation in 
human endothelial cells. Ghrelin exerts an 
endothelium-independent vasodilatory effect. Ghrelin 
administration decreases mean arterial pressure 
without changing heart rate and improves cardiac 
contractility and left ventricular function in chronic heart 
failure.  
Isgaard and 
Johansson, 2005 
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Ghrelin stimulates 
bone formation 
Ghrelin stimulates proliferation and differentiation of 
oestoblasts in vitro. Proliferation of osteoblasts was 
inhibited by the GRLN-R antagonist [D-lys3]-GHRP-
6. In vivo ghrelin increases bone mineral density in 
both normal and GH-deficient rats 
Fukushima et al., 
2005 
Ghrelin may inhibit 
insulin secretion 
Depending on the system used to measure the 
response, ghrelin has been shown to both increase 
and decrease insulin secretion. For example, in rat 
pancreatic islets and in vivo ghrelin was able to 
increase insulin secretion. In humans acute 
administration of ghrelin inhibits both spontaneous 
and arginine-stimulated insulin secretion. 
Broglio et al., 
2001; Date et al., 
2002b; Broglio et 
al., 2003; Salehi 
et al., 2004 
Ghrelin increases 
glucose release 
Along with a transient decrease in insulin secretion, 
acute ghrelin administration in humans increases 
plasma glucose levels.  
Broglio et al., 
2003 
Ghrelin can increase 
cell proliferation in 
some cell lines, but 
the GHs may have an 
anti-proliferative effect  
Ghrelin and the GRLN-R have been detected in a 
number of neoplastic cells and in vitro experiments 
suggest that ghrelin and GHs can modulate 
proliferation of several human tumour cell lines. 
However, GHs have been shown to have an anti-
proliferative effect in breast cancer cell lines not 
expressing the GRLN-R. DNA synthesis and 
proliferation of CALU-1 lung carcinoma cells that do 
not express the GRLN-R were shown to be inhibited 
by peptidyl GHs but not by non-peptidyl GHs and 
ghrelin. 
Ghe et al., 2002; 
Cassoni et al., 
2004; Ghigo et al., 
2005 
 
1.6 Ghrelin-null or GRLN-R-null models 
There have been multiple studies investigating the effects of knocking-out the GRLN-R in 
vivo. Initially the physiological importance of the GRLN-R in the hypothalamus of rats 
was tested by using antisense GRLN-R mRNA expression under the control of a tyrosine 
hydroxylase promoter, to impair GRLN-R function in the arcuate nucleus (Shuto et al., 
2002). This confirmed that ghrelin and the GRLN-R were involved in energy homeostasis 
and appetite stimulation as rats with attenuated GRLN-R expression displayed lower body 
weights, less adipose tissue, reduced daily food intake and smaller birth weights than their 
wild-type counterparts. In contrast to the wild-type rats, administration of exogenous 
ghrelin or growth hormone secretagogues failed to increase feeding. In female rats GH 
secretion and insulin-like growth factor-1 levels were reduced, however there was no effect 
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in males, suggesting that the ghrelin/GRLN-R system is more physiologically important in 
the regulation of GH secretion in females.  
The development of complete GRLN-R knock-out animals showed that the GRLN-R is 
essential for the stimulatory effects of ghrelin on GH secretion and orexigenic properties 
(Sun et al., 2004). However, GRLN-R-null mice showed no difference in body 
composition or growth compared to wild-type mice littermates (Sun et al., 2004); 
suggesting that the GRLN-R does not have a significant role in the determination of body 
composition or growth.  
In studies of ghrelin-null mice, one group showed that: size, growth rate, food intake, body 
composition, reproduction, gross behaviour and tissue pathology were indistinguishable 
from wild-type littermates (Sun et al., 2003). Another group suggested the only difference 
between ghrelin-null mice and their wild-type littermates was the preferential use of lipids 
rather than carbohydrates in maintaining energy balance particularly under high fat 
conditions; which led to a trend towards ghrelin-null mice having leaner body composition 
after 6 weeks on a high-fat diet (Wortley et al., 2004). However, it is possible that other 
hormonal systems may compensate for the lack of ghrelin or for the inability of the GRLN-
R to respond to ghrelin. 
In contrast to the previous studies, Zigman and colleagues demonstrated that GRLN-R-null 
mice did not show any differences in body weight and composition compared to wild-type 
mice until 19 weeks of age. After 19 weeks on a calorie-dense diet, GRLN-R-null mice 
showed significantly less accumulation of body weight and body fat content; in female 
mice body fat mass was almost 50 % less than wild-type mice (Zigman et al., 2005). 
Several suggestions were given as to why the results of this study were different to 
previously published studies. These included the duration of exposure to a high-fat diet, 
animal age when the high-fat diet was administered and fat content of the food (Zigman et 
al., 2005). Indeed, in a follow-up study in ghrelin-null mice Wortley and colleagues 
demonstrated that exposure of ghrelin-null mice to a high-fat diet at a young age (6 weeks 
of age) reduced the weight gain (associated with decreased adiposity, increased energy 
expenditure and increased locomotor activity) compared to wild-type mice (Wortley et 
al.,2005). These studies suggest that ghrelin/GRLN-R plays a role in energy regulation 
causing an increase in adiposity 
In a different approach, transgenic animals were engineered to over-express the GRLN-R 
in GHRH neurones; these animals showed a basal up-regulation of activity in the GHRH-
Kirstie Ann Bennett, 2009  Chapter 1, 33 
GH axis and a reduction of adiposity (particularly in female rats) without effect on other 
GRLN-R-mediated signals (Lall et al., 2004). In mice engineered to display increased 
ghrelin expression and production in the stomach and brain, increased circulatory ghrelin 
was associated with hyperphagia, increased energy expenditure, glucose intolerance, 
decreased glucose-stimulated insulin secretion and reduced leptin sensitivity (Bewick et 
al., 2009). By knocking-out the gene for the G protein α subunit Gα11 in neuronal and glial 
precursor cells of mice, Wettschureck and colleagues demonstrated that mice died 3-6 
weeks after birth as anorectic dwarfs. Both plasma GH and hypothalamic GHRH were 
reduced and postnatal proliferation of pituitary cells was strongly impaired. The effects of 
ghrelin were reduced at the hypothalamic level due to impairment of GRLN-R signalling 
which may have contributed to the GHRH deficiency and abnormal feeding behaviour 
(Wettschureck et al., 2005).  
Together these studies support the role of ghrelin/the GRLN-R in appetite regulation and 
energy homeostasis but also demonstrate that other mechanisms may take over to 
compensate for a lack of ghrelin or its receptor. Interestingly, two of these studies have 
also shown that is a difference in ghrelin/GRLN-R regulation between sexes as the GRLN-
R seems to be more important in maintaining body weight and regulating GH secretion in 
female rats and mice than in males (Shuto et al., 2002; Zigman et al., 2005). This, 
potentially, could lead to differences in the effectiveness of ghrelin/GRLN-R treatments in 
males and females, although further studies are needed to investigate this.  
1.7 Clinical trials and therapeutic potential of GRLN-R 
agonists/antagonists 
Due to the affects of ghrelin and the growth hormone secretagogues in amplifying GH 
release and appetite stimulation, it has been suggested that agonists of the GRLN-R would 
be clinically useful in the treatment of GH deficiency and the treatment of cachexia whilst 
inverse agonists could potentially be useful in the treatment of obesity; here the reasoning 
behind these suggestions are briefly discussed. 
1.7.1 Cachexia 
Cachexia is a syndrome of muscle wasting, increased metabolic rate and a decrease in 
appetite that accompanies a variety of chronic diseases such as cancer and heart failure 
(Tisdale et al., 1997). Thus agonists of the GRLN-R could be useful in the treatment of 
cachexia by increasing appetite and muscle mass. Indeed a recent phase II study into the 
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effects of the growth hormone secretagogues, RC-1291, showed that after 12 weeks of 
administration in subjects predominantly presenting with lung cancer, RC-1291 led to a 
significant improvement in total body mass as well as a trend towards increased lean mass 
(Garcia et al., 2007). An increase in appetite was also reported in another study where 
subjects with melanoma or breast or colon cancers were treated with a single intravenous 
infusion of ghrelin, this led to a 31 % increase in food intake in a single meal compared to 
subjects receiving placebo (Neary et al., 2004).  
1.7.2 GH deficiency 
GH deficiency in children is usually treated by GH injections administered daily; although 
this is effective it has a number of drawbacks including the need for parenteral 
administration and high cost (Chapman et al., 1997). This makes the non-peptidyl growth 
hormone secretagogues attractive targets for the treatment of GH deficiency. In one small 
trial (9 men) oral administration of MK-677 for four days significantly increased GH and 
insulin-like growth factor-1 levels in men with childhood onset GH deficiency (Chapman 
et al., 1997). In a study of 18 children with idiopathic GH deficiency treatment with MK-
677 increased GH and insulin-like growth factor-1 levels. However, in the most severely 
GH-deficient children there was an apparent lack of response to MK-677 (Codner et al., 
2001). The authors of this study suggested that the lack of an MK-677 response in these 
children was due to a disconnection between the hypothalamus and pituitary (Codner et al., 
2001), although this was not demonstrated directly. 
GH secretion decreases with age, leading to decreases in fat-free (muscle) mass (Zadik et 
al., 1985; Janssen et al., 2000), which is a major risk factor for frailty, loss of independence 
and physical disability in elderly persons (Fantin et al., 2007). This makes the GH 
releasing effects of ghrelin and the growth hormone secretagogues attractive therapeutic 
targets for the treatment of age-related GH decrease. A short-term (2 year) pilot study (65 
people) by Nass and colleagues on the effects of MK-677 in healthy older adults 
demonstrated that subjects who received MK-677 showed sustained increases in the 
amplitude of pulsatile growth hormone secretion and insulin-like growth factor 1 levels to 
those seen in young adults. MK-677 also increased fat-free mass compared to placebo, 
likely due to the concomitant increase in intracellular water. Possibly as a result of appetite 
stimulation, body mass increased more in MK-677 recipients, indeed a reported side-effect 
of MK-677 was a feeling of increased appetite which subsided after a few months of 
treatment (Nass et al., 2008).    
Kirstie Ann Bennett, 2009  Chapter 1, 35 
1.7.3 Obesity 
Due to the high constitutive activity of the GRLN-R a compound that acts as an efficient 
inverse agonist could be used as an anti-obesity agent, as a neutral antagonist may not be 
effective in vivo (Holst et al., 2003). However, a naturally occurring mutation of the 
GRLN-R, which results in the change of an alanine residue for a glutamic acid residue in 
ECL2 of the GRLN-R, has been associated with the development of an obese phenotype in 
vivo that develops during puberty (Pantel et al., 2006). This suggests that the constitutive 
activity of the GRLN-R is important in vivo and that other mechanisms may compensate 
for the loss of constitutive receptor activity leading to an obese phenotype. However, the 
obese phenotype could be due to the persistent lack of constitutive activity of the GRLN-R 
in a particular period in the development of the carrier (Holst and Schwartz, 2006). 
Interestingly, a vaccine against ghrelin has been developed and in adult male rats this has 
the effect of slowing weight gain by decreasing feed efficiency (Zorrilla et al., 2006). 
However the benefits were not passed on to humans, with phase I and II clinical trials 
showing ghrelin vaccination had no effect on weight loss 
(http://www.cytos.com/doc/Cytos_Press_E_061107.pdf); perhaps not that surprising when 
food intake in humans is not always driven by hunger but by comfort and ‘boredom-
eating’.   
Future anti-obesity therapies may now focus on inhibiting the actions of GOAT, as 
inhibiting GOAT is predicted to decrease the amount of octanylated ghrelin in the body, 
leading to a reduction in the orixegenic effects of ghrelin in vivo. 
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1.8 GPCR structure 
1.8.1 Introduction to the G protein-coupled receptor 
superfamily 
The GRLN-R belongs to the G protein-coupled receptor (GPCR) family, the largest 
superfamily of cell surface receptors, encoded for by approximately 3-4 % of the human 
genome (Foord, 2002). The GPCR superfamily includes receptors for diverse types of 
endogenous ligands, such as amines, peptides, amino acids, glycoproteins, prostanoids, 
phospholipids, fatty acids, nucleosides, nucleotides and a variety of sensory stimuli such as 
odorants, pheromones and photons of light (Kristiansen, 2004). As their name suggests, 
GPCRs transduce an extracellular signal into a cellular response via activation of guanine 
nucleotide binding proteins (G proteins) (although there is also evidence that GPCRs may 
signal through G protein-independent pathways, see section 1.10.3).  
GPCRs are an important pharmacological target as mutations within GPCR genes have 
been linked to the development of many diseases such as: retinitis pigmentosa, hypo- and 
hyper-thyroidism, nephrogenic diabetes insipidus and even carcinomas (Schoneberg et al 
2004). Indeed of the clinically marketed drugs around 30 % are targeted against GPCRs, 
however, out of the 800 or so receptors that make up the GPCR superfamily these drugs 
only act on approximately 30 receptors (Wise et al., 2004) leaving enormous potential for 
this family in future drug discovery programmes. 
1.8.2 GPCR classification 
Members of the GPCR family can be split into three major classes (classes A-C) and three 
smaller classes (D-F), with receptors within a class showing greater than 20 % sequence 
homology within the TM domains (Kristiansen, 2004). Apart from the 7TM architecture 
there are no obvious similarities between classes. 
1.8.2.1 Class A 
The GRLN-R belongs to the class A or rhodopsin-like receptors. This is the largest and 
most studied class of GPCRs, consisting of around 670 human receptors (Gloriam et al., 
2007). Within the class A GPCRs the GRLN-R belongs to small subset of receptors for 
peptide hormones and neuropeptides, which include the motilin receptor (GPR38), the 
putative obestatin receptor (GPR39), neurotensin receptors 1 and 2 and the neuromedin 
receptors 1 and 2 (Camina, 2006). The GRLN-R shows the highest sequence homology 
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with GPR38, showing 52 % overall homology or 87 % sequence homology within the TM 
domains (Peeters, 2005). Unlike the GRLN-R, GPR38 does not exhibit any constitutive 
activity. 
Class A GPCRs contain highly conserved residues, mainly within their TM domains. Thus 
to facilitate comparison of residues across class A GPCRs, Ballesteros and Weinstein 
devised a numbering system that assigns two numbers to each residue within the TM 
domains. The first number refers to the TM domain the residue is found in i.e. 1 for TMI. 
The second number is relative to the most conserved residue in the helix, which is assigned 
the number 50; with the numbers decreasing towards the N-terminus and increasing 
towards the C-terminus (Ballesteros & Weinstein, 1995). The most highly conserved 
residues in each TM domains are: an asparagine (N1.50) residue in TMI; an aspartic acid 
(D2.50) in TMII; an arginine (R3.50) residue in TMIII; a tryptophan (W4.50) in TMIV and 
proline residues in TMV, TMVI and TMVII (P5.50, P6.50 and P7.50). Where appropriate, 
Ballesteros-Weinstein numbering will be used throughout this thesis to allow comparison 
of residues in the GRLN-R with other class A GPCRs. 
1.8.2.2 Class B 
Class B GPCRs consist of the secretin and adhesion family of receptors – including 
receptors such as the GHRH receptor. The receptors are characterised by a long N-
terminus which (in almost all cases) contain conserved cysteine residues that form a 
network of three disulphide bonds – creating a globular domain involved in ligand binding 
(Bazarsuren et al., 2002).   
1.8.2.3 Class C 
Class C GPCRs (also known as the glutamate family) consist of 22 receptors including 
those for the neurotransmitters glutamate (the eight metabotropic glutamate receptors) and 
γ-aminobutyric acid (GABA – the GABAB receptors). Members of this class have a large 
N-terminus region comprising of the ‘Venus Fly-trap’ domain. The domain comprises two 
lobes with a cleft in between which forms the ligand-binding site. Binding of a ligand leads 
to closure of this domain, resulting in activation of the receptor. For the majority of class C 
receptors the Venus Fly-trap domain is connected to the 7 TM bundle by a cysteine-rich 
region (Pin et al., 2004). 
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1.8.2.4 Classes D, E and F 
There are a few minor groups of GPCRs which have no apparent sequence identity with 
the other classes, these are the pheromone receptors (class D) and the frizzled/smoothened 
receptors (class E) found in yeast as well as the cAMP receptors (class F) found in 
Dictyostelium discoideum (Bockaert and Pin, 1999).   
1.8.3 GPCR crystal structure 
Until recently, the only high-resolution structural information for GPCRs was limited to 
that of the rhodopsin receptor (determined by Palczewski et al., 2000), a naturally abundant 
receptor that is highly specialised for the detection of light (Kobilka and Schertler, 2008). 
GPCRs for diffusible hormones and neurotransmitters have been difficult to crystallise due 
to their inherent structural flexibility (Kobilka and Schertler, 2008). However, in 2007 the 
second GPCR crystal structure was published, that of the human β2-adrenergic receptor 
(β2AR) (Rosenbaum et al., 2007; Cherezov et al., 2007; Rasmussen et al., 2007), a receptor 
more typical of the GPCR superclass in the sense that its ligands, adrenaline and 
noradrenaline, are diffusible and the receptor is expressed at relatively low levels in native 
tissue (Cherezov et al., 2007). To stabilise the receptor structure β2AR crystals were 
generated in two ways; with a monoclonal antibody (Fab 5) raised against the flexible third 
intracellular loop (Rasmussen et al., 2007) or with the third intracellular loop replaced with 
the small soluble protein T4 lysozyme (Rosenbaum et al., 2007; Cherezov et al., 2007). 
The receptor was also further stabilised by the binding of a diffusible ligand (the partial 
inverse agonist carazolol), which had the effect of stabilising the receptor in one 
conformation, aiding receptor crystallisation (Cherezov et al., 2007).  
2008 saw the publication of the crystal structure of the bovine opsin receptor in complex 
with the carboxy terminus of the G protein transducin (Park et al., 2008), which is expected 
to represent the active state of the rhodopsin receptor (the rhodopsin receptor consists of 
the protein opsin and the covalently bound ligand molecule called 11-cis retinal which 
prevents the protein from signalling; Schwartz and Hubbell, 2008). 2008 also saw the 
publication of the crystal structure of the turkey β1-adrenergic receptor in complex with the 
antagonist cyanopindolol (Warne et al., 2008) and the adenosine A2A receptor in complex 
with the high-affinity antagonist ZM241385 (with the third intracellular loop replaced with 
T4 lysozyme and the C-terminus tail deleted; Jaakola et al., 2008). All these structures 
have provided new information about the structural organisation of GPCRs and the 
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potential mechanisms involved in receptor activation and will be discussed with respect to 
the GRLN-R. 
1.8.4 GRLN-R structure 
1.8.4.1 TM domains 
The GRLN-R, like all GPCRs, is predicted to comprise of 7 transmembrane (TM)-
spanning α-helical domains, connected by three intracellular loops (ICL) and three 
extracellular loops (ECL). This results in the N-terminus and the C-terminus being on 
different sides of the plasma membrane, with the N-terminus being located on the 
extracellular side and the C-terminus being located on the intracellular side (Figure 1-1). 
The membrane orientation of the GRLN-R has been confirmed by Feighner and colleagues 
who demonstrated, using indirect immunofluorescence, that an antibody raised against a 
predicted intracellular peptide (from the C-terminus of the GRLN-R) only reacted upon 
permeabilisation of HEK293 or COS-7 cells transfected to express the human GRLN-R. In 
contrast an antibody raised against a predicted extracellular peptide (part of ECL2) reacted 
without prior cell permeabilisation (Feighner et al., 1998).  
Although to date no crystal structure is available for the GRLN-R, it is expected that the 
TM helices of the GRLN-R will be slightly ‘kinked’ due to the presence of glycine and 
proline residues and tilted from the plane of the membrane; a prediction based on the 
findings from the crystal structures of the rhodopsin receptor, the β2AR, the β1AR and the 
adenosine A2A receptor (Palczewski et al.,2000; Cherezov et al., 2007; Rosenbaum et al., 
2007; Rasmussen et al., 2007; Warne et al., 2008; Jaakola et al., 2008). These kinks are 
thought to enable the structural rearrangements required for G protein activation 
(Yohannan et al., 2004). 
The GRLN-R contains the highly conserved E/DRY motif at the intracellular end of TMIII 
(conserved among 72 % of class A GPCRs; Kobilka and Deupi, 2007). The E/DRY 
sequence may be critical for G protein binding. For example, mutating R1363.50 in the 
motilin receptor, GPR38, to either an alanine or a histidine residue inhibits the signalling of 
the receptor to motilin (as measured through calcium mobilisation) without affecting the 
affinity of motilin for the receptor (Tokunaga et al., 2007).  
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Figure 1-2 – Snake plot diagram of the GRLN-R. Residues that are conserved throughout class 
A GPCRs and used for Ballesteros-Weinstein numbering are shown outlined in red (N in TM1; D in 
TMII; R in TMIII and P in TM V-VII). Also shown (in yellow) are residues that are typically 
conserved throughout class A GPCRs. These include two asparagine residues in the N-terminus 
(occurring as part of the N-X-S/T motif) that are predicited to undergo N-linked glycosylation; two 
cysteine residues (top of TMIII and in ECL2) that are predicted to form a di-sulphide bond; E/DRY 
and NPXXY motifs in TMIII and TMVII, respectively, that are thought to be important in stabilising 
the inactive state of receptors and a CWLP fingerprint motif (TMVI) that is thought to act as a 
rotomer toggle switch important for receptor activation. Helix VIII is predicted to form between the 
serine residue (S327) and a proline residue (P342) in the C-terminus of the GRLN-R (marked by a 
red dotted line). Also shown are several serine and threonine residues within the C-terminus tail 
that are predicted to undergo phosphorylation by second messenger kinases and G protein 
receptor kinases. PKC phosphorylation sites (S/T-X-R/K) are marked with a bracket. A di-leucine 
motif (LL) and a tyrosine-based motif (YRVAV; boxed) are thought to be important in binding the 
adaptor protein AP-2, leading to internalisation of the receptor. Lastly, residues shown in black (a 
glutamic acid residue in TMIII and phenylalanine residues in TM VI-VII) are thought to be important 
in receptor activation (the glutamic acid residue forms a salt-bridge with the positively charged 
amine group of ghrelin and the growth hormone secretagogues; whilst the phenylalanine residues 
are thought to be important in maintaining the constitutive activity of the GRLN-R).   
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In the rhodopsin receptor an interaction between a glutamic acid residue 134 (E3.49) and an 
arginine residue (R3.50) in the E/DRY sequence with a glutamic acid residue (E6.30) and a 
threonine residue (T6.34) at the cytoplasmic end of TMVI, is predicted to stabilise the 
inactive state of the receptor by allowing the formation of an ‘ionic lock’. Breakage of the 
ionic lock is thought to occur upon receptor activation. In support of this constitutively 
active mutants (CAMs) can be generated by the neutralisation of aspartic acid/glutamic 
acid charges at the cytoplasmic end of TMVI. This has been demonstrated for a number of 
receptors e.g. β2AR (Rasmussen et al., 1999); rhodopsin (Cohen et al., 1993) and the 
muscarinic M1 receptor (Lu et al., 1997). In the β2AR the arginine residue in the E/DRY 
sequence (R1313.50) is not close enough to E2686.30 in TMVI to form a hydrogen bond, thus 
the ionic lock is not formed. It has been suggested that the lack of an ionic lock may be due 
to the receptor being partially constitutively active or signalling through interaction with 
scaffold proteins (Lefkowitz et al., 2008). However the salt bridge is lacking in the 
structure of the β1AR and the A2A receptor, receptors that lack any measurable constitutive 
activity, thus suggesting that the ionic lock is not an essential feature of maintaining class 
A GPCRs in their inactive state (Warne et al., 2008; Jaakola et al., 2008).  
The GRLN-R contains a highly conserved class A motif, the NPXXY motif, in TMVII 
which is thought to be important in stabilising the inactive state of receptors by allowing 
TMVII to interact with TMVI. The GRLN-R also contains a CWLP fingerprint motif, 
which may play an important role in receptor activation acting as a rotomer toggle switch. 
The CWLP motif and residues that are involved in the maintenance of the constitutive 
activity of the GRLN-R are discussed in section 1.8.5. 
1.8.4.2 Extracellular regions 
As with the vast majority of class A receptors, the GRLN-R contains two cysteine residues 
that are predicted to form a disulphide bond. One cysteine residue is located at the top of 
TMIII (C1163.25) whilst the other cysteine residue is located in ECL2 (C198). This 
disulphide bond appears to be important for correct protein folding of the GRLN-R as 
Feighner and colleagues have shown mutation of C1163.25 to A116 disrupted cell surface 
trafficking of the GRLN-R (Feighner et al., 1998).  
Virtually all GPCRs, from all classes, possess at least one N-linked glycosylation site (an 
oligosaccharide linked to the nitrogen in the side chain amide of an asparagine residue) in 
their extracellular regions. N-linked glycosylation occurs at the consensus sequence: N-X-
S/T, where X can be any amino acid except proline or asparagine (Kristiansen, 2004). 
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Mutagenesis of the consensus sequence shows that glycosylation is vital for the cell-
surface expression of some receptors e.g. the angiotensin 1 receptor (Lanctot et al., 2006) 
but has no significant influence on the distribution of others e.g. the muscarinic M2 
receptor (van Koppen and Nathanson, 1990). There are two predicted N-linked 
glycosylation sites in the GRLN-R located in the N-terminus of the receptor at N13 and 
N27. Deletion of amino acids 1-35 in the N-terminus of the GRLN-R has no effect on the 
cell surface expression or the ligand-dependent and independent signalling of the receptor 
(Holst et al., 2009) thus it appears glycosylation has no effect on the cell surface 
expression of the GRLN-R.  
The crystal structure of the β2AR demonstrated that the ECL2 contains a helix that permits 
extracellular ligands access to the ligand-binding site (Cherezov et al., 2007), which is in 
contrast to the rhodopsin receptor that displays a buried β-sheet structure in this region 
(Palczewski et al., 2000) which effectively shields the binding site from the extracellular 
compartment (Lefkowitz et al., 2008). Basing the folding of the TM segments of the 
GRLN-R on the structure of the rhodopsin receptor and modelling the extra-membrane 
regions to different templates to favour local homologies, Pedretti and colleagues predict 
that, in the inactive state, ECL2 of the GRLN-R partially penetrates the TM domains 
forming the upper part of the polar ligand-binding pocket. However, in the closed state the 
receptor ECL2 forms a more folded conformation, which results in ECL2 moving away 
from the TM domains (Pedretti et al., 2007).  
1.8.4.3 Intracellular regions 
The crystal structures of the β1AR and the A2A receptor reveal that ICL2 forms a small 
helix which disrupts the formation of the ionic lock between the E/DRY sequence at the 
base of TMIII with residues in TMVI (Warne et al., 2008; Jaakola et al., 2008). However, 
the crystal structure of the constitutively active β2AR reveals that ICL2 does not form a 
helix (Rosenbaum et al., 2007; Cherezov et al., 2007; Rasmussen et al., 2007). This 
suggests that ICL2 may act as a control switch, facilitating G protein interactions (Jaakola 
et al., 2008). The conformation of ICL2 in the GRLN-R has not yet been established. 
In addition to the 7 TM spanning domains, crystal tructures of the rhodopsin receptor, the 
β2AR and the β1AR demonstrated the presence of a small helix, helix VIII, perpendicular 
to the membrane at the intracellular end of TMVII. Helix VIII is believed to be common to 
all class A GPCRs (Katragadda et al., 2004). In the rhodopsin receptor palmitoylation (the 
attachment of a palmitic acid via a thioester bond) of cysteine residues 322 and 323 
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anchored the helix to the membrane - effectively creating a fourth intracellular loop 
(Palczewski et al., 2000). Using the structure of the rhodopsin receptor as a template, 
Pedretti and Vistoli modelled the GRLN-R and predicted that helix VIII was formed from 
S327 to P342 and was located perpendicular to helix VII (Pedretti and Vistoli, 2007). 
Predicted helix VIII is rich in positively charged residues (K328; R329; R331; R336), 
which may anchor the helix to phospholipidic heads (Sakmar et al., 2002) making the C-
terminal tail of the GRLN-R (after helix VIII) shorter than the average GPCR, consisting 
of less than 30 amino acids (Holliday et al., 2007).  Interestingly putative Helix VIII in the 
GRLN-R has also been described to contain the proposed nuclear localisation sequence 
KKYR (Lee et al., 2004). 
In addition, in the C-terminal tail of the GRLN-R multiple residues are found that are 
thought to be important in the termination of receptor signalling, including several serine 
and threonine residues, a di-leucine motif (LL) and four potential PKC phosphorylation 
sites (S/T-X-R/K) (see section 1.10.4 for further details).  
1.8.5 Residues contributing to the constitutive activity of the 
GRLN- R 
Previous studies have indicated that the activation of GPCRs involves an inward 
movement of TMVI and VII towards TMIII in the main ligand-binding pocket at the 
extracellular sides of these helices (Elling et al., 1999; Ghanouni et al., 2001). This led to 
the development of the global toggle-switch model for the activation of GPCRs (Elling et 
al., 2006) where TMVI (and to some degree TMVII), is predicted to perform a vertical see-
saw movement around a pivot point located close to the middle of the membrane (where 
the conserved proline residue is located; Schwartz et al., 2006). Pivoting of TMVI around 
P6.50 results in the extracellular side of TMVI tilting into the main TM bundle, whilst the 
intracellular end of the helix tilts away from the main TM bundle. In support of the global 
toggle-switch for receptor activation, the crystal structure of bovine opsin receptor shows 
that, compared to the inactive rhodopsin receptor structure, TMVI shows a large tilt, 
accompanied by a smaller motion of TMVII at the intracellular side of the receptor (Park et 
al., 2008; Schwartz and Hubbell, 2008).  
Several micro-switches (residues highly conserved during evolution) that switch between 
substantially different conformations in the inactive versus active receptor states are 
believed to be integral components of the global toggle-switch model for GPCR activation 
(Nygaard et al., 2009). One of these micro-switches is W6.48 in the conserved CWLP motif.  
Kirstie Ann Bennett, 2009  Chapter 1, 44 
The GRLN-R contains the conserved CWLP fingerprint motif in TMVI. In the rhodopsin 
receptor inactive structure the indole side-chain of W2656.48 is situated vertically at the 
interface between TMIII and TMVI, stabilised by an interaction with a structural water 
molecule, preventing the movement of the outer segment of TMVI (Shi et al., 2002; 
Schwartz et al., 2006). It has been suggested that W6.48 functions as a rotomer toggle 
switch as upon receptor activation, the rotomeric state of the indole side-chain alters, 
allowing the indole side-chin of W6.48 to interact with F5.47 in TMV (Nygaard et al., 2009). 
This moves the side-chain away from the interface between TMIII and TMVI straightening 
the proline kink of TMVI (Schwartz and Rosenkilde, 1996; Schwartz et al., 2006).  
In the GRLN-R the ligand-independent signalling of the receptor appears to be controlled 
by a cluster of aromatic amino acid residues located at the interface between TMIII, TMVI 
and TMVII. Using a systematic mutagenesis approach Holst and colleagues demonstrated 
that aromatic-aromatic interactions between residues F2796.51 F3097.39 and F3127.42 could 
act as a tethered agonist, stabilising the receptor in the active conformation in the absence 
of agonist by stabilising the active, inward-bend conformation of TMVI obtaining 
constitutive activation of the rotamer toggle switch (Holst et al., 2004; Schwartz et al., 
2006). The aromatic-aromatic interactions appeared to be important for maintaining the 
constitutive activity of the GRLN-R as constitutive activity of the GRLN-R could only be 
observed if the residue at position 3127.42 was a phenylalanine residue or a tyrosine residue. 
By changing the size and hydrophobicity/aromaticity of the side chain of F2796.51 in the 
presence of large hydrophobic residues at F3097.39 and F3127.42, the constitutive activity of 
the receptor could be ‘tuned’-up or down (Holst et al., 2004). Thus it has been suggested 
that these large aromatic side chains act as tethered agonists to obtain constitutive 
activation of the toggle switch (Holst et al., 2004; Schwartz et al., 2006). 
Interestingly two naturally occurring missense mutations of the GRLN-R have been 
identified which appear to ablate the constitutive activity of the receptor. These mutations 
are A204 to E204 in ECL2 and F2796.51 to L2796.51 in TMVI (Wang et al., 2004). The 
F279L mutation is within the cluster of amino acids shown to be important for the 
constitutive activity of the GRLN-R. However, the A204E mutation is distinct from 
residues shown to be important for maintaining the constitutive activity of the GRLN-R, so 
the mechanism of how mutation of this residue affects the constitutive activity of the 
GRLN-R is unknown. Interestingly for the free fatty acid receptor 1 (FFA1) two glutamic 
acid residues in ECL2 are thought to form interactions with two arginine residues located 
in the TM domains (R1835.39 and R2587.35) to create two ionic locks. These ionic locks are 
broken upon agonist binding, whilst mutation of the glutamic acid residues to alanine 
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residues results in constitutive receptor activation (Sum et al., 2009). Thus it is conceivable 
that the alanine residue in ECL2 of the GRLN-R is required for constitutive activation of 
the receptor by disrupting the formation of an ionic lock between ECL2 and a residue in 
the TM domains.      
1.8.6 Ligand-binding pocket of the GRLN-R 
Interestingly comparison of the cDNA of the human GRLN-R to the teleost puffer fish 
GRLN-R reveals that there is 58 % homology between these two receptors. Furthermore 
the growth hormone secretagogues MK-677, GHRP-6 and L-163,540 were all shown to be 
capable of activating the puffer fish GRLN-R indicating that the ligand-binding pocket of 
the GRLN-R has been conserved for at least 400 million years (Smith et al., 1999).  
Studies into ghrelin and the growth hormone secretagogues have shown that the presence 
of a basic amino acid group is important for their bioactivity (Momany et al., 1984; Smith 
et al., 1993; McDowell et al., 1995; Patchett et al., 1995). Mutagenesis studies have shown 
that a glutamic acid residue in TMIII (E1243.33) of the GRLN-R appears to be a key residue 
for the binding of these ligands (Feighner et al., 1998) and is expected to be similarly 
disposed (but not identical) to D1133.32 in the β2AR which forms a salt bridge with the 
positively charged amine group of the catecholamines. Indeed, mutating E1243.33 to 
Q1243.33 (which alters the charge at this position) ablates GRLN-R signalling to ghrelin, 
MK-677, GHRP-6 and L-692,585. Restoration of function of the E124Q3.33
 
mutant can be 
achieved by a complementary change in the MK-677 ligand through modification of its 
amine side-chain into the corresponding alcohol (Feighner et al., 1998). Mutating E1243.33 
to D1243.33 (which conserves the charge at this position) has been demonstrated to be non-
disruptive to ligand binding and receptor activation (Feighner et al., 1998). Thus E1243.33 
in the GRLN-R acts as a key charge-charge interaction point, stabilising the positive 
charge of the basic amino group in ghrelin and the growth hormone secretagogues. 
Interestingly this residue is also conserved in GPR38 (E1193.33) where it has been shown to 
be a key charge-charge interaction for small molecule agonists of the receptor, such as 
erythromycin (Xu et al., 2005). 
Besides E1243.33, ghrelin and the growth hormone secretagogues GHRP-6, MK-677, L-
692,429, SM-130686 and SM-157740 also appear to interact with residues in TMVI 
(F2796.51, R2836.55 and F2866.58) and TMVII (Holst et al., 2009), thus the main ligand-
binding pocket of the GRLN-R appears to be confined to the interface between the 
extracellular ends of TMIII, TMVI and TMVII (Holst et al., 2006).  
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Ghrelin also appears to make contact with residues in the ECLs as substitution of Q302 to 
a A302 in ECL3 and E197 to Q197 in ECL2 had a small effect on the potency of ghrelin 
(causing around a 5-6 fold decrease in the potency of ghrelin) (Holst et al., 2009); this fits 
well with the concept that larger, peptide ligands tend to exploit mainly residues at the 
most extracellular end of the helices and the extracellular domains (Schwartz and Holst, 
2006). 
The growth hormone secretagogues share overlapping, but not identical binding sites with 
ghrelin on the GRLN-R, with the differences mainly in the residues with which they 
interact with in TMVII. Here MK-677 and L-692,429 were shown to be affected by 
substitutions at N3057.35 and F3097.39, whilst SM-130686 and SM-157740 were affected by 
substitutions of (the more deeply located) F3127.42 (Holst et al., 2009). In TMIV 
substitution of I1784.60 affected the growth hormone secretagogues but to different extents, 
having a large impact for GHRP-6 (130-fold decrease in potency) but not so much on the 
response to MK-677 (5.3-fold decrease in potency). The same could be seen for mutation 
of D992.60 in TMII where the potency of MK-677 was decreased by greater than 1300-fold, 
whereas the potency of L-692,585 was actually increased by 6-fold (Holst et al., 2009).   
Interestingly two naturally occurring missense mutations of the GRLN-R have been 
identified that appear to affect the signalling of the receptor, either ablating the response to 
ghrelin (I1343.43 to T1343.43) or by increasing the potency of ghrelin (V1604.42 to M1604.42) 
(Liu et al., 2007). The effect of these mutations on the signalling of the growth hormone 
secretagogues has not been studied to date. 
1.8.7 Ligand-binding pocket for SPA 
Like ghrelin and the growth hormone secretagogues, the inverse agonist SPA is positively 
charged but mutation of the glutamic acid residue E1243.33 (E124Q) does not affect 
signalling of SPA as much as mutation of D992.60 to an N992.60. Indeed mutation of 
E1243.33 only causes around a 14-fold decrease in SPA potency whereas mutation of 
D992.60 causes a 47-fold change in potency (Holst et al., 2006). Thus it appears that the 
SPA binding pocket extends towards TMII and that the negatively charged D992.60 makes a 
charge-charge interaction with the positively charged amino group of SPA (Holst et al., 
2006). Indeed the SPA binding pocket also appears to extend towards TMVI with mutation 
of I1784.60 to A1784.60 causing a 22-fold decrease in the potency of SPA.  
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It is predicted that the central aromatic tripeptide of SPA (WFW) interacts with the 
aromatic cluster in TMVI and VII of the GRLN-R thus preventing the inward movement of 
TMVI and TMVII (Holst et al., 2006), thereby preventing the constitutive activation of the 
receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kirstie Ann Bennett, 2009  Chapter 1, 48 
1.9 Dimerisation 
1.9.1 Introduction to dimerisation 
Although GPCRs are often thought of as acting as monomers there is a wealth of evidence 
to suggest that many GPCRs can form dimers, or higher-order oligomers, that may be 
important for their function (Milligan et al., 2006). Dimerisation may occur between 
identical receptors (homo-dimerisation) or between non-identical receptors (hetero-
dimerisation) and has been established in class A (e.g. the chemokine receptors CXCR1 
and CXCR2 receptors; Wilson et al., 2005), class B (e.g. the secretin
 
receptor; Harikumar 
et al., 2008) and class C GPCRs (e.g. the metabotropic glutamate receptors; Kniazeff et al., 
2004).  
Dimerisation of GPCRs in the endoplasmic reticulum (ER) has been shown to be required 
for the maturation and cell-surface expression of many GPCRs (Bulenger et al., 2005). A 
classical example of this is the GABAB receptor. The GABAB receptor was cloned in 1997, 
however, expression of the receptor in a heterologous system resulted in a discrepancy 
between the binding affinities of agonists for the receptor compared to those measured 
from the endogenous GABAB receptor expressed in the brain (Kaupmann et al., 1997). 
Within a year after the cloning of the GABAB receptor, three groups simultaneously 
published that the functional receptor is actually composed of a hetero-dimer between two 
receptor subunits: GABAB1 and GABAB2 (White et al., 1998; Kaupmann et al., 1998; Jones 
et al., 1998). The endogenous ligand GABA binds to GABAB1 with the GABAB2 subunit 
coupling to a G protein and acting as a chaperone. The GABAB1 subunit contains an ER-
retention motif within the C-terminal tail, the interaction of GABAB1 with the C-terminal 
tail of GABAB2 masks the ER-retention motif allowing the hetero-dimer to be exported 
from the ER and trafficked to the cell surface (Pagano et al., 2001; Margeta-Mitrovic et al., 
2000).  
As well as affecting receptor trafficking, dimerisation has also been shown to modify 
receptor signalling. For example, the orexin-1 antagonist SB-674042, which has no affinity 
for the cannabinoid receptor CB1, was shown to decrease the potency of a CB1 agonist 
(WIN 55,212-2) when the cannabinoid receptor CB1 and the orexin receptor orexin-1 were 
co-expressed in HEK293 cells. This effect was dependent on the receptors forming a 
hetero-dimer and demonstrates that the formation of dimers allows a ligand at one receptor 
to modulate the function of a receptor for which it has no significant and inherent affinity 
(Ellis et al., 2006). 
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1.9.2 Dimerisation of the GRLN-R 
Akin to the GABAB receptor, dimerisation of the GRLN-R has been suggested to be 
important for the correct trafficking of the receptor to the plasma membrane. The GRLN-R 
has been demonstrated to form a homo-dimer in two independent studies (Jiang et al., 
2006; Leung et al., 2007). As the GRLN-R contains a potential nuclear localisation signal 
(KKYR) in putative helix VIII (Lee et al., 2004) the GRLN-R may need to exist as a dimer 
to mask the nuclear retention signal, to allow trafficking of the receptor to the plasma 
membrane (Leung et al., 2007).  
As well as forming homo-dimers the GRLN-R has also been reported to form hetero-
dimers; both with the GHs-R1b (Leung et al., 2007) and with the dopamine D1 receptor 
(Jiang et al., 2006). It is thought that hetero-dimerisation of the GRLN-R with GHs-R1b 
reduces the cell surface expression, and hence constitutive activity, of the GRLN-R by 
translocating the receptor to the nucleus (acting as a dominant negative mutant of the 
GRLN-R), although there needs to be a 13-fold excess of GHs-R1b to the GRLN-R for this 
to occur (Leung et al., 2007). Thus the formation of a GRLN-R/GHs-R1b hetero-dimer 
could fail to mask the nuclear localisation signal at the C-terminus of the GRLN-R causing 
nuclear retention of the dimer (Leung et al., 2007). Indeed mRNA for both the GRLN-R 
and the GHs-R1b have been described to co-exist in the same tissues (Gnanapavan et al., 
2002) and in the same cells, for example, in a cell-line prepared from pancreatic 
adenocarcinoma cells, thus it is possible that GRLN-R/GHs-R1b hetero-dimers exist in 
vivo (Duxbury et al., 2003).  
When the GRLN-R and the dopamine receptor D1R are co-expressed in the same cells, the 
addition of ghrelin appears to amplify dopamine signalling (Jiang et al., 2006). This 
mechanism involves dimerisation of the GRLN-R with the D1R (which has been 
demonstrated to occur in co-immunoprecipitation and saturation bioluminescence 
resonance energy transfer experiments). As the GRLN-R and D1R are co-expressed within 
the same neurones in vivo (and have also been shown to co-localise in a SK-N-SH 
neuronal cell line which endogenously expresses both receptors) (Jiang et al., 2006) it 
suggests that ghrelin can amplify the signalling of the D1R in vivo.  
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1.10 GPCR signalling 
This section will focus on the G protein-dependent and independent signalling of the 
GRLN-R. Following this, the mechanisms that can modulate GRLN-R signalling 
(desensitisation/endocytosis; constitutive activation and allosteric modulation) will be 
discussed. 
1.10.1 Introduction to G proteins 
Ligand-induced activation of the GRLN-R causes a profound change in the TM helices 
which affects the conformation of ICLs and uncovers masked G protein binding sites 
allowing interaction with heterotrimeric G proteins (Camina, 2006). Heterotrimeric G 
proteins consist of three subunits α, β and γ and act to couple changes in receptor 
conformation into cellular responses within the cell via activation of second messenger 
pathways.  
In its inactive state, a G protein has a molecule of guanosine 5’ diphosphate (GDP) bound. 
Receptor activation (via ligand binding or constitutive activity) results in a conformational 
change that allows the receptor to associate more effectively with G proteins. The receptor 
acts as a guanine nucleotide exchange factor by promoting the release of the molecule of 
GDP from the G protein, which is exchanged for a molecule of guanosine 5’ triphosphate 
(GTP). As GTP is present at a higher concentration within the cell than GDP this leads to 
fast binding of GTP. Binding of GTP leads to a conformational change causing the 
dissociation of the heterotrimer into two signalling subunits: an α subunit and a βγ 
complex. These subunits can then interact with their effectors to cause amplification in 
signal via second messenger pathways. The α subunit has intrinsic GTPase activity and so 
hydrolyses the terminal phosphate of GTP to form a molecule of GDP (+ Pi), which returns 
the α subunit into an inactive state and promotes the reassociation with the βγ complex – 
ceasing signalling (Figure 1-3).  
The GTPase activity of the α subunit can be modified by the binding of proteins known as 
G protein Activity modifying Proteins (GAPs) including the Regulators of G protein 
Signalling (RGS) family of proteins.  The RGS proteins reduce the signal transmitted by 
the α subunit by increasing the rate of GTP hydrolysis, returning G protein to the GDP-
bound state in a shorter time scale (De et al., 2000). 
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Figure 1-3 – The G protein activation cycle (adapted from Milligan and Kostenis, 2006). In the 
inactive state the α subunit of the G protein has a molecule of GDP bound and is able to associate 
with the βγ complex. Upon activation the GPCR undergoes a conformational change that results in 
an increase in affinity for the G protein. As a result the GDP molecule is exchanged for a GTP 
molecule on the α subunit. This reduces the affinity of the α subunit for the βγ complex, leading to 
dissociation into two signalling complexes (the α and the βγ complexes) which can interact with 
their effectors, transducing the external signal into an intracellular response. Signalling is halted by 
the hydrolysis of GTP to GDP (+ Pi) by the intrinsic activity of the α subunit. RGS proteins can 
increase the rate of GTP hydrolysis, returning the G protein to the GDP bound state in a shoter 
time scale.  
 
Interestingly several studies have suggested that the G protein may not always dissociate 
into α and βγ complexes upon G protein activation; instead there may be a rearrangement 
in the conformation of these subunits (Bunemann et al., 2003; Frank et al., 2005). However 
this may be specific for the Gαq/11 (Galés et al., 2005) and Gαi/o family (Bunemann et al., 
2003) (see below) as activation of another G protein family (Gαs) has been shown to be 
consistent with the classical model of G protein subunit dissociation (Janetopoulos et al., 
2001). 
1.10.2 G
 
protein coupling of the GRLN-R 
There are 21 G protein α subunits encoded for by 16 genes resulting in subunits that range 
in size from 39-52 kDa (Downes and Gautam, 1999). The α subunits can be classified, 
based on sequence homology, into four subfamilies: Gαs, Gαi/o, Gαq/11 and Gα12/13; with 
even the most diverse α subunits exhibiting 50 % sequence homology (Milligan and 
Kostenis, 2006).  
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1.10.2.1 Gαq/11 
The Gq/11 family consists of Gαq, Gα11, Gα14, Gα15 and Gα16 with Gαq/11 ubiquitously 
expressed and Gα15/16 expressed in hematopoietic cells (Milligan and Kostenis, 2006). This 
family activates phospholipase Cβ (PLCβ) isoforms which hydrolyse phosphatidyl inositol 
[4,5] bisphosphate (PIP2) into 1,2 diacylglycerol (DAG) and inositol [1,4,5] trisphosphate 
(IP3).  IP3 binds and activates IP3-sensitive Ca2+ channels on the ER, releasing Ca2+ which 
causes an elevation in intracellular [Ca2+] ([Ca2+]i), whilst DAG activates the downstream 
enzyme protein kinase C (PKC) (Figure 1-4). Activation of the Gαq/11 G protein family can 
be specifically blocked by YM-254890 (isolated from Chromobacterium sp), which 
specifically blocks the exchange of GDP for GTP on the G protein α subunit (Takasaki et 
al., 2004). 
Cloning of the GRLN-R revealed that the GRLN-R was coupled to the Gαq/11 pathway; 
more specifically, the GRLN-R was found to couple to Gα11 but not Gαq (Howard et al., 
1996)
.
 Since then, coupling of the GRLN-R to the Gαq/11 pathway has been confirmed in 
numerous other studies, which have used calcium mobilisation and inositol phosphate 
assays to measure activation of the GRLN-R, both upon treatment with ghrelin and the 
growth hormone secretagogues (McKee et al., 1997; Kojima et al., 1999; Holst et al., 2004; 
Holliday et al., 2007; Holst et al., 2009).  
Although the GRLN-R is expected to couple principally to Gαq/11, there is also evidence 
that the GRLN-R is able to couple to, and activate, multiple G protein pathways, i.e. the 
receptor appears to be promiscuous. Promiscuity has been demonstrated for a number of 
other GPCRs, for example: the β2AR activates both Gαs and Gαi (Kilts et al., 2000); the 
metabotropic glutamate 1a receptor can activate Gαi and Gαq/11 (Hermans et al., 2000) and 
the muscarinic 1 receptor is preferentially coupled to Gαq/11 but can also activate Gαi/o 
(Offermanns et al., 1994). Indeed, it appears that receptors may display multiple active 
conformations as situations in which a ligand acting at a promiscuous receptor can 
preferentially activate one G protein pathway over another have been described, a property 
termed ‘functional selectivity’ (Urban et al., 2007). This has been demonstrated for the 
serotonin receptor 5-HT2C where the ligand DOI was shown to preferentially activate Gαs 
over Gαq/11 (Berg et al., 1998). 
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Figure 1-4 – Signalling pathways of the GRLN-R. A. Signalling through the Gαq/11 pathway. 
Activation of the Gαq/11 pathway activates PLCβ, which hydrolyses PIP2 into IP3 and DAG. DAG 
activates the downstream kinase PKC whilst IP3 can activate IP3 sensitive channels on the ER 
causing an increase in [Ca2+]i. B. Signalling through Gαs and Gαi/o pathways. Activation of the Gαs 
pathway stimulates adenylate cyclase, which generates cAMP from ATP. cAMP activates the 
downstream kinase protein kinase A (PKA). The Gαi/o pathway acts to inhibit adenylate cyclase 
activation. C. In the Gα12/13 pathway, G protein activation causes the activation of Rho guanine 
exchange factors (Rho GEFs), which are linked to the activation of Rho. Rho activates rho-
dependent kinase (ROCK), which stimulates c-Jun N-terminal kinase (JNK) and the formation of 
stress fibres and in part, through these events, activates serum response factor transcription. 
Activation of Gαs; Gαi/o and Gα12/13 remains little studied for the GRLN-R.  
A 
B 
C 
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1.10.2.2 Gαs 
The Gαs family is named due to their ability to stimulate adenylate cyclase. The family 
consists of Gαs(S); Gαs(L); Gαs(XL) and Gαolf – with Gαs being ubiquitously expressed and Gαolf 
expression limited to olfactory neurones, certain central nervous system ganglia, digestive 
tract and urogenital tract (Milligan and Kostenis, 2006). The Gαs family acts to stimulate 
adenylate cyclase activity, which converts ATP to cAMP. The rise in cAMP in the cytosol 
activates protein kinase A (PKA) (Figure 1-4). 
In vivo studies of the GRLN-R have suggested that the receptor may be able to couple to 
the Gαs G protein family. In rat NPY-containing neurones, ghrelin-induced calcium 
mobilisation has been proposed to occur through activation of the Gαs pathway as a protein 
kinase A inhibitor (H89) reduced the ghrelin-induced calcium response (Kohno et al., 
2003). In ovine somatotrophs, growth hormone secretion in response to treatment with 
GHRP-6 and GHRP-2 has been suggested to be mediated through activation of the Gαs 
pathway (Wu et al., 1997). The ability of the human GRLN-R to couple to Gαs in 
recombinant systems remains controversial, with some studies suggesting the GRLN-R can 
couple to Gαs (Rossi et al., 2008; Caminos et al., 2005) whilst others suggest that it cannot  
(Cunha and Mayo, 2002; Casanueva et al., 2008).
 
1.10.2.3 Gαi/o 
The Gαi/o family is named due to their ability to inhibit adenylate cyclase activation (Figure 
1-4) and consists of Gαo1, Gαo2, Gαi1-i3, Gαz, Gαt1/2 and Gαgust subtypes. Gαo1-2 is expressed in 
neurones, neuroendocrine cells, astroglia and the heart. Gαi1-i3 is expressed in neurones, Gαz 
in platelets, neurones, adrenal chromaffin cells and neurosecretory cells, Gαt1 in rod outer 
segments and taste buds, Gαt2 in cone outer segments and Gαgust in the sweet and bitter taste 
buds and the chemoreceptor cells in the airways (Milligan and Kostenis, 2006). Pertussis 
toxin (PTx) can catalyse the ADP ribosylation of a cysteine residue 4 amino acids from the 
C-terminal which prevents functional interaction of the α subunit (apart from Gαz) with the 
receptor.  
As well as activating the Gαs pathway, the GRLN-R has been demonstrated to activate the 
Gαi/o pathway in cell lines endogenously expressing the GRLN-R (Kim et al., 2004; 
Maccarinelli et al., 2005). For example, ghrelin suppression of glucose-induced insulin 
release in rat pancreatic islet β cells was shown to be mediated through the G protein 
subunit Gαi2, as ghrelin suppression of insulin release was sensitive to treatment with PTx 
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and completely abolished by treatment with the antisense oligonucleotide specific for the 
Gαi2 subunit (but not by antisense oligonucleotides specific for Gαi1 or Gαi3) (Dezaki et al., 
2007). Furthermore this suppression of glucose-induced insulin release was reduced by 
treatment with the GRLN-R antagonist [D-lys3]-GHRP-6 (Dezaki et al., 2007) suggesting 
ghrelin was exerting its actions through the GRLN-R coupled to Gαi2.  The ability of the 
GRLN-R to couple to the Gαi/o pathway has also been demonstrated in recombinant 
systems expressing the human GRLN-R (Camina et al., 2007) or co-expressing the human 
GRLN-R and Gαi (Bassil et al., 2007).  
Although it may appear counter-productive for a receptor to be able to couple to both Gαi/o 
and Gαs the ability of the GRLN-R to couple to these proteins may depend on their local 
and subcellular concentration. Indeed there is considerable evidence to suggest that GPCR 
signalling components are organised together into lipid rafts, which can act to regulate 
GPCR signal transduction (Insel et al., 2005).  
1.10.2.4 Gα12/13 
The Gα12/13 family is the least understood G protein family; it is ubiquitously expressed and 
associated with communications between heterotrimeric G proteins and cellular reponses 
mediated by monomeric GTP-binding proteins (Rho), including morphology (e.g. actin 
reorganisation) and cell proliferation (Riobo and Manning, 2005) (Figure 1-4). 
The GRLN-R has been proposed to activate the serum response element-mediated 
transcription mainly through activation of Gα13 (Holst et al., 2004) although this pathway 
may also be activated by various G protein systems such as Gαq, Gαi and G protein βγ 
subunits (Mao et al., 1998; Gruijthuijsen et al., 2002; Niu et al., 2003). 
1.10.3 G protein-independent signalling  
1.10.3.1 The mitogen-activated protein kinase cascade 
Extracellular-regulated kinases (ERKs) belong to a large family of kinases collectively 
known as the mitogen-activated protein kinases (MAPKs) (Miller and Lefkowitz, 2001). 
The activation of ERK1/2 occurs via activation of the Ras-dependent cascade. Classically, 
activation of the Ras-dependent cascade occurs via G protein activation, which leads to 
activation of Raf-1, a MAPK kinase kinase, which phosphorylates the downstream MAPK 
kinases MEK1 and MEK2. MEK1 and MEK2 can then phosphorylate ERK1 and ERK2 
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(Miller and Lefkowitz, 2001). ERK1/2 activation leads to the translocation of the active 
cytoplasmic kinase to the nucleus where it activates numerous transcription factors 
involved in mitogenesis and proliferation (Miller and Lefkowitz, 2001). The β-arrestins 
serve as multifunctional adaptors, scaffolding and/or signal transducers that connect the 
activated receptor with diverse signalling molecules within the cell (Lefkowitz and 
Shenoy, 2005; Reiter and Lefkowitz, 2006) including members of the ERK-MAPK signal 
transduction pathway, such as the non-receptor tyrosine kinase Src (Luttrell et al., 1999). 
For some GPCRs, such as the angiotensin II type 1A receptor (AT1A), ERK1/2 activation 
has been demonstrated to occur via a G protein-independent pathway. In a study by Wei et 
al. (2003) β-arrestin was shown to act as a signal transducer entirely independent of G 
protein activation. Using a modified angiotensin II peptide ([Sar1,Ile4,Il8]-angiotensin II), 
which is unable to activate G protein, recruitment of β-arrestin 2 to the receptor led to 
activation of ERK1/2, although this was only to a level around 50 % of that achieved by 
wild-type angiotensin II (Wei et al., 2003). Further studies into ERK1/2 activation by 
angiotensin II (acting on the AT1A receptor) have demonstrated that activation of ERK1/2 
occurs in a biphasic manner, with a rapid and transient response mediated via G protein 
activation, and a slower, more prolonged response via β-arrestin activation (Ahn et al., 
2004). 
1.10.3.2 G protein-independent signalling of the GRLN-R 
In addition to signalling via activation of G proteins, the GRLN-R has also been 
demonstrated to signal through a G protein-independent pathway, mediated by β-arrestin 1 
and β-arrestin 2 (Camina et al., 2007). The activation of ERK1/2 occurs in a biphasic 
manner, with the rapid ERK stimulation occurring via a G protein-dependent mechanism 
(through the coupling to Gαq/11 and Gαi/o pathways), with the slower, persistant activation 
of ERK1/2 being dependent on both β-arrestin 1 and 2. It is thought that the β-arrestin-
dependent ERK1/2 activation occurs via a mechanism that involves entry of the GRLN-R 
into a multi-protein complex with Src-1, Raf-1, ERK1/2 and perhaps other components of 
the MAPK cascade (Camina et al., 2007). 
1.10.4 Desensitisation and endocytosis  
The signalling response mediated by receptor activation can be halted at the level of the 
receptor through the physical uncoupling of the receptor from the G protein, a process 
known as desensitisation. Desensitisation acts as a protective mechanism against receptor 
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over-stimulation allowing a fast attenuation (within seconds) of the signal after agonist 
exposure, allowing the cell to respond to several successive extracellular stimuli over time 
(Chuang et al., 1996). There are two mechanisms of desensitisation; heterologous and 
homologous desensitisation. 
Heterologous desensitisation occurs when an activated GPCR causes desensitisation of 
surrounding receptors. Binding of an agonist causes activation of second messenger 
kinases, for example, PKA and PKC. Once activated, PKA and PKC can phosphorylate 
serine and threonine residues in the C-terminal tail and ICL3 of GPCRs, resulting in a 40-
50 % loss of receptor function (Chuang et al., 1996). As they do not distinguish between 
activated and non-activated receptors, this can lead to the desensitisation of surrounding 
inactive receptors.  
In contrast to heterologous desensitisation, homologous desensitisation is the specific 
desensitisation of active receptor. Following activation, the receptor is phosphorylated at 
serine and threonine residues in the C-terminus and ICL3 either by second messengers 
produced via G protein activation (such as PKA and PKC) or by G protein receptor kinases 
(GRKs). GRKs are proteins that are recruited to the receptor after receptor activation, at 
least partly by dissociated Gβγ subunits (Kristiansen, 2004). GPCR phosphorylation causes 
minimal desensitisation, but increases the affinity of the receptor for the binding of 
cytosolic proteins named arrestins.  
There are two main classes of arrestins – the visual and cone arrestins and the β-arrestins 
(which are ubiquitously expressed outside the retina, with their highest expression in 
neuronal tissue and in the spleen; Attramadal et al., 1992). Phosphorylation of active 
receptor by GRKs causes arrestin translocation from the cytosol to the plasma membrane 
where arrestin binds to the receptor, physically uncoupling the G protein-receptor complex.  
Following desensitisation the receptor may become physically removed from the cell 
surface into intracellular membrane vesicles, a process known as endocytosis. The classical 
pathway in which an activated GPCR is endocytosed is through the formation of clathrin-
coated pits. β-arrestins 1 and 2 contain two recognition sites which allow them to link 
GPCRs with two components of the endocytic machinery; clathrin and the β2-adaptin 
subunit of the clathrin adapter protein 2 (AP-2) complex (Goodman, Jr et al., 1996; 
Laporte et al., 1999). The AP-2 complex also binds to clathrin and dynamin (Kirchhausen, 
1999). Dynamin is a GTPase that pinches off the vesicle to allow transport of the clathrin-
coated vesicle into the cytosol (Hinshaw and Schmid, 1995; Takei et al., 1996). Once 
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internalised a receptor can then either be recycled back to the cell surface or targeted to the 
lysosome for degradation.  
Interestingly, for the GRLN-R the process by which the receptor is internalised in response 
to ghrelin differs to that involved in the constitutive internalisation of the receptor.  
1.10.4.1 Ghrelin-mediated GRLN-R desensitisation and 
endocytosis 
The GRLN-R appears to undergo homologous desensitisation as, upon exposure to ghrelin, 
a rapid attenuation of the ghrelin response is observed, resulting from a combination of 
uncoupling of the receptor from G protein and internalisation of the receptor into 
intracellular compartments (Camina et al., 2006). Although there are several potential PKC 
phosphorylation sites in the C-terminal tail of the GRLN-R (see Figure 1-2), the 
homologous desensitisation of the GRLN-R does not appear to be mediated by PKC, as 
pre-treatment with the phorbol ester phorbal-12-myristate-13-acetate (PMA), which 
activates PKC, failed to reduce specific binding of [His[125I]]-ghrelin to the GRLN-R 
(which shows the receptor is still located at plasma membrane) (Camina et al., 2004). 
However PKC was shown to cause heterologous desensitisation of surrounding receptors 
susceptible to regulation by PKC, such as the lysophosphatidic acid (LPA) receptor 
(Camina et al., 2004).  
Two studies have suggested that ghrelin-activated GRLN-R is internalised principally by a 
clathrin-coated pit mechanism (Camina et al., 2004; Holliday et al., 2007). Ghrelin 
stimulation of the GRLN-R has been shown to cause receptor phosphorylation, recruiting 
β-arrestin 2 to the receptor. The receptor-β-arrestin 2 complex is then internalised via 
vesicles that co-localised with transferrin – a marker of clathrin-mediated endocytosis and 
recycling compartments. It appears that the clathrin-coated pits then become early 
endosomes by dropping their clathrin coat, as the GRLN-R co-localises with an early 
endosome marker ‘early endosome autoantigen 1’ (EEA1) (Camina et al., 2004) and the 
monomeric G protein Rab5a (which is essential for docking of EEA1 to the endosomal 
membrane; Patki et al., 1997; Simonsen et al., 1998; Mills et al., 1998; Christoforidis et al., 
1999). It is suggested that ghrelin then dissociates from the receptor in the acidified 
endosomal compartments where it is subsequently degraded by the lysosomes (Figure 1-5).   
Following internalisation, the GRLN-R appears to recycled back to the plasma membrane 
as, in one study, 360 min after ghrelin stimulation, in the presence of cyclohexamide 
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(which blocks de novo protein sysnthesis) the level of GRLN-R measured at the plasma 
membrane in radioligand binding studies was close to the level measured before ghrelin 
treatment (Camina et al., 2004). In support of this Holliday and colleagues demonstrated 
that the GRLN-R was found localised in Rab 11a-positive compartments, compartments 
that mediate slow recycling such as the perinuclear recycling compartment (PNRC) 
(Holliday et al., 2007).  
Receptor re-sensitisation determines the frequency of ghrelin response (Camina et al., 
2006). In a study by Camina et al. (2004) the maximal internalisation of the GRLN-R (in 
CHO and HEK293 cells transfected to express the GRLN-R) was observed within 20 min 
of the ghrelin stimulus whilst the whole recycling process was shown to take around 3-6 h. 
This fits in well with physiological studies, which have shown that growth hormone release 
in response to ghrelin is blunted if one pulse is given 60 min after an initial pulse, whereas 
the full GH response is seen if the pulses are separated by 180, 240 or 360 min (Tolle et al., 
2001).  
Depending on their association with β-arrestins, GPCRs can be classed into one of two 
classes; class A or class B. Class A receptors have a higher affinity for β-arrestin 2 than β-
arrestin 1; whereas class B receptors have equally affinity for β-arrestins 1 and 2 (Oakley 
et al., 2000). As class A receptors bind to β-arrestin 2 in a transient manner the receptor-β-
arrestin complex dissociates rapidly when the receptor is internalised (Pierce and 
Lefkowitz, 2001; Luttrell and Lefkowitz, 2002). In contrast class B receptors exhibit 
slower recycling kinetics as they form more stable receptor-β-arrestin complexes, resulting 
in internalisation of the whole complex into endosomes (Luttrell and Lefkowitz, 2002). 
Due to the extremely slow recycling kinetics of the GRLN-R compared to other GPCRs 
(Luttrell and Lefkowitz, 2002), it appears that the GRLN-R is internalised via a class B 
mechanism, however, this needs to be further explored. 
1.10.4.2 Constitutive GRLN-R endocytosis 
Although the ghrelin-induced internalisation of the GRLN-R was shown to be β-arrestin 2 
mediated, the constitutive internalisation of the GRLN-R persisted in the presence of a 
dominant negative version of β-arrestin that competes for interaction with clathrin 
(Holliday et al., 2007). Indeed constitutive internalisation of the GRLN-R was also 
detected in mouse embryonic fibroblasts that lack both β-arrestin 1 and 2 (Kohout et al., 
2001) that had been transfected with the GRLN-R (Holliday et al., 2007). However, 
constitutive internalisation of the GRLN-R was mediated through clathrin-coated pits (e.g. 
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the internalisation was dependent on both Rab 5 and Rab 11); thus it appears that the 
constitutive internalisation of the GRLN-R is β-arrestin-independent but may instead 
internalise through interaction with, for example, AP-2 (Holliday et al., 2007) (Figure 1-5). 
Indeed it is possible that AP-2 interacts directly with the GRLN-R, as the C-terminus of the 
GRLN-R contains a dileucine motif (LL) and a tyrosine-based motif (YRVAV) that can 
act as binding sites for AP-2 (Kirchausen et al., 1997; Holliday et al., 2007). 
Upon treatment for 15-30 min with the inverse agonist SPA, the constitutive internalisation 
of the GRLN-R was ablated (Holliday et al., 2007; Holst et al., 2004). This suggests that 
the constitutive internalisation of the GRLN-R occurs at a faster rate than the 3-6 h 
measured for the ghrelin-induced internalisation, although more studies are needed to 
compare both ligand-dependent and ligand-independent receptor internalisation within the 
same study.  
Interestingly, the C terminal tail of the GRLN-R has been shown to contain information 
that leads to the constitutive internalisation of the receptor. For example, Holliday and 
colleagues conducted a study with chimeric receptors, where the C terminal tail of the 
GRLN-R (from the NPXXY motif) was swapped with the C-terminal tail of the related 
(and constitutively active but not constitutively internalised) receptor GPR39 (and vice 
versa). Unlike the wild-type GRLN-R, which was predominantly located in intracellular 
regions of cells, the GRLN-R receptor with the C-terminal tail of GPR39 was localised 
primarily at the plasma membrane. The converse chimera (GPR39 with the GRLN-R C-
terminal tail) showed reduced cell surface expression, but receptor that did reach the 
surface was constitutively internalised (Holliday et al., 2007). For the GRLN-R, the 
constitutive activity of the receptor appears to be necessary but not sufficient for GRLN-R 
endocytosis, as blocking the constitutive activity of the GRLN-R with SPA leads to a 
redistribution of the GRLN-R to the plasma membrane. However in the GRLN-R receptor 
chimera with the GPR39 tail constitutive endocytosis is greatly reduced suggesting that 
other regulatory elements in the C terminus are also needed (Holliday et al., 2007). 
1.10.5 Constitutive activity 
1.10.5.1 Introduction to constitutive activity 
In 1989 Costa & Herz introduced the concept of constitutive activity (in which a receptor 
can form a spontaneously active conformation in the absence of ligand) after the discovery 
that the δ opioid receptor could signal in the absence of ligand (Costa and Herz, 1989). 
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Figure 1-5 – Endocytosis of the GRLN-R (adapted from Holliday et al., 2007). Endocytosis of 
the GRLN-R occurs via two distinct pathways. Ligand-dependent internalisation occurs via 
interaction of the activated receptor with β-arrestin-2 (and presumably AP-2). The receptor is 
internalised via clathrin-coated pits, which discard their clathrin coats to become early endosomes 
(as demonstrated by co-localisation with the early endosome markers EEA1 and Rab 5). It is 
thought that ghrelin dissociates from the receptor in the early endosomes and is subsequently 
degraded in lysosomes. The internalised GRLN-R is expected to be able to signal via G protein-
independent mechanism to activate the MAPK pathway. Receptor is then recycled back to the 
plasma membrane via recycling endosomes such as the peri-nuclear recycling compartment 
(PNRC) (where the GRLN-R co-localises with Rab 11). This cycle shows very slow kinetics (3-6 h), 
which suggests the receptor internalises via a class B mechanism. The constitutive internalisation 
of the GRLN-R does not require β-arrestins. Instead it has been suggested that AP-2 can bind to 
the C-terminus of the GRLN-R to internalise the GRLN-R via a clathrin-coated pit-mediated 
mechanism. Once again the clathrin-coated pits are expected to become early endosomes by 
shedding their clathrin coat and the receptor is recycled back to the plasma membrane via a Rab 
11-positive compartment. The constitutive internalisation and recycling of the GRLN-R appears to 
be much faster (15-30 min) than the ligand-induced internalisation/recycling of the GRLN-R.  
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Since then many GPCRs, across all classes have been shown to be constitutively active 
including the class A β2AR (Milano et al., 1994); the class B calcitonin receptor (Cohen et 
al., 1997) and the class C metabotropic glutamate receptors (Prezeau et al., 1996). 
Naturally occurring mutations in receptors that cause ligand-independent activation have 
also been identified and linked to diseases such as congenital night blindness (in the case 
of the rhodopsin receptor; Rao et al., 1994). Indeed there is reason to believe that a degree 
of constitutive activity occurs in all GPCRs (the one exception being the highly-specialised 
rhodopsin receptor) (Bond and Ijzerman, 2006).  
The methods used to study constitutive activity rely heavily on in vitro studies, which may 
lead to over-expression of the receptor and, consequently, constitutive receptor activity 
may be an artefact of the expression system (Seifert and Wenzel-Seifert, 2002). 
Nevertheless, studies of GPCRs in native systems (e.g. the β2AR in turkey erythrocyte 
membranes; Mewes et al., 1993) and intact organs (β2AR in normal heart tissue; Varma et 
al., 1999) have clearly demonstrated that constitutive activity occurs in native systems.  
1.10.5.2 Receptor activation models and receptor theory 
Various models have been proposed and modified to explain the activation of GPCRs as 
our knowledge of receptor activation has expanded (Rang, 2006). One of the simplest 
models is the two-state model, which states that a receptor exists in equilibrium between an 
inactive (Ri) and an active (Ra) state. In the absence of agonist, the majority of receptor 
exists as Ri, whilst binding of an agonist alters the equilibrium to favour formation of Ra. 
To incorporate binding of G protein, the extended ternary complex model was formed  
(Figure 1-6; Samama et al., 1993), which takes into account the interactions between 
receptor and G protein in addition to interactions between receptor and agonist, thus 
allowing a receptor to form a Ra state that can couple to G protein (and transduce a signal) 
in the absence of agonist (i.e. it incorporates constitutive receptor activation).  
Ligands acting on GPCRs can be characterised by the nature of their effects, governed by 
affinity (how tightly a ligand binds to a receptor) and efficacy (the ability of a ligand, once 
bound, to elicit a response) (Kenakin, 2001). Thus ligands can be classified as agonists 
(full or partial), inverse agonists (full or partial) or antagonists. A full agonist (which 
displays high affinity for the Ra state) is able to produce a system maximal response, 
whereas a partial agonist would produce a measurable but submaximal response. An 
inverse agonist has higher affinity for the Ri state rather than Ra, thus it favours formation 
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Figure 1-6 – The extended ternary complex model. The model describes the spontaneous 
formation of an active receptor state (Ra) from inactive receptor (Ri) according to the allosteric 
constant L. The active receptor can form a complex with G protein spontaneously (RaG) or after 
agonist (A) activation (ARaG). KA and KG are the equilibrium dissociation constants of the ligand-
receptor and G protein-receptor complexes, respectively. The term α refers to differences in affinity 
for a ligand for Ra over Ri, whilst γ denotes the multiple differences in affinity of the receptor for G 
protein when ligand is bound to receptor. 
 
of Ri, blocking constitutive receptor activation. Like agonists, inverse agonists can be 
classed either as full inverse agonists (fully able to block constitutive activity) or as partial 
inverse agonists (those which only partially block constitutive activity). An antagonist is a 
ligand which has equal affinity for Ri and Ra, thus it produces no change in the equilibrium 
between Ri and Ra (i.e. it has no efficacy), but can block the actions of an agonist either 
reversibly (a competitive antagonist) or irreversibly (non-competitive antagonist).  
1.10.5.3 Constitutive activity of the GRLN-R 
Before 2003 the majority of studies into the pharmacology of the GRLN-R focused on 
measuring calcium mobilisation as a read-out of receptor activation. In this assay the 
GRLN-R appeared to be devoid of any constitutive activity. However, in 2003 Holst and 
colleagues discovered that the GRLN-R was constitutively active in inositol phosphate 
accumulation assays (i.e. via activation of the Gαq/11 pathway) and in assays measuring 
cAMP-responsive element (CRE) binding protein phosphorylation (which measures 
activation of both the Gαq/11 and Gαs pathways) (Holst et al., 2003). Thus the lack of 
constitutive activity of the GRLN-R in the calcium mobilisation assays appeared to be due 
to the fact that calcium has to be kept within strict margins within cells (Holst et al., 2003). 
A year after the first reports of the constitutive activity of the GRLN-R, constitutive 
activity of the GRLN-R was also measured in the serum-response element-mediated 
transcription pathway, a pathway which is expected to be activated by Gα13 for the GRLN-
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R (Holst et al., 2004) (but may also be activated by Gαi or Gβγ; Mao et al., 1998; 
Ponimaskin et al., 2002; Gruijthuijsen et al., 2002; Niu et al., 2003).  
To investigate whether the receptor was truly constitutively active, gene-dosing 
experiments were performed showing that constitutive CRE-binding protein 
phosphorylation increased in COS-7 cells as GRLN-R cDNA was increased; although the 
same was not true for the motilin receptor, GPR38, in which the basal activity of the 
receptor remained the same (Holst et al., 2004). This clearly demonstrated that the 
constitutive activity of the GRLN-R was not an artefact of receptor over-expression. 
Furthermore as downregulation of CRE-mediated gene transcription was shown to be a 
major signal transduction pathway for the effects of the anoretic hormone leptin in 
NPY/AGRP-containing neurones in vivo, it suggests that constitutive activation of CRE-
mediated gene transcription by the GRLN-R (Shimizu-Albergine et al., 2001) played an 
important role in appetite regulation (Holst & Schwartz, 2004).  
Generally it is very difficult to determine the in vivo physiological importance of 
constitutive activity (Holst et al., 2003). However, rather interestingly, analyses of 
naturally occurring missense mutations at the GRLN-R (which ablate the ligand-
independent activity of the GRLN-R) have been associated with the development of an 
obese/short stature phenotype in vivo (Wang et al., 2004; Pantel et al., 2006), thus 
demonstrating that constitutive activity appears to serve an important function in vivo. 
Whilst the finding that a high level of GH secretion could be measured in isolated pituitary 
cells that express the GRLN-R (Cervia et al., 2002) which, as cultured isolated cells should 
mean they are devoid of any hormonal tone, suggests the GH release is being mediated via 
the constitutive activity of the GRLN-R and this likely occurs in vivo.  
It is worth noting that the GRLN-R does not appear to display any constitutive 
activity/constitutive internalisation when expressed in CHO cells (i.e Camina et al., 2004; 
Camina et al., 2006). This appears to be a cell-specific effect as constitutive activity has 
been measured in other recombinant expression systems such as HEK293 cells (Holliday et 
al., 2007) and COS-7 cells (Holst et al., 2003; Holst et al., 2004) and may reflect the 
absence of machinery required for signal generation or receptor internalisation. 
Furthermore the GRLN-R does not appear to constitutively activate the MAPK pathway 
(as measured through ERK1/2 phosphoryation) (Holst et al., 2004). The reason for this is 
not clear as constitutive activation of the MAPK pathway can be measured for other 
constitutively active receptors, such as the virally encoded receptor ORF-74 (Smit et al., 
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2002). On the other hand, other regulatory mechanisms may be in place to stop excessive 
ERK activation, regulating constitutive signalling of the GRLN-R. 
1.10.6 Allosterism 
1.10.6.1 Introduction to allosterism 
The primary binding site for the endogenous ligand on a GPCR is termed the orthosteric 
site, however ligands may also bind to a topographically distinct site on the receptor; a site 
termed the allosteric site. Although allosteric modulators (ligands that bind to the allosteric 
site) are well established as research tools and therapeutic agents of ion channels, they 
have not been a traditional focus of drug discovery efforts of GPCRs (Conn et al., 2009). 
Recently the potential of allosteric modulators as therapeutic targets of GPCRs has been 
proven with two allosteric modulators entering the market, cinacalcet, a modulator of the 
calcium-sensing receptor (Harrington and Fotsch, 2007) and maraviroc, a modulator of the 
chemokine receptor CCR5 (Dorr et al., 2005). 
Allosteric modulators can act to modify the affinity of the orthosteric ligand for a receptor 
and/or modulate the efficacy of orthosteric ligands. For example, when both the orthosteric 
and allosteric sites are occupied by ligand, an allosteric interaction between the sites occurs 
allowing the allosteric modulator to increase or decrease the affinity of the orthosteric 
ligand for the receptor (i.e. the allosteric modulator shows positive or negative co-
operativity, respectively). An allosteric effect on efficacy can be shown as changes in the 
potency and/or efficacy of the orthosteric ligand, as demonstrated by the action of the 
allosteric modulator CGP7930, which enhances both the potency and efficacy of GABA at 
the GABAB receptor (Urwyler et al., 2001).  
In addition, ‘allosteric agonists’ have also been identified, which are ligands that express 
the property of agonism in the absence of bound orthosteric ligand (May et al., 2007). This 
was first demonstrated for the adenosine A1 receptor, where the allosteric modulator PD 
81723 was shown to be able to activate the Gαi/o pathway on its own but it was also shown 
to enhance the binding of the orthosteric radioligand [3H]-cyclohexyladenosine when both 
ligands were present (Bruns and Fergus, 1990). 
1.10.6.2 Detecting an allosteric effect 
Ideally to confirm an allosteric mode of action three criteria need to be met. Firstly, the co-
operativity between an allosteric ligand and an orthosteric ligand means that allosteric 
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interactions are proposed to have a saturable or ‘ceiling’effect; whereby increasing 
concentrations of the allosteric modulator fail to shift the concentration-response curve of 
the orthosteric ligand any further. Thus one of the characteristics of an allosteric interaction 
is that there is saturability in effect. Secondly, allosteric effects are predicted to show 
‘probe-dependence’. This is because co-operativity can change with each ligand so that an 
allosteric modulator can inhibit the binding of one orthosteric ligand whilst having no 
effect on a second orthosteric ligand (Leach et al., 2007). This has been demonstrated for 
the chemokine receptor CCR5 where the allosteric modulator GSK873140 creates a 
receptor conformation that inhibits binding of the orthosteric ligand CCL3 without 
affecting binding of a second orthosteric ligand CCL5 (Watson et al., 2005). Thirdly, as 
dissociation of the orthosteric ligand is altered by the presence of an allosteric ligand (the 
binding of an allosteric modulator to a GPCR causes a conformational change that alters 
association or dissociation rate constants that govern binding of the orthosteric ligand) an 
alteration in the kinetics of binding of an orthosteric probe to the receptor in the presence 
of an allosteric modulator can be used as a determination of an allosteric effect. 
1.10.6.3 Allosteric modulation of the GRLN-R 
Holst and colleagues have suggested that L-692,429 and GHRP-6 are allosteric agonists of 
the GRLN-R, as co-administration of ghrelin with either L-692,429 or GHRP-6 acted to 
increase or decrease the potency of ghrelin as well as acting to increase the efficacy of 
ghrelin. However co-administration of ghrelin with MK-677 had no effect on the potency 
of ghrelin although MK-677 acted to increase the efficacy of ghrelin (Holst et al., 2005). 
Both GHRP-6 and L-692,429 failed to fully compete with binding of the orthosteric probe 
[His[125I]]-ghrelin which suggested that these compounds were binding at a site on the 
receptor distinct from ghrelin, whereas MK-677 could fully compete for ghrelin binding 
(suggesting that MK-677 was a simple orthosteric ligand). Thus L-692,429 and GHRP-6 
were termed ‘ago-allosteric modulators’; a term coined to describe ligands that function 
both as agonists and as allosteric modulators of the potency and/or efficacy of the 
orthosteric ligand (Schwartz and Holst, 2006). Although in the study by Holst et al. (2005) 
none of the three hallmarks of an allosteric effect were investigated thoroughly. 
However, allosteric modulation of the GRLN-R by L-692,429 and GHRP-6 is complicated 
by the finding that these ligands share an overlapping binding site with ghrelin on the 
receptor. Thus to account for this observation the GRLN-R was proposed to exist as a 
dimer where ghrelin could bind to one protomer of the dimer leaving the second protomer 
free to bind GHRP-6 or L-692,429 whereby they could exert their allosteric effects (Holst 
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et al., 2005). This model also allows MK-677 to co-bind with ghrelin accounting for the 
increase in efficacy of ghrelin in the presence of MK-677 (in the absence of any allosteric 
effects). Allosterism across a dimer has been demonstrated for the chemokine receptors. 
Using a hetero-dimer formed by CCR2 and CCR5, dissociation of [125I]MCP-1 from CCR2 
was shown to be strongly increased by the presence of unlabelled MIP-1β, a ligand for 
CCR5, suggesting that ligand binding in one monomer induced a conformational change in 
the partner, resulting in faster dissociation of the bound ligand (Springael et al., 2006).  
1.11 Project aims 
The GRLN-R has become an attractive therapeutic target, mainly due to its effects in 
stimulating GH release and its role in the regulation of appetite and energy homeostasis. 
Although the signalling of the GRLN-R through the activation of the Gαq/11 pathway is 
well studied there is a lack of information about the signalling of the receptor through other 
pathways, such as Gαi/o.  
The aim of this project was to investigate activation of the Gαi/o pathway in a heterologous 
system. Specifically to: 
1. Further investigate ago-allosteric modulation of the GRLN-R in the Gαi/o pathway. 
2. Compare the signalling of the GRLN-R through activation of the Gαq/11 pathway 
and the Gαi/o pathway to see if there is any difference in the potencies and/or 
efficacies of ghrelin and the growth hormone secretagogues in these pathways 
3. Investigate whether naturally occurring mutations of the GRLN-R (A204E and 
I134T) affect the function of the GRLN-R through both the Gαq/11 and Gαi/o 
pathways. 
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2 Materials and methods 
2.1 General reagents, enzymes and kits 
Alpha Biotech Ltd., London, UK 
GF/C Glass fibre filters 
BDH, Lutterworth, Leicestershire, UK 
22 mm coverslips, acetic acid, formaldehyde, methanol, microscope slides, KOH, sodium 
formate 
Biorad, Hemel Hempstead, UK 
1 x 8 formate form 200-400 mesh size Dowex resin 
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK 
CaCl2, D-glucose, ethanol, ethylene glycol, isopropranolol, glacial acetic acid, glycerol, 
glycine, 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), KCl, KH2PO4, 
methanol, 3-(N-Morpholino)propanesulfonic acid (MOPS), NaCl, sodium dodecyl sulphate 
(SDS), sucrose, MnCl2. 
Flowgen Biosciences Ltd., Nottingham, UK 
Agarose 
GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, UK 
Full range Rainbow™ molecular weight markers, protein G, wheat germ agglutinin 
(WGA)-polystyrene LEADseeker imaging beads  
Greiner Bio-One Ltd., Stonehouse, UK 
96 deepwell blocks 
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Invitrogen Ltd., Paisley, UK 
ER-Tracker™ red (glibenclamide BODIPY® TR), NuPage Novex pre-cast 4-12 % Bis-
Tris gels, NuPage MOPS SDS running buffer, WGA-Alexa Fluor® 594 conjugate 
Konica Europe, Hohenbrunn, Germany 
X-ray film 
Merck Chemicals Ltd., Beeston, Nottingham, UK 
Luria-Bertani (LB)-agar, LB-bouillon, nonident P-40 (NP-40), pansorbin beads  
Perkin Elmer Life and Analytical Science, Boston, MA 
AlphaScreen cAMP assay kit, Ultima Gold XR liquid scintillation cocktail, Unifilter® 96 
well GF/B filter block  
Perbio Science UK Ltd., Cramlington, Northumberland, UK 
Supersignal West Pico chemiluminescent substrate (ECL) 
Promega UK Ltd., Southampton, UK 
All restriction endonucleases, T4 DNA ligase, Pfu DNA polymerase, Wizard™ Plus SV 
miniprep kit 
Qiagen, Crawley, West Sussex, UK 
QiaQuick PCR purification kit, QiaQuick gel extraction kit, Qiafilter maxi-prep kit 
Roche Diagnostics Ltd., Lewes, East Sussex, UK 
Complete EDTA-free protease inhibitor tablets, DNA molecular weight marker X, Endo-β-
acetylglucosaminidase H (Endo H), peptide-N4-(acetyl-β-glucosaminyl)-asparagine 
amidase (PNGaseF) 
 
Kirstie Ann Bennett, 2009  Chapter 2, 70 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
Ammonium formate, ampicillin, ascorbic acid, BCA solution A, bromophenol blue, bovine 
serum albumin (BSA), deoxycholic acid (sodium salt), CHAPS (3-[(3-Cholamidopropyl) 
dimethylammonio]-1-propanesulfonate hydrate), dimethyl sulfoxide (DMSO), 
dithiothreitol (DTT), ethylenediaminetetraacetic acid (EDTA), ethylene glycol-O,O’-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), ethidium bromide, ethylene glycol, 
Ficoll, forskolin, guanine diphosphate (GDP), glycerol, guanine triphosphate (GTP), 
guanosine 5’-O-(3-thio)-triphosphate (GTPγS), HCl, 3-isobutyl-1-methylxanthine (IBMX), 
lithium chloride, MgCl2, orange G, perchloric acid, polyethylenimine (PEI), pluronic F-
127, RbCl2, Na2HPO4, di-sodium orthophosphate, di-sodium tetraborate, sodium acetate, 
sodium azide, NaCl, NaH2PO4, NaOH, Triton X-100, Tween-20, Tris-base, xylene cyanol.  
Stratagene, Amsterdam, The Netherlands 
QuikChange® site directed mutagenesis kit 
 
Thermo Electron, Ulm, Germany 
Immu-mount, all oligonucleotides used for PCR reactions  
Whatman International Ltd., Maidstone, UK 
Protran® nitrocellulose transfer membrane 
2.2 Antibodies and antisera 
Abcam, Cambridge, Cambridgeshire, UK 
Rabbit anti-calnexin polyclonal antibody 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
Donkey anti-mouse IgG-horse radish peroxidase (HRP) conjugate, donkey anti-rabbit IgG-
HRP conjugate 
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Roche Diagnostics Ltd., Lewes, East Sussex, UK 
Monoclonal mouse anti-haemagglutinin (HA) antibody (clone 12CA5), anti-vesicular 
stomatitis virus glycoprotein (VSV-G) antibody 
GFP antisera and all G protein antisera were produced in-house. G protein antisera were 
raised against peptides based on the last 10 amino acids of the C-terminal tail. 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
Rabbit anti-goat IgG-HRP conjugate, rabbit anti-GFP N-terminus antibody. 
2.3 Pharmacological compounds 
Bachem (UK) Ltd., St. Helens, Merseyside, UK 
Ghrelin (human), [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance P (SPA), (amino acid 
sequence: His-D-Arg-Pro-Lys-Pro-D-Phe-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2) 
GlaxoSmithKline, Harlow, Essex, UK 
MK-677 (systemic name: 2-Amino-2-methyl-N-[1-(1-methylsulfonylspiro[2H-indole-3,4'-
piperidine]-1'-yl)-1-oxo-3-(phenylmethoxy)propan-2-yl]propanamide) was kindly supplied 
by Alan Wise 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
Growth hormone releasing peptide-6 (GHRP-6) (amino acid sequence: His-D-Trp-Ala-
Trp-D-Phe-Lys-NH2) 
Tocris, Avonmouth, Bristol, UK 
L-692,585 (systemic name: 3-[[(2R)-2-Hydroxypropyl]amino]-3-methyl-N-[(3R)-2,3,4, 5-
tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3-
yl]-butanamide) 
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2.4 Radiochemicals  
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
[35S]GTPγS, [3H]myo-inositol 
Perkin Elmer life and analytical science, Boston, MA 
[His[125I]]-ghrelin 
2.5 Tissue culture disposables and reagents 
American Tissue Culture Collection, Rockville, USA 
HEK293T cells 
Clontech, Saint-Germain-en-Laye, France 
pECFP-N1 vector 
Costar, Cambridge, MA., USA 
5 mL, 10 mL and 25 mL pipettes, 25 cm2, 75 cm2 and 125 cm2 vented tissue culture flasks, 
6 well plates, 10 cm2 dishes 
Invitrogen BV, Groningen, The Netherlands 
Blasticidin, Dulbecco's modified Eagle's medium (DMEM) (- sodium pyruvate), Flp-In T-
REx HEK293 cell line, foetal bovine serum (FBS), L-glutamine (200 mM), Hank’s 
buffered saline solution (HBSS), Lipofectamine transfection reagent, minimal essential 
medium (MEM) non-essential amino acids, new born calf serum (NBCS), optimem, 100 x 
penicillin-streptomycin mix, Versene, zeocin 
Roche Applied Science, Lewes, East Sussex, UK 
Hygromycin B 
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Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
DMEM (- sodium pyruvate, + L-glutamine, + 4.5 g/L glucose) 0.25 % trypsin-EDTA, 
pertussis toxin, poly-D-lysine  
2.6 Buffers and solutions  
2.6.1 Molecular biology buffers and solutions 
Buffer 1 (for the preparation of competent bacteria) 
30 mM potassium acetate, 0.1 M RbCl2, 10 mM CaCl2, 50 mM MnCl2 and 15 %(w/v) 
glycerol; pH 5.8. The solution was filter sterilised (through a 0.2 µm filter) and stored at 4 
°C. 
Buffer 2 (for the preparation of competent bacteria) 
10 mM MOPS (pH 6.5), 75 mM CaCl2, 10 mM RbCl2, 15 %(w/v) glycerol; pH 6.5. The 
solution was filter sterilised (through a 0.2µM filter) and stored at 4 °C. 
DNA loading buffer (3 x) 
15 %(w/v) Ficoll (dissolved in H2O and autoclaved), 200 µL saturated bromophenol blue, 
200 µL saturated orange G, 25 µL saturated xylene cyanosol. 
Laemmli buffer (5 x) 
0.4 M DTT, 0.17 M SDS, 50 mM Tris-base, 5 M urea, 0.01 %(w/v) bromophenol blue. 
Buffer was stored at –20 ºC. 
Phosphate buffered saline (PBS) (10 x) 
137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 10.2 mM Na2HPO4; pH 7.4. 1 x PBS was 
prepared by diluting the stock 1:10 in H2O. 
20 % Pluronic F-127 
A 20 %(w/v) solution was prepared by dissolving pluronic F-127 in DMSO at 37 °C. 
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Tris acetate-EDTA (TAE) buffer (50 x) 
40 mM Tris-base, 1 mM EDTA (pH 8), 5.71 %(v/v) glacial acetic acid. 1 x TAE was 
prepared by diluting 1:50 prior to use. 
Tris-EDTA (TE) buffer 
10 mM Tris-base, 0.1 mM EDTA; pH7.4. Buffer was stored at 4 °C.  
2.7 Molecular biology protocols 
2.7.1 Preparation of LB plates 
LB-agar was prepared as per manufacturer’s instructions. The solution was autoclaved and 
allowed to cool to 50 °C before addition of the appropriate antibiotic: ampicillin (final 
concentration 50 µg/mL for pcDNA3, pcDNA3.1, pcDNA5 and pOG44 vectors; 
Invitrogen) or kanamycin (final concentration 30 µg/mL for pECFP-N1 vector; Clontech). 
The medium was gently mixed to ensure antibiotic was distributed equally before 
approximately 25 mL was poured into a Petri dish. The plates were left to set at room 
temperature before storage at 4 °C. Unused plates were discarded after 1 month.  
2.7.2 Preparation of competent bacterial cells 
XL1 blue cells (a strain of Escherichia coli) were streaked out onto an LB agar plate (in 
the absence of antibiotics) and incubated for 16 h (37 °C). A single colony was used to 
inoculate a 5 mL culture of LB media, which was incubated for 16 h in a shaking incubator 
(37 °C). This culture was added to 100 mL of LB media and grown in a shaking incubator 
(37 °C) until the optical density of 0.48 at 550 nm was reached. The culture was chilled on 
ice for 5 min, then centrifuged in sterile falcon tubes (3220 x g; 10 min; 4 °C) to pellet the 
bacteria. The supernatant was removed and the pellet re-suspended in 20 mL of competent 
bacteria buffer 1. The suspension was incubated on ice for 5 min prior to centrifugation 
(3220 x g; 10 min; 4 °C). The supernatant was carefully removed and the pellet re-
suspended in 2 mL of competent bacteria buffer 2. After incubation on ice for 15 min the 
competent bacteria were aliquoted into sterile Eppendorf tubes and stored at –80 °C. 
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2.7.3 Transformation of competent bacteria 
An aliquot of competent bacteria was allowed to thaw on ice; 1-10 ng of DNA was 
incubated with 50 µL of competent bacteria (15 min; 4 ºC). The bacteria were subjected to 
heat-shock (90 s; 42 ºC) and returned to ice for 2 min before the addition of 450 µL of LB 
medium. The cells were incubated in a shaking incubator (45 min; 37 ºC) to allow 
recovery. 100 µL of the reaction was spread onto an LB plate containing the appropriate 
antibiotic and incubated inverted overnight at 37 oC.  
2.7.4 Preparation of plasmid DNA  
2.7.4.1 Mini preps 
DNA was purified using Wizard™ Plus SV miniprep kit. 1.5 mL of a bacterial culture was 
pelleted by centrifugation (16,000 x g; 5 min) and subsequently resuspended in 250 µL of 
re-suspension buffer (50 mM Tris-HCl, 10 mM EDTA, 100 µg/mL RNase A; pH 7.5) by 
gentle pipetting. Cells were lysed by addition of 250 µL of lysis buffer (200 mM NaOH, 1 
%(w/v) SDS) and 10 µL alkaline phosphatase. Lysis was terminated after 5 min by the 
addition of 350 µL of neutralisation buffer (4.09 M guanidine hydrochloride, 0.76 M 
potassium acetate, 2.12 M glacial acetic acid; pH 4.2). The cell lysates were centrifuged 
(16,000 x g; 10 min) and the supernatant loaded onto miniprep columns. The columns were 
centrifuged (16,000 x g; 1 min) and washed twice with 750 µL wash buffer (60 mM 
potassium acetate, 10 mM Tris, 60 %(v/v) ethanol; pH 7.4). After washing, bound DNA was 
eluted from the column by addition of 100 µL sterile water by centrifugation (16,000 x g; 1 
min) into sterile 1.5 mL Eppendorf tubes. 
2.7.4.2 Maxi preps 
The Qiagen Qiafilter kit was used to produce larger scale DNA samples. A 100 mL culture 
of transformed bacteria was pelleted by centrifugation (3220 x g ; 30 min; 4 oC). Media 
was carefully removed and the pellet resuspended in 10 mL of chilled buffer P1 (50 mM 
Tris-HCL, 10 mM EDTA, 100 µg/µL RNase A; pH 8.0). Cells were lysed at room 
temperature by the addition of 10 mL buffer P2 (200 mM NaOH, 1 %(w/v) SDS). After 10 
min incubation cell lysis was stopped and the solution neutralised by the addition of 10 mL 
of buffer P3 (3 M potassium acetate; pH 5.5). The solution was applied to a QIAfilter 
cartridge and left for 10 min at room temperature to settle. Meanwhile, a Qiagen tip 500 
was equilibrated by the addition of buffer QBT (750 mM NaCl, 50 mM MOPS, 15 %(v/v) 
isopropanol; pH 7.0). After 10 min the cell solution was added onto the equilibrated tip and 
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allowed to drain by gravity flow. The column was washed with 60 mL of buffer QC (1 M 
NaCl, 50 mM MOPS, 15 %(v/v) isopropanol; pH 7.0) and the DNA eluted by the addition of 
15 mL of buffer QF (1.25 M NaCl, 50 mM Tris-HCl, 15 %(v/v) isopropanol; pH 8.5). The 
DNA was precipitated by the addition of 10.5 mL isopropranol and pelleted by 
centrifugation (12,000 x g; 30 min; 4 ºC). The DNA pellet was washed with 5 mL of room 
temperature 70 %(v/v) ethanol and then centrifuged (12,000 x g; 15 min; 4 oC). The 
supernatant was carefully removed and the pellet allowed to air-dry prior to re-suspension 
in 1 mL of sterile H2O. 
2.7.5 Quantification of DNA 
Quantification of DNA samples was performed by examining the absorbance of a 1:100 
dilution of the sample at 260 nm. An A260 value of 1 unit was taken to correspond to 50 
µg/mL of double stranded DNA. The A280 value of sample was also measured to assess the 
purity of the DNA solution. A DNA solution with A260/A280 ratio of between 1.7 and 2.0 
was considered pure enough for use.  
2.7.6 DNA digestion with restriction endonucleases 
Digests were prepared using the appropriate restriction enzyme (1-2 units), buffer (as 
specified by the manufacturer), and DNA, in a final volume of 20 µL. Control reactions 
were carried out using 1 µg DNA and preparative reactions (i.e. to prepare an insert for 
ligation) were carried out using 5 µg DNA. Reactions were incubated at 37 oC for a 
minimum of 2 h.  
2.7.7 DNA gel electrophoresis 
Digested DNA samples or PCR reactions were examined using gel electrophoresis. 
Samples were diluted in 3x DNA loading buffer. A 1 %(w/v) agarose gel in 1x TAE was 
prepared; the mixture was gently heated to allow the agarose to fully dissolve before the 
addition of 2.5 mg/mL ethidium bromide. The mixture was poured into a horizontal gel 
tank and once set, immersed in 1x TAE. Samples were loaded and the gels run at 75 mA 
for 20-30 min. The DNA fragments were visualised using ultraviolet light. The size of each 
fragment was assessed by comparison with DNA molecular marker X. 
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2.7.8 DNA purification from agarose gels 
The DNA fragments of interest were excised from the DNA electrophoresis gel and 
purified using the QiaQuick gel extraction kit as per the manufacturer’s instructions. DNA 
was eluted from the purification column using 30 µL sterile H2O. 
2.7.9 Ligation of DNA 
Digested PCR fragments were ligated into plasmid vector using T4 DNA ligase. A ratio of 
1:3 and 1:6 vector to PCR product was incubated (16 h, 4 °C) with 1 unit of ligase and 1 
µL 10 x ligase buffer, in a final volume of 10 µL. The ligation reactions were transformed 
as detailed in section 2.7.3. 
2.7.10 Polymerase chain reaction 
2.7.10.1 Standard PCR 
The polymerase chain reaction (PCR) was used to amplify specific sections of DNA and 
introduce epitope tags and/or restriction sites. Pfu DNA polymerase was selected for its 
proofreading ability. All reactions were performed using sterile materials. The PCR 
reactions were set up as follows:  
Pfu polymerase buffer (10 x)    5 µL 
DMSO (optional)     5 µL 
Deoxynucleotide tri-phosphates (dNTPs)  5 µL 
(0.25 mM of each dATP, dCTP, dGTP, dTTP) 
Primer sense: 25 pmol/µL     1 µL 
Primer antisense: 25 pmol/µL    1 µL 
DNA template: 50 ng/µL    1 µL 
Pfu enzyme: 1 unit     1 µL 
dH2O to a final volume of     50 µL 
Reactions were carried out on an Eppendorf gradient Thermocycler. PCR cycles used were 
as follows (annealing temperatures were dependent on the melting temperatures [Tm] of 
the primers used):  
1. Preheating   95 oC  5 min 
2. Denaturation   95 oC  1 min 
3. Annealing   50-60 oC  1 min 
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4. Extension   72 oC  3 min 
5.  Repeat from step 2.     29 times 
6. Final extension  72 oC  10 min 
7. Hold    4 oC 
2.7.10.2 QuikChange mutagenesis PCR 
The QuikChange site-directed mutagenesis method was used to make single point 
mutations in GRLN-R. Primer design and PCR conditions were performed according to the 
manufacturer’s instructions.  
PCR reactions were carried out using with the following components: 50 ng DNA 
template, 15 pM of both forward and reverse primers, a final concentration of 10 µM 
dNTP mix and 1 µL (2.5 U) Pfu DNA polymerase to a total volume of 50 µL with reaction 
buffer. Samples were cycled 30 times in an Eppendorf Thermocycler system under the 
following conditions:  
 Cycle 1:  95 oC for 30 secs 
 Cycles 2-30:  95 oC for 30 secs,  
50 oC for 1 min  
68 oC for 7 min 
The product was incubated with 1 µL (10 U) DpnI restriction enzyme (60 min; 37 oC) to 
allow the digestion of parental methylated dsDNA. The digested mutated DNA and 
appropriate controls were then transformed into XL1 blue cells following the protocol 
described in section 2.7.3 
2.7.11 PCR purification 
PCR products were purified using the QiaQuick PCR purification kit as per manufacturer’s 
instructions. DNA was eluted from the purification column using 30 µL of sterile H2O. 
2.7.12 DNA sequencing 
DNA sequencing was performed by ‘The Sequencing Service’ (School of Life Sciences, 
University of Dundee, Scotland) using Applied Biosystems Big-Dye Ver 3.1 chemistry on 
an Applied Biosystems model 3730 automated capillary DNA sequencer. Sequences 
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obtained were compared with the sequence of the human GRLN-R (accession number 
Q92847). 
2.7.13 Generation of the VSV-G-GRLN-R-eCFP construct 
To generate the VSV-G-GRLN-R-eCFP construct, primers were designed to add 
restriction sites to GRLN-R, a vesicular stomatitis virus (VSV-G) tag at the N-terminus 
and to remove the stop codon at the C-terminus. Human GRLN-R cDNA in pcDNA3.1 
was supplied by GlaxoSmithKline. 
Sense primer to add a VSV-G tag and HindIII site:  
5’-
CCTCACCTAAGCTTGCCACCATGTACACCGACATCGAAATGAACCGCCTTGGT
AAGTGGAACGCGACGCCCAGCGAAGAG-3’ 
Anti-sense primer to add a KpnI site and remove the stop codon: 
5’-GTATGCGATGGTACCTGTATTAATACTAGATTCTGTCCA-3’ 
The HindIII and KpnI sites are shown in bold italics; the VSV-G tag is underlined. A 
vector (pcDNA3) containing eCFP between KpnI and NotI sites and the amplified DNA 
fragment were both sequentially digested with HindIII and KpnI. The amplified fragment 
was then ligated into the pcDNA3-eCFP vector in frame with eCFP. 
2.7.14 Generation of the HA-GRLN-R-A204E-eCFP constuct 
Primers were designed to alter a single base to change A204 to E204 using the Qiagen 
QuikChange mutagenesis kit (using the conditions described in section 2.7.10.2) with 
GRLN-R-pcDNA3.1 vector as a template. 
Sense 5’- CACCGAGTTTGAGGTGCGCTCTG – 3’ 
Anti-sense 5’ – CAGAGCGCACCTCAAACTCGGTG – 3’ 
The altered base is shown in bold. The template was digested with DpnI to leave mutated 
plasmid. Sequencing was used to confirm the introduction of the mutation. 
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Primers were then used to add N- and C-terminal restriction sites, a HA tag at the N-
terminus and to remove the STOP codon at the C terminus of GRLN-R-A204E-pcDNA3.1.  
Sense primer to add a HA tag and a HindIII site – 
 5’ - 
CCTCACCTAAGCTTGCCACCATGTATCCTTACGACGTTCCTGACTACGCATGGA
ACGCGACGCCCAGCGAAGAG – 3’ 
Anti-sense to add KpnI site and remove the stop codon 
5’ – GTATGCGATGGTACCTGTATTAATACTAGATTCTGTCCA – 3’ 
The HindIII and KpnI sites are shown in bold italics; the HA tag is underlined. The 
amplified fragment and vector containing eCFP (pECFP-N1) were sequentially digested 
with HindIII and KpnI. The fragment was ligated in-frame with eCFP and transformed into 
competent XL1-Blue bacteria. Colonies were picked and the sequences of positive clones 
were verified using DNA sequencing. 
2.7.15 Generation of the HA-GRLN-R-I134T-eCFP construct 
The GRLN-R-I134T mutation was performed using a standard PCR-based mutagenesis 
technique. Two sets of primers were designed, a set to mutate I134 to T134 (‘mutation 
primers’) and a set to allow the amplification of the full length receptor incorporating 
restriction sites at the N- and C-terminals (‘extreme primers’). A PCR reaction was set up 
using GRLN-R in pcDNA3.1 as the template (using the conditions outlined in section 
2.7.10.1). One reaction contained the sense mutation primer and an anti-sense extreme 
primer designed to remove the STOP codon and add a KpnI restriction site at the C-
terminus of GRLN-R. 
Sense 5’ – CACGGTGCTCACCACCACAGCGCTGAGCGTC- 3’ 
Anti-sense 5’ – GTATGCGATGGTACCTGTATTAATACTAGATTCTGTCCA 
The mutated base is shown in bold and the KpnI restriction site in bold italics. 
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In parallel, a second reaction containing a sense primer designed to add a HA tag and a 
HindIII restriction site and the anti-sense mutation primer was set up, using the conditions 
outlined in section 2.7.10.1. 
Sense 5’ – 
CCTCACCTAAGCTTGCCACCATGTATCCTTACGACGTTCCTGACTACGCATGGA
ACGCGACGCCCAGCGAAGAG – 3’ 
Anti-sense 5’ – GACGCTCAGCGCTGTGGTGGTGAGCACCGTG – 3’  
The HindIII restriction site is shown in bold italics, the HA tag is underlined and the 
mutated base shown in bold. 
The products from both reactions were PCR purified (as in section 2.7.11), diluted 1:200 in 
sterile H2O and 0.5 µL of each product used as a template for another PCR reaction. In this 
reaction the extreme primers were used to amplify the template. The product from this 
reaction was sequenced to confirm the presence of the mutation. 
The amplified fragment and vector containing eCFP (pECFP-N1) were sequentially 
digested with HindIII and KpnI. The fragment was ligated in-frame with eCFP and 
transformed into competent XL1-Blue bacteria. Colonies were picked and the sequences of 
positive clones were verified using DNA sequencing. 
2.8 Cell culture protocols 
2.8.1 Maintenance of HEK293T cells 
Human embryonic kidney cells stably expressing the SV40 large T-antigen (HEK293T) 
were grown in DMEM (-sodium pyruvate) supplemented with 10 %(v/v) NBCS and 2 mM 
L-glutamine. Cells were grown in a humidified incubator (95 % air/5 % CO2; 37 oC). 
2.8.2 Maintenance of Flp-In™ T-REx™ HEK293 cells 
Cells were maintained in DMEM (with 4.5 g/L glucose, L-glutamine, - sodium pyruvate). 
The media was supplemented with 10 %(v/v) FCS, 1 %(v/v) penicillin/streptomycin mix, 1 
%(v/v) MEM non-essential amino acid mix and 10 µg/mL blasticidin. Cells were grown in a 
humidified incubator (95 % air/5 % CO2; 37 °C). 
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2.8.3 Passage of cells 
Confluent HEK293T or Flp-In™ T-REx™ HEK293 cells were washed once with sterile 
PBS to remove all traces of media. Sterile 0.25 % trypsin-EDTA solution was then added 
to the cells and flasks were gently rotated to cover the monolayer and placed in the 
incubator (for up to 5 min) until cells became detached. Once detached, 7 mL of fresh 
media was added to inactivate the trypsin and the cells were centrifuged at 288 x g (5 min; 
25 °C). The resulting pellet was resuspended in fresh media and the suspension split into 
flasks, dishes, plates or coverslips as required. 
2.8.4 Transient transfection 
Transfection of cells was performed when the cells had reached 60-70 % confluency. 
Briefly, for a 10 cm2 dish, 5 µg of DNA was diluted in optimem to a final volume of 600 
µL. To this 20 µL of Lipofectamine diluted in 580 µL optimem was added dropwise. The 
resulting mixture was incubated for 30 min (25 ºC). During this period cells were washed 
with optimem. After 30 min media was removed from the cells and the 
DNA/Lipofectamine/optimem mix added, made up to a volume of 5 mL with fresh 
optimem. After 5-7 h the transfection mixture and replaced with the appropriate growth 
media. The amount of DNA transfected was scaled up or down depending on the 
dimensions of the culture vessel.  
2.8.5 Generation of a Flp-In™ T-REx™ HEK293 inducible cell 
line  
Flp-In™ T-REx™ HEK293 cells were transfected with 0.8 µg of the GRLN-R construct 
(in pcDNA5/FRT/TO vector) and 7.2 µg pOG44 vector using Lipofectamine as described 
in section 2.8.4. After 48 h, the medium was changed to Flp-In™ T-REx™ HEK293 media 
(as detailed in section 2.8.2) with 200 µg/mL hygromycin to allow selection of stably 
transfected cells. A doxycycline titration and time course was performed to determine 
optimal time and doxycycline concentration required to initiate expression of receptor.  
2.8.6 Cell harvesting 
Transfected cells were harvested 24-48 h post-transfection. Stably transfected Flp-In T-
REx HEK293 cells were harvested after 16 h doxycycline treatment. In both instances the 
media was removed and cells were washed three times in 5 mL ice cold PBS. Cells were 
scraped from the dish using a disposable cell scraper and transferred to a 15 mL centrifuge 
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tube and centrifuged (288 x g; 5 min; 4 oC). After discarding the supernatant, the cell pellet 
was frozen at –80 oC until required. 
2.8.7 Pertussis toxin treatment 
Cells were treated with 25 ng/mL Bordella pertussis toxin added to appropriate growth 
media. Cells were grown in a humidified incubator (95 % air/5 % CO2; 37 °C) for 16 h 
prior to cell harvesting. 
2.9 Biochemical assays and other methods of 
analysis 
2.9.1 Preparation of cell membranes 
Harvested pellets were thawed and re-suspended in Tris-EDTA buffer. The cells were 
homogenised (50 passes of a Teflon-in-glass homogeniser) and the resulting suspension 
centrifuged (288 x g; 10 min; 4 °C) to remove unbroken cells and nuclei. The supernatant 
was ultracentrifuged (50,000 x g; 30 min; 4 °C) in an Optima TLX Ultracentrifuge 
(Beckam Coulter, Palo Alto, CA). The resulting pellet was re-suspended in Tris-EDTA 
buffer and passed 10x through a 25-gauge needle. The protein concentration was 
determined as detailed in section 2.9.3 and the membranes stored at –80 oC until required. 
2.9.2 Preparation of cell lysates 
Cells were grown on 6-well sterile tissue culture plates. 1x radioimmunoprecipitation 
(RIPA) buffer was made fresh on the day of the assay by diluting 2 x RIPA (100 mM 
HEPES, 300 mM NaCl, 2 %(v/v) Triton X-100, 1 %(w/v) sodium deoxycholate, 0.2 % (w/v) 
SDS; pH 7.4) buffer in H2O – this was supplemented with 0.5 M sodium fluoride, 0.5 M 
EDTA, 0.2 M NaPO4, 5 %(v/v) ethylene glycol and 1 x EDTA-free protease cocktail 
inhibitor tablet. Cells were washed 3 x 5 min with PBS before the addition of 200-500 µL 
1 x RIPA buffer. The mixture was rotated for 1 h at 4 oC on a rotating wheel before 
centrifugation (16,000 x g; 4 ºC; 30 min) to pellet cellular debris. Protein concentration 
was determined (as described in section 2.9.3) and the lysates diluted to the required 
concentration before the addition of Laemmli buffer. Lysates were stored at –20 ºC until 
required.  
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2.9.3 Bicinchoninic acid protein quantification 
The protein concentration of samples was quantified using the BCA assay. This assay 
utilises bicinchoninic acid (BCA) and copper sulphate solutions. Protein reduces Cu(II) 
ions to Cu(I) ions in a concentration-dependent manner. Reduced Cu(I) can be bound by 
BCA which causes a colour change that has an absorption maximum of 562 nm. BSA of 
known concentrations (0.2-2.2 mg/mL) was used to construct a standard curve, which 
allows the concentrations of unknown samples to be established. A 1:50 ratio of reagent A 
(1 %(w/v) BCA, 2 %(w/v) Na2C03, 0.16 %(w/v) sodium tartrate, 0.4 % (w/v) NaOH, 0.95 %(w/v) 
NaHCO3; pH 11.25) : reagent B (4 %(w/v) CuSO4) was mixed and 200 µL of this solution 
added to 10 µL of protein standard or unknown sample in a 96-well ELISA plate. The 
assay was incubated (30 min; 37 oC) before the absorbance was read at 600 nm.  
2.9.4 Deglycosylation with Endo H or PNGaseF 
To 30 µg of protein 1 unit (U) of PNGaseF or 1 mU of Endo H was added. Samples were 
digested overnight (4 ºC) before being resolved by sodium dodecyl sulphide 
polyacrylamide gel electrophoresis (SDS-PAGE; section 2.9.6) followed by western 
blotting (section 2.9.7). 
2.9.5 Co-immunoprecipitation 
Cells were grown in 6-welled plates and receptor expression induced by addition of 
doxycycline (6 ng/mL). Protein G beads (15 µL/sample) were washed twice in IPP500 (10 
mM Tris-base, 500 mM NaCl, 0.1 %(v/v) NP-40, 0.1 %(v/v) Tween-20, 0.1 %(w/v) CHAPS, 
0.1 %(w/v) BSA; pH 8.0) and incubated rotating with 2 µL anti-GFP antibody for 16 h at 4 
°C. Cells were washed twice with PBS before the addition of 750 µL of IPP100 (10 mM 
Tris-base, 100 mM NaCl, 0.1 %(v/v) NP-40, 0.1 %(v/v) Tween-20, 0.1 %(w/v) CHAPS and 0.1 
%(w/v) BSA; pH 8.0) supplemented with an EDTA-free protease inhibitor cocktail tablet, to 
lyse the cells. This mixture was rotated for 1 h at 25 °C before centrifugation (16,000 x g; 
10 min; 4 °C). At this stage an aliquot of sample was removed to measure protein 
concentration (as detailed in section 2.9.3) and the protein concentrations of the samples 
were equalised. To investigate protein expression a 200 µL sample of lysate was reserved 
and to this 50 µL of 5x Laemmli buffer with was added. Protein G beads were washed two 
times in IPP500 then twice in IPP100. The remainder of the lysates were added to the 
washed protein G beads. After 16 h incubation on a rotating wheel (4 ˚C) the samples were 
centrifuged (800 x g; 1 min; 4 °C) and washed two times with IPP100, twice with IPP500 
and once with 10 mM Tris pH 8.0 with EDTA-free protease inhibitor cocktail. Any 
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remaining liquid was removed using a 30G needle before the addition of 30 µL 2x 
Laemmli buffer. Both the immunoprecipitated samples and the cell lysates were then 
subjected to SDS-PAGE and western blotting. 
2.9.6 Sodium dodecyl sulphide polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Protein samples were resolved using SDS-PAGE. Precast NuPage Novex Bis-Tris gels 
with a 4-12 % acrylamide concentration were locked into an XCell Surelock mini-cell gel 
tank and covered in NuPage MOPS SDS buffer. To allow estimation of protein weight, 
samples were compared with the full range molecular weight Rainbow marker. The gel 
was run at 200 V until the dye front reached the base of the gel.  
2.9.7 Western blotting 
Following separation of samples by SDS-PAGE (as detailed in section 2.9.6) proteins were 
electrophoretically transferred onto nitrocellulose using the XCell II blot module. Proteins 
were transferred at 30 V (1 h) in transfer buffer (0.2 M glycine, 25 mM Tris and 20 % (v/v) 
methanol). To block non-specific binding sites, the membrane was incubated on a rotating 
incubator for 2 h at room temperature in 5 %(w/v) low-fat milk, PBS+ 0.1 %(v/v) Tween 20 
(PBS-Tween). The membrane was incubated (16 h; 4 °C) with primary antibody in 5 %(w/v) 
low fat milk dissolved in PBS-Tween containing the required antibody dilution (Table 2-
1). The membrane was washed three times for 5 min in PBS-Tween. Secondary antibody 
linked to horseradish peroxidase was diluted in 5 %(w/v) low fat milk dissolved in PBS-
Tween and incubated with the membrane at room temperature for 1 h. The membrane was 
washed three times for 5 min in PBS-Tween followed by incubation with ECL solution for 
5 min and exposure to blue Kodak film as required. 
Table 2-1 – Primary and secondary antibody dilutions used for western blotting 
Primary antibody
 
Dilution factor
 
Secondary antibody
 
Dilution factor
 
Anti-GFP (raised in sheep) 1:10000 Anti-goat 1:20000 
Anti-GFP 1:10000 Anti-rabbit 1:10000 
Anti-HA 1:5000 Anti-mouse 1:10000 
Anti-VSV-G 1:2000 Anti-rabbit 1:10000 
Anti-calnexin 1:5000 Anti-rabbit 1:10000 
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2.9.8 [35S]GTPγS binding assay with immunoprecipitation step  
This assay was used to measure G protein activation via the Gαq/11 pathway. [35S]GTPγS 
binding experiments were initiated by the addition of 10 µg of membranes (prepared as 
described in section 2.9.1) to assay buffer (20 mM HEPES; 3 mM MgCl2; 100 mM NaCl; 
1 µM GDP; 0.2 mM ascorbic acid; pH 7.4) and 50 nCi [35S]GTPγS containing the test 
compound. Non-specific binding was determined by addition of 100 µM cold (i.e. 
unlabelled) GTPγS. Reactions were incubated for 30 min at 30 oC before the reaction was 
terminated by the addition of 500 µL of ice-cold assay buffer supplemented with a 
protease-cocktail inhibitor tablet. Samples were centrifuged (16,000 x g; 10 min; 4 oC) and 
the resulting pellets were re-suspended in 50 µL solubilisation buffer (100 mM Tris, 200 
mM NaCl, 1 mM EDTA, 1.25 %(v/v) NP-40, 0.2 %(w/v) SDS; pH 7.4). Samples were pre-
cleared for 1 h by the addition of 60 µL of a mixture of pansorbin beads in bead buffer (2 
% BSA(w/v), 0.1 %(w/v) sodium azide; pH 7.4) i.e. 40 µL bead buffer and 20 µL pansorbin 
mix per sample. Samples were centrifuged (16,000 x g; 10 min; 4 oC) and the supernatant 
transferred to clean Eppendorf tubes. Immunoprecipitation was performed by addition of 
50 µL of protein G beads with rabbit anti-Gαq anti-sera (approximately a 1:200 dilution; 
Mitchell et al., 1993) and subsequently rotated for 16 h at 4 ºC. The beads were centrifuged 
(16,000 x g; 5 min; 4 oC) and washed with 500 µL ice-cold solubilisation buffer. The 
remaining liquid was removed, 1 mL of liquid scintillation cocktail added and bound 
radioactivity was determined using a 5 min [35S] counting programme on a LS 6500 
scintillation counter (Beckman Coulter, Palo Alto, CA).  
2.9.9 [35S]GTPγS filtration binding assay 
This assay was used to measure G protein activation via the Gαi/o pathway. Cell membranes 
(10 µg), 10 µM GDP and 0.1 nM [35S]GTPγS and ligand were mixed in a final volume of 1 
mL GTPγS filtration buffer (20 mM HEPES, 100 mM NaCl, 6 mM MgCl2, 0.1 %(w/v) 
BSA; pH 7.4). The assay was incubated for 30 min at 30 ºC before termination by rapid 
filtration through GF/C filters pre-soaked in ice-cold PBS using a Brandell cell harvester 
(Brandell, Gaithersberg, MA). The filters were washed three times in 3 mL ice-cold PBS 
and allowed to air-dry before transfer to tubes and the addition of 3 mL liquid scintillation 
cocktail. Bound radioactivity was determined using a 5 min [35S] counting programme on a 
LS 6500 scintillation counter (Beckman Coulter, Palo Alto, CA).  
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2.9.10 [35S]GTPγS scintillation proximity assay 
This assay was used to measure [35S]GTPγS binding in membranes prepared from a stable 
cell line expressing Gαo1 and transiently transfected with GRLN-R (kindly supplied by 
GlaxoSmithKline). In this assay carbohydrate residues in cell membranes (prepared from 
cells expressing the receptor of interest) are bound to wheat germ agglutinin (WGA) on the 
outside of the LEAD-seeker imaging beads, which are filled with scintillant. These beads 
emit light when an emission from an isotope occurs in close proximity i.e. when 
[35S]GTPγS binds to receptor. 
The test compound (0.5 µL), diluted in DMSO, was stamped onto a 384-well Lumitrac 200 
white plate, using the Biomek FX (Beckman Coulter, Palo Alto, CA). DMSO alone was 
used as a negative control. Cell membranes were defrosted, diluted to 50 µg/mL and added 
to scintillation proximity assay buffer (20 mM HEPES, 100 mM NaCl, 10 mM MgCl2; pH 
7.4) supplemented with 0.05 %(v/v) BSA and 0.05 %(v/v) pluronic F-127. WGA-polystyrene 
LEADseeker imaging beads and GDP were added to the membrane/assay buffer mixture at 
a concentration of 2 mg/mL and 8 µM, respectively, and pre-coupled under gentle shaking 
in the dark for 30 min at room temperature. [35S]GTPγS was diluted to 1.2 nM in assay 
buffer. To each well of the 384-well plate 25 µL of the membrane/assay/GDP/bead 
mixture and 25 µL of diluted [35S]GTPγS was added and the plate sealed and centrifuged 
(800 x g; 2 min; 25 °C). The assay was incubated in the dark for 80 min at 25 °C and read 
for 5 min in a Viewlux platereader (Perkin Elmer, Boston, MA) in luminescene mode at an 
emission of 613 nm and 6 x binning.  
For competition [35S]GTPγS experiments the assay was performed as above except that the 
compound that is kept at a fixed concentration was pre-incubated with the assay 
buffer/membrane/bead/GDP mixture at 2 x the final concentration.  
2.9.11 [His[125I]]-ghrelin association and dissociation binding 
assay 
Radioligand binding assays were performed by addition of 5 µg cell membranes to ice-cold 
assay buffer (50 mM Tris-base, 2 mM EGTA, 0.1 %(w/v) BSA; pH 7.3) in a final volume of 
150 µL in cooled 96-well blocks. To determine non-specific binding, cold ghrelin was 
added to a final concentration of 1 µM. At various time points a final concentration of 83 
pM [His[125I]]-ghrelin was added to the wells. As a control to determine binding of 
radioactivity to filters, membranes were replaced with assay buffer. The assay was 
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terminated by rapid filtration through GF/B filters pre-soaked in 0.5 %(w/v) PEI and the 
filters were washed three times in 1 mL ice-cold assay buffer. The filters were allowed to 
air-dry before the addition of 100 µL scintillation cocktail. The filters were read (1 
min/well) on a Topcount NXT™ microplate scintillation counter (Packard Instrument Co, 
Downers Grove, IL). 
Dissociation binding experiments were carried out as above. Association and dissociation 
was staggered so that the whole plate was harvested at the same time. 
2.9.12 Two point dissociation assay 
5 µg of cell membranes in ice-cold assay buffer (50 mM Tris-base, 2 mM EGTA, 0.1 
%(w/v) BSA; pH 7.3) was added to cooled 6 mL glass binding tubes. To determine non-
specific binding, 30 µL of a final concentration of 1 µM cold ghrelin was added. 
Association of [His[125I]]-ghrelin to the GRLN-R was initiated by the addition of a final 
concentration of 83 pM of radioligand. After 120 min, dissociation was initiated by the 
addition of 10 µL of a final concentration of 1 µM cold ghrelin plus 10 µL of buffer or 
varying concentrations of GHRP-6, L-692,585 or MK-677. After 60 min of dissociation, 
the experiment was terminated by rapid filtration through GF/C filters presoaked in 0.5 
%(w/v) PEI using a Brandel cell harvester (Brandell, Gaithersburg, MA). The filters were 
washed three times with 3 mL ice-cold assay buffer and counted using a 60 s [125I] 
counting programme on a LS 6500 scintillation counter (Beckman Coulter, Palo Alto, CA). 
Association and dissociation was staggered so the whole assay could be harvested at the 
same time.  
2.9.13 [His[125I]]-ghrelin competition binding assay 
Competition assays were set up as described in section 2.9.11 with the addition of varying 
concentrations of cold ligands. After the addition of 83 pM [His[125I]]-ghrelin the assay 
was incubated for 2 h at 4 ºC. The assay was terminated and results measured as described 
in section 2.9.11. 
2.9.14 Total inositol phosphate accumulation assay 
Cells were seeded onto poly-D-lysine-coated 12 well sterile tissue culture plates and grown 
to 80-90 % confluence on the day of the assay. Sixteen hours prior to the assay, the media 
was replaced with media supplemented with 1 µCi/mL [3H]myo-inositol in the presence or 
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absence of 6 ng/mL doxycycline and the cells left in a humidified incubator for 16 h to 
allow incorporation of [3H]myo-inositol. Subsequently, the medium was removed and cells 
washed twice with 1 mL Krebs-Ringer buffer (145 mM NaCl, 20 mM HEPES, 1.3 mM 
MgCl2, 1.2 mM NaH2PO4, 5 mM KCl, 1.3 mM CaCl2, 10 mM glucose; pH 7.4) 
supplemented with 10 mM LiCl. A further 1 mL of Krebs-Ringer buffer with LiCl was 
added to the cells and the cells were incubated for 30 min at 37 ºC in a humidified 
incubator. LiCl blocks the breakdown of inositol phosphates into myo-inositol, leading to 
accumulation of inositol phosphates within the cell. Inositol phosphate formation was 
stimulated by the addition of ligand in Krebs-Ringer buffer supplemented with 0.25 %(w/v) 
BSA and 10 mM LiCl for 30 min (37 ºC; 5 % CO2/95 % air). The assay was terminated by 
lysis of the cells by addition of 250 µL of ice-cold 1.5 M perchloric acid and incubation for 
30 min. An aliquot (0.75 mL) of the mixture was removed and neutralised by the addition 
of 300 µL of 2 M KOH in 1 M Tris-base. The samples were centrifuged (800 x g; 5 min; 4 
ºC) and a 0.75 mL sample of the supernatant was mixed with 2.5 mL of 5 mM disodium 
tetraborate containing 0.5 M EDTA (pH 7.2). 
Total inositol phosphates were extracted by ion-exchange chromatography on formate-
form Dowex columns according to the method of Berridge and Irvine (1989). Samples 
were applied to Dowex columns and allowed to drain by gravity flow, then washed four 
times with 2.5 mL 5 mM disodium tetraborate in 60 mM sodium formate to remove 
unbound [3H]myo-inositol and [3H]glycerolphosphoinositol. Columns were placed over 20 
mL scintillation vials and total inositol phosphates eluted by the addition of 2x 2.5 mL of 1 
M ammonium formate in 0.1 M formic acid, followed by addition of 10 mL scintillation 
fluid to the eluant. Radioactivity was determined using a 120 s [3H] counting programme 
on a LS 6500 scintillation counter (Beckman Coulter, Palo Alto, CA).  
After use the columns were reformed by 4 x 2.5 mL washes with 0.4 M formic acid, 
followed by 4 x 2.5 mL washes with H2O. Columns were then capped and stored in 2.5 mL 
H2O.  
2.9.15 cAMP accumulation assay 
The level of cAMP accumulation was measured using a AlphaScreen cAMP assay kit. 
Stimulation buffer (0.5 mM IBMX, 5 mM HEPES, 0.1 % BSA, diluted in 1 x HBSS; pH 
7.4) and detection buffer (5 mM HEPES, 0.1 % BSA, 0.3 % Tween-20, pH 7.4) were 
prepared fresh on the day of assay. For 384-data points 1U/15 µL of donor beads and 
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biotinylated cAMP were added to detection buffer and the volume made up to 6 mL. This 
mixture was incubated with gentle agitation in the dark (30 min; 25 ºC).  
Cells were seeded as to be 70-90 % confluent on the day of the assay and were treated with 
6 ng/mL doxycycline (16 h) to induce receptor expression. Cells were subsequently 
detached by addition of 5 mL Versene (5 min; 37 ºC) and collected by centrifugation (275 
x g; 5 min). The pellet was re-suspended in PBS and the cells counted using a 
haemocytometer. The cell mixture was centrifuged again (275 x g; 5 min) before 
supernatant was decanted and the pellet re-suspended to a final concentration of 10,000 
cells/µL in PBS. An acceptor bead/cell mix was prepared by adding 0.2 U/µL anti-cAMP 
acceptor beads to 400 µL of the cell solution, which was subsequently made to 2 mL using 
stimulation buffer. 
For Gαi/o assays forskolin was diluted to 0.4 µM in stimulation buffer and ligand was 
diluted to four times the final concentration required. A 1:1 ratio of ligand and forskolin 
was then prepared. For Gαs assays ligand was diluted to two times the final concentration 
required in stimulation buffer. 
All assays were carried out in 384-well white opaque plates (Perkin Elmer, Boston, MA), 5 
µL of acceptor bead/cell mix were added to each well followed by 5 µL of ligand or 
ligand/forskolin mix. Plates were sealed and incubated in a humidified incubator (37 ºC; 5 
% CO2/95 % air) for 30 min. After 30 min 15 µL of detection mixture was added per well 
and the plate incubated in the dark for 1 hr (25 ºC). The plate was read on an EnVision 
multilabel plate reader (Perkin Elmer, Boston, MA).  
2.9.16 Membrane staining 
Cells were grown on poly-D-lysine coated coverslips in 6-welled plates and receptor 
expression was induced with 6 ng/mL doxycycline (16 h), as required. Cells were washed 
2x 5 min with 2 mL room-temperature PBS, before the cells were fixed by the addition of 
2 mL 3.7 %(v/v) formaldehyde for 10 min. Cells were washed three times for 5 min with 
PBS. WGA-Alexa Fluor® 594 conjugate was diluted in PBS to a concentration of 10 
µg/mL, added to the plates and samples were incubated for 30 min in the dark. Coverslips 
were mounted onto microscope slides using Immu-mount and stored in the dark at 4 ºC 
before being imaged using epifluorescence microscopy (section 2.9.18) 
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2.9.17 Endoplasmic reticulum (ER) staining 
Cells were grown on poly-D-lysine coated coverslips in 6-welled plates; receptor 
expression was induced by the addition of 6 ng/mL doxycycline for 16 h. Subsequently, 
cells were rinsed twice with 2 mL room temperature PBS before incubation in a humidified 
incubator with 1 µM ER-Tracker™ red (BODIPY glibenclamide which binds to 
sulphonylurea receptors of ATP-sensitive potassium channels prominenet on the ER) for 
20 min at 37 ˚C. Cells were then washed two times for 5 min with 2 mL room-temperature 
PBS before samples were fixed for 10 min with 2 mL 3.7 %(v/v) formaldehyde. Cells were 
washed three times for 5 min with PBS before coverslips were mounted onto microscope 
slides and stored as described in section 2.9.16. 
2.9.18 Epifluorescence microscopy 
Formaldehyde-fixed cells were imaged using an inverted Nikon TE2000-E microscope 
(Nikon Instruments, Melville, NY) equipped with a x 60 (NA_1.4) oil-immersion Plan 
Fluor Apochromat lens, a z axis linear encoder, and a cooled digital Cool Snap-HQ CCD 
camera (Roper Scientific/Photometrics, Tucson, AZ). Epifluorescence excitation light was 
generated by an ultrahigh point intensity 75-watt xenon arc Optosource lamp (Cairn 
Research, Faversham, Kent) coupled to a computer-controlled Optoscan monochromator 
(Cairn Research, Faversham, Kent). The monochromator was set to 436/12 nm for 
excitation of eCFP. eCFP excitation light was transmitted through the objective lens using 
a 455DCLP single pass dichroic. eCFP fluorescence emission was controlled via a high 
speed filter wheel device (Prior Instruments Ltd., Cambridge, Cambridgeshire) containing 
HQ480/40 nm emitter. Images were collected using a Cool Snap-HQ digital camera 
operated in 12-bit mode. Computer control of all electronic hardware and camera 
acquisition was achieved using Metamorph software (version 6.3.3; Molecular Devices 
Corp., Downing, PA). 
2.9.19 Analysis of cell surface and intracellular receptors 
Fluorescent microscopy was used to image fluorescently-tagged receptors. To 
quantitatively measure the fluorescence intensity, images were deconvoluted using an 
iterative and constrained algorithm (Autodeblur software, version 9.3.6, Autoquant 
Imaging, Watervliet, NY) to produce high-resolution images that were used to identify 
groups of adjacent pixels or ‘segments’ that corresponded to receptors located on the cell 
surface or intracellular vesicles. A manual segmentation method, using the object counting 
module of the Autoquant imaging software, was used to quantify the mean total 
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fluorescence intensity values corresponding to receptors located at the membrane surface 
and the cytoplasm of the cell. The total fluorescence pixel intensity measured from 
membrane and intracellular receptor segmented pixels was expressed as a percentage of the 
total eCFP fluorescent intensity. 
2.9.20 Data analysis 
2.9.20.1 General 
Data was analysed using GraphPad Prism 4.0 (GraphPad software Inc., San Diego, CA). 
Data is expressed as the mean ± the standard error of the mean (S.E.M). Statistical and 
post-hoc analysis appropriate to the data were applied as indicated in individual chapters. 
Differences were considered to be statistically significant if p<0.05. 
Unless otherwise stated, concentration-responses curves were analysed with non-linear 
regression (sigmoidal concentration-response curves with Hill slopes constrained to 1). 
2.9.20.2 Global fit model 
The global fit model (Motulsky and Christopoulos, 2004) was used to analyse Schild 
regression data using GraphPad Prism 4.0 software (GraphPad software Inc., San Diego, 
CA). 
Equation 2-1 – Global fit model described by Motulsky and Christopoulos (2004). 
 
In the global fit equation (Equation 2-1): Y = response, Top represents the maximal 
asymptote of the curves, Bottom represents the lowest asymptote (basal response) of the 
curves, log EC50 represents the logarithm of the agonist EC50 in the absence of 
antagonist/inverse agonist, [A] represents the concentration of the agonist, [B] represents 
the concentration of the antagonist/inverse agonist, nH represents the Hill slope of the 
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negative logarithm of the concentration of antagonist that shifts the agonist EC50 by a 
factor of 2 (Langmead et al., 2005).  
To test whether the Schild slope was statistically different to unity an F-test was used, if 
the slope was not significantly different to unity the data was re-fitted with the Schild slope 
= 1 to allow determination of the pKB. F-tests were also used to allow comparison of fit 
between two equations. 
2.9.20.3 Modified operational model of allosterism 
A modified version of the operational model of allosterism (formulated by Leach et al., 
2007; modified by Dr. Christopher Langmead, GlaxoSmithKline) was used to determine 
whether data generated in Chapter 3 reflected an interaction between ghrelin and the 
growth hormone secretagogues that was allosteric or simply competitive in nature. Data 
was kindly analysed by Dr. Christopher Langmead using GraphPad Prism version 5.0 
(GraphPad software Inc., San Diego, CA). 
The [35S]GTPγS binding datasets studying the effect of multiple, fixed concentrations of 
ghrelin on concentration-response curves to GHRP-6, MK-677 or L-692,585 were 
analysed globally according to a modified version of an operational model of allosterism 
which accounts for allosteric modulation of affinity, efficacy and allosteric agonism. The 
equation represents a simplified model whereby it is assumed that the concentration-
response curve data is to a full agonist Equation 2-2: 
Equation 2-2 – Modified operational model of allosterism (originally described by Leach et 
al., 2007) 
( ) ( )( )( )
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Where Y = response, Basal is the response in the absence of ligand, [A] is the 
concentration of orthosteric ligand and [B] is the concentration of allosteric ligand, EC50 is 
the midpoint of the full agonist concentration-response curve, KB is the equilibrium 
dissociation constant of the putative allosteric ligand, τB denotes the capacity of the 
putative allosteric ligand to exhibit agonism (a function of the intrinsic efficacy and 
receptor expression) and α.β represents a net affinity/efficacy co-operativity parameter 
which describes the effect of the putative allosteric ligand on agonist function. The terms 
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EM and n denote the maximal possible system response and the slope factor of the 
transducer function that links occupancy to response, respectively. 
If the interaction between ghrelin and GHRP-6, MK-677 or L-692,585 were competitive, 
then the value of αβ would be zero (because the value of the affinity cooperativity factor, 
α, would be zero) and Equation 2-2 would reduce to that for the interaction of a partial 
agonist and full agonist binding to the same site. Therefore, the datasets were analysed 
under two conditions – where the value of αβ is left to float or constrained to zero. 
Comparison of the two fits was performed using Akaike’s Information Criterion (AICc; 
Motulsky and Christopoulos, 2004) to determine which fit was most likely to be correct. 
In order to further validate the results of the interaction studies, complementary 
experiments were performed in which the effects of multiple, fixed concentrations of 
GHRP-6, MK-677 or L-692,585 on concentration-response curves to ghrelin was 
examined. These data were analysed using a re-cast version of Equation 2-2 such that the 
concentration of ghrelin is the independent variable on the x-axis (i.e. full agonist versus 
partial agonist). As previously, the datasets were analysed under two conditions (where the 
value of αβ is left to float or constrained to zero) and the fits compared using AICc. 
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3 Investigating ago-allosteric modulation of the 
GRLN-R via activation of the Gαi/o pathway   
3.1  Introduction 
Allosteric modulators are defined as ligands that act to increase or decrease the actions of 
an orthosteric agonist or antagonist (i.e. an agonist or antagonist which binds to the same 
site as the endogenous ligand), by combining with a distinct, or ‘allosteric’, site on a 
receptor macromolecule (Neubig et al., 2003). Within the Pharmaceutical industry, 
allosteric modulators have attracted a great deal of attention as they may have many 
advantages over orthosteric ligands. For example, because, by definition, allosteric 
modulators only modulate the effect of the existing orthosteric ligand, allosteric 
modulators display a saturability of effect. Thus large doses of modulators can be 
administered with a lower propensity towards target-based toxicity than orthosteric ligands 
(Conn et al. 2009). Indeed, allosteric modulators have proven to be clinically useful drugs 
with two GPCR modulators entering the market; maraviroc, a drug launched for the 
treatment of HIV infections, and cinacalcet, a drug licensed to treat disorders of the 
calcium-sensing receptor, such as hyperparathyroidism (Conn et al., 2009).  
In 2005 a study published by Thue Schwartz’s group demonstrated GHRP-6 and L-
695,429 acted as allosteric regulators of the GRLN-R. The growth hormone secretagogues 
(GHRP-6, L-692,429 and MK-677) had been previously described as agonists of the 
GRLN-R (Howard et al., 1996). However, in Schwartz’s study it was found that, when co-
administered with ghrelin, the growth hormone secretagogues all acted to increase the 
maximum efficacy of ghrelin (Holst et al., 2005). Furthermore, co-administration of 
ghrelin with either L-692,429 or GHRP-6 either increased or decreased (respectively) the 
potency of ghrelin (Holst et al., 2005). Therefore GHRP-6 and L-692,429 could act both as 
agonists of the GRLN-R and as allosteric enhancers or allosteric antagonists of ghrelin 
function. To describe the effects of GHRP-6 and L-692,429 the term ‘ago-allosteric 
modulator’ was created; this defines a ligand that functions both as an (allosteric) agonist 
and as an allosteric modulator of the efficacy and/or the potency of an orthosteric ligand 
(Schwartz and Holst, 2006; Holst et al., 2005).  
Although by definition the binding site of an allosteric modulator is distinct from the 
orthosteric site (Neubig et al., 2003), in general binding sites for allosteric modulators are 
not well defined and, for the muscarinic acetylcholine receptors at least, may be located
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Figure 3-1 - Ago-allosteric modulation of the GRLN-R (adapted from Holst et al., 2005). A 
dimeric model was chosen by Holst et al. (2005) to explain the changes in ghrelin efficacy upon co-
administration with GHRP-6, L-692,429 and MK-677, as well as to explain the positive and 
negative modulation of ghrelin signalling upon co-administration with L-692,429 and GHRP-6 
(respectively). A. Ghrelin only binds to one protomer of the dimer. B. Due to their smaller size it is 
hypothesised that the growth hormone secretagogues could bind to both protomers leading to an 
increase in the observed maximum signalling compared to the maximum signalling achieved by 
ghrelin. C. Co-binding and co-activation of ghrelin with L-692,429 leads to an increase in the 
maximum signalling achieved by ghrelin alone, whilst shifting the ghrelin concentration-response 
curve to the left i.e. increasing the potency of ghrelin. D. Co-binding and co-activation of ghrelin 
with MK-677 leads to an increase in the maximum signalling achieved by ghrelin alone but has no 
effect on the potency of ghrelin. E. Co-binding and co-activation of ghrelin and GHRP-6 leads to an 
increase in the maximum signalling achieved by ghrelin alone, whilst shifting the concentration-
response curve to ghrelin to the right, i.e. decreasing the potency of ghrelin. 
 
close to the orthosteric site (Christopoulos and Kenakin, 2002; Birdsall and Lazareno, 
2005). Indeed mutational studies of the GRLN-R have demonstrated that the binding sites 
for GHRP-6, L-692,429 and MK-677 overlap with, but are not identical to, the binding site 
for ghrelin (Feighner et al., 1998; Holst et al., 2009). Thus to describe the ago-allosteric 
properties of the growth hormone secretagogues a model was formed which relied on the 
GRLN-R existing as a homo-dimer (Figure 3-1; Holst et al., 2005). Ghrelin, due to its large 
size, was predicted to only bind to one protomer of the homo-dimer, leaving the second 
protomer free to bind the growth hormone secretagogues which acted as co-agonists (MK-
677) and as positive (L-692,429) or negative (GHRP-6) modulators of ghrelin function 
(Holst et al., 2005).     
A C B 
D E 
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To date, functional studies of allosterism at the GRLN-R have been limited to studying the 
activation of the Gαq/11 pathway. However, there is a large body of evidence to suggest that 
many GPCRs interact with more than one type of G protein α subunit (Wess, 1998). 
Examples include receptors that can activate G proteins from the same subfamily, like the 
dopamine D2 receptor that can activate Gαi1-3 and Gαo1 (Gazi et al., 2003), to receptors that 
can activate G proteins from all four distinct families such as the thyrotrophin receptor 
(Laugwitz et al., 1996). Indeed the GRLN-R has been previously described to couple to the 
Gαq/11 (Howard et al., 1996; Kojima et al., 1999), Gα13 (Holst et al., 2005), Gαs (Kohno et 
al., 2003; Rossi et al., 2008) and Gαi  (Bassil et al., 2007; Dezaki et al., 2007; Esler et al., 
2007) pathways. 
The aim of this study was to explore the allosteric modulation of the GRLN-R in the Gαi/o 
pathway by testing whether the growth hormone secretagogues could act both as co-
agonists and as allosteric modulators of ghrelin function through activation of Gαo1.  
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3.2 Results 
3.2.1 The GRLN-R can activate the Gαi/o  pathway 
To measure activation of the Gαi/o pathway by the GRLN-R, [35S]GTPγS binding assays 
were utilised. [35S]GTPγS binding assays measure one of the earliest steps in GPCR 
signalling, the loss of GDP and the loading of GTP or, in this case, [35S]GTPγS (a poorly 
hydrolysable analogue of GTP) onto the α-subunit of heterotrimeric G proteins. Thus 
incorporation of [35S]GTPγS into G protein can be used as a measurement of receptor 
activation.  
 Membranes were prepared from HEK293 cells transfected to express Gαo1, or to co-
express Gαo1 and the GRLN-R, and challenged with 1 µM ghrelin; a concentration of 
ghrelin that was shown to be maximally effective in stimulating Gαq/11 responses, such as 
calcium mobilisation and inositol phosphate accumulation (Holst et al., 2005). The 
expression of Gαo1 was confirmed using anti-Gαo1 antisera (data not shown). After 
stimulation with ghrelin, the assay was terminated by rapid filtration through glass fibre 
filters, which allowed separation of G protein-bound [35S]GTPγS from unbound 
[35S]GTPγS. Terminating [35S]GTPγS binding assays by the use of a filtration step is  
 
 
Figure 3-2 - Testing the ability of the GRLN-R to couple to Gαi/o . Membranes were prepared 
from HEK293 cells expressing Gαo1 (white bars) or co-expressing Gαo1 and the GRLN-R (black 
bars). The ability of membranes to respond to 1 µM ghrelin or 1 µM SPA (20 min; 30 °C) was 
tested using a [35S]GTPγS binding assay to measure G protein activation. G protein-bound 
[35S]GTPγS was separated from the reaction mixture by rapid filtration through GF/C filters soaked 
in 1 x PBS and bound  [35S]GTPγS measured (for 5 min) using liquid-scintillation spectrometry. 
Data is expressed as the percentage of the maximum response achieved in each assay. Data 
points represent the mean ± S.E.M of three independent experiments performed in triplicate.
 
***p<0.001, **p<0.01 when compared using a one-way ANOVA with Tukey’s multiple comparison 
test.  
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particularly suited to measure the activation of the Gαi/o family of G proteins due to a 
combination of their high rate of basal nucleotide exchange and relatively high expression 
levels in HEK293 cells (Milligan, 2003).  
In this study a one-way ANOVA with Tukey’s multiple comparison test confirmed that the 
addition of 1 µM ghrelin caused a significant (p<0.001) increase in bound [35S]GTPγS in 
membranes co-expressing Gαo1 and the GRLN-R (Figure 3-2). This was not observed in 
membranes of equivalent cells transfected to express Gαo1 but not the GRLN-R, suggesting 
ghrelin was exerting its effect through activation of the GRLN-R. The lack of a ghrelin 
signal in the absence of the GRLN-R meant that HEK293 cells provided a useful null 
background in which to study the pharmacology of the GRLN-R. 
In membranes from HEK293 cells co-expressing the GRLN-R and Gαo1, a significantly 
higher level of basal [35S]GTPγS loading was observed than in membranes from HEK293 
cells transfected to express Gαo1 but not the GRLN-R (p<0.001), thus indicating that the 
GRLN-R could constitutively activate the Gαi/o pathway. To further explore this, the 
response of membranes to 1 µM SPA was also tested. SPA has been described as an 
inverse agonist of the GRLN-R, with a concentration of 1 µM SPA being sufficient to fully 
inhibit the constitutive activity of the GRLN-R in the Gαq/11 pathway (Holst et al., 2003).  
Indeed in this study the addition of 1 µM SPA significantly (p<0.01) lowered the recovery 
of bound [35S]GTPγS in membranes co-expressing the GRLN-R and Gαo1 compared to 
values obtained in the absence of ligand (basal conditions) (Figure 3-2). However, in 
membranes expressing Gαo1 but not the GRLN-R, SPA failed to alter the levels of 
[35S]GTPγS binding compared to basal conditions. Together these results confirmed that 
the GRLN-R could constitutively activate the Gαi/o pathway. 
3.2.2 The growth hormone secretagogues can activate the Gαi/o  
pathway  
Previous studies have shown that GHRP-6, MK-677 and L-692,585 act as agonists at 
GRLN-R via activation of the Gαq/11 pathway (Howard et al., 1996; Holst et al, 2005; Holst 
et al., 2009; Feighner et al., 1998). Whilst ghrelin has been demonstrated to activate Gαi/o 
(Bassil et al., 2007; Dezaki et al., 2007; Esler et al., 2007), there is currently a lack of data 
in the literature demonstrating the ability of the growth hormone secretagogues to activate 
this pathway. To test whether the growth hormone secretagogues could evoke a GRLN-R 
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Figure 3-3 - Testing the response of the GRLN-R through activation of the Gαi/o pathway in 
response to ghrelin and the growth hormone secretagogues. A [35S]GTPγS scintillation 
proximity assay was used to generate concentration-response curves to ghrelin, GHRP-6, L-
692,585 and MK-677 by incubating membranes, prepared from HEK293 cells co-expressing Gαo1 
and the GRLN-R, with varying concentrations of ligand for 80 min (25 °C). Activation of the GRLN-
R was assessed by measurement of G protein-bound [35S]GTPγS (5 min/plate using a Viewlux 
platereader). Data are expressed as a percentage of the maximum response achieved by ghrelin. 
Data points represent the mean ± S.E.M of three individual experiments performed in triplicate. 
 
response through Gαi/o, membranes (kindly supplied by GlaxoSmithKline) prepared from 
HEK293 cells co-expressing both the GRLN-R and Gαo1 were incubated with increasing 
concentrations of ghrelin, GHRP-6, L-692,585 (a commercially available derivative of L-
692,429) and MK-677. The responses of the GRLN-R were measured using a [35S]GTPγS 
scintillation proximity assay, which allowed measurement of [35S]GTPγS binding in a 
high-throughput format. 
In the scintillation proximity assay, beads filled with scintillant and coated with wheat-
germ agglutinin are used to measure receptor activation. Briefly, carbohydrate residues 
present on cell membranes (prepared from cells expressing the receptor of study) bind to 
the wheat-germ agglutinin on the surface of the beads. When an emission from an isotope 
occurs in close proximity to the beads (i.e. when [35S]GTPγS binds to G protein following 
receptor activation) the beads emit light. Measurement of emitted light allows 
quantification of [35S]GTPγS binding.   
The results of the [35S]GTPγS binding assays revealed that ghrelin, GHRP-6, L-692,585 
and MK-677 all caused a concentration-dependent increase in [35S]GTPγS binding (Figure 
3-3). Fitting the data to dose-response curves allowed the potency and efficacy values of 
each ligand to be obtained, as displayed in Table 3-1. Statistical tests revealed that GHRP-
6 and L-692,585 acted with significant lower potencies than ghrelin (p<0.01; as measured 
using a one-way ANOVA with Dunnett’s post-hoc test). Comparing the efficacies of MK-
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677, GHRP-6 and L-692,585 to ghrelin revealed that the growth hormone secretagogues all 
acted with significantly higher efficacies than ghrelin (p<0.05; as measured using a one-
way ANOVA with Dunnett’s post-hoc test). Thus GHRP-6, L-692,585 and MK-677 could 
be classed as ‘super-agonists’ in activating the Gαi/o pathway. 
Table 3-1 – Potency and efficacy of ghrelin and the growth hormone secretagogues as 
measured using a [35S]GTPγS scintillation proximity assay. 
 
Ligand pEC50 ± S.E.M Emax ± S.E.M 
Ghrelin 9.11± 0.10 95.4 ± 3.4 
MK-677 9.21 ± 0.12** 139.6 ± 9.9* 
GHRP-6 7.85 ± 0.13 139.5 ± 5.4* 
L-692,585 7.60 ± 0.17** 145.4 ± 14.0* 
Data represents the mean ± S.E.M of three independent experiments performed in triplicate. 
*p<0.05, **p<0.01 as measured using a one-way ANOVA with Dunnett’s post-hoc test. Emax values 
quoted in this Table (and all subsequent Tables) are the predicted top asymptotes of sigmoidal 
concentration-response curves fitted to the data. 
 
3.2.3 Effect of ghrelin on the potency and efficacy of the 
growth hormone secretagogues  
To further explore the effects of the ghrelin and the growth hormone secretagogues in the 
Gαi/o pathway and to investigate the suggestion that the growth hormone secretagogues 
could act as allosteric regulators of the ghrelin response (Holst et al., 2005), a series of 
[35S]GTPγS binding studies were performed in membranes co-expressing the GRLN-R and 
Gαo1. Concentration-response curves were generated to GHRP-6, MK-677 and L-692,585 
in the presence of multiple, fixed concentrations of ghrelin. The concentrations of ghrelin 
chosen were 10 pM, 0.1 nM, 0.3 nM, 1 nM and 100 nM, which corresponded to 0, 20, 25, 
60 and 100 % of the level of [35S]GTPγS binding that could be achieved by maximally 
effective concentrations of ghrelin, as shown in Figure 3-3.
 
 
3.2.3.1 GHRP-6 
The addition of increasing concentrations of ghrelin caused a concentration-dependent 
increase in the loading of [35S]GTPγS at GHRP-6 concentrations of 1 pM to 10 nM (Figure 
3-4A). Indeed compared to GHRP-6 acting alone, co-administration of 1 pM GHRP-6 with 
0.3-100 nM ghrelin statistically increased [35S]GTPγS binding (p<0.05 at 0.3 nM ghrelin; 
p<0.001 at 1 nM ghrelin and 100 nM ghrelin; as measured using a one-way ANOVA with 
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Figure 3-4    - Testing the effect of ghrelin on the response of the GRLN-R to GHRP-6, L-
692,585 and MK-677. Using a [35S]GTPγS scintillation proximity assay, concentration-response 
curves to A. GHRP-6, B. L-692,585 and C. MK-677 were generated in the presence of increasing 
concentrations of ghrelin (10 pM-100 nM, as indicated) in membranes prepared from HEK293 cells 
co-expressing Gαo1 and the GRLN-R. The assay was incubated for 80 min (25 °C) before receptor 
activation was assessed by measurement of G protein-bound [35S]GTPγS (5 min/plate using a 
Viewlux platereader). Datasets were fitted with sigmoidal concentration-response curves with Hill 
slopes shared across each dataset. Hill slopes (± S.E.M): GHRP-6 = 0.89 ± 0.09, L-692,585 = 0.87 
± 0.10; MK-677 = 0.78 ± 0.10. Data is expressed as a percentage of the maximum response 
achieved in the absence of ghrelin. Data points represent the mean ± S.E.M of three independent 
experiments performed in triplicate.
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Dunnett’s post-hoc test). In contrast, at higher concentrations of GHRP-6, ghrelin appeared 
to have little effect on the level of [35S]GTPγS binding (possibly as at high concentrations 
of GHRP-6 [35S]GTPγS levels reached the system maximal response) . Indeed, co-
administration of 1 µM GHRP-6 with 1 pM-100 nM ghrelin had no effect on the efficacy 
of GHRP-6 (p=0.87; as measured using a one-way ANOVA with Dunnett’s post hoc test). 
As Figure 3-4 shows, the co-administration of either 1 nM or 100 nM ghrelin significant 
reduced the potency of GHRP-6 (p<0.01; as measured using a one-way ANOVA with 
Dunnett’s post-hoc test).  
Table 3-2 – Potency and efficacy of GHRP-6 in the presence of increasing concentrations of 
ghrelin.
 
Condition pEC50 ± S.E.M Emax ± S.E.M 
GHRP-6 8.55 ± 0.02 99.6 ± 1.0 
+ 10 pM ghrelin 8.41 ± 0.05 110.6 ± 1.9
 
+ 0.1 nM ghrelin 8.40 ± 0.70 106.5 ± 2.4 
+ 0.3 nM ghrelin 8.17 ± 0.13 105.0 ± 3.8 
+ 1 nM ghrelin 7.31 ± 0.22** 106.5 ± 4.0 
+ 100 nM ghrelin 7.55 ± 0.35** 93.4 ± 2.8 
Efficacy is displayed as the percentage of the maximum efficacy to GHRP-6 in the absence of 
ghrelin. Data is expressed as the mean ± S.E.M of three individual experiments performed in 
triplicate. **p<0.01 as measured using a one-way ANOVA with Dunnett’s post-hoc test. 
 
3.2.3.2 L-692,585 
Co-administration of ghrelin with L-692,585 produced results that were similar to those 
obtained for GHRP-6. For example, at low concentrations of L-692,585 (1 pM-30 nM) the 
co-administration of ghrelin caused a concentration-dependent increase in [35S]GTPγS 
binding (Figure 3-4B). Indeed a one-way ANOVA with Dunnett’s post-hoc test revealed 
that the level of [35S]GTPγS loading after challenging membranes with 1 pM L-692,585 
was significantly increased by the co-administration of 0.3-100 nM ghrelin (p<0.05 after 
co-administration of 1 pM L-692,585 and 0.3 nM ghrelin; p<0.01 after co-administration 
of 1 pM L-692,585 and 1 nM or 100 nM ghrelin). At high concentrations of L-692,585, 
ghrelin (up to a concentration of 1 nM), appeared to have little effect on [35S]GTPγS 
binding. Indeed statistical tests revealed co-administration of 10 pM-1 nM ghrelin did not 
significantly alter the level of [35S]GTPγS binding achieved after challenging membranes 
with 1 µM L-692,585 (p>0.05; as compared using a one-way ANOVA). However, co-
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administration of L-692,585 with 100 nM ghrelin significantly (p<0.05) reduced the 
maximum efficacy of [35S]GTPγS binding measured in response to L-692,585 alone. 
Although there was a trend for the potency of L-692,585 to be reduced as ghrelin 
concentration increased, this was only deemed significant upon co-administration of 1 nM 
ghrelin (p<0.01; measured using a one-way ANOVA with Dunnett’s post-hoc test) (Table 
3-3).  
Table 3-3 - Potency and efficacy of L-692,585 in the presence of increasing concentrations 
of ghrelin.  
Condition pEC50 ± S.E.M Emax ± S.E.M 
L-692,585 7.77 ± 0.03 101.3 ± 1.4 
+ 10 pM ghrelin 7.65 ± 0.03 111.4 ± 1.7 
+ 0.1 nM ghrelin 7.65 ± 0.05 102.3 ± 2.0 
+ 0.3 nM ghrelin 7.50 ± 0.13 102.0 ± 4.4 
+ 1 nM ghrelin 6.80 ± 0.12** 111.5 ± 3.0 
+ 100 nM ghrelin 7.84 ± 0.25 90.3 ± 1.6* 
Efficacy is displayed as a percentage of the maximum efficacy to L-692,585 in the absence of 
ghrelin. Data is expressed as the mean ± S.E.M of three individual experiments performed in 
triplicate. *p<0.05, **p<0.01 as measured using a one-way ANOVA with Dunnett’s post-hoc test. 
 
3.2.3.3 MK-677 
The trend seen upon the co-administration of ghrelin with GHRP-6 or L-692,585 was 
continued for MK-677. At low concentrations of MK-677 (1 pM -1 nM) co-administration 
of ghrelin significantly increased [35S]GTPγS binding (p<0.05 after the addition of 0.3 nM 
ghrelin; p<0.01 after the addition of 1 nM or 100 nM ghrelin; measured using a one-way 
ANOVA with Dunnett’s post-hoc test) (Figure 3-4C). At higher MK-677 concentrations (1 
nM -1 µM) ghrelin appeared to have no additional effect on [35S]GTPγS binding. Indeed at 
a concentration of 1 µM MK-677, a one-way ANOVA revealed that, compared to MK-677 
acting on its own, the addition of ghrelin had no significant effect on [35S]GTPγS binding 
(p=0.16).  
The results of the [35S]GTPγS binding studies revealed that the co-administration of 
ghrelin with GHRP-6, L-692,585 or MK-677 caused an increase in the level of [35S]GTPγS 
binding at low concentrations of the growth hormone secretagogues, at high concentrations 
of ghrelin (100 nM), co-administration of ghrelin and GHRP-6 had no effect on the 
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maximum [35S]GTPγS binding compared to GHRP-6 acting alone (p>0.05), whilst co-
administration of 100 nM ghrelin with either L-692,585 or MK-677 significantly decreased 
the maximum level of [35S]GTPγS binding compared to L-692,585 or MK-677 acting 
alone (p<0.05). Ghrelin significantly decreased the potency GHRP-6, L-692,585 and MK-
677 when high concentrations of ghrelin (1 nM and/or 100 nM) were co-administered with 
the growth hormone secretagogues. This suggested that ghrelin was exerting a negative 
allosteric effect on the signalling of GHRP-6, L-692,585 and MK-677, with the presence of 
ghrelin shifting the concentration-response curves to each of the growth hormone 
secretagogues to the right. 
Table 3-4 - Potency and efficacy of MK-677 in the presence of increasing concentrations of 
ghrelin.  
Condition pEC50 ± S.E.M Emax ± S.E.M 
MK-677 9.58 ± 0.03 99.7 ± 0.8 
+ 10 pM ghrelin 9.43 ± 0.03 105.1 ± 0.9 
+ 0.1 nM ghrelin 9.27 ± 0.06 96.8 ± 1.3 
+ 0.3 nM ghrelin 9.16 ± 0.13 93.7 ± 2.6 
+ 1 nM ghrelin 8.32 ± 0.10** 107.1 ± 1.5 
+ 100 nM ghrelin 7.82 ± 0.89** 94.6 ± 2.3* 
Efficacy is displayed as a percentage of the maximum efficacy to MK-677 in the absence of ghrelin. 
Data is expressed as the mean ± S.E.M of three individual experiments performed in triplicate. 
*p<0.05, **p<0.01 when compared using a one-way ANOVA with Dunnett’s post-hoc test. 
 
To investigate if the effect that ghrelin had on the concentration-response curves to the 
growth hormone secretagogues was allosteric or competitive in nature; data was fitted to a 
modified operational model of allosterism originally described by Leach et al. (2007) 
(Equation 3-1; see Materials and methods, section 1.9.20.3 for details on the definitions 
used).  
Equation 3-1 – Modified version of an operational model of allosterism (Leach et al., 2007). 
 
 
If the interaction between ghrelin and the growth hormone secretagogues is competitive in 
nature, then the co-operativity factor, α (which denotes the magnitude by which the 
affinity of each ligand is modified by the concomitant binding of the other; Christopoulos 
et al., 2004), would be equal to zero. This means in the operational model of allosterism 
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the parameter αβ (where β is used to describe any allosteric effects on ligand efficacy) 
would equal zero. If the interaction between ghrelin and the growth hormone 
secretagogues was allosteric in nature, then α could be greater than, less than or equal to 
one, which would describe situations in which the allosteric ligand imparted positive, 
negative or neutral effects (respectively) on the affinity of the orthosteric ligand.  
The [35S]GTPγS data was fitted to the modified operational model of allosterism (Leach et 
al., 2007) first with αβ constrained to zero and then with αβ left unconstrained (Figure 3-5). 
Comparison between the two fits was assessed using Akaike’s Information Criterion 
(AICc; Motulsky and Christopoulos, 2004).  
Akaike’s Information Criterion is not a null hypothesis based test; therefore it does not 
measure ‘significance’. Instead AICc indicates a preference for a model, for example, an 
AICc value of –0.5 would indicate a preference of 1.5-fold for one model over another 
model. The parameters determined by fitting the data from Figure 3-4 with the modified 
operational model of allosterism, as well as the AICc results, are listed in Table 3-5. 
Table 3-5 – Parameters determined from fitting the [35S]GTPγS data (which investigates the 
effect of increasing concentrations of ghrelin on concentration-response curves to the 
growth hormone secretagogues; Figure 3-4) with the modified model of allosterism. 
Parameter MK-677 GHRP-6 L-692,585 
pEC50 9.4 (9.3 – 9.6) 8.5 (8.4 – 8.6) 7.8 (7.7 – 7.9) 
pKghrelin 8.8 (8.6 – 9.0) 8.8 (8.6 – 9.0) 8.9 (8.7 – 9.0) 
Log τghrelin 0.48 (0.35 – 0.61) 0.60 (0.44 – 0.76) 0.58 (0.44 – 0.71) 
Em 98 (95 – 101) 102 (97 – 106) 103 (98 – 107) 
αβ 0 0 0 
Difference in AICc N/A -1.8 -0.6 
pEC50 is the negative logarithm of the EC50 of the synthetic agonist to stimulate [35S]GTPγS 
binding; pKghrelin is the negative logarithm of the equilibrium dissociation constant for ghrelin binding 
to the ghrelin receptor; Log τghrelin is the logarithm of the agonist operational efficacy parameter for 
ghrelin; Em is the maximal system response level; αβ is the net affinity and efficacy cooperativity 
factor governing the interaction between ghrelin and the synthetic agonists. The difference in AICc 
value quoted represents the preference for the data fit where the value of αβ = 0 compared to a fit 
where the value of αβ was left unconstrained. Where ‘N/A’ is quoted, a comparison was not 
possible as the dataset failed to fit a model where αβ was not constrained to zero. Numbers in 
paratheses represent 95 % confidence intervals.
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Figure 3-5 – Testing the effects of ghrelin on the response of the GRLN-R to A. GHRP-6 B.L-
692,585 or C. MK-677 using a modified operational model of allosterism. Data generated in 
the [35S]GTPγS binding studies (shown in Figure 3-4) was fitted by Dr Christopher Langmead 
(GlaxoSmithKline) to an modified operational model of allosterism (Equation 3-1) described by 
Leach et al. (2007). Data shown here is fitted with αβ = 0 to describe a situation where ghrelin and 
the growth hormone secretagogues compete in a competitive fashion. Data was also fitted with αβ 
unconstrained (to describe an allosteric mode of interaction) however an F-test and Akaike’s 
Information Criterion showed data was best fitted to describe a competitive interaction.                  
A 
B 
C 
GHRP-6 only 
+ 10 pM ghrelin 
+ 0.1 nM ghrelin 
+ 0.3 nM ghrelin 
+ 1 nM ghrelin 
+ 100 nM ghrelin 
L-692,585 only 
+ 10 pM ghrelin 
+ 0.1 nM ghrelin 
+ 0.3 nM ghrelin 
+ 1 nM ghrelin 
+ 100 nM ghrelin 
MK-677 only 
+ 10 pM ghrelin 
+ 0.1 nM ghrelin 
+ 0.3 nM ghrelin 
+ 1 nM ghrelin 
+ 100 nM ghrelin 
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Figure 3-6 – Data simulated with an operational model of allosterism with the parameter αβ 
constrained to describe competitive or allosteric modes of interaction. Taking the EC50 of 
GHRP-6 (determined in Figure 3-4) and the KB and τ values for ghrelin, data was simulated with the 
modified version of the operational model of allosterism (Leach et al., 2007) by Dr Christopher 
Langmead (GlaxoSmithKline). The parameter αβ was set to A. equal 0 (to describe a competitive 
mode of interaction) B. equal to 1 which describes a net neutral co-operativity between GHRP-6 
and ghrelin, and C. equal to 0.1 which would describe a situation where ghrelin imparts a negative 
co-operative effect on GHRP-6 binding. The key curve is that generated in the presence of 100 nM 
ghrelin, which predicts a large shift in the curve if the interaction were competitive.  
 
 
 
 
A                                           B 
C 
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The use of AICc showed that in each instance data was best fit with the model where αβ 
was constrained to zero (demonstrated in Figure 3-6); to further test this (as AICc does not 
measure significance) a comparison by extra sum of squares test was performed, this 
showed there was no significant preference for an allosteric mechanism for any dataset 
(p>0.05). Thus data from the [35S]GTPγS binding studies did not provide evidence in 
favour of an allosteric mode of interaction between ghrelin and the growth hormone 
secretagogues, but favoured a competitive model. Thus ghrelin, which acts as a partial 
agonist with respect to the actions of the growth hormone secretagogues (see Figure 3-3), 
could be viewed as competing against the growth hormone secretagogues for binding to 
the orthosteric site on the GRLN-R.  
3.2.4 Effect of the growth hormone secretagogues on the 
potency and efficacy of ghrelin 
To further investigate the interaction between ghrelin and the growth hormone 
secretagogues the experimental protocol was reversed so that the effect of varying 
concentrations of the growth hormone secretagogues on ghrelin signalling could be 
assessed. Thus concentration-response curves to ghrelin were performed in the presence of 
multiple, fixed concentrations of GHRP-6, L-692,585 or MK-677. The responses of the 
GRLN-R in membranes prepared from HEK293 cells co-expressing the GRLN-R and Gαo1 
were measured using a
 
[35S]GTPγS scintillation proximity assay. 
3.2.4.1 GHRP-6 
Concentration-response curves to ghrelin were performed in the presence of 0.1, 1, 10 and 
100 nM of GHRP-6. At these concentrations GHRP-6 produced a [35S]GTPγS response 
around 0 % (at 0.1 and 1 nM GHRP-6), 60 % (10 nM GHRP-6) or 115 % (100 nM GHRP-
6) of the maximum [35S]GTPγS response achieved by ghrelin (Figure 3-3). 
Fitting the data to concentration-response curves revealed that at low concentrations of 
ghrelin (1 pM-3 nM), co-administration of GHRP-6 increased [35S]GTPγS binding in a 
concentration-dependent manner (Figure 3-7A). For example, statistical tests revealed that 
at 1 pM of ghrelin the addition of 1 nM, 10 nM or 100 nM of GHRP-6 significantly 
increased the level of [35S]GTPγS binding achieved by ghrelin acting on its own (p<0.01; 
compared using a one-way ANOVA with Dunnett’s post-hoc test). Indeed co-
administration of 1 pM ghrelin with either 10 nM or 100 nM GHRP-6 actually caused an 
increase in [35S]GTPγS binding that was above the level of binding achieved by incubation 
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Figure 3-7   - Testing the effect of GHRP-6, L-692,585 and MK-677 on the response of the 
GRLN-R to ghrelin. Using a [35S]GTPγS scintillation proximity assay, concentration-response 
curves to ghrelin were generated in the presence of increasing concentrations of A. GHRP-6 B. L-
692,585 C. MK-677 in membranes prepared from HEK293 cells co-expressing Gαo1 and the GRLN-
R. The assay was incubated for 80 min (25 °C) before incorporation of [35S]GTPγS into G protein 
was assessed by measurement of G protein-bound [35S]GTPγS (5 min/plate using a Viewlux 
platereader). Datasets were fitted with sigmoidal concentration-response curves with Hill slopes 
shared across each dataset. Hill slopes (± S.E.M): GHRP-6 = constrained to 1, L-692,585 = 1.14 ± 
0.28; MK-677 = 1.07 ± 0.31. Data is expressed as a percentage of the maximum response 
achieved by ghrelin in the absence of growth hormone secretagogues. Data points represent the 
mean ± S.E.M of three independent experiments performed in triplicate. 
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of membranes with a maximally effective concentration of ghrelin alone (p<0.01; as 
measured using a one-way ANOVA with Dunnett’s post-hoc test). 
Strikingly, as the concentration of ghrelin increased, the level of [35S]GTPγS binding 
achieved by high concentrations of GHRP-6 (10 nM or 100 nM) decreased. Co-
adminstration of 0.1 nM or 100 nM GHRP-6 significantly decreased the potency of ghrelin 
(p<0.05 and p<0.01, respectively: as compared using a one-way ANOVA with Dunnett’s 
post-hoc test) (Table 3-6). 
Table 3-6 - Potency and efficacy of ghrelin in the presence of increasing concentrations of 
GHRP-6.  
Condition pEC50 ± S.E.M Emax ± S.E.M Response at 1 pM ghrelin ± S.E.M 
Ghrelin 8.64 ± 0.02 100.2 ± 0.7 8.5 ± 0.6 
+ 0.1 nM GHRP-6 8.32 ± 0.21* 108.3 ± 7.6 29.5 ± 39.0 
+ 1 nM GHRP-6 8.01 ± 0.08 103.1 ± 1.5 68.8 ± 5.5 
+ 10 nM GHRP-6 9.01 ± 0.15 134.3 ± 2.2** 132.8 ± 13.1** 
+ 100 nM GHRP-6 7.67 ± 0.15** 187.6 ± 2.5** 188.9 ± 7.03** 
Efficacy is displayed as a percentage of the maximum efficacy to ghrelin in the absence of GHRP-
6. Data is expressed as the mean ± S.E.M of three individual experiments performed in triplicate. 
*p<0.05; **p<0.01 when compared using a one-way ANOVA with Dunnett’s post-hoc test. 
 
3.2.4.2 L-692,585 and MK-677  
Ghrelin concentration-response curves were also performed in the presence of 3 nM, 10 
nM, 30 nM and 1 µM of L-692,585 (producing approximately 20, 45, 80 or 150 % of the 
maximum [35S]GTPγS response produced by ghrelin), or 30 pM, 0.1 nM, 1 nM or 3 nM 
MK-677 (producing approximately 20, 75 or 115 % of the maximum [35S]GTPγS response 
produced by ghrelin; shown in Figure 3-3). 
Increasing the concentrations of both L-692,585 or MK-677 increased [35S]GTPγS binding 
in the presence of low concentrations of ghrelin (Figure 3-7B and C). For example, a one-
way ANOVA with Dunnett’s post-hoc test revealed that at a ghrelin concentration of 1 
pM, co-addition of GHRP-6 or MK-677 significantly increased [35S]GTPγS binding 
(p<0.05 after addition of 3 nM L-692,585, p<0.01 after addition of 10 nM, 30 nM and 1 
µM L-692,585 and p<0.05 after addition of 30 pM or 0.1 nM MK-677, p<0.01 after 
addition of 1 nM or 3 nM MK-677).  
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Co-administration of ghrelin with 30 nM and 1 µM L-692,585 or 0.3 nM – 3 nM MK-677 
increased [35S]GTPγS binding compared to the level achieved when challenging 
membranes with a maximally effective concentration of ghrelin. For example, a one-way 
ANOVA with Dunnett’s post-hoc test revealed that there was a significant increase in the 
maximum [35S]GTPγS binding achieved by ghrelin after co-administration of 1 µM L-
692,585 and 0.3 nM – 3 nM MK-677 (p<0.01). A one-way ANOVA also revealed that co-
addition of L-692,585 had no effect on the potency of ghrelin (p=0.09; Table 3-7) whereas 
the addition of 0.03 nM MK-677 significantly (p<0.05; as measured using a one-way 
ANOVA with Dunnett’s post-hoc test) lowered the potency of ghrelin compared to ghrelin 
acting alone (Table 3-8).    
Table 3-7 - Potency and efficacy of ghrelin in the presence of increasing concentrations of 
L-692,585.  
Condition pEC50 ± S.E.M Emax ± S.E.M Response at 1 pM ghrelin ± S.E.M 
Ghrelin 8.54 ± 0.05
 
97.3 ± 1.8 0.3 ± 1.3 
+ 3 nM L-692,585 8.03 ± 0.27 111.7 ± 7.7 59.0 ± 13.9 
+ 10 nM L-692,585 Not fitted Not fitted 88.7 ± 9.8** 
+ 30 nM L-692,585 9.53 ± 0.78 129.8 ± 10.6* 131.1 ± 18.9** 
+ 1 µM L-692,585 7.80 ± 0.39 177.9 ± 5.6** 175.3 ± 13.0** 
Efficacy is displayed as a percentage of the maximum efficacy to ghrelin in the absence of L-
692,585. Data is expressed as the mean ± S.E.M of three individual experiments performed in 
triplicate. **p<0.01 when compared using a one-way ANOVA with Dunnett’s post-hoc test. 
 
Table 3-8 - Potency and efficacy of ghrelin in the presence of increasing concentrations of 
MK-677.  
Condition pEC50 ± S.E.M Emax ± S.E.M Response at 1 pM ghrelin ± S.E.M 
Ghrelin 8.54 ± 0.02 96.0 ± 0.8 0.5 ± 2.6 
+ 0.03 nM MK-677 7.84 ± 0.06* 117.2 ± 1.8** 74.6 ± 2.9* 
+ 0.1 nM MK-677 8.03 ± 0.31 121.5 ± 6.6** 81.2 ± 34.0* 
+ 1 nM MK-677 9.07 ± 0.12 159.0 ± 1.7** 162.9 10.0** 
+ 3 nM MK-677 8.50 ± 0.07 190.8 ± 1.3** 195.0 ± 3.8** 
Efficacy is displayed as a percentage of the maximum efficacy to ghrelin in the absence of MK-677. 
Data is expressed as the mean ± S.E.M of three individual experiments performed in triplicate. 
*p<0.05; **p<0.01 when compared using a one-way ANOVA with Dunnett’s post-hoc test. 
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Figure 3-8 - Testing the effect of A. GHRP-6, B. L-692,585 and C. MK-677 on the response of 
the GRLN-R to ghrelin using a modified operational model of allosterism. Data generated in 
the [35S]GTPγS binding studies (shown in Figure 3-7) was fitted by Dr Christopher Langmead 
(GlaxoSmithKline) to an modified operational model of allosterism (Equation 3-1) described by 
Leach et al. (2007). Data shown here is fitted with αβ = 0 to describe a situation where ghrelin and 
the growth hormone secretagogues compete in a competitive fashion. Data was also fitted with αβ 
unconstrained (to describe an allosteric mode of interaction) however an F-test and Akaike’s 
Information Criterion showed data was best fitted to describe a competitive interaction.
A 
B 
C 
Ghrelin only 
+ 0.1 nM GHRP-6 
+ 1 nM GHRP-6 
+ 10 nM GHRP-6 
+ 100 nM GHRP-6 
Ghrelin only 
+ 3 nM L-692,585 
+ 10 nM L-692,585 
+ 30 nM L-692,585 
+ 1 µM L-692,585 
Ghrelin only 
+ 30 pM MK-677 
+ 0.1 nM MK-677 
+ 1 nM MK-677 
+ 3 nM MK-677 
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Figure 3-9 – Data simulated with an operational model of allosterism with the parameter αβ 
constrained to describe competitive or allosteric modes of interaction. Taking the EC50 of 
ghrelin (determined in Figure 3-7) and the KB and τ values for GHRP-6 (Table 3-9), data was 
simulated with the modified version of the operational model of allosterism (Leach et al., 2007) by 
Dr Christopher Langmead (GlaxoSmithKline). The parameter αβ was set to A. equal 0 (to describe 
a competitive mode of interaction) B. equal to 1 which describes a net neutral co-operativity 
between GHRP-6 and ghrelin, and C. equal to 0.1 which would describe a situation where GHRP-6 
imparts a negative co-operative effect on ghrelin binding. The key curve is that generated in the 
presence of 100 nM GHRP-6, which shows that the response to 1 µM ghrelin would be significantly 
greater in the presence of 100 nM GHRP-6 than that achieved in the absence of GHRP-6 if a 
negative or neutral allosteric interaction between ghrelin and GHRP-6 was occuring. 
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Once again data was modelled with the modified operational model of allosterism (Leach 
et al., 2007; Materials and methods section 1.9.20.3) to determine whether the interaction 
between ghrelin and the growth hormone secretagogues was allosteric or competitive in 
nature. Comparison of data fits to the operational model of allosterism (Equation 3-1) was 
assessed using AICc. However, the operational model of allosterism was re-cast such that 
ghrelin, the partial agonist, was the independent variable on the x-axis (parameters 
measured by fitting the data to the modified operational model of allosterism are displayed 
in Table 3-9). As previously, data was best fit to a competitive rather than an allosteric 
model of ligand interaction (Figure 3-8), as demonstrated in Figure 3-9. Thus ghrelin and 
the growth hormone secretagogues appeared to be competing for binding to the same site 
on the GRLN-R. 
Table 3-9 - Parameters determined from fitting the [35S]GTPγS data (which investigates the 
effect of increasing concentrations of the growth hormone secretagogues on the 
concentration-response curves to ghrelin; Figure 3-7) with the modified model of 
allosterism. 
Parameter MK-677 GHRP-6 L-692,585 
pEC50 10.0 (9.0 – 10.1) 8.3 (8.2 – 8.5) 7.9 (7.8 – 8.1) 
pKghrelin 8.1 (7.8 – 8.3) 8.4 (8.1 – 8.6) 8.3 (8.0 – 8.5) 
Log τghrelin 0.17 (0.07 – 0.28) -0.06 (-0.17 – 0.04) 0.11 (0.01 – 0.21) 
Em 177 (169 - 185) 191 (179 – 203) 171 (162 – 179) 
αβ
 
0 0 0 
Difference in AICc -0.5 N/A -1.8 
pEC50 is the negative logarithm of the EC50 of the synthetic agonist to stimulate [35S]GTPγS 
binding; pKghrelin is the negative logarithm of the equilibrium dissociation constant for ghrelin binding 
to the ghrelin receptor; Log τghrelin is the logarithm of the agonist operational efficacy parameter for 
ghrelin; Em is the maximal system response level; αβ is the net affinity and efficacy cooperativity 
factor governing the interaction between ghrelin and the synthetic agonists. The difference in AICc 
value quoted represents the preference for the data fit where the value of αβ = 0 compared to a fit 
where the value of αβ was left unconstrained. Where ‘N/A’ is quoted, a comparison was not 
possible as the dataset failed to fit a model where αβ was not constrained to zero. Numbers in 
paratheses represent 95 % confidence intervals. 
 
3.2.5 Kinetics of [His[125I]]-ghrelin binding  
Allosteric ligands are predicted to alter the kinetics of binding of orthosteric ligands to the 
receptor of study (Langmead and Christopoulos, 2006; May et al., 2007), an effect that can 
be monitored as a change in the dissociation rate of a radiolabelled orthosteric ligand in the 
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presence of an allosteric ligand (Kostenis and Mohr, 1996). Before the effect that GHRP-6, 
L-692,585 and MK-677 had on the dissociation of [His[125I]]-ghrelin from the GRLN-R 
could be investigated, a radioligand binding assay had to be established and the kinetics of 
[His[125I]]-ghrelin binding in the absence of the growth hormone secretagogues assessed. 
To study the association of [His[125I]]-ghrelin binding to the GRLN-R, membranes co-
expressing Gαo1 and the GRLN-R were incubated in ice-cold assay buffer with the 
inclusion of cold ghrelin, where appropriate, used to determine non-specific binding. The 
concentration of membranes chosen ensured that less than 10 % of the total radioactivity 
added bound to the GRLN-R. The assay was terminated by rapid filtration through GF/B 
plates pre-soaked in 0.5 %(w/v) PEI. Pre-soaking the GF/B plates in 0.5 %(w/v) PEI was found 
to prevent excessive binding of the radioligand to the plates (data not shown), as 
previously described by Muccioli et al. (2001). 
Specific binding of [His[125I]]-ghrelin to the GRLN-R was calculated by subtracting the 
values obtained in the presence of cold ghrelin (non-specific binding) from the values 
obtained in the absence of cold ghrelin (total binding). This showed that [His[125I]]-ghrelin 
binding increased over time (Figure 3-10). The use of an F-test showed that the data was 
best fitted to a one-site exponential association curve, which revealed that the binding of  
[His[125I]]-ghrelin increased until around 120 min where the response reached a plateau, 
yielding an observed association rate constant (Kobs) of 0.03 ± 0.005 min-1. 
To study the dissociation kinetics of [His[125I]]-ghrelin from the GRLN-R, 83 pM of 
[His[125I]]-ghrelin was incubated at 4 ºC with membranes co-expressing Gαo1 and the 
GRLN-R. After 120 min, 10 µL of a final concentration of 1 µM ghrelin was added to the 
reaction mixture to prevent re-association of the radioligand (by competing against 
radiolabelled ghrelin for binding to the GRLN-R). Again, specific binding was calculated 
by the subtraction of the values of non-specific binding from total binding. 
The addition of cold ghrelin caused the specific binding of [His[125I]]-ghrelin to decrease 
with time. An F-test revealed that the dissociation data was best fitted with a one-phase 
exponential decay curve, which yielded a dissociation rate constant (Koff) of 0.02 ± 0.002 
min-1 (or a Koff of 0.01 ± 0.002 min-1, calculated by fitting data with a semi-log plot) 
(Figure 3-11). Using Equation 3-2 and Equation 3-3 allowed the determination of the 
kinetically derived equilibrium dissociation constant (KD) of 2.53 x 10-10 M. 
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Figure 3-10 - Association of [His[125I]]-ghrelin to the GRLN-R. The specific binding of [His[125I]]-
ghrelin to the GRLN-R was measured over varying time periods (0-120 min) in membranes co-
expressing the GRLN-R and Gαo1. Binding was carried out at 4 °C with non-specific binding 
determined by the inclusion of 1 µM cold ghrelin and the addition of a final concentration of 83 pM 
[His[125I]]-ghrelin staggered so that the assay was terminated by rapid filtration through 96-well 
GF/B filter plates pre-soaked in 0.5 %(w/v)  PEI after 2 h. Filters were allowed to air-dry before the 
addition of 100 µL scintillation cocktail to each filter. Bound radioactivity was measured using a 
[125I]counting programme on a Topcount NXT™ microplate scintillation counter. Data points 
represent the mean ± S.E.M of three independent experiments performed in triplicate. Data was 
expressed as the percentage of the maximum specific binding achieved and fitted to a one-site 
exponential association curve, yielding a Kobs value of 0.03 ± 0.005 min-1. 
 
Equation 3-2 – Determination of Kon.  
Kon = (Kobs - Koff)/[radioligand] 
Where Kon is the association rate constant; Kobs is the observed association rate constant; Koff is the 
dissociation rate constant and [radioligand] is the final concentration of radioligand in M. 
 
Equation 3-3 – Determination of KD.  
KD = Koff/Kon 
Where KD is the equilibrium dissociation constant; Koff is the dissociation rate constant and Kon is 
the association rate constant. 
 
3.2.6 Ghrelin and the growth hormone secretagogues compete 
for [His[125I]]-ghrelin binding 
The specific binding of [His[125I]]-ghrelin to the GRLN-R was measured in membranes co-
expressing the GRLN-R and Gαo1 in the presence of increasing concentrations of ghrelin, 
GHRP-6, L-692,585 and MK-677. Ghrelin and the growth hormone secretagogues were all 
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Figure 3-11 - Dissociation of [His[125I]]-ghrelin from the GRLN-R. Following association (to 
equilibrium, 120 min), the dissociation of [His[125I]]-ghrelin from the GRLN-R was measured over 
varying time periods in membranes co-expressing the GRLN-R and Gαo1. Binding was carried out 
at 4 °C for 2 h with non-specific binding determined by the inclusion of 1 µM cold ghrelin before re-
association of [His[125I]]-ghrelin was inhibited by the addition of 1 µM cold ghrelin for varying 
amounts of time (0-180 min). The assay was terminated by rapid filtration through 96-well GF/B 
filter plates pre-soaked in 0.5 %(w/v)  PEI. Filters were allowed to air-dry before the addition of 100 
µL scintillation cocktail to each filter. Bound radioactivity was measured using a [125I]counting 
programme on a Topcount NXT™ microplate scintillation counter. Data points represent the mean 
± S.E.M of three independent experiments performed in triplicate and are expressed as a 
percentage of the maximum specific binding achieved in each assay. A. Data is fitted to a one-site 
exponential decay curve, yielding a Koff of 0.02 ± 0.002 min-1 B. Semi-log plot of dissociation 
yielded a Koff of 0.01 ± 0.002 min-1.
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able to compete with [His[125I]]-ghrelin in a concentration-dependent manner to limit the 
specific binding of ghrelin, although sufficiently high concentrations of L-692,585 could 
not be employed in these studies to allow adequate fitting of the data (Figure 3-12). The 
use of an F-test revealed that ghrelin, GHRP-6 and MK-677 were best fit to a monophasic 
competition curve with Hill slopes (determined from fitting the data to variable-slope dose-
response curves) not significantly different from unity (Table 3-10). As the IC50 can 
change depending on experimental conditions used, the pKi for each ligand was calculated. 
To determine the pKi from the pIC50 values the Cheng-Prusoff equation was used 
(Equation 3-4; Cheng and Prusoff, 1973). 
Equation 3-4 – Cheng-Prusoff equation for determining the Ki from the IC50.  
 
Where IC50 is the concentration of ligand that blocks specific binding by 50 %, KD is the affinity of 
the radioligand for the receptor and [radioligand] is the concentration of the radioligand in M. The 
equation was originally described by Cheng and Prusoff (1973). 
 
Table 3-10 – Ghrelin and the growth hormone secretagogues compete for [His[125I]-ghrelin 
binding. 
 
Ligand pIC50 pKi Hill slope 
Ghrelin 9.06 ± 0.34 8.97 ± 0.27 -0.59 ± 0.41 
GHRP-6 8.29 ± 0.60 7.51 ± 0.71 -0.52 ± 0.63 
MK-677 8.12 ± 0.33 8.14 ± 0.08 -0.67 ± 0.49 
L-692,585 < 5.00 < 6.00 Not fitted 
Data is expressed as the mean ± S.E.M of three individual experiments performed in triplicate. F-
test showed data was best fitted to a one-site competition model which allowed pIC50 and pKi 
values to be obtained. Hill slope values were obtained from fitting the data to a variable-slope 
sigmoidal dose-response curve. The use of an F-test revealed the Hill slope values obtained were 
not significantly different from unity. 
 
 
 
 
 
Ki =   IC50 
1 +
[radioligand]
KD
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Figure 3-12  - The specific binding of [His[125I]-ghrelin is inhibited by the presence of ghrelin 
and the growth hormone secretagogues. Binding of a final concentration of 83 pM [His[125I]]-
ghrelin to membranes co-expressing Gαo1 and the GRLN-R was measured in the presence or 
absence of varying concentrations of ghrelin, MK-677, GHRP-6 and L-692,585. Binding was 
carried out at 4 °C for 2 h with non-specific binding determined by the inclusion of 1 µM cold 
ghrelin, before the assay was terminated by rapid filtration through 96-well GF/B filter plates pre-
soaked in 0.5 %(w/v)  PEI. Filters were allowed to air-dry before the addition of 100 µL scintillation 
cocktail to each filter. Bound radioactivity was measured using a [125I]counting programme on a 
Topcount NXT™ microplate scintillation counter. Data points represent the mean ± S.E.M of three 
independent experiments performed in triplicate. Data is expressed as a percentage of the 
maximum specific binding achieved in the absence of competing ligand and fitted to a one-site 
competition model. 
 
 
3.2.7 The growth hormone secretagogues do not alter the time 
course of [His[125I]]-ghrelin dissociation 
The data from the competition binding experiments was consistent with ghrelin and the 
growth hormone secretagogues competing for a common binding site. To further test this 
the effect of ghrelin and the growth hormone secretagogues on the dissociation of 
[His[125I]]-ghrelin was explored.  
The dissociation of [His[125I]]-ghrelin from the GRLN-R was measured in membranes co-
expressing the GRLN-R and Gαo1 (Figure 3-13). Re-association of [His[125I]]-ghrelin was 
inhibited by the addition of cold ghrelin to the reaction mixture, in the presence or absence 
of 0.3 µM L-692,585. Data was best fitted to a one-phase exponential decay model 
(assessed using an F-test). This revealed that the Koff in the absence of L-692,585 was 0.02 
± 0.002 min-1 whilst the Koff in the presence of L-692,585 was 0.02 ± 0.004 min-1, 
comparing the Koff values obtained using a un-paired two-tailed t-test revealed there was 
no significant differences in the values obtained (p=0.85). Thus L-692,585 had no effect on 
the dissociation rate of [His[125I]]-ghrelin. To further test the effects of the growth hormone 
secretagogues on the dissociation of [His[125I]]-ghrelin from the GRLN-R, two-point  
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Figure 3-13 - L-692,585 does not affect the dissociation rate of [His[125I]]-ghrelin from the 
GRLN-R. Following association (to equilibrium, 120 min), the dissociation of [His[125I]]-ghrelin from 
the GRLN-R was measured over varying time periods in membranes co-expressing the GRLN-R 
and Gαo1. Binding was carried out at 4 °C for 2 h with non-specific binding determined by the 
inclusion of 1 µM cold ghrelin before re-association of [His[125I]]-ghrelin was inhibited by the 
addition of 1 µM cold ghrelin ± 0.3 µM L-692,585 for varying amounts of time (0-180 min). The 
assay was terminated by rapid filtration through 96-well GF/B filter plates pre-soaked in 0.5 %(w/v)  
PEI. Filters were allowed to air-dry before the addition of 100 µL scintillation cocktail to each filter. 
Bound radioactivity was measured using a [125I]counting programme on a Topcount NXT™ 
microplate scintillation counter. Data points represent the mean ± S.E.M of three independent 
experiments performed in triplicate. Data is expressed as the percentage of the maximum specific 
binding achieved in each assay and is fitted to a one-site exponential decay curve. The Koff of 
[His[125I]]-ghrelin in the presence of L-692,585 was calculated as 0.02 ± 0.004 min-1. 
 
dissociation experiment were used. Two-point dissociation experiments are a simplified 
procedure for studying radioligand dissociation, where only the amount of radioligand 
bound at the start and after a fixed interval of dissociation are measured (Kostensis and 
Mohr, 1996), allowing the amount of radiolabel used in each experiment to be reduced. 
However, this method is only valid for use if full time-course of radioligand dissociation is 
monophasic both in the absence and presence of modulator (Kostenis and Mohr, 1996; 
Lazareno and Birdsall, 1995), which was the case in this study. 
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Figure 3-14 - GHRP-6, L-692,585 and MK-677 do not affect the dissociation rate of [His[125I]]-
ghrelin from the GRLN-R. Following association, the dissociation of [His[125I]]-ghrelin from 
membranes co-expressing the GRLN-R and Gαo1 was measured 0 min and 60 min after the 
addition of 1 µM ghrelin in the presence or absence of varying concentrations of  A. GHRP-6, B. L-
692,585 or C. MK-677. The assay was terminated by rapid filtration through GF/C filters pre-
soaked in 0.5 %(w/v) PEI. Filters were allowed to air-dry and bound [His[125I]]-ghrelin measured for 
60 s using a [125I] counting programme on a LS 6500 scintillation counter. Data points represent the 
mean ± S.E.M of three independent experiments performed in triplicate. Data is expressed as the 
percentage of specific binding achieved in the absence of competitor and fitted with linear 
regression. 
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Specific binding of [His[125I]]-ghrelin in membranes co-expressing the GRLN-R and Gαo1 
was measured 60 min after administration of cold ghrelin in the presence or absence of 
increasing concentrations of GHRP-6, MK-677 and L-692,585 and data fitted with linear-
regression (Figure 3-14).  
The use of a one-way ANOVA revealed that dissociation of [His[125I]]-ghrelin was not 
altered by co-administration of ghrelin with either GHRP-6 (p=0.99), L-692,585 (p=0.45) 
or MK-677 (p=0.47). Thus even at maximally effective concentrations of the growth 
hormone secretagogues there was no change in the rate of dissociation of [His[125I]]-
ghrelin compared to that achieved by ghrelin acting on its own; data consistent with the 
lack of an allosteric effect of the growth hormone secretagogues on the binding of 
[His[125I]]-ghrelin. 
3.2.8 The inverse agonist SPA competes with ghrelin and the 
growth hormone secretagogues  
To investigate whether ghrelin and the growth hormones did bind to similar sites on the 
GRLN-R, the effect of incubation of SPA on [35S]GTPγS binding evoked by ghrelin, 
GHRP-6, L-692,585 and MK-677 was tested.  
A [35S]GTPγS scintillation proximity assay was used to measure the response of ghrelin or 
the growth hormone secretagogues at a concentration that evoked a response around 80 % 
of the maximum signalling achieved by each ligand in the [35S]GTPγS binding assays (as 
measured in Figure 3-3). Concentration-response curves to SPA were then generated in the 
presence of EC80 concentrations of ghrelin, GHRP-6, L-692,585 and MK-677 (Figure 
3-15). In all instances, SPA was able to decrease [35S]GTPγS binding in a concentration-
dependent manner, thus acting as an antagonist at the GRLN-R. Fitting dose-response 
curves to the data allowed determination of pIC50 values of SPA, as listed in Table 3-11.  
Table 3-11 – Potency values of SPA in inhibiting an EC80 concentration of ghrelin, GHRP-6, 
L-692,585 or MK-677.
 
Ligand
 
pIC50 ± S.E.M 
Ghrelin 5.98 ± 0.13 
MK-677 6.85 ± 0.15 
GHRP-6 6.62 ± 0.21 
L-692,585 6.38 ± 0.12 
Data is expressed as the mean ± S.E.M of three individual experiments performed in triplicate.
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Figure 3-15 - SPA competes with ghrelin and the growth hormone secretagogues for 
binding to the GRLN-R. A [35S]GTPγS scintillation proximity assay was used to measure the 
response of membranes co-expressing the GRLN-R and Gαo1 to A. 3 nM ghrelin, B. 30 nM GHRP-
6, C. 0.3 µM L-692,585 or D. 1 nM MK-677 in the presence of varying concentrations of the inverse 
agonist SPA (80 min; 25 °C). Activation of the GRLN-R was assessed by measurement of G 
protein-bound [35S]GTPγS (5 min/plate using a Viewlux platereader).Data points represent the 
mean ± S.E.M of three individual experiments performed in triplicate. Data is normalised with 100 
% being the response achieved by the EC80 concentration of growth hormone secretagogues in the 
absence of SPA and 0 % being the basal response of the membranes.
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To determine whether SPA acted in a competitive or non-competitive manner Schild 
analysis was used; where concentration-response curves to ghrelin, GHRP-6, L-692,585 
and MK-677 were performed in the presence of multiple, fixed concentrations of SPA.  
 Data was globally fitted with the equation described by Motulsky and Christopoulos 
(2004) (Equation 3-5).  
 
Equation 3-5 - Global-fit model described by Motulsky and Christopoulos (2004). 
 
Definitions of the terms in Equation 3-4 are described in Materials and methods, section 1.9.20.2. 
 
Fitting of the data to the global fit model revealed that SPA caused a concentration-
dependent decrease in the baseline of the concentration-response curves to ghrelin and the 
growth hormone secretagogues. This is best demonstrated in Figure 3-16 which showed at 
a GHRP-6 concentration of 1 pM the addition of 0.3-10 µM of SPA caused a significant 
decrease in [35S]GTPγS binding (p<0.05; as measured using a one-way ANOVA with 
Dunnett’s post-hoc test). Thus, due to the inverse agonist effects of SPA, the data from the 
Schild analysis appeared poorly fitted to the global fit model (Figure 3-16), indeed re-
analysing the data so that for each curve the basal values of [35S]GTPγS were 
unconstrained led to a better fit of the data (measured using an F-test) and reduced the 
apparent affinity of SPA for the GRLN-R. However, as there was a distinct trend for the 
baseline of the curves to decrease (which breaks the rules of Schild analysis which requires 
that parallel shifts of the concentration-response curves should occur with no dimunition in 
maxima; Kenakin, 2006) the data was normalised to remove the basal level of [35S]GTPγS 
binding. Once again this reduced the apparent affinity of SPA for the GRLN-R (Table 
3-12; Figure 3-17).   
Fitting the data to the global fit model resulted in Schild slopes that were not significantly 
different to 1 (p>0.05; measured using an F-test). Thus SPA could be seen to act as a 
competitive antagonist. Constraining the Schild slope to 1 allowed measurement of the 
affinity of SPA for the GRLN-R (pKB). Comparing pKB values using a one-way ANOVA 
with Tukey’s multiple comparison test revealed that the affinity of SPA for the GRLN-R 
was significantly lower (p<0.01) in the presence of ghrelin than the affinity of SPA for the 
GRLN-R measured in the presence of either GHRP-6 or L-692,585.
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Figure 3-16 - SPA competes with GHRP-6 binding in a concentration-dependent manner. 
Using a [35S]GTPγS scintillation proximity assay, concentration-response curves to GHRP-6 were 
performed in the presence of varying concentrations SPA, in membranes co-expressing the GRLN-
R and Gαo1. After incubation for 80 min (25 °C) G protein-bound [35S]GTPγS was measured (5 
min/plate using a Viewlux platereader). A. White bar shows the level of [35S]GTPγS binding in 
response to 1 pM GHRP-6 in the absence of SPA. In the presence of SPA (black bars), binding of 
[35S]GTPγS in response to 1 pM GHRP-6 is reduced in a concentration-dependent manner. 
*p<0.05; as measured using a one-way ANOVA with Dunnett’s post-hoc test. B. Data was fitted 
with the global fit model (Motulsky and Christopoulos, 2004) C. Fitting the data to the global fit 
model with the baseline values removed revealed that SPA acts as a competitive antagonist. Data 
points represent the mean ± S.E.M of three independent experiments performed in triplicate.
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Figure 3-17 - SPA acts as a competitive antagonist in antagonising the effects of ghrelin, L-
692,585 and MK-677. Using a [35S]GTPγS scintillation proximity assay, concentration-response 
curves were generated to A. ghrelin, B. L-692,585 or C. MK-677 in the presence of varying 
concentrations of SPA, in membranes prepared from HEK293 cells co-expressing the GRLN-R and 
Gαo1. The responses of the GRLN-R were assessed after 80 min incubation (25 °C) by measureing 
G-protein bound [35S]GTPγS (5 min/plate, read on a Viewlux platereader). Data points represent 
the mean ± S.E.M of three independent experiments performed in triplicate. Data is expressed as 
fluorescence counts over basal and is fitted with a global fit model described by Motulsky and 
Christopoulos (2004).
A 
B 
C 
   128  
Table 3-12 - Interaction between the inverse agonist SPA with ghrelin and the growth 
hormone secretagogues.  
Ligand 
Raw data 
pA2 ± S.E.M pKB ± S.E.M Slope significantly  
different to 1? 
Ghrelin 8.05 ± 0.54 7.57 ± 0.29 No 
MK-677 8.22 ± 0.24 8.09 ± 0.16 No 
GHRP-6 8.86 ± 0.22 8.35 ± 0.15 No 
L-692,585 8.51 ± 0.29 8.48 ± 0.17 No 
Raw data unconstrained basal values
 
Ghrelin 7.50 ± 0.76 7.01 ± 0.34 No 
MK-677 7.93 ± 0.40 7.13 ± 0.05 No 
GHRP-6 8.03 ± 0.29 7.89 ± 0.20 No 
L-692,585 7.97 ± 0.36 7.75 ± 0.23 No 
Normalised data 
Ghrelin 6.89 ± 0.43 6.58 ± 0.18 No 
MK-677 7.21 ± 0.19 7.10 ± 0.10 No 
GHRP-6 7.61 ± 0.15 7.49 ± 0.09 No 
L-692,585 7.61 ± 0.17 7.45 ± 0.10 No 
Concentration-response curves to ghrelin, MK-677, GHRP-6 and L-692,585 in the presence of 
increasing concentrations of the substance P analogue were generated and the data fitted with a 
global fit model described by Motulsky and Christopoulos (2004). Table lists the pA2 value of the 
substance P analogue, whilst constraining the Schild slope to 1 allowed determination of the pKB. 
F-tests were used to determine whether the Schild slope was significantly different from 1. 
Removing the base line values of [35S]GTPγS binding in the presence of SPA (normalised data) led 
to a decrease in the apparent affinity of SPA. 
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3.3 Discussion 
3.3.1 Ago-allosteric models 
To explain the ago-allosteric effects of GHRP-6 and L-692,429 on the signalling of 
ghrelin, Holst and colleagues generated a complex model which relied on the GRLN-R 
existing as a homo-dimer (Holst et al., 2005). Although not studied by Holst et al. (2005), 
to date, two studies have demonstrated that the GRLN-R can form a homo-dimer (Jiang et 
al. 2006; Leung et al., 2007). Indeed, there have been multiple studies investigating 
receptor dimerisation that have described situations in which a ligand with a high affinity 
and/or potency for one GPCR have affected the pharmacology, function and/or cellular 
distribution of a second GPCR for which they have no direct affinity (Ellis et al., 2006; 
Parenty et al., 2008; Sohy et al., 2007; Milligan, 2008).     
Given the evidence that GPCRs can form dimers, or higher oligomer structures, it is not 
inconceivable that allosteric modulation across the dimer interface may occur, a concept 
recently discussed by Milligan and Smith (2007) and Springael et al. (2007). Indeed, 
evidence to support allosteric modulation in receptor dimers has been supplied by studies 
into allosteric regulation of the GABAB receptor. The GABAB receptor is an obligatory 
hetero-dimeric receptor composed of two subunits; GABAB1 and GABAB2 (White et al., 
1998; Kaupmann et al., 1998; Jones et al., 1998). Interestingly, Binet and colleagues 
demonstrated that the positive allosteric modulator CGP7930 activated a mutant receptor 
that consisted solely of the GABAB2 subunit, as the endogenous ligand GABA binds solely 
to the GABAB1 subunit, this data suggests CGP7930 could be imparting its allosteric effect 
across the dimer (Binet et al., 2004). However, it is much more challenging to investigate 
allosteric modulation across a homo-dimer. One approach that could be used is to generate 
an asymmetrical homo-dimer (or pseudo-hetero-dimer) between a wild-type receptor and a 
second receptor mutated to alter its affinity to ligand, allowing the effects of allosteric 
modulators to be explored in a receptor dimer that displays unique pharmacology at each 
of the protomers (Damian et al., 2006; Sartania et al., 2007).  
Since the homo-dimeric model of ago-allosteric modulation was proposed, two further 
models have been developed to explain, in principle at least, how ago-allosteric modulation 
of a receptor may occur when the binding sites for the orthosteric and allosteric ligands 
overlap. In one model, binding of the allosteric ligand involves interaction of the ligand 
with residues that are part of the orthosteric binding site. When both the allosteric and 
orthosteric ligands are present, the orthosteric ligand occupies the binding site with high 
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affinity leaving the ago-allosteric modulator to adopt, at least partially, a different binding 
mode (Schwartz and Holst, 2007). In the second model, the orthosteric and allosteric 
ligands can bind to the receptor molecule at different points in time. The conformational 
interchanges of the receptor could then occur on a timescale that is relatively slow 
compared with the assay conditions at which receptor signalling is measured. Thus the 
ago-allosteric modulator could bias the receptor population for agonist binding and action 
– a process termed ‘time-resolved allostery’ (Schwartz and Holst, 2007).  
Surprisingly, and in direct contrast to the original study by Holst et al. (2005), in this study 
no evidence was found to suggest that the growth hormone secretagogues acted as ago-
allosteric modulators of the GRLN-R. Instead, data supported a much simpler model of 
interaction, where ligands of distinct efficacy competed for binding to the orthosteric site 
of the GRLN-R.  
3.3.2 The growth hormone secretagogues act as super- 
agonists in the Gαi/o pathway 
Previous studies exploring the activation of the GRLN-R in COS-7 cells transfected to 
express the human GRLN-R demonstrated that both GHRP-6 and MK-677 acted with 
higher efficacies than ghrelin (i.e. they acted as ‘super-agonists’), either in increasing 
inositol phosphate accumulation (GHRP-6) or increasing serum-responsive element 
transcription or arrestin mobilisation (MK-677) (Holst et al., 2005). However, the study 
also revealed inconsistencies in the efficacies of the growth hormone secretagogues, 
depending on the assay end-point measured. For example, even though in the inositol 
phosphate accumulation assays GHRP-6 acted as a super-agonist, within the same 
pathway, calcium mobilisation studies showed GHRP-6, L-692,429 and MK-677 acted 
with efficacies equal to that of ghrelin (Holst et al., 2005). Discrepancies in the efficacies 
of the growth hormone secretagogues within the Gαq/11 pathway may have resulted from 
the functional assays used to measure activation of the GRLN-R; as feedback, cross-
regulation and even convergence of different effector systems may also be measured in 
downstream functional assays, complicating experimental results (Wess, 1998). To avoid 
this the actions of ghrelin, GHRP-6, L-692,585 and MK-677 in this study were explored at 
the level of receptor binding (via the use of radioligand binding studies) and at the level of 
G protein activation (with [35S]GTPγS binding studies): thus allowing measurement of 
ligand efficacies and potencies in a response system close to receptor activation.  
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Initial [35S]GTPγS binding assays revealed that the GRLN-R constitutively activated the 
Gαi/o pathway as expression of the GRLN-R led to a significant increase in [35S]GTPγS 
loading, an increase that was inhibited by incubation with SPA. Indeed, SPA has 
previously been shown to act as an inverse agonist in the Gαq/11 pathway as SPA acted to 
decrease inositol phosphate levels observed upon GRLN-R expression to the levels 
achieved in the absence of receptor (Holst et al., 2003). Although ghrelin has previously 
been demonstrated to activate Gαi (Bassil et al., 2007; Dezaki et al., 2007; Esler et al., 
2007), to date there is a lack of data in the literature demonstrating the ability of the growth 
hormone secretagogues to activate the Gαi/o pathway. In this study, GHRP-6, L-692,585 
and MK-677 were all able to evoke a concentration-dependent increase in [35S]GTPγS 
binding in membranes co-expressing the human GRLN-R and the G protein α-subunit 
Gαo1. Furthermore, GHRP-6, L-692,585 and MK-677 were all demonstrated to act as 
super-agonists; a finding that proved to be particularly important in the interpretation of the 
data gained from subsequent radioligand binding and functional studies.  
3.3.3 GHRP-6, L-692,585 and MK-677 are not ago-allosteric 
modulators of the GRLN-R–evidence from binding studies 
It is generally accepted that binding studies offer the most sensitive and direct means to 
detect the effect that an allosteric ligand imparts on binding of an orthosteric ligand. Thus 
radioligand binding studies have been widely used to investigate allosteric regulation of 
many GPCRs (May et al., 2003; Chan et al., 2008; Valant et al., 2008; Redka et al., 2008).  
Competition binding studies used to explore [His[125I]]-ghrelin binding to the GRLN-R 
revealed that ghrelin, GHRP-6 and MK-677 all fully competed with [His[125I]]-ghrelin 
binding in a concentration-dependent manner, resulting in pIC50 and pKi values similar to 
published values (see Table 3-11). A trend was also seen for the specific binding of 
[His[125I]]-ghrelin to decrease upon treatment with ‘cold’ L-692,585 but sufficiently high 
concentrations could not be explored to allow accurate determination of the pIC50 or to 
determine whether L-692,585 fully competed with [His[125I]]-ghrelin binding. Interestingly 
in functional studies the pEC50 of L-692,585 binding to the GRLN-R was shown to be 7.60 
± 0.17, so it would be expected that L-692,585 should fully inhibit [His[125I]]-ghrelin 
binding at the concentrations tested. As potency is dependent on both affinity and efficacy 
of a ligand for a receptor, this suggests that L-692,585 has a low affinity for the GRLN-R 
but acts with high efficacy.     
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The finding that MK-677 and GHRP-6 fully competed with [His[125I]]-ghrelin binding 
supported previous reports that ghrelin and the growth hormone secretagogues could bind 
to overlapping sites on the GRLN-R; mutagenesis studies found upon binding to the 
GRLN-R; ghrelin, GHRP-6, L-692,429, L-692,585 and MK-677 all made contact with a 
glutamic acid residue in TMIII (E1243.33) (Feighner et al., 1998; Holst et al., 2009). 
Importantly mutation of E1243.33 did not affect the cell surface expression or constitutive 
activity of the GRLN-R, suggesting the affect of this mutation on binding of ghrelin and 
the growth hormone secretagogues was not due to disturbance of the receptor structure 
(Holst et al., 2009). 
Interestingly, the finding that GHRP-6 fully competed with [His[125I]]-ghrelin binding 
contradicted with the results of the original study demonstrating the ago-allosteric 
properties of the growth hormone secretagogues (Holst et al., 2005). However, the effects 
of GHRP-6 on [His[125I]]-ghrelin binding agreed both with the findings of Ma et al. (2007) 
(Table 3-13) and with the apparently overlapping binding sites of ghrelin and GHRP-6 
(Feighner et al., 1998; Holst et al., 2009).  
By establishing association and dissociation kinetics of [His[125I]]-ghrelin binding to the 
GRLN-R an estimate of the equilibrium dissociation constant (KD) for [His[125I]]-ghrelin 
binding was calculated, yielding a KD of 2.53 x 10-10 M. This KD value was close to both 
kinetically derived KD values (1x10-10 M for [His[125I]]-ghrelin binding to human heart; 
Katugampola et al., 2001) and KD values obtained from saturation binding experiments 
(4.4x10-10 and 4.1x10-10 M for [125I-Tyr4]-ghrelin binding to hypothalamus or pituitary, 
respectively; Muccioli et al., 2001 and 5.1x10-10 for the binding of [125I-Tyr4]-ghrelin to 
guinea pig ventricle; Bedendi et al., 2003).  
Binding of an allosteric ligand to a GPCR results in the formation of a new structure due to 
the conformational change that ensues (May et al., 2007); thus binding of an allosteric 
ligand is predicted to alter the kinetics of binding of an orthosteric agonist. As it is difficult 
to determine whether an inhibitive effect on radioligand association is allosteric or 
competitive in nature (Kostensis and Mohr, 1996) the most common way to investigate an 
allosteric effect in binding assays is to measure the dissociation of an orthosteric ligand, as 
the only way dissociation of a pre-bound receptor-orthosteric ligand complex can be 
modified is by concomitant binding of a modulator to a topographically distinct and vacant 
site (May et al., 2007). Thus in addition to allowing the calculation of the KD for ghrelin 
binding, determination of the kinetics of [His[125I]]-ghrelin binding to the GRLN-R 
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Table 3-13 – pIC50 and pKi values of ghrelin, MK-677 and GHRP-6 competing for binding 
against radiolabelled ghrelin.  
Ligand pIC50 ± S.E.M  pKi ± S.E.M 
Ghrelin In this study: 9.06 ± 0.34 
Ghrelin competing with [125I]-Tyr4 ghrelin for 
binding in guinea pig ventricle1: 8.09 ± 0.90 
Ghrelin competing with [125I]-ghrelin binding 
to human GRLN-R transfected into CHO 
cells4: 9.15 
Ghrelin competing for [125I]-ghrelin binding to 
human GRLN-R transfected into COS-7 
cells5: 9.55 
In this study: 8.97 ± 0.27 
Ghrelin competing for [125I]-ghrelin 
binding to human GRLN-R 
transfected into COS-7 cells2: 8.6 
MK-677 In this study: 8.29 ± 0.60 
MK-677 competing for [125I]-ghrelin binding to 
human GRLN-R transfected into CHO cells4: 
9.05 
In this study: 8.14 ± 0.67 
MK-677 competing for [125I]-ghrelin 
binding to human GRLN-R 
transfected into COS-7 cells2: 8.18  
GHRP-6 In this study: 8.12 ± 0.33  
GHRP-6 fully competed for [125I]-ghrelin 
binding to intact HEK293 cells transfected to 
express human ghrelin expression; no pIC50 
or pKi values given6 
In this study: 7.51 ± 0.52 
GHRP-6 competing for [125I]-ghrelin 
binding to human GRLN-R 
transfected into NIH-3T3 cells3: 8.6 ± 
0.0 
GHRP-6 did not compete for [125I]-
ghrelin binding to human GRLN-R 
transfected into COS-7 cells2 
Values shown correspond to results from this study and to results recorded in the literature (some 
studies failed to quote S.E.M values). References: 1Bedendi et al. (2003), 2Holst et al. (2005), 3Ma 
et al., (2007), 4Mousseaux et al. (2006), 5Traebert et al. (2002), 6Camina et al., 2004. 
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allowed the effects of the growth hormone secretagogues on the dissociation of [His[125I]]-
ghrelin to be explored. 
Two-point kinetic experiments showed the growth hormone secretagogues had no effect on 
the dissociation of [His[125I]]-ghrelin from the GRLN-R, as co-administration of ghrelin 
with increasing concentrations of GHRP-6, L-692,585 and MK-677 had no effect on the 
observed dissociation kinetics of [His[125I]]-ghrelin; even at growth hormone secretagogue 
concentrations that were shown to be maximally effective in stimulating [35S]GTPγS 
binding. This inferred that ghrelin and the growth hormone secretagogues bound to the 
same site on the GRLN-R. Furthermore, as ligand affinity is defined as the ratio of ligand 
association rates to dissociation rates, the results of this study suggests that co-
administration of the growth hormone secretagogues may have no effects on the affinity of 
ghrelin for the GRLN-R.  
3.3.4 GHRP-6, L-692,585 and MK-677 are not ago-allosteric 
modulators of the GRLN-R–evidence from functional studies 
The use of binding assays means that only changes that affect the affinity of a radiolabelled 
ligand for a receptor will be detected (Kenakin, 2008). However, it is now recognised that 
in addition to effects on affinity, allosteric ligands can also modulate agonist efficacy and 
even act as agonists in their own rights (Langmead and Christopoulos, 2006). For example, 
the allosteric antagonist of the metabotropic glutamate receptor mGluR1, 7-
hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester (CPCCOEt), has no 
effect on [3H]-glutamate binding but decreases the maximum efficacy of glutamate in a 
concentration-dependent fashion (Litschig et al., 1999).  
In the original study by Holst and colleagues, inositol phosphate accumulation assays 
showed co-administration of GHRP-6 or L-692,429 resulted in either a rightwards or a 
leftwards shift in the concentration-response curve to ghrelin, demonstrating either a 
decrease or an increase (respectively) in the potency of ghrelin (Holst et al., 2005). Thus to 
explore potential allosteric effects of the growth hormone secretagogues on ghrelin 
signalling, [35S]GTPγS binding studies were utilised. Concentration-response curves to 
ghrelin generated in the presence of increasing concentrations of the growth hormone 
secretagogues revealed that there was a trend for the growth hormone secretagogues to 
decrease the potency of ghrelin, although the potency of ghrelin was not significantly 
reduced at all concentrations tested (likely due to the large variance in some of the 
datasets); appearing to support an allosteric interaction between ghrelin and the growth 
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hormone secretagogues. However, a more complex effect on the efficacy of ghrelin was 
revealed.  
Concentration-response curves to ghrelin showed that at relatively low concentrations of 
ghrelin, co-administration of increasing concentrations of the growth hormone 
secretagogues caused a concentration-dependent increase in [35S]GTPγS binding, as the 
growth hormone secretagogues were acting as agonists in their own right. At the highest 
concentrations of the growth hormone secretagogues tested, [35S]GTPγS binding was 
increased over and above that achieved by ghrelin alone. Indeed, at the highest 
concentrations of the growth hormone secretagogues, increasing concentrations of ghrelin 
actually inhibited maximum [35S]GTPγS binding, bringing [35S]GTPγS levels down to 
around those observed for a maximally effective concentration of ghrelin in the absence of 
the growth hormone secretagogues.  
Reversing the experimental protocol allowed the potencies and efficacies of the growth 
hormone secretagogues to be measured in the presence of increasing concentrations of 
ghrelin. However, as ghrelin acts as a high efficacy partial agonist in respect to the growth 
hormone secretagogues, the window in which to examine the interaction was limited. At 
relatively low concentrations of ghrelin, ghrelin had no effect on the potencies of the 
growth hormone secretagogues, but due to its agonist effects increased the level of 
[35S]GTPγS binding in a concentration-dependent manner. At high concentrations of 
ghrelin there was a significant reduction in the potencies (pEC50) of the growth hormone 
secretagogues, which appeared to support an allosteric interaction between the ligands. 
However, the trend towards decreasing potencies of the growth hormone secretagogues 
could also be explained by the finding that ghrelin acts as a partial agonist in regards to the 
growth hormone secretagogues. In a situation when both a full agonist and partial agonist 
are present, a partial agonist can compete with the full agonist for receptor occupancy, 
producing a net decrease in the activation of the receptor achieved by the full agonist 
alone, thus functionally the partial agonist acts as a competitive antagonist. This has been 
demonstrated at the dopamine D2 receptor where co-administration of the endogenous 
agonist dopamine with the partial agonist aripiprazole, resulted in aripiprazole acting to 
functionally antagonise dopamine signalling (Burris et al., 2002). 
Many models have been formulated to describe allosteric modulation (Lazareno and 
Birdsall, 1995; Ehlert, 1988; Hall, 2000; Christopoulos and Kenakin, 2002); the simplest of 
these is the ternary complex model (Ehlert, 1988; see Figure 3-18), which describes 
allosteric effects in terms of changes in ligand-binding affinities only (Langmead and  
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Figure 3-18 – The allosteric ternary complex model. The allosteric ternary complex model 
(Ehlert, 1988) describes the interaction between an orthosteric (A) and allosteric (B) ligand on 
binding to a receptor (R) (in terms of changes in affinity only). The interaction is described in terms 
of the orthosteric and allosteric equilibrium dissociation constants (KA and KB) and the co-
operativity factor α, which describes the interaction between the two binding sites.     
 
Christopoulos, 2006). The magnitude and direction of the allosteric effect on ligand-
binding affinity is quantified by the co-operativity factor, α. An α>1 would describe a 
situation of positive co-operativity (i.e. the allosteric modulator is capable of binding to the 
receptor where it acts to increase the affinity of the orthosteric ligand for the receptor); α<1 
would describe negative co-operativity (where the allosteric modulator decreases the 
affinity of the orthosteric ligand for the receptor) and α=1 would describe a neutral effect 
(i.e. unaltered ligand affinity at equilibrium). An α of zero describes the situation of simple 
competition between the two ligands for binding to the orthosteric site of a receptor. Since 
the allosteric ternary complex model does not take into account any allosteric effects on 
efficacy, the model has been extended to include the co-operativity factors β and γ, which 
determines the efficacy of the orthosteric and allosteric ligand, respectively (Langmead and 
Christopoulos, 2006). Although these models are useful in understanding how allosteric 
modulation occurs, it is generally very difficult to fit such models to experimental data, 
thus ‘operational models of allosterism’ have been developed to incorporate both 
mechanistic and empirical factors for quantification of allosteric properties (Conn et al., 
2009).  
To determine whether the results from the [35S]GTPγS binding experiments described an 
allosteric or competitive interaction between ghrelin and the growth hormone 
secretagogues, data was analysed using a modified version of the operational model of 
allosterism proposed by Leach et al. (2007). Data was fitted both when the co-operativity 
factor α was set to zero (a situation which would describe a simple competitive interaction) 
and when α was left to ‘float’ (to allow quantification of α). In all instances data was best 
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fitted to describe a competitive effect, providing further evidence to support a situation 
where ghrelin and the growth hormone secretagogues competed for binding to the 
orthosteric site of the GRLN-R. 
3.3.5 SPA acts as a competitive antagonist at the GRLN-R 
If ghrelin and the growth hormone secretagogues did bind to overlapping binding sites on 
the GRLN-R, then a ligand that acts as a competitive antagonist of the ghrelin response 
would be expected to antagonise the responses to the growth hormone secretagogues. To 
further investigate this a [35S]GTPγS assay was used to test the effect of the inverse 
agonist, SPA, on the response of the GRLN-R to ghrelin, GHRP-6, L-692,585 and MK-
677. This revealed that SPA competed with ghrelin and the growth hormone secretagogues 
in a concentration-dependent manner to fully inhibit [35S]GTPγS binding achieved by EC80 
concentrations of ghrelin and the growth hormone secretagogues. Schild analysis 
demonstrated that this antagonistic effect was competitive in nature.  
The binding pocket of SPA on the GRLN-R has previously been shown to overlap with 
that of ghrelin (Holst et al., 2006), making contact with the key glutamic acid residue 
(E1243.33) in TMIII, shown to be important for binding of ghrelin and the growth hormone 
secretagogues. However, as SPA also makes contact with residues outside the ghrelin-
binding pocket, extending the SPA binding pocket towards TMII and TMIV of the GRLN-
R (Holst et al., 2006) it cannot be determined whether ghrelin and the growth hormone 
secretagogues bind to the same site on the GRLN-R. Indeed, it is impossible to determine 
from data gained from Schild analysis alone if ligand binding sites overlap (Neubig et al., 
2003), thus the results from this experiment can only confirm that binding of ghrelin or the 
growth hormone secretagogues is mutually exclusive of the binding of SPA. 
The finding that SPA acts as a competitive antagonist contrasts with a previous report 
which described SPA as acting as a non-competitive antagonist of ghrelin function, tested 
at the human GRLN-R expressed in COS-7 cells (Holst et al., 2003). However, the data 
supplied by Holst et al. (2003) appeared to demonstrate that SPA acted as a competitive 
antagonist, as there was a clear leftwards shift of the ghrelin concentration-response curve 
in the presence of 1 µM SPA.   
Interestingly, due to the inverse agonist effects of SPA, there was a distinct trend for the 
baseline of the concentration-response curves to ghrelin and the growth hormone 
secretagogues to be lowered in a concentration-dependent manner by co-administration 
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with SPA. However, concentration-response curves reflecting inverse agonism do not 
conform to the strict requirements of Schild analysis (i.e. that parallel shifts of 
concentration-response curve will occur with no dimunition in maxima) (Kenakin, 2006). 
Indeed, fitting data to the global fit model (Motulsky and Christopoulos, 2004) showed that 
due to the inverse agonists effects of SPA, the control curve (i.e. to agonist in the absence 
of SPA) was poorly fitted. To correct for the inverse agonist effects data was fitted to the 
global fit model (Motulsky and Christopoulos, 2004) after removal of baseline values of 
[35S]GTPγS binding. This resulted in the lowering of estimates of the affinity of SPA for 
the GRLN-R. 
Comparing the pKB values of SPA binding to the GRLN-R revealed that SPA acted with a 
lower affinity for the GRLN-R when ghrelin was present (compared to when SPA was co-
administered with either GHRP-6 or L-692,585). The nature of the agonist should not alter 
pKB values, thus agonist-dependent antagonist pKB values may be a sign of allosteric 
interaction (Christopoulos and Kenakin, 2002). Alternatively agonist-dependent pKB 
values may demonstrate the formation of a unique receptor conformation, leading to an 
alteration in system-dependent activity manifest as differential antagonist affinities in the 
presence of different agonists (Hay et al., 2005). The data from the experiments performed 
in this Chapter support a simple competitive mode of interaction between ghrelin and the 
growth hormone secretagogues, thus the lower affinity of SPA for the GRLN-R in the 
presence of ghrelin compared to the growth hormone secretagogues suggest that ghrelin 
could be binding and stabilising a receptor state which exhibits a different conformation 
than that achieved by binding of the growth hormone secretagogues to the orthosteric site. 
This is supported by the study by Holst et al. (2009) who demonstrated that ghrelin and the 
growth hormone secretagogues have overlapping but not identical binding sites on the 
GRLN-R, indeed as ghrelin is a large peptide it would be expected to interact with residues 
outside the main ligand pocket (i.e. within ECL2) thus it is conceivable that this could alter 
the active receptor conformation achieved by binding of ghrelin compared to the growth 
hormone secretagogues.  
3.4 Summary 
Studies by Holst et al. (2008) and Feighner et al. (1998) demonstrated that the binding sites 
for ghrelin and the growth hormone secretagogues overlap - a finding supported in this 
study by the results from competition binding studies and dissociation studies. Initial 
[35S]GTPγS binding studies provided evidence that ghrelin acted as a partial agonist in 
respect to the growth hormone secretagogues; this was an important finding for explaining 
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the changes in efficacy observed upon co-administration of ghrelin with the growth 
hormone secretagogues. Although subsequent [35S]GTPγS studies showed a trend towards 
the potencies of the growth hormones decreasing in the presence of increasing 
concentrations of ghrelin, this could be explained by ghrelin acting functionally as a 
competitive antagonist, a finding supported by analysis of the data with a modified 
operational model of allosterism (Leach et al., 2007).  
The results from this study do not attempt to replicate the model system used by Holst and 
colleagues (Holst et al., 2005), nor do they reject the conclusions that the growth hormone 
secretagogues act as ago-allosteric modulators of ghrelin function, at least in the Gαq/11 
pathway. However, in this study, the apparent allosteric actions of the growth hormone 
secretagogues in activating Gαo1 can be fully attributed to features of ligand efficacy.  
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4 Construction of a Flp-In™ T-REx™ HEK293 cell 
line expressing the GRLN-R  
4.1 Introduction 
Antibodies can be useful for detecting GPCR expression, function and movement, however 
they may not be available for the receptor being studied or may be unsuitable for use due 
to low sensitivity and selectivity. To combat this epitope tags are commonly placed at the 
N- or C-terminus of GPCRs. Epitope tags are small peptides to which commercially 
available antibodies are readily obtainable and include the eleven amino acid, virally 
encoded transmembrane protein, vesicular stomatitis virus glycoprotein (VSV-G) (Kreis, 
1986). In addition to these small tags, GPCRs may be linked to larger reporter molecules 
such as green fluorescent protein (GFP). GFP is a relatively small (27 kDa) protein 
originally isolated from the jellyfish Aequorea victoria (Morise et al., 1974), which 
possesses the ability to fold into a functional protein in a variety of expression systems 
without the need for substrate or accessory protein (Giepmans et al., 2006). Upon 
excitation with blue (395 nm) light GFP autofluoresces, emitting green light (with a 
wavelength of 508 nM), allowing the localisation of GFP, and any protein that is linked to 
it, to be visualised within a cell.  
The introduction of point mutations into GFP has led to the development of a wide range 
of GFP variants that display distinct spectral properties. For example, altering six amino 
acids in GFP leads to the formation of enhanced cyan fluorescent protein (eCFP), a protein 
that fluoresces upon excitation with 430 nm light (Heim and Tsien, 1996). Due to 
improved efficiency of protein folding, eCFP displays enhanced brightness and improved 
solubility compared to GFP (Heim and Tsien, 1996; Cormack et al., 1996; Heim et al., 
1995).  
Although epitope tags and fluorescent fusion proteins are used widely in biochemical and 
pharmacological research, several considerations must be addressed to check that the 
addition of these tags/proteins to GPCRs do not alter receptor function. These include 
confirmation that modifying the receptor does not alter receptor expression and/or 
localisation, responsiveness to ligands or coupling to G proteins.  
Ghrelin is a large peptide hormone that, as well as making contact with residues in the TM 
domains, is expected to bind to residues in the external domains of the GRLN-R, thus 
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tagging the receptor at the N-terminus could alter ligand binding properties. The C-
terminus of the GRLN-R contains multiple residues that are thought to be important in 
terminating both the ligand-dependent and ligand-independent signalling of the GRLN-R 
(Camina et al., 2006; Holliday et al., 2007); hence the addition of eCFP to the C-terminus 
of the GRLN-R could potentially interfere with the pharmacology of the receptor.  
The aims of this study were to: 
1. Create a GRLN-R construct tagged at the N-terminus with VSV-G and at the C-
terminus with eCFP.  
2. Create a cell line expressing the VSV-G-GRLN-R-eCFP construct to aid 
pharmacological studies of the GRLN-R and test whether tagging the GRLN-R 
alters receptor localisation and function. It was decided to create a Flp-In™ T-
REx™ HEK293 cell line, which places the gene of interest under the control of a 
tetracycline operon so receptor expression only occurs on the addition of 
tetracycline, to aid studies into the constitutive activity of the receptor. This would 
allow comparison of [35S]GTPγS binding in the absence and presence of receptor 
expression within the same cell line. 
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4.2 Results 
4.2.1 Generation of an inducible cell line expressing GRLN-R 
To allow detection of the GRLN-R, a VSV-G tag (YTDIEMNRLGK) was added directly 
after the initiating methionine residue at the N-terminus of the receptor and an eCFP 
protein fused to the C-terminus using PCR (Figure 4-1). The inclusion of the VSV-G tag 
and eCFP fusion protein were confirmed using DNA sequencing. To construct a Flp-In™ 
T-REx™ HEK293 cell line expressing the GRLN-R, VSV-G-GRLN-R-eCFP was cloned 
into the inducible expression vector pcDNA5/FRT/TO placing VSV-G-GRLN-R-eCFP 
gene expression under the control of a cytomegalovirus (CMV) promoter. The CMV 
promoter contains two copies of a tetracycline operon system (TeTO2), thus in the absence 
of tetracycline (or the related antibiotic doxycycline), two molecules of tetracycline 
repressor, expressed by the host cell line, can bind to each copy of the TeTO2; inhibiting 
gene expression (Figure 4-2). 
The pcDNA5/FRT/TO vector containing VSV-G-GRLN-R-eCFP was co-transfected with 
a pOG44 (a Flp-recombinase expression plasmid) into the Flp-In™ T-REx™ HEK293 cell 
line allowing homologous recombination to occur between the Flp recombinase target 
(FRT) site in the host cell line and the Flp-recombinase in the pcDNA5/FRT/TO vector 
(Figure 4-2). This placed VSV-G-GRLN-R-eCFP under the control of the tetracycline 
operon and ensured that gene expression only occurred from a single, defined 
chromosomal locus.   
To select cells in which VSV-G-GRLN-R-eCFP had been stably integrated, hygromycin B 
was added to the media 48 h after transfection. Only successfully integrated  
 
 
 
 
 
 
Figure 4-1 - Schematic diagram of the GRLN-R construct. PCR was used to add a HindIII site 
and a VSV-G tag at the N-terminus as well as to add a KpnI restriction site and remove the STOP 
codon at the C-terminus of the GRLN-R. The resulting PCR product and vector (pcDNA3) 
containing eCFP were sequentially digest with HindIII and KpnI, before VSV-G-GRLN-R was 
ligated into the vector in-frame with eCFP.
    GRLN-R  VSV-G        eCFP 
pcDNA3 
HindIII KpnI NotI 
N C 
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Figure 4-2 - Schematic diagram illustrating the construction of the Flp-In T-REx HEK293 
cell line (adapted from Invitrogen’s Flp-In™ T-REx™ HEK293 cell line product guide). A. 
VSV-G-GRLN-R-eCFP was ligated into a pcDNA5/FRT/TO plasmid which contained a hygromycin 
resistance gene lacking a promoter and START codon. This placed VSV-G-GRLN-R-eCFP under 
the control of a CMV promoter containing two TetO2 sequences. Binding of two molecules of 
tetracycline (Tet) repressor produced by the Flp-In T-REx HEK293 cells to each of these 
sequences suppressed gene expression. B. Upon co-transfection of the pcDNA5/FRT/TO with 
pOG44 the Flp-recombinase in pOG44 mediated a homologous recombination event between the 
FRT sites in the host cells and pcDNA5/FRT/TO vector - integrating VSV-G-GRLN-R-eCFP into the 
genome at the FRT site. C. Integration of pcDNA5/FRT/TO bought the SV40 promoter and START 
codon (from the lac Z zeocin gene) into proximity to the hygromycin resistance gene conferring 
cells hygromycin resistance. D. To induce gene expression either tetracycline or doxycycline (used 
in these studies) can be added to the cells, this binds with high affinity to the Tet repressor causing 
a conformational change in the repressor rendering it unable to bind to the Tet operator. The 
dissociation of the doxycycline:repressor from the complex allows induction of transcription of the 
specific gene of interest, in this case, the GRLN-R gene. 
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pcDNA5/FRT/TO vector confers hygromycin resistance to the cells, as the hygromycin 
resistance gene lacks a promoter and start codon until successful integration into the 
parental Flp-In™ T-REx™ HEK293 cell line (where it is brought into close proximity to a 
SV40 promoter and ATG initiation codon). 
4.2.2 Testing VSV-G-GRLN-R-eCFP protein expression 
To test protein expression Flp-In™ T-REx™ HEK293 cells transfected with VSV-G-
GRLN-R-eCFP (hereafter referred to as GRLN-R cells) were grown in media 
supplemented with 1 µg/mL doxycycline for 72 h. Membranes were prepared and 
immunoblotted using anti-GFP antiserum (antiserum that can detect eCFP; Lopez-
Gimenez et al., 2007) (Figure 4-3). Upon doxycycline treatment receptor expression was 
detected with an apparent molecular mass of around 105-160 kDa. As the mobility of the 
species was larger than expected, samples were treated with peptide-N4-(acetyl-β-
glucosaminyl)-asparagine amidase (PNGaseF) – an enzyme that cleaves most common 
glycan moieties. PNGaseF treatment decreased the apparent molecular mass of the 105-
160 kDa species to around 50-70 kDa. 
Strikingly, treating GRLN-R cells with doxycycline (1 µg/mL; 72 h) led to considerable 
cell detachment with the remaining cells appearing rounded compared to uninduced cells 
(Figure 4-4). As uninduced cells appeared healthy and as, within our laboratory, Flp-In™ 
T-REx™ cell lines created with other receptors (for example, the orexin 1 receptor; Ellis et 
al., 2006) did not show the same phenotype, it appeared that the effect was mediated by 
expression of the receptor construct. Thus to optimise doxycycline treatment a time course 
of doxycycline induction was assessed using lysates prepared from GRLN-R cells treated 
with 1 µg/mL doxycycline for 0-12 h. Samples were resolved by SDS-PAGE followed by  
Figure 4-3 - Testing doxycycline induction in the Flp-In™ T-REx™ HEK293 cell line 
expressing VSV-G-GRLN-R-eCFP. Cells were incubated in media with (+) or without (-) 1 µg/mL 
doxycycline (as indicated). A. After 72 h cells were harvested, membranes prepared and resolved 
by SDS-PAGE followed by immunoblotting with anti-GFP antiserum. B. After 72 h of doxycycline 
treatment membranes were prepared and 30 µg of sample treated with 1 U PNGaseF (16 h; 4 °C; 
as indicated). Samples were resolved by SDS-PAGE followed by immunoblotting with sheep anti-
GFP antiserum. Immunoblots shown are representative of three individual experiments. 
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Figure 4-4 - Brightfield microscopy images of GRLN-R cells in their basal state and upon 
receptor expression. Cells were grown on coverslips and were treated with or without 1 µg/mL 
doxycycline for 72 h (37 °C). Cells were fixed using formaldehyde (3.7 %(v/v); 10 min; 25 °C), 
mounted onto microscope slides and visualised using brightfield microscopy. Inducing GRLN-R 
expression led to rounding of the cells. Images shown are representative of three individual 
experiments. 
 
immunoblotting using anti-GFP antiserum (Figure 4-5). This showed expression of the 
GRLN-R construct increased in a time-dependent manner, with a large proportion of 
mature receptor detected at all time points beyond 6 h.   
Lysates were also prepared from GRLN-R cells that had been grown in media 
supplemented with varying concentrations of doxycycline (0–50 ng/mL) for 16 h. The time 
of 16 h was chosen for ease of receptor induction for future experiments. Lysates were 
resolved by SDS-PAGE and immunoblotted with anti-GFP antiserum alongside control 
lysates prepared from parental Flp-In™ T-REx™ HEK293 cells. Incubation of GRLN-R 
cells with 3-50 ng/mL doxycycline, led to a concentration-dependent increase in the 
intensity of two diffuse signals; one with an apparent molecular mass of around 105 kDa 
and another with an apparent molecular mass of around 70 kDa (Figure 4-5).  
To confirm that increasing the concentration of doxycycline led to an increase in protein 
expression and to test that the addition of N- and C-terminal tags to the GRLN-R did not 
affect the ability of the receptor to signal to ghrelin, a functional assay was utilised (Figure 
4-5). Membranes prepared from GRLN-R cells, transfected with Gαo1 and induced with 0-
25 ng/mL doxycycline for 16 h, were tested for their ability to produce a response in a 
[35S]GTPγS binding assay. A one-way ANOVA with Dunnett’s post-hoc test showed that 
at concentrations of 6 and 25 ng/mL doxycycline there was a significant increase in 
[35S]GTPγS binding in response to ghrelin (p<0.01). Interestingly, only at a concentration 
of 25 ng/mL doxycycline was the GRLN-R inverse agonist, SPA, able to reduce 
[35S]GTPγS binding to below the level obtained in the absence of ligand (p<0.05).
- doxycycline + doxycycline 
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Figure 4-5 - Optimising the time and concentration of doxycycline required for GRLN-R 
expression. GRLN-R cells were treated with A.1 µg/mL doxycycline for varying amounts of time 
(0-12 h) or B. with varying concentrations of doxycycline (0-50 ng/mL) for 16 h. Cells were 
harvested and lysates prepared before samples were resolved by SDS-PAGE and immunoblotted 
with sheep anti-GFP antiserum (C = control lysates prepared from parental Flp-In™ T-Rex™ 
HEK293 cells). C. GRLN-R cells were treated with varying concentrations of doxycycline (dox.) (0-
25 ng/mL) for 16 h. Cells were harvested and membranes prepared. A [35S]GTPγS binding assay 
was used to measure the response of membranes to 1 µM ghrelin or 1 µM SPA (20 min; 30 °C). G 
protein-bound [35S]GTPγS was separated from the reaction mixture by rapid filtration through GF/C 
filters soaked in 1 x PBS and bound  [35S]GTPγS measured (for 5 min) using liquid-scintillation 
spectrometry. Data points represent mean ± S.E.M for three independent experiments performed in 
triplicate, data is expressed as the percentage of [35S]GTPγS bound at basal conditions at each 
concentration. *p<0.05, **p<0.01 when compared using a one-way ANOVA with a Dunnett’s post-
hoc test. D. Raw data of [35S]GTPγS binding in membranes prepared from GRLN-R cells treated 
with 0-25 ng/mL doxycycline. *p<0.05, **p<0.01 when compared using a one-way ANOVA with a 
Dunnett’s post-hoc test. Data shown is from one experiment performed in triplicate and is 
representative of the results from three separate experiments.
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Analysis of the raw data from the experiments revealed that basal [35S]GTPγS binding was 
significantly increased after addition of only 3 ng/mL doxycycline (p<0.05 for 3 ng/mL 
doxycycline; p<0.01 for 6 ng/mL and 25 ng/mL doxycycline; measured using a one-way 
ANOVA with Dunnett’s post-hoc test). 
As treatment with 6 ng/mL doxycycline for 16 h lead to a statistically significant increase 
in [35S]GTPγS binding in response to ghrelin, this time and concentration was chosen for 
receptor induction in all future experiments. Using these conditions GRLN-R cells also 
appeared less rounded (data not shown). 
4.2.3 Localisation of VSV-G-GRLN-R-eCFP 
To test for proper protein folding and expression, as well as to examine receptor 
localisation, eCFP at the C-terminus of the GRLN-R was viewed by epifluorescence 
microscopy. In the absence of doxycycline no fluorescence signal was observed (Figure 
4-6). Upon doxycycline induction eCFP fluorescence, and hence receptor, was observed 
both at the plasma membrane and in vesicles within the cell, a distribution potentially 
consistent with the receptor being constitutively active and internalised. The addition of 
ghrelin (1 µM; 30 min; 37 ºC) prior to formaldehyde-fixation led to a redistribution of 
receptor with a loss of cell surface expression and an increase in the appearance of vesicles 
within the cell.  
4.2.4 Effect of the ghrelin, the growth hormone secretagogues 
and the inverse agonist, SPA, on GRLN-R localisation 
To assess whether treatment with maximally effective concentrations (1 µM) of ghrelin, 
GHRP-6, L-692,585 or MK-677 could internalise the GRLN-R, cells were induced with 
doxycycline and stimulated for 30 min (37 ºC), prior to formaldehyde-fixation. The plasma 
membrane was visualised by staining carbohydrate residues with WGA-Alexa Fluor®594 
conjugate prior to fixation. To view GRLN-R and plasma membrane localisation, eCFP 
was excited with 436/12 nm and Alexa Fluor®594 with 575/12 nm light (Figure 4-7). 
Upon the addition of doxcycline GRLN-R was localised both at the plasma membrane and 
in vesicles within the cell. Treatment with ghrelin and the growth hormone secretagogues 
resulted in an increase in the appearance of large punctuate vesicles inside the cell, with a 
corresponding loss of eCFP fluorescence at the plasma membrane.
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Figure 4-6 - Epifluorescence microscopy of GRLN-R cells in their basal state (- doxycycline) 
and after induction with doxycycline. VSV-G-GRLN-R-eCFP receptor expression was viewed by 
excitation of eCFP with 436/12 nm light. In the absence of doxycycline a fluorescent signal could 
not be detected. Upon doxycycline induction the GRLN-R could be detected both in vesicles 
throughout the cell and at the plasma membrane. Upon stimulation with 1 µM ghrelin (30 min; 37 
°C) a redistribution of receptor was seen with an increase in punctate vesicles within the cells with 
a corresponding loss of cell surface receptor. Scale bar width represents 20 µm. Images are 
representative of three individual experiments.
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Figure 4-7 - Localisation of GRLN-R after treatment with ghrelin, GHRP-6, L-692,585, MK-677 
or SPA (cont’d overleaf). Induced GRLN-R cells were treated with a maximally effective 
concentration of agonist (1 µM; 30 min) or inverse agonist (1 µM; 30 min or 16 h). Cells were 
formaldehyde-fixed before the plasma membrane was stained with WGA-Alexa Fluor® -594 
conjugate. Cells were mounted onto slides and visualised using epifluorescence microscopy. The 
images of GRLN-R (psuedo-coloured green) and plasma membrane (red) were aligned (as seen in 
colour combine column) with overlapping regions shown as a yellow colour. Images are 
representative of three individual experiments. Scale bar width = 20 µm 
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Figure 4-7 - Localisation of GRLN-R after treatment with ghrelin, GHRP-6, L-692,585, MK-677 
or SPA (cont’d). Induced GRLN-R cells were treated with a maximally effective concentration of 
agonist (1 µM; 30 min) or inverse agonist (1 µM; 30 min or 16 h). Cells were formaldehyde-fixed 
before the plasma membrane was stained with WGA-Alexa Fluor® -594 conjugate. Cells were 
mounted onto slides and visualised using epifluorescence microscopy. The images of GRLN-R 
(psuedo-coloured green) and plasma membrane (red) were aligned (as seen in colour combine 
column) with overlapping regions shown as a yellow colour. Images are representative of three 
individual experiments. Scale bar width = 20 µm 
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Figure 4-8 - Proportion of GRLN-R detected at the plasma membrane after the treatment of 
GRLN-R cells with ghrelin and the growth hormone secretagogues. Autoquant software was 
used to determine the proportion of receptor both at the plasma membrane and in intracellular 
regions of cells after treatment with 1 µM ghrelin, GHRP-6, L-692,585 MK-677 (30 min) or SPA (30 
min and 16 h). Data points represent the mean ± S.E.M of the quantification of three cells.*p<0.05 
**p<0.01 when compared to basal using a one-way ANOVA with a Dunnett’s post-hoc test. 
 
As SPA is an inverse agonist of the GRLN-R it would be expected to ablate the 
constitutive activity and internalisation of the GRLN-R. To test whether SPA altered 
GRLN-R localisation, cells were induced with doxycycline and treated with 1 µM SPA for 
either 30 min or 16 h. As SPA is a peptide ligand it is expected to be membrane-
impermeable, therefore, SPA should only bind to the GRLN-R located at the plasma 
membrane. If receptor internalisation and recycling took longer than 30 min, than GRLN-R 
would still be visible as vesicles within the cell. After 30 min of SPA treatment, GRLN-R 
was still detected within intracellular regions of the cells, whereas after 16 h treatment the 
majority of receptor was located at the plasma membrane. 
Internalisation was quantified using Autoquant software to determine the proportion of 
eCFP fluorescence at the plasma membrane and inside the cell (Figure 4-8). Using a one-
way ANOVA with Dunnett’s post-hoc test it was shown that there was a significant 
decrease in plasma membrane localised receptor upon stimulation with ghrelin, GHRP-6 
(p<0.01), L-692,585 and MK-677 (p<0.05). Treatment with 1 µM SPA for 30 min did not 
alter the proportion of eCFP expressed at the plasma membrane, however, treatment with 1 
µM SPA for 16 h significantly increased the amount of plasma membrane located receptor 
(p<0.01; one-way ANOVA with Dunnett’s post-hoc test). 
 
 
** ** 
* * 
** 
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Figure 4-9 – Testing the ability of ghrelin and growth-hormone secretagogues to evoke a 
[35S]GTPγS response in GRLN-R cells transfected to express Gαo1. Concentration-response 
curves to ghrelin, MK-677, GHRP-6 and L-692,585 (20 min; 30 °C) were performed membranes 
from induced GRLN-R cells transfected with Gαo1. G protein-bound [35S]GTPγS was separated from 
the reaction mixture by rapid filtration through GF/C filters soaked in 1 x PBS and bound  
[35S]GTPγS measured (for 5 min) using liquid-scintillation spectrometry.  Data points represent 
mean ± S.E.M of three independent experiments performed in triplicate. 
 
4.2.5 Response of GRLN-R through Gαi/o activation 
In Chapter 3 the ability of GRLN-R to activate Gαi/o was assessed. In order to determine 
whether the pharmacology of GRLN-R had been altered by the addition of epitope tags 
concentration-response curves to ghrelin, GHRP-6, L-692,585 and MK-677 were 
constructed using a [35S]GTPγS binding assay in membranes prepared from GRLN-R cells 
transfected with Gαo1 (Figure 4-9). The efficacy and potency values obtained are displayed 
in Table 4-1. 
The efficacy and potency of the growth hormone secretagogues were compared to the 
values obtained for ghrelin using a one-way ANOVA with Dunnett’s post-hoc test. As 
before, GHRP-6, L-692,585 and MK-677 acted as super-agonists having a significantly 
higher efficacy than ghrelin (p<0.01). There were no differences in the values obtained for 
the potencies or efficacies of ghrelin and the growth hormone secretagogues acting at the 
wild-type (untagged) receptor compared to the epitope-tagged (tagged) receptor. 
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Table 4-1 - Potency and efficacy values of ligands acting at GRLN-R via Gαi/o activation as 
measured using a [35S]GTPγS binding assay.  
pEC50 ± S.E.M Max. efficacy ± S.E.M Ligand 
Tagged receptor Untagged receptor Tagged receptor Untagged receptor 
Ghrelin 9.19 ± 0.16 9.11 ± 0.10 98.1 ± 1.9 95.4 ± 3.4
 
MK-677 9.28 ± 0.24 9.21 ± 0.12 167.8 ± 8.4 139.6 ± 9.9 
GHRP-6 8.01 ± 0.07 7.85 ± 0.13 152.7 ± 6.5 139.5 ± 5.4 
L-692,585 7.20 ± 0.03 7.60 ± 0.17 150.5 ± 8.0 145.4 ± 14.0 
Efficacy values are displayed as the percentage of the maximum response obtained to ghrelin. 
Datasets were fitted with sigmoidal concentration-response curves with a Hill slopes constrained to 
1. Comparing pEC50 values between the tagged and untagged receptor showed there was no 
significant differences in the potencies or efficacies of ghrelin and the growth hormone 
secretagogues acting at the tagged or untagged receptor. Values shown represent the mean ± 
S.E.M of three independent experiments performed in triplicate and compared using an un-paired, 
two-tailed t-test. 
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4.3 Discussion 
4.3.1 The Flp-In™ T-REx™ HEK293 cell line allows control of 
GRLN-R expression 
Tagging the GRLN-R at the N-terminus with VSV-G and at the C- terminus with eCFP 
allowed the receptor to be detected in immunoblotting and epifluorescence microscopy 
experiments. Using the VSV-G-GRLN-R-eCFP construct a Flp-In™ T-REx™ HEK293 
cell line expressing the receptor construct under the control of a tetracycline operon was 
created. The use of the GRLN-R cell line in immunoblotting, epifluorescence microscopy 
and functional studies demonstrated that tagging the receptor had no effect on the 
localisation and signalling of the GRLN-R. Furthermore, in the absence of doxycycline the 
VSV-G-GRLN-R-eCFP construct could not be detected, demonstrating that expression of 
the GRLN-R gene occurred in a doxycycline-dependent manner.   
4.3.2 GRLN-R is modified by N-linked glycosylation 
Upon GRLN-R expression, immunoblotting of membranes prepared from GRLN-R cells 
revealed that the VSV-G-GRLN-R-eCFP construct existed with an apparent molecular 
mass that was greater than predicted (with a diffuse signal being observed running at 105 
kDa instead of the predicted 70 kDa). However, during migration through the ER and the 
Golgi apparatus, GPCRs undergo post-translational modifications to achieve their mature 
status, with common modifications including the formation of disulphide bonds and the 
addition of oligosaccharides to the side-chain of asparagine residues (N-linked 
glycosylation). Two asparagine residues in the N-terminus of the GRLN-R are predicted to 
undergo N-linked glycosylation as they occur as part of a N-X-S/T motif.  Indeed, in this 
study, the GRLN-R was shown to undergo N-linked glycosylation as treatment of 
membrane samples with PNGaseF, an enzyme that hydrolyses all common types of N-
linked glycan chains, decreased the molecular mass of the 105 kDa species to around 50-
70 kDa. The diffuse nature of the 105 kDa signal detected in immunoblotting was likely 
due to the effect of glycan residues on the movement of protein through the separating gel 
during SDS-PAGE as carbohydrate residues can interfere with peptide-SDS interactions 
(Wheatley and Hawtin, 1999).  
PNGaseF cleaves all common glycan moieties and so does not distinguish between high-
mannose and complex glycosylated receptor forms. Upon receptor induction 
immunoblotting revealed the presence of two species – one form with an apparent 
molecular mass of 70 kDa and a larger form with an apparent molecular mass of around 
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105 kDa. Although not tested in this study the lower molecular mass species is expected to 
correspond to immature receptor and the larger form to mature receptor.  
N-linked glycosylation has been demonstrated to be vital for the correct cell-surface 
expression of some GPCRs, such as the angiotensin receptor AT1 (Lanctot et al., 2006). 
However, this is not universally true as for other receptors disruption of N-linked 
glycosylation has no effect on receptor distribution (van Koppen and Nathanson, 1990). 
Indeed truncation of the N-terminus of the GRLN-R (from residues 1-35 which includes 
the asparagine residues that are predicted to undergo glycosylation) had no effect on the 
distribution of the GRLN-R (Holst et al., 2009); thus suggesting that glycosylation is not 
essential for the trafficking of the GRLN-R to the cell surface. 
4.3.3 GRLN-R expression can be altered by time or 
concentration of doxycycline induction 
By altering the time and concentration of doxycycline treatment in GRLN-R cells the level 
of receptor expression could be altered. For example, there was a time-dependent increase 
in GRLN-R expression in GRLN-R cells treated with 1 µg/mL doxycycline for 0-12 h, 
observed as an increase in intensity of 105 kDa and 70 kDa signals. After only 6 h of 
doxycycline treatment, the majority of GRLN-R existed with an apparent molecular mass 
of 105 kDa suggesting the formation of glycosylated, mature GRLN-R, which would 
indicate that the receptor had been synthesised, folded and transported to the plasma 
membrane. Immunoblotting of membranes prepared from cells induced with varying 
concentrations of doxycycline (0-50 ng/mL) showed that, at doxycycline concentrations of 
6 ng/mL and above, the majority of the GRLN-R existed as a form with an apparent 
molecular mass of 105 kDa. As functional assays showed that 6 ng/mL was the lowest 
concentration of doxycycline to which a significant response to ghrelin was measured, 
treatment of GRLN-R cells for 16 h with 6 ng/mL doxycycline was deemed optimal to 
stimulate receptor expression.  
The use of recombinant systems to express GPCRs may lead to receptors being over-
expressed compared to the receptor level observed in vivo. Although in this study care was 
taken to optimise receptor expression, allowing the lowest possible level of GRLN-R 
expression to be used for these and future studies, even at this level receptor over-
expression is likely due to the extremely low levels of endogenous GRLN-R in vivo. For 
example, GRLN-R expression levels have been reported as being 8 fmol/mg in human left 
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ventricle (Katugampola et al., 2001) and 6 fmol/mg in rat pituitary gland (McKee et al., 
1997). 
4.3.4 GRLN-R displays constitutive activity and internalisation 
The GRLN-R has been reported to display a high degree of constitutive activity in the 
Gαq/11 pathway (Holst et al., 2003). Early studies of constitutive activity by Costa and Herz 
showed high levels of receptor expression could uncover the existence of spontaneously 
active receptors (Costa and Herz, 1989). In this study, the constitutive activity of GRLN-R 
was shown to be linked to the level of receptor expression, as binding of [35S]GTPγS was 
increased in a doxycycline-concentration-dependent fashion in membranes prepared from 
GRLN-R cells. However, the response of the GRLN-R to the inverse agonist SPA only 
reached statistical significance upon induction with 25 ng/mL doxycycline.  
In Chapter 3 the basal [35S]GTPγS loading observed upon expression of the GRLN-R was 
significantly reduced by the addition of 1 µM SPA. The membrane preparations used in 
Chapter 3 (supplied by GlaxoSmithKline) were prepared from HEK293 cells that had been 
transfected to express the GRLN-R using a Bacman virus, which, due to a higher 
transfection efficiency, would likely result in higher levels of GRLN-R expression. Thus 
the differences in GRLN-R expression levels may explain why SPA had a more marked 
effect in Chapter 3 than demonstrated here (Figure 4-5). 
Interestingly, for some GPCRs, the perceived constitutive activity has been demonstrated 
to be due to the presence of an endogenous agonist in the cell line used to express the 
receptor. For example, the free fatty acid 1 receptor showed a high degree of basal 
[35S]GTPγS loading in HEK293 cells, however, the addition of fatty acid-free BSA to the 
assay media reduced the apparent constitutive activity of the receptor, suggesting the 
presence of an endogenous fatty acid that is stripped away upon addition of fatty acid-free 
BSA (Stoddart et al., 2007). Other GPCRs, such as the protease-activated receptors, even 
have their own ligand encoded within their N-termini. Upon cleavage by thrombin or 
trypsin the ligand is exposed thus enabling it to activate the receptor. Furthermore, the N-
terminal domain of the melanocortin-4 receptor (a receptor involved in appetite 
suppression) has been demonstrated to function as a tethered ligand that maintains the 
‘constitutive’ activity of this receptor (Srinivasan et al., 2004). In the GRLN-R, the 
presence of phenylalanine residues in TMVI and TMVII (F2796.51, F3097.39 and F3127.42) 
have been suggested to act as tethered agonists, maintaining the receptor in an active 
conformation (Schwartz and Holst, 2007). This study has made no attempt to rule out the 
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possibility that an agonist expressed in HEK293 cells (or the phenylalanine residues in 
TMVI and TMVII) cause the apparent constitutive activity of the GRLN-R, but it does 
confirm that tagging of the GRLN-R does not ablate the constitutive activity of the 
receptor. 
Epifluorescence photographs showed that upon induction with 6 ng/mL doxycycline the 
GRLN-R was located both at the plasma membranes and in vesicles within the cell - a 
localisation consistent with a constitutively internalising receptor. Other studies, in both 
recombinant systems (Holliday et al., 2007) and in cells endogenously expressing the 
GRLN-R (Abizaid et al., 2006; Dass et al., 2003; Kleinz et al., 2006; Dixit et al., 2006) 
agree with this. In contrast, a study in CHO cells stably expressing the GRLN-R modified 
by the addition of a GFP tag to the C-terminus showed the GRLN-R to be plasma 
membrane localised (Camina et al., 2004). As the ability to observe constitutive activity is 
not just dependent on intrinsic receptor properties but on the specific cellular background, 
the apparent constitutive activity of a given GPCR may vary in different expression 
systems (Seifert and Wenzel-Seifert, 2002). For example, at similar expression levels, low 
constitutive activity of the µ-opioid receptor was seen when this receptor was transfected 
into CHO cells while, conversely, expression in HEK293 cells led to detection of moderate 
levels of activity (Burford et al., 2000; Selley et al., 2000). Indeed, although constitutive 
activity of the GRLN-R can be measured both in HEK293 and COS-7 cells (Holliday et 
al., 2007; Holst et al., 2003; Holst et al., 2004) to date constitutive activity and constitutive 
internalisation of the GRLN-R has not been detected in CHO cells (Camina et al., 2004; 
Camina et al., 2006), suggesting the absence of machinery required for constitutive signal 
generation and receptor internalisation in CHO cells (although the GRLN-R can still 
internalise upon stimulation with ghrelin; Camina et al., 2004).  
In the epifluorescence microscopy experiments, only upon addition of 1 µM SPA for 16 h 
was the GRLN-R demonstrated to be enriched at the plasma membrane. In contrast, 30 min 
of SPA treatment had no significant effect on GRLN-R localisation, although this time was 
sufficient for SPA to reduce constitutive activation of the GRLN-R in the [35S]GTPγS 
binding assays. As SPA is a peptide ligand it is expected that it is cell-impermeable; 
therefore it should only bind to receptors expressed at the cell surface. This suggests that 
the receptor internalisation and recycling process takes over 30 min, however, as only two 
time points were tested the exact kinetics of constitutive receptor internalisation could not 
be determined. Ligand-independent internalisation and recycling of the GRLN-R has been 
shown to take around 15-30 min in both COS-7 and HEK293 cells (Holliday et al., 2007; 
Holst et al., 2004), although this time scale is very rapid compared to the time-course of 
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receptor internalisation and recycling upon ghrelin treatment (3-6 h in CHO cells; Camina 
et al., 2004). To allow comparison of the ligand-dependent and ligand-independent 
internalisation of the GRLN-R, further experiments are needed to measure constitutive and 
agonist-induced internalisation, both within the same study and expression system. 
4.3.5 Constitutive activity of GRLN-R appears to be detrimental 
to HEK293 cells 
Upon the addition of 1 µg/mL doxycycline for 72 h, cells appeared rounded compared to 
cells uninduced with doxycycline, furthermore there was a considerable level of cell 
detachment. This effect was receptor mediated as reduction in receptor expression led to 
less prominent cell changes. Although not investigated further in this study, the cell 
rounding phenotype is likely to be mediated by the constitutive activity of the GRLN-R. 
This is supported by a study conducted in Kostenis’s group where the expression of the 
constitutively active sphingosine 1-phosphate-5 receptor (S1P5) led to a similar receptor-
dependent cell rounding and detaching phenotype as observed here. This effect was cell 
line-independent as it was seen after receptor was expressed in HEK293, NIH-3T3, COS-7 
and RH7777 cells (Niedernberg et al., 2003).  
The cell rounding phenotype shown in this study may be due to constitutive activation of 
the Gαq/11 pathway, which could induce calcium release from the endoplasmic reticulum 
and cause an influx of exogenous calcium into the cell. Calcium is an important signalling 
molecule that needs to be buffered within stringent margins. Constitutive release of 
calcium could, therefore, trigger the cell to undergo apoptosis. Surprisingly, GRLN-R has 
actually been shown to have an anti-apoptotic effect in primary cultured rat cortical 
neurones – an effect abolished by treatment with the GRLN-R antagonist/inverse agonist 
[D-lys-3]-GHRP-6 (Chung et al., 2008). 
Actin cytoskeleton and cell rounding responses are frequently mediated by the Gα12/13 
pathway to which the GRLN-R may also couple (Holst et al., 2005) therefore it is possible 
that the receptor is constitutively activating the Gα12/13 pathway, leading to the changes in 
cell morphology; a suggestion that warrants further investigation. 
4.3.6 Ghrelin and the growth hormone secretagogues can 
internalise the GRLN-R 
The eCFP tag provided an ideal way to monitor the localisation of GRLN-R in intact cells, 
allowing the internalisation of receptor to various ligands to be assessed. Maximally 
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effective concentrations of ghrelin, GHRP-6, L-692,585 and MK-677 all caused a marked 
redistribution in the localisation of the GRLN-R. This was demonstrated by a significant 
loss of fluorescent signal at the plasma membrane with a corresponding increase in the 
appearance of large punctate vesicles within the cell, characteristic of receptor endocytosis. 
The GRLN-R has previously been shown to internalise to treatment with ghrelin and 
GHRP-6 (Camina et al., 2004) however to the best of my knowledge the effect of GHRP-6 
and L-692,585 on receptor distribution has not previously been studied.  
The ability of the growth hormone secretagogues to internalise GRLN-R could not be 
predicted from their ability to activate the Gαi/o pathway as not all agonists are able to 
internalise GPCRs. For example, the µ-opioid receptor could be internalised upon 
treatment with etorphine but not by morphine even though both ligands promote a Gαi/o-
mediated response (Zhang et al., 1998). Internalisation is not inherently dependent on 
ligand potency or efficacy. Clinical trials on the GPR38 agonist ABT-229 showed that 
although ABT-229 was less potent than motilin (the endogenous agonist) it was more 
potent at inducing desensitisation and internalisation of GPR38 (Thielemans et al., 1995). 
4.3.7 Tagging the GRLN-R does not affect receptor 
pharmacology 
Comparing the potencies and efficacies of ghrelin and the growth hormone secretagogues 
acting on the wild-type (untagged) and modified (tagged) receptor showed that there was 
no differences in the responses of these receptors. Thus the [35S]GTPγS data shows that 
even with the N- and C-terminal modifications, ligands can still bind to the GRLN-R and 
the GRLN-R can still bind to (and activate) G protein. This has also been demonstrated for 
other receptors such as the α1A adrenoceptor (Stanasila et al., 2003). 
4.3.8 Summary 
The results of this chapter have shown that modifying the GRLN-R with both N- and C-
terminal epitope tags does not affect receptor localisation and pharmacology. Furthermore, 
the Flp-In™ T-Rex™ HEK293 cell line expressing the VSV-G-GRLN-R-eCFP construct 
proved to be an extremely useful tool in studying both the ligand-dependent and ligand-
independent activation of the GRLN-R.
  160  
5 Exploring the promiscuous G protein coupling 
of the GRLN-R 
5.1 Introduction 
It is now appreciated that instead of exhibiting just a single active state, GPCRs may 
display multiple active conformations. This has been elegently demonstrated in studies on 
the purified β2 adrenoceptor labelled with a fluorescent probe (fluorescein malemide) at an 
environmentally sensitive cysteine residue (C265) located in the third intracellular loop at 
the cytoplasmic end of TMVI (Ghanouni et al., 2001; Swaminath et al., 2004). Using 
fluorescent lifetime spectroscopy to detect changes in the fluorophore, and therefore 
changes in the conformational state of the β2 adrenoceptor, it could be seen that binding of 
the full agonist isoproterenol resulted in the display of two distinct conformational states of 
the receptor. However, binding of the partial agonist dobutamine to the β2 adrenoceptor led 
to a significant change in the fluorescent lifetime of one of these conformational states, 
demonstrating that different agonists stabilise different, or ‘agonist-specific’, receptor 
states (Ghanouni et al., 2001; Kobilka, 2002).  
Further evidence for agonist-specific receptor states has come from the observation that 
changes in the potencies and/or efficacies of a panel of ligands acting on a single receptor 
type can be measured upon activation of different pathways, a property that can be 
described by the term ‘functional selectivity’ (Urban et al., 2007). Functional selectivity 
has been demonstrated at the pituitary adenylate cyclase-activating peptide (PACAP) 
receptor, where the agonists PACAP1-27 and PACAP1-38 could stimulate PACAP receptor-
mediated adenylate cyclase activation with equal potencies, but only PACAP1-38 could 
evoke an increase in inositol phosphate levels through activation of phosholipase Cβ 
(Spengler et al., 1993). Functional selectivity, as demonstrated by differences in ligand 
efficacies, has been shown at the serotonin type 2C receptor (5-HT2C) where the agonists 
(±)-2.5-Dimethoxy-4-iodoamphetamine (DOI) and 5-hydroxytryptamine (5-HT) displayed 
equal efficacies in activation of the arachidonic acid pathway, whilst DOI elicited only 60 
% of the 5-HT-induced increase in inositol phosphate accumulation (Berg et al., 1998).  
The GRLN-R has been described as a promiscuous receptor being able to couple to Gαq/11 
(Howard et al., 1996), Gαi/o (Bassil et al., 2007; Esler et al., 2007), Gαs (Rossi et al., 2008; 
Kohno et al., 2003) and Gα13 (Holst et al., 2005). The aim of this chapter was to further 
explore the promiscuous coupling of the GRLN-R, by comparing the activation of Gαq/11
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and Gαi/o pathways in response to ghrelin and the growth hormone secretagogues. To 
achieve this responses of the GRLN-R were measured both at the level of G protein 
activation, by the use of [35S]GTPγS binding assays, and in whole cell second messenger 
signalling assays. 
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5.2 Results 
5.2.1 Testing Gαi/o coupling to GRLN-R  
[35S]GTPγS filtration binding and scintillation proximity assays (shown in Chapters 3 and 
4) are generally thought to reflect Gαi/o signalling, thus it was assumed that the responses in 
the [35S]GTPγS filtration binding assays were mediated solely through Gαo and 
endogenous Gαi/o expressed in the Flp-In™ T-REx™ HEK293 cells. In this chapter I 
sought to confirm that this signalling was indeed Gαi/o mediated by the use of selective 
pharmacological inhibitors. The interaction between a receptor and the Gαi/o class of G 
proteins can be abolished by Bordella pertussis toxin (PTx)-mediated ADP-ribosylation of 
a cysteine residue four residues from the extreme C-terminus. Thus GRLN-R cells were 
co-incubated with 6 ng/mL doxycycline and 25 ng/mL PTx for 16 h. Following cell 
harvesting, membranes were prepared and the response to treatment with 1 µM ghrelin 
measured. To confirm that the response was not mediated through the Gαq/11 family, 
membranes were challenged with 1µM ghrelin in the presence of 0.1 µM YM-254890 
(Figure 5-1). YM-254890 is a toxin isolated from Chromobacterium species that 
specifically blocks the exchange of GDP for GTP on the α-subunit of the Gαq/11 family of 
G proteins (Takasaki et al., 2004).  
A one-way ANOVA with Tukey’s multiple comparison test revealed that treating 
membranes from uninduced GRLN-R cells with 1 µM ghrelin did not increase [35S]GTPγS 
binding compared to basal values (p>0.05). Inducing GRLN-R expression led to a 
significant increase in binding (p<0.01) in response to ghrelin stimulation. Indeed, binding 
of [35S]GTPγS in membranes co-incubated with YM-254890 and ghrelin also showed a 
significant increase over basal levels (p<0.01) – an effect that was not statistically different 
to that obtained in the absence of YM-254890 (p>0.05). Treatment of membranes with 
PTx or a combination of PTx and YM-254890 attenuated the response to ghrelin (p>0.05; 
compared to basal values in uninduced cells). Thus it appears that the filtration method 
indeed measured predominantly Gαi/o-mediated [35S]GTPγS binding in this system. 
To assess if PTx and YM-254890 were having an effect on the basal levels of [35S]GTPγS 
binding, a one-way ANOVA was performed on the combined raw data obtained from these 
experiments. There was no significant difference in levels of basal [35S]GTPγS binding 
(p=0.75).
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Figure 5-1 –
 
The GRLN-R can couple to the Gαi/o pathway. GRLN-R cells were transfected with 
Gαi/o and receptor expression induced, as required, with 6 ng/mL doxycycline (dox.) for 16 h. A. To 
test receptor coupling to Gαi/o membranes were prepared from GRLN-R cells treated with 25 ng/mL 
PTx (16 h) and the response to 1 µM ghrelin (20 min; 30 ºC) measured. To test receptor coupling 
to Gαq/11 the response to 1 µM ghrelin was measured after co-administration with 0.1 µM YM-
254890 (20 min; 30 °C). G protein-bound [35S]GTPγS was separated from the reaction mixture by 
rapid filtration through GF/C filters soaked in 1 x PBS and bound  [35S]GTPγS measured (for 5 min) 
using liquid-scintillation spectrometry. Data points represent the mean ± S.E.M of four independent 
experiments performed in triplicate. Data is expressed as the percentage of the response over 
basal values obtained in each of the conditions outlined above. N/s = non-significant, **p<0.01 
when compared using a one-way ANOVA with Tukey’s multiple comparison test. B. Raw data 
obtained for the basal levels of [35S]GTPγS loading after treatment with YM-254890, PTx or a 
combination of the two. Data points represent the mean ± S.E.M of four independent experiments 
performed in triplicate.  
 
In Chapter 4, I demonstrated that, in membranes from GRLN-R cells enriched with Gαo1, 
the GRLN-R could increase [35S]GTPγS binding upon treatment with ghrelin and the 
growth hormone secretagogues. However, transfection of extra G protein into the cells 
creates a stimulus-bias which could force GRLN-R to couple to non-preferred G protein 
species.
 
Thus to test whether the GRLN-R could couple to Gαi/o in GRLN-R cells, a 
[35S]GTPγS filtration assay was conducted in the absence of exogenous G protein (Figure  
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Figure 5-2 - The GRLN-R can respond to ghrelin in the absence of exogenous G protein. 
GRLN-R cells were induced with 6 ng/mL doxycycline (16 h) and membranes prepared. A 
[35S]GTPγS filtration binding assay was used to measure [35S]GTPγS binding at basal levels and 
after treatment with 1 µM ghrelin (20 min; 30 °C). G protein-bound [35S]GTPγS was separated from 
the reaction mixture by rapid filtration through GF/C filters soaked in 1 x PBS and bound  
[35S]GTPγS measured (for 5 min) using liquid-scintillation spectrometry. Data points represent the 
mean ± S.E.M of three independent experiments performed in duplicate. * p<0.05 as measured 
using an unpaired, two-tailed t-test. 
 
5-2). An unpaired, two-tailed t-test revealed a significant increase in [35S]GTPγS binding 
upon treatment with 1 µM ghrelin (p<0.05). Overall there was around a 1.2-fold increase in 
signal upon stimulation with ghrelin, compared to around a 2-fold increase observed upon 
the transfection of additional G protein.  
5.2.2 Response of GRLN-R through Gαq/11 activation 
The [35S]GTPγS filtration assay is limited to measuring the activation of the Gαi/o family of 
G proteins due to a combination of the high rate of basal guanine nucleotide exchange of 
Gαi/o and their relatively high expression levels in HEK293 cells (Milligan, 2003). To 
measure activation of other G proteins, [35S]GTPγS binding assays are commonly 
employed, using an immunoprecipitation step to separate G protein-bound [35S]GTPγS 
from unbound [35S]GTPγS (e.g Stoddart et al., 2008; Parenty et al., 2008). Thus in this 
study, to measure activation of Gαq/11, a [35S]GTPγS binding assay with an 
immunoprecipitation step was performed in membranes prepared from induced GRLN-R 
cells transfected with Gαq (Figure 5-3), where [35S]GTPγS-bound Gαq was measured 
following immunoprecipitation with anti-Gαq antisera.  
To investigate whether the GRLN-R constitutively activated the Gαq pathway, Gαq was 
transfected into GRLN-R cells and receptor expression was induced with 6 ng/mL 
doxycycline (16 h). Receptor expression led to a significant increase in basal loading of 
[35S]GTPγS (p<0.001), a response 17.6 ± 2.6 % over the basal response measured in the 
absence of the GRLN-R. Ghrelin stimulation significantly increased [35S]GTPγS binding in  
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Figure 5-3 - Ghrelin and the growth hormone secretagogues can increase [35S]GTPγS 
binding via activation of the Gαq/11 pathway in membranes prepared from GRLN-R cells. A. 
To test whether GRLN-R was constitutively active in the Gαq pathway, membranes were prepared 
from GRLN-R cells transfected with Gαq and receptor expression either induced with 6ng/mL 
doxycycline (16 h) (black bars) or left uninduced (white bars). [35S]GTPγS binding was measured at 
basal levels and after stimulation with 1µM ghrelin (30 min; 30 °C), as indicated. Gαq was 
immunoprecipitated from the reaction mixture using anti-Gαq antiserum and bound [35S]GTPγS 
measured using liquid scintillation spectrometry (5 min/sample). Data is expressed as the 
percentage of the maximum response to ghrelin in doxycycline-induced cells. Data points represent 
the mean ± S.E.M of five independent experiments performed in triplicate. ***p <0.001 as 
measured using a one-way ANOVA with Tukey’s multiple comparison test. B. Concentration-
response curves to ghrelin, MK-677, GHRP-6 and L-692,585 (30 min; 30 °C) were performed on 
membranes prepared from induced GRLN-R cells transfected with Gαq. Data points represent the 
mean ± S.E.M of three independent experiments performed in triplicate.  
 
membranes prepared from induced GRLN-R cells (p<0.001), but had no significant affect 
in membranes prepared from uninduced GRLN-R cells (p>0.05). 
To obtain potency and efficacy values for ghrelin and the growth hormone secretagogues 
through Gαq/11 activation, concentration-response curves were generated (Figure 5-3) using 
a [35S]GTPγS binding assay with an immunoprecipitation step. Table 5-1 displays the 
values obtained. A one-way ANOVA with Dunnett’s post-hoc test showed that L-692,585 
was significantly less potent than ghrelin in inducing a Gαq/11 response (p<0.01). There was 
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no statistical difference in the efficacy of the ligands compared to ghrelin as determined 
using a one-way ANOVA (p=0.51). 
Table 5-1 – Potency and efficacy values of ligands acting at GRLN-R via Gαq activation as 
measured using a [35S]GTPγS binding assay with immunoprecipitation step.  
Ligand pEC50 ± S.E.M Emax ± S.E.M 
Ghrelin 9.03 ± 0.13 94.3 ± 4.0 
MK-677 9.05 ± 0.15 98.7 ± 4.8 
GHRP-6 7.98 ± 0.23 113.2 ± 10.9 
L-692,585 7.11 ± 0.20** 116.5 ± 12.7 
Data is expressed as mean ± S.E.M of three-seven individual experiments performed in triplicate. 
Emax is the maximum response of ligand expressed as the percentage of the maximum response to 
ghrelin. **p<0.01 when responses were compared to ghrelin using a one-way ANOVA with 
Dunnett’s post-hoc test. 
 
Sensitivity of the [35S]GTPγS signal to YM-254890 was tested to confirm that the response 
to ghrelin measured in the [35S]GTPγS binding assay with immunoprecipitation step was 
solely mediated through Gαq. As it was shown in Chapter 3 and 4 (and Figure 5-1 of this 
chapter) that the GRLN-R could couple to Gαi/o the effect of PTx (25 ng/mL; 16 h) on 
[35S]GTPγS binding was also investigated. Cells were transfected with Gαq, receptor 
expression
 
induced with 6 ng/mL doxycycline (16 h; as required) and challenged with 
either 1 µM ghrelin or 1 µM SPA.  As Figure 5-4 demonstrates, no significant effect on 
[35S]GTPγS binding could be detected in membranes prepared from uninduced GRLN-R 
cells treated with either ghrelin or SPA. The addition of 1 µM ghrelin caused a significant 
increase in bound [35S]GTPγS, both in membranes prepared from induced cells and 
induced cells treated with PTx (p<0.001). This effect was abolished upon treatment with 
YM-254890 or upon co-incubation with YM-254890 and PTx.  
To assess if PTx and YM-254890 altered basal levels of [35S]GTPγS binding a one-way 
ANOVA with Tukey’s multiple comparison test was performed on the combined raw data. 
The effect of 1 µM of the inverse agonist SPA was also assessed. This revealed that 
receptor expression led to a significant increase in basal loading of [35S]GTPγS in 
membranes from doxycycline-induced cells and doxycycline-induced cells treated with 
PTx (p<0.001 and p<0.01, respectively). Incubation with 1 µM SPA caused a significant 
reduction in binding of [35S]GTPγS in membranes prepared from doxycycline-induced 
GRLN-R cells although this was not significant in membranes prepared from PTx treated 
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Figure 5-4 – The [35S]GTPγS binding assay with immunoprecipitation step solely measures 
activation of the Gαq/11 pathway. GRLN-R cells were transfected with Gαq/11 and induced with 6 
ng/mL doxycycline (16 h). A. To test receptor coupling to Gαi/o, membranes were prepared from 
GRLN-R cells treated with 25 ng/mL PTx (16 h) and the response to 1 µM ghrelin and 1 µM SPA 
measured (30 min; 30 °C). To test receptor coupling to Gαq/11 the response to 1 µM ghrelin and 1 
µM SPA was measured after co-administration with 0.1 µM YM-254890 (30 min; 30 ºC), as 
indicated. Gαq was immunoprecipitated from the reaction mixture using anti-Gαq antiserum and 
bound [35S]GTPγS measured using liquid scintillation spectrometry (5 min/sample). Data points 
represent the mean ± S.E.M of four independent experiments performed in triplicate. Data is 
expressed as the percentage of the response over basal values obtained in each of the conditions 
outlined above. ***p<0.001 when compared using a one-way ANOVA with Tukey’s multiple 
comparison test.  B. Raw data obtained for the basal levels of [35S]GTPγS loading after treatment 
with YM-254890, PTx or a combination of the two. Data points represent the mean ± S.E.M of three 
independent experiments performed in triplicate. * p<0.05, **p<0.01 and ***p<0.001 when 
measured using a one-way ANOVA with Tukey’s multiple comparison test
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Figure 5-5 – The Gαq/11 inhibitor YM-254890 inhibits the response of the GRLN-R to ghrelin in 
[35S]GTPγS binding assays performed using an immunoprecipitation step. GRLN-R cells were 
transfected with Gαq/11 and receptor expression induced with 6 ng/mL doxycycline (16 h). 
Membranes were prepared and incubated with 1 µM ghrelin and varying concentrations of YM-
254890 (30 min; 30 °C). Gαq was immunoprecipitated from the reaction mixture using anti-Gαq 
antiserum and bound [35S]GTPγS measured using liquid scintillation spectrometry (5 min/sample). 
Data is expressed as the percentage of ghrelin Emax, with 100 % set as the signal to ghrelin in the 
absence of YM-254890 treatment and 0 % set as the signal obtained in the absence of ghrelin or 
YM-254890 treatment. Data points represent the mean ± S.E.M of one experiment performed in 
triplicate.  
 
cells. Treatment with YM-254890 abolished the increase in basal binding of [35S]GTPγS 
that was seen upon GRLN-R expression. Indeed the level of [35S]GTPγS binding achieved 
upon YM-254890 treatment was not significantly different to that achieved upon 
incubation with SPA (Figure 5-4). 
To further test the response of the GRLN-R in the Gαq/11 pathway the sensitivity of the 
response to ghrelin was measured in the presence of the Gαq/11 inhibitor YM-254890 
(Figure 5-5). A concentration-response curve was generated to YM-254890 (n = 1) in the 
presence of 1 µM ghrelin. Fitting of the data with a concentration-response curve yielded a 
pEC50 value of 8.05 ± 0.32 (n = 1). Data was normalised so that 100 % equalled the level 
of bound [35S]GTPγS observed upon treatment with 1 µM ghrelin in the absence of YM-
254890 and 0 % equalled the level of bound [35S]GTPγS obtained upon GRLN-R 
expression in the absence of ghrelin and YM-254890. Normalisation of the data revealed 
that YM-254890 could lower the level of [35S]GTPγS binding to below that observed upon 
GRLN-R expression, suggesting that YM-254890 was reducing the constitutive activity of 
the GRLN-R. At low concentrations of YM-254890 it appeared that YM-254890 could 
compete with ghrelin for binding to the GRLN-R so that only around 25 % of the 
maximum ghrelin signal could be obtained.  
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A 
Figure 5-6 – Ghrelin and the growth hormone secretagogues can evoke a response in 
inositol phosphate accumulation assays. GRLN-R expression was induced as required with 6 
ng/mL doxycycline (16 h) and media supplemented with 1 µCi/mL [3H]myo-inositol (16 h). Prior to 
the assay, media was replaced with Krebs-Ringer buffer supplemented with 10 mM lithium chloride 
to block the breakdown of inositol phosphates into myo-inositol. A. Cells were stimulated with 1 µM 
ghrelin (30 min; 37 °C) as indicated, in the absence (white bars) or presence (black bars) of the 
GRLN-R. After ligand-stimulation cells were lysed with perchloric acid and [3H]total inositol 
phosphates isolated from the mixture using ion-exchange chromatography. The amount of [3H]total 
inositol phosphates accumulated were measured using liquid scintillation spectrometry (120 
s/sample). Data points represent the mean ± S.E.M of four experiments performed in duplicate. 
***p<0.001; **p< 0.01, *p<0.05 as measured using a one-way ANOVA with Tukey’s multiple 
comparison test. B. Concentration-response curves to ghrelin, MK-677, GHRP-6 and L-692,585 
were performed (as described above) in induced GRLN-R cells (30 min; 37 °C). Data points 
represent the mean ± S.E.M of three-six experiments performed in duplicate.  
 
5.2.3 Whole cell assays to measure Gαq/11 response  
[35S]GTPγS experiments are useful for measuring one of the first steps in signal 
transduction; activation of G proteins. However, these assays need to be performed in 
membranes or detergent-treated cells as [35S]GTPγS is membrane-impermeable. As 
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GRLN-R couples to Gαq/11 an inositol phosphate accumulation assay was established to 
measure functional responses to ghrelin and the growth hormone secretagogues in an intact 
cell system (using native Gαq/11 expressed in HEK293 cells). This assay measures the 
accumulation of [3H]total inositol phosphates, synthesised from [3H]myo-inositol by the 
cell. Breakdown of [3H]total inositol phosphates back into [3H]myo-inositol was inhibited 
by the addition of 10 mM lithium chloride to the assay buffer which was added to the cells 
30 min prior to stimulation with ligand. Subsequently, ligand was diluted in assay buffer 
containing LiCl and cells stimulated with this mixture for 30 min.   
A one-way ANOVA with Tukey’s multiple comparison test revealed that inducing 
receptor expression led to a significant increase in the generation of [3H]total inositol 
phosphates (p<0.01), which could be further increased by incubation with 1 µM ghrelin 
(p<0.001). The level of basal [3H]total inositol phosphates accumulated after receptor 
induction was 48.5 ± 5.6 % above that obtained in the absence of the GRLN-R. In the 
absence of the GRLN-R, ghrelin treatment had no effect on the level of inositol phosphate 
accumulation that was observed in basal conditions (Figure 5-6).   
Concentration-response curves were generated to ghrelin, GHRP-6, L-692,585 and MK-
677 (Figure 5-6) using an inositol phosphate accumulation assay, which allowed the 
measurement of the potency and efficacy of each of the compounds in activating the Gαq/11 
pathway (Table 5-2). A one-way ANOVA with Dunnett’s post-hoc test showed there was 
no significant difference in potencies (p=0.14) or efficacies (p=0.16) of GHRP-6, L-
692,585 or MK-677 compared to ghrelin.  
Table 5-2 Potency and efficacy values of ligands acting at GRLN-R as measured using an 
inositol phosphate accumulation assay.  
Ligand pEC50 ± S.E.M Emax ± S.E.M 
Ghrelin 9.22 ± 0.11 97.5 ± 4.8 
MK-677 9.43 ± 0.13 121.4 ± 7.3 
GHRP-6 9.05 ± 0.19 99.1 ± 9.5 
L-692,585 9.24 ± 0.22 92.7 ± 7.9 
Data is expressed as mean ± S.E.M of three-four individual experiments performed in triplicate. 
Emax is the maximum response of ligand expressed as the percentage of the maximum response to 
ghrelin. 
To investigate the effect of YM-254890 on the constitutive activity of the GRLN-R, 
GRLN-R cells were induced with doxycycline and concentration-response curves to YM- 
254890 and SPA were generated (Figure 5-7). Data was normalised so that 0 % was the 
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Figure 5-7 – Both YM-254890 and SPA can reduce the constitutive activity of the GRLN-R in 
inositol phosphate accumulation experiments.
 Cells were incubated with 6 ng/mL doxycycline 
(16 h) to induce GRLN-R expression, as required, and media supplemented with 1 µCi/mL 
[3H]myo-inositol (16 h). Prior to the assay, media was replaced with Krebs-Ringer buffer 
supplemented with 10 mM lithium chloride to block the breakdown of inositol phosphates into myo-
inositol. Subsequently, concentration-response curves to A. SPA or B. YM-254890 were generated 
(30 min; 37 °C). After ligand-stimulation cells were lysed with perchloric acid and [3H]total inositol 
phosphates isolated from the mixture using ion-exchange chromatography. The amount of [3H]total 
inositol phosphates accumulated were measured using liquid scintillation spectrometry (120 
s/sample). Data is expressed as percentage of signal obtained by doxycycline induction, with 0% 
set as the signal obtained in the absence of GRLN-R. For the SPA concentration-response curve 
the data points represent the mean ± S.E.M of three independent experiments performed in 
duplicate. For the YM-254890 concentration-response curve data points represent the mean ± 
S.E.M of one experiment performed in triplicate. 
 
level of inositol phosphates accumulated in the absence of the GRLN-R and 100 % was the 
level of  inositol phosphates obtained in the presence of the GRLN-R. This yielded pEC50 
values of 8.21 ± 0.32 for YM-254890 (n = 1) and 7.59 ± 0.45 for SPA (n = 3). 
Normalisation of the data showed that at maximally effective concentration of YM-254890 
and SPA there was a 56.7 ± 6.9 % and 49.1 ± 20.5 % reduction, respectively, in the level 
of inositol phosphates accumulated. These results suggest that, in the inositol phosphate  
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Figure 5-8 – Illustration of the AlphaScreen cAMP technology (adapted from the cAMP 
AlphaScreen product guide, Perkin Elmer). The AlphaScreen cAMP assay utilises a Tr-FRET 
based technology which measures energy transfer from ‘donor beads’ to ‘acceptor beads’ that are 
provided in the AlphaScreen kit. Briefly, donor beads are coated in streptavidin to which 
biotinylated cAMP can bind, whilst the acceptor beads are coated in an anti-cAMP antibody. If 
biotinylated cAMP binds to the anti-cAMP antibody it brings the donor bead in close proximity to the 
acceptor bead. Upon excitation of the donor bead with a laser at 680 nm, singlet oxygen energy 
(*O2) produced by the donor bead is transferred to fluorescent acceptors within the acceptor bead. 
This generates a signal with a wavelength of around 560-620 nm. cAMP synthesised within cells 
can compete with biotinylated cAMP, binding to the antibody on the acceptor beads; in this 
situation energy transfer between the donor and acceptor beads does not occur as the beads are 
not in close enough proximity.      
   
accumulation assay,  neither YM-254890 or SPA were fully inhibiting the constitutive 
activity of the GRLN-R. 
 
5.2.4 Whole cell assay to measure Gαi/o activation 
An AlphaScreen cAMP accumulation assay was used to measure Gαi/o responses in intact 
GRLN-R cells. This assay utilises time-resolved fluorescence resonance energy transfer 
(Tr-FRET) technology to measure changes in cAMP levels within cells. Briefly, a donor 
bead is coated in streptavidin to which biotinylated cAMP molecules can bind via their 
biotin moiety. The acceptor beads are coated with an anti-cAMP antibody to which the 
biotinylated cAMP also binds, this time via the cAMP part of the molecule. Excitation with 
light at 680 nm causes the donor bead to convert ambient oxygen to single state oxygen, 
which can diffuse up to 250 nm before decaying. If the donor bead is in close proximity to 
the acceptor bead, the energy from the oxygen singlet is passed to fluorescent acceptors in 
the acceptor bead. This leads to a fluorescent signal of 520-620 nm being generated  
 
 = biotinylated cAMP 
    
 
 = cAMP 
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Figure 5-9 - The GRLN-R does not signal through the Gαi/o pathway in an intact cell assay. 
Cells were induced with 6 ng/mL doxycycline (16 h) and the response to 1 µM ghrelin (30 min; 37 
°C) measured using an AlphaScreen cAMP accumulation assay. Data is expressed as the 
percentage of the response compared to that achieved by 0.1 µM forskolin. Data points represent 
the mean ± S.E.M of three independent experiments performed in triplicate. Data is expressed as 
the percentage of the cAMP response achieved by 0.1 µM forskolin. 
 
(Figure 5-8). Synthesised cAMP from within a cell competes with the biotinylated cAMP 
on the acceptor bead – thus decreasing the amount of FRET occurring proportionally to 
amount of cAMP produced. Consequently, a Gαs response is seen as a decrease in the 
FRET signal. To obtain a Gαi/o response, the level of cAMP within a cell needs to be 
increased by activation of the enzyme adenylate cyclase, this is most commonly achieved 
by addition of forskolin. Upon activation of the Gαi/o family of G proteins, the activity of 
adenylate cyclase is inhibited, leading to a decrease in cAMP levels, thus increasing the Tr-
FRET signal obtained. For ease of interpretation all cAMP AlphaScreen results presented 
in this chapter are expressed as the percentage of the response of cells to 0.1 µM forskolin. 
GRLN-R cells were treated with doxycycline to induce receptor expression. A standard 
curve of forskolin stimulation was constructed (data not shown) and a concentration of 0.1 
µM forskolin, which produced a response around the EC50, was chosen to activate 
adenylate cyclase. To test if ghrelin could evoke a response via Gαi/o activation, cells were 
co-incubated for 30 min at 37 ºC with 0.1 µM forskolin and 1 µM ghrelin (Figure 5-9). 
There was no significant response to ghrelin in this assay (p=0.95), suggesting that either 
the GRLN-R could not couple to the Gαi/o pathway in intact GRLN-R cells or that it is not 
possible to measure cAMP inhibition in response to GRLN-R activation in these cells.  
5.2.5 Whole cell assay to measure Gαs activation 
Further investigation revealed that an increase in cAMP levels (therefore a Gαs-mediated 
response) could be observed in response to ghrelin in doxycycline-induced GRLN-R cells. 
Thus concentration-response curves were generated to ghrelin and the growth hormone 
secretagogues using the AlphaScreen cAMP accumulation assay (Figure 5-10). The 
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potency and efficacy values are obtained in Table 5-3. Comparing the potency and efficacy 
values obtained for GHRP-6, L-692,585 and MK-677 to ghrelin using a one-way ANOVA 
with Dunnett’s post-hoc test revealed that L-692,585 exhibited a significantly lower 
potency and efficacy (p<0.05) than ghrelin. 
Table 5-3 – Potency and efficacy values of ligands acting at GRLN-R as measured using a 
cAMP accumulation assay.  
Ligand pEC50 ± S.E.M Emax ± S.E.M 
Ghrelin 8.78 ± 0.15 93.2 ± 5.0 
MK-677 8.66 ± 0.21 85.0 ± 6.6 
GHRP-6 7.85 ± 0.19 91.9 ± 7.3 
L-692,585 7.97 ± 0.21* 70.0 ± 5.8* 
Data is expressed as mean ± S.E.M of three individual experiments performed in triplicate. Emax is 
the maximum response to ligand expressed as the percentage of the maximum response to 
ghrelin. * p<0.05 when responses were compared to ghrelin using a one-way ANOVA with 
Dunnett’s post-hoc test. 
 
To test whether ghrelin and the growth hormone secretagogues could evoke a cAMP 
response in the absence of GRLN-R expression, GRLN-R cells were incubated with 1 µM 
ghrelin, GHRP-6, L-692,585 or MK-677 and the response measured using an AlphaScreen 
cAMP accumulation assay. There was no significant response to ghrelin and the growth 
hormone secretagogues (p=0.06; tested using a one-way ANOVA), thus showing GRLN-R 
expression was required for a Gαs-mediated response in GRLN-R cells. 
Finally, the ability of the GRLN-R to constitutively activate the Gαs pathway was tested. 
Doxycycline-induced GRLN-R cells were treated with 1 µM SPA and the level of 
accumulated cAMP was compared to the level of cAMP obtained in basal conditions using 
an unpaired, two-tailed t-test (Figure 5-11). SPA had no significant effect on cAMP 
accumulation compared to that observed in basal conditions (p=0.35). Furthermore, there 
was no significant difference in cAMP accumulation measured in the absence and presence 
of GRLN-R expression (p=0.10), thus further demonstrating that there was no measurable 
constitutive activation of the GRLN-R via activation of the Gαs pathway
  175 
 
 
Figure 5-10 – The GRLN-R can signal through the Gαs pathway after challenge with ghrelin 
and the growth hormone secretagogues in an intact cell assay. A. GRLN-R expression was 
induced by treatment of GRLN-R cells with 6 ng/mL doxycycline (16 h). Concentration-response 
curves were generated to ghrelin, GHRP-6, MK-677 and L-692,585 (30 min; 37 °C) in intact GRLN-
R cells using an AlphaScreen cAMP accumulation assay. Data points represent the mean ± S.E.M 
of three independent experiments performed in triplicate. B. Testing the ability of ghrelin and the 
growth hormone secretagogues to evoke a response in uninduced GRLN-R cells. Uninduced 
GRLN-R cells were incubated with 1 µM ghrelin, GHRP-6, MK-677 or L-692,585 (30 min; 37 °C) 
and the response measured using an AlphaScreen cAMP accumulation assay. Data points 
represent mean ± S.E.M of three independent experiments performed in triplicate. Data is 
expressed as the percentage of the cAMP response achieved by 0.1 µM forskolin. 
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Figure 5-11  – The GRLN-R does not appear to constitutively activate the Gαs pathway in an 
intact cell assay. GRLN-R expression was induced by the treatment of GRLN-R cells with 6 
ng/mL doxycycline (16 h).A.The effect of treatment with 1 µM SPA  (30 min; 37 °C) on the level of 
cAMP accumulated upon GRLN-R expression was measured. B. The difference in the levels of 
cAMP accumulation in uninduced (white bar) and induced (black bar) GRLN-R cells were 
measured. In both experiments data points represent the mean ± S.E.M of three individual 
experiments performed in triplicate. Data is expressed as the percentage of the cAMP response 
achieved by 0.1 µM forskolin.
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5.3 Discussion 
5.3.1 Comparison of signaling of the GRLN-R  as measured 
using Gαq/11 and Gαi/o [35S]GTPγS binding assays  
Although some studies have used [35S]GTPγS binding assays to measure ghrelin-induced 
activation of the Gαi/o pathway (i.e. both Bassil et al., 2007 and Dezaki et al., 2007 have 
demonstrated a response to ghrelin through activation of Gαi) none of these studies have 
been extended to investigate the effects that the growth hormone secretagogues have on 
[35S]GTPγS binding. Furthermore, there is a total lack of [35S]GTPγS binding data 
investigating Gαq/11-mediated signalling of the GRLN-R in response to either ghrelin or the 
growth hormone secretagogues. 
In this study [35S]GTPγS binding assays proved extremely useful tools for studying the 
pharmacology of the GRLN-R. For example, although mammalian cells express a number 
of endogenous G proteins to which the GRLN-R may couple, the use of selective G protein 
inhibitors revealed that the [35S]GTPγS filtration binding assays measured a ghrelin 
response solely mediated through a PTx-sensitive (Gαi/o) family of G proteins, whilst the 
[35S]GTPγS binding assay with immunoprecipitation step exclusively measured a YM-
254890-sensitive (Gαq/11) response. Furthermore, as it is best to measure maximum 
efficacy of a ligand in a response system close to the receptor, where fewer compounds 
would reach the maximum system response (Strange, 2008); [35S]GTPγS binding assays 
provided an excellent system for allowing comparison of the potencies and efficacies of 
ghrelin and the growth hormone secretagogues measured through the activation of Gαq/11 
and Gαi/o pathways. 
Comparison of the Gαq/11 and Gαi/o [35S]GTPγS binding assays revealed that, although there 
was little difference in the potencies of ghrelin and the growth hormone secretagogues 
(Table 5-4), in the Gαi/o pathway the growth hormone secretagogues all acted as super-
agonists compared to the response obtained upon ghrelin treatment (see Chapter 4, Figure 
4-9 or Table 5-5). In contrast, measurement of the Gαq/11 pathway showed that ghrelin and 
the growth hormone secretagogues acted with equal efficacies. These findings demonstrate 
that the GRLN-R exhibits functional selectivity. Furthermore, as the potencies of ghrelin 
and the growth hormone secretagogues do not alter between the Gαq/11 and Gαi/o signalling 
pathways it can be extrapolated that the growth hormone secretagogues stabilise a receptor 
structure that favours coupling to Gαi/o.     
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5.3.2 The GRLN-R can activate Gαq 
Interestingly, in this study ghrelin and the growth hormone secretagogues could evoke a 
Gαq-mediated [35S]GTPγS response. Studies into the activation of the GRLN-R though 
activation of the Gαq/11 pathway have focused on measuring inositol phosphate 
accumulation or calcium mobilisation. Only one study, the initial cloning of the GRLN-R, 
has investigated to which G protein in the Gαq/11 family the GRLN-R couples, reporting 
that in Xenopus oocytes the receptor can activate Gα11 but not Gαq (Howard et al., 1996). 
The differences in the expression systems (mammalian HEK293 cells versus amphibian 
Xenopus oocytes) could account for the discrepancies between these studies. As the level 
of Gαq transfected in the study by Howard et al. (1996) was not reported, it is possible that 
the G protein concentration in the Xenopus oocytes may not have been high enough to 
measure activation of Gαq as the GRLN-R could preferentially to Gα11.  It would be 
interesting to investigate this further.  
5.3.3 Inositol phosphate accumulation assays  
In contrast to the [35S]GTPγS binding assays, there have been a number of studies that 
have used inositol phosphate accumulation assays (Holst et al., 2003; Holst et al., 2004; 
Holst et al., 2007; Liu et al., 2007; Van Craenenbroeck, et al., 2004) or cAMP 
accumulation assays (Rossi et al., 2008; Caminos et al., 2005) to measure activation of the 
GRLN-R.  
Generation of concentration-response curves in the inositol phosphate accumulation assay 
revealed that the potencies of ghrelin, GHRP-6 and MK-677 in this study were similar to 
those previously published (Holst et al., 2003). However, in contrast to Schwartz’s group 
who found that GHRP-6 acted as a super-agonist (Holst et al., 2003), in this study, and 
consistent with the Gαq/11 [35S]GTPγS binding results, GHRP-6 acted with efficacy equal to 
that of ghrelin. Indeed in this study the efficacies of ghrelin and the growth hormone 
secretagogues and the potencies of ghrelin and MK-677, measured in the inositol 
phosphate accumulation assays were all similar to those measured in the Gαq/11 [35S]GTPγS 
binding assays (Tables 5-4 and 5-5). However, GHRP-6 and L-692,585 acted with 
significantly higher potencies in the inositol phosphate accumulation assay compared to 
the [35S]GTPγS binding assays, which may reflect a difference in receptor reserve between 
[35S]GTPγS binding assays and inositol phosphate assays. 
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Nucleotide exchange is one of the earliest measurable stages in the stimulus-response 
cascade, therefore the potency of compounds tested in the [35S]GTPγS binding assays 
would be expected to be lower than responses measured in further downstream assays, 
which are subjected to a degree of amplification. Such response amplification has been 
observed in receptors such as the chemokine receptor CXCR2 (Hall et al., 1999) and the 
dopamine D2 receptor (Gardner et al., 1997). In contrast, a lack of signal amplification may 
reflect interaction with a receptor that is only poorly coupled to the G protein of study. As 
the potencies of both ghrelin and MK-677 are not significantly greater in the inositol 
phosphate accumulation assay than the potencies measured in the Gαq/11 [35S]GTPγS 
binding assay, this may reflect poor coupling of the GRLN-R to Gαq/11. However, the low 
levels of amplification of the MK-677 and ghrelin responses could be an artefact of the 
system due to the enrichment of G protein in the [35S]GTPγS binding assays that could 
alter coupling efficiency (which depends on the ratio of G protein to receptor; Kenakin, 
1997).    
It is important to bear in mind that the inositol phosphate accumulation assays were 
performed in intact cells; consequently the response to ghrelin and the growth hormone 
secretagogues could include activation of other G protein-dependent or even G-protein-
independent pathways.  For example, Gierschik and colleagues demonstrated that PLCβ 
activity could be stimulated by G protein βγ-subunits released via activation of Gαi/o family 
of G proteins (Camps et al., 1992). Thus, activation of the Gαi/o family of G proteins by 
ghrelin or the growth hormone secretagogues could lead to activation of PLCβ, thereby 
increasing inositol phosphate levels within the cells. Thus activation of Gαi/o may be 
responsible for the apparent increase in potency of GHRP-6 and L-692,585 in the inositol 
phosphate accumulation assay. This could be assessed by measurement of inositol 
phosphate accumulation in the presence of PTx – although such studies were beyond the 
scope of this thesis.  
5.3.4 cAMP accumulation assays 
In Chapters 3 and 4 the GRLN-R was shown to couple to the Gαi/o family of G proteins in a 
[35S]GTPγS filtration binding assay, yet in this chapter it was found that ghrelin could not 
decrease the level of cAMP accumulation achieved by incubation of GRLN-R cells with an 
EC50 concentration of forskolin. Further experiments are needed to test whether the 
GRLN-R does not couple to Gαo1 in intact GRLN-R cells or whether the absence of a 
decrease in cAMP accumulation was because AC was not inhibited in these experiments. 
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This could be achieved by reproducing the experiment with a positive control (i.e. by 
activating Gαi–coupled bradykinin 2 receptors which are endogenously expressed in 
HEK293 cells; Kramarenko et al., 2009). If bradykinin 2 receptors mediate a Gαi/o response 
in the GRLN-R this could suggest that the GRLN-R does not couple to Gαi/o.  Is is also 
possible that the GRLN-R may not couple to the Gαi/o pathway in HEK293 cells as the 
receptor may preferentially couple to endogenous Gαq/11 or even Gαs. 
Initial [35S]GTPγS binding experiments were performed in the presence of exogenous Gαo1, 
yet coupling of the receptor to Gαo1 in HEK293 cells may be expected to have no effect on 
cAMP accumulation. The Gαo subfamily of G proteins inhibits the adenylyl cyclase 
isoform AC1, which is only expressed in the brain adrenal medulla (Sunahara and Taussig, 
2002). Although Gαo can inhibit the adenylyl cyclase isoforms AC5 (expressed in heart, 
brain, kidneys, liver, lung, uterus and brown adipose tissue; Haber et al., 1994) and AC6 
(ubiquitously expressed; Haber et al., 1994) it does so less potently than the Gαi G protein 
subfamily (Sunahara and Taussig, 2002). Furthermore, the significant response to ghrelin 
in [35S]GTPγS binding studies in the absence of exogenous G protein confirms that 
coupling of GRLN-R to Gαi/o was not an artefact due to the enrichment of cells with Gαo1. 
This suggests that in this system the GRLN-R can couple to Gαo1 but not to Gαi. Indeed, the 
expression pattern of the ghrelin receptor and Gαo1 overlap, as Gαo1 is the most abundantly 
expressed G protein in the nervous system (Offermanns, 2001).  
In a study by Bassil et al. (2007), ghrelin was able to increase [35S]GTPγS binding in 
HEK293 cells co-expressing the GRLN-R and Gαi , suggesting that the GRLN-R could 
signal through Gαi activation. Thus further studies are required to further elucidate whether 
the GRLN-R can couple to Gαi1-3 and Gαo1. This could be achieved by testing the response 
to ghrelin in PTx-treated GRLN-R cells transfected with PTx-insensitive versions of Gαi1, 
Gαi2,Gαi3 and Gαo1, a system previously used by our group to study the promiscuous 
coupling of the dopamine D2 receptor (Lane et al., 2007). 
In the absence of forskolin, ghrelin could evoke an increase in cAMP accumulation, 
therefore demonstrating coupling of the GRLN-R to Gαs, which is in agreement with other 
recombinant studies into the pharmacology of the GRLN-R (Rossi et al., 2008; Caminos et 
al., 2005). Indeed, ghrelin increased cAMP accumulation with a pEC50 value of 8.78 ± 0.15 
which is in close agreement to the pEC50 value published by Rossi et al. (pEC50 8.28; Rossi 
et al. 2008). The concentration-response curves generated using the cAMP accumulation 
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assay revealed that ghrelin and the growth hormone secretagogues all acted with similar 
potencies as measured in the [35S]GTPγS binding assays, with MK-677 and GHRP-6 
exhibiting similar efficacies to those measured in the Gαq/11 [35S]GTPγS binding assays and 
inositol phosphate accumulation assays. However, in the cAMP accumulation assay, L-
692,585 acted as a partial agonist, having a significantly lower efficacy and potency than 
ghrelin in the Gαs pathway, thus suggesting that L-692,585 only weakly couples to the Gαs 
pathway.  
It is well known that overexpression of a receptor can lead to an increase in receptor 
reserve and in this condition a partial agonist may appear to have full intrinsic activity 
(Adham et al., 1993; Watts et al., 1995; Pohjanoksa et al., 1997). Therefore it is hard to 
compare the efficacies in downstream effector systems such as the inositol phosphate 
accumulation and cAMP pathways, which may exhibit different degrees of receptor 
reserve. Furthermore, negative or positive feedback, cross-regulation and even 
convergence of different effector systems may also be contribute to measures of 
downstream functional assays complicating experimental results (Wess 1998). Thus further 
experiments are needed to measure Gαs activation in the [35S]GTPγS binding assay to allow 
comparison of the responses to the Gαi/o and Gαq/11 pathways. For example, use of the 
[35S]GTPγS binding assay with immunoprecipitation of Gαs would allow a direct 
comparison to activation of the Gαq/11 pathway and of the responses obtained in the intact 
cell Gαs assay. 
5.3.5 The GRLN-R may be promiscuous in vivo 
The findings from this study have clearly demonstrated that the GRLN-R is a promiscuous 
receptor, coupling to Gαi/o, Gαq/11 and Gαs in the GRLN-R cell line. However, receptor 
coupling to G protein in the native cell environment not only depends on the relative 
affinities of the receptor for different G proteins but also on the relative proportions and 
availability of receptors and G proteins. Indeed, it is well established that altering the G 
protein to GPCR ratio can alter ligand function and receptor pharmacology (Milligan, 
2000). Nevertheless, promiscuity cannot be seen as purely an artefact of recombinant 
systems as there are numerous examples of it occurring in vivo or in cell lines 
endogenously expressing the receptor of study. For example, the δ opioid receptor, 
endogenously expressed in NG108-115 cells, has been shown to activate Gαi2-3 and Gαo1-2 
in response to the receptor agonist DADLE
 
(Prather et al., 1994). Conversely, the presence 
of multiple G protein families does not necessarily result in receptor promiscuity. For 
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example, use of a recombinant system to study the dopamine D2 receptor ligands p-
tyramine and S-(-)-3PPP showed these ligands were agonists at Gαo1 but could not elicit a 
response via activation of Gαi1-3 (Lane et al., 2007).  
In support of the findings from this study, are several examples of ghrelin activating Gαs, 
Gαq/11 and Gαi/o pathways in cell lines endogenously expressing the GRLN-R. The GRLN-
R has been reported to couple to Gαq/11 in a cell line from a rat pituitary adenoma 
endogenously expressing GRLN-R (Falls et al., 2006) and in the AR42J cell line from rat 
pancreas (Lai et al., 2005). Evidence for a Gαi/o interaction in vivo is demonstrated in a 
study by Dezaki et al., (2007) which showed that GRLN-R activates Gαi2 in rat pancreatic 
islet β-cells. In 3T3-L1 preadipocytes the mitogenic effect of ghrelin is mediated via 
PI3K/Akt and MAP kinase signalling via a PTx-sensitive G protein (Kim et al., 2004).  
The ability of the GRLN-R to couple to Gαs is more controversial. In NPY neurones the 
cAMP pathway has been implicated in ghrelin-induced calcium mobilisation as a protein 
kinase A inhibitor reduced the calcium response, indicating the Gαq/11 pathway is not solely 
responsible for the calcium signal observed (Kohno et al., 2003). In cultured porcine 
pituitary cells, GRLN-R activation led to an increase in cAMP comparable to that obtained 
by activation of the Gαs coupled growth hormone releasing hormone (GHRH) receptor. 
Furthermore, ghrelin acted additively in increasing cAMP levels in porcine somatotrophs 
when co-administered with GHRH (Malagon et al., 2003). However, studies in 
recombinant systems suggest that Gαs signalling may not be mediated solely through 
GRLN-R activation. In one study using HeLa-T4 cells, GRLN-R could not increase cAMP 
levels in response to ghrelin. Meanwhile, co-activation of GRLN-R and GHRH produced 
an increase in the cAMP response compared to GHRH activation alone. This response was 
not altered upon inhibition of signalling molecules associated with GRLN-R activation e.g. 
phospholipase Cβ. A possible explanation for the potentiation of signalling was the 
formation of heterodimers of GRLN-R and GHRH  (Cunha and Mayo, 2002). 
Interestingly, GHRH has been described as an allosteric modulator of the GRLN-R, acting 
as an agonist in calcium mobilisation assays but when co-administered with ghrelin, 
GHRH decreases the potency of ghrelin (Casanueva et al., 2008). However, the Casanueva 
study found that neither ghrelin nor GHRH could induce a significant effect on cAMP 
levels in HEK293 cells (Casanueva et al., 2008). Thus the ability of the GRLN-R to couple 
to Gαs in vivo remains inconclusive. 
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5.3.6 Constitutive activity of the GRLN-R in the Gαq/11 and Gαs 
pathways 
The GRLN-R is recognised as a highly constitutively active receptor, based upon the 
receptor exhibiting a high degree of constitutive activity in inositol phosphate 
accumulation assays (Holst et al., 2003). However, it cannot be assumed that the GRLN-R 
would constitutively activate every G protein pathway to which it is coupled. For example, 
it is possible that a promiscuous receptor can constitutively activate one pathway but be 
silent in another, as seen by the α1b adrenoceptor mutated at C128 (C128F) that is able to 
constitutively activate Gαq/11 pathway but not the Gαs pathway (Perez et al., 1996).  
In agreement with multiple studies (e.g. Holst et al., 2003; Holst et al., 2004; Holst and 
Schwartz, 2004; Liu et al., 2007) the GRLN-R was shown to constitutively activate the Gαq 
pathway. This was demonstrated by the increase in basal loading of [35S]GTPγS upon 
expression of the GRLN-R, which was fully inhibited by incubation with either YM-
254890 or SPA. Indeed YM-254890 was shown to inhibit [35S]GTPγS binding to a level 
below that achieved by expression of the GRLN-R, demonstrating YM-254890 could 
inhibit the constitutive activity of the GRLN-R.  
Interestingly, SPA, at maximally effective concentrations, decreased inositol phosphate 
accumulation to a level that was still 50.9 % above that observed in the absence of GRLN-
R expression. This suggests that other receptors, or other proteins for example, insulin-like 
growth factor (El-Shewy et al., 2006) were activating Gαq/11. However, treatment with YM-
254890 alone was still not sufficient to return inositol phosphate accumulation to the level 
obtained in the absence of the GRLN-R. Even at maximally effective concentrations, the 
response was still 43.3 % above that measured in the absence of receptor. Thus the residual 
level of inositol phosphates appeared not to be generated by either activation of the GRLN-
R or the Gαq/11 pathway, but by non-Gαq/11 mediated pathways, such as from cross-talk with 
other endogenous receptors expressed in HEK293 cells. It is possible that the continued 
accumulation of inositol phosphates observed could be due to signalling of GRLN-R 
through Gαq/11 activation from within intracellular compartments. Indeed Gαq/11 is 
distributed both on the plasma membrane and in intracellular compartments (Hughes et al., 
2001) and an endosomal G protein signalling pathway has previously been described in 
yeast (Slessareva et al., 2006). As the GRLN-R is continually internalising and recycling, 
the cell-impermeable compounds SPA and YM-254890 would be unable to bind to and 
inhibit the signalling of internalised GRLN-R. However, by trapping the GRLN-R in 
endosomes, Holliday et al. (2007) demonstrated a selective inhibition of the constitutive 
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inositol phosphate accumulation mediated by the GRLN-R, suggesting that the GRLN-R 
does not signal upon internalisation through the Gαq/11 pathway. 
The results of this study are of contrast to those of Holst et al. (2003) who have previously 
shown that the inverse agonist SPA is a full inverse agonist, fully inhibiting the 
constitutive accumulation of inositol phosphates mediated by the GRLN-R (Holst et al., 
2003). The differences in the ability of SPA to fully inhibit the constitutive accumulation 
of inositol phosphates in this study and in Schwartz’s group may be solely due to the 
expression system used; HEK293 cells in this study and COS-7 cells in the study by Holst 
et al. (2003), although no attempt was made to further investigate this in the present study. 
The pIC50 values of SPA acting to decrease the constitutive activity of the GRLN-R were 
in close agreement in this study (8.21 ± 0.13) with the study by Holst et al. (2003) (8.3 ± 
0.7).  
Comparing the constitutive activity in the Gαq/11 assays revealed that the constitutive 
activity of the GRLN-R was significantly higher in the inositol phosphate accumulation 
assays than the [35S]GTPγS binding assays. This was presumably due to amplification of 
the GRLN-R-mediated signal, as the response measured in the inositol phosphate 
accumulation assay is further down the stimulus-response pathway than the response 
measured in the [35S]GTPγS binding assay.  
In contrast to the Gαq/11 pathway, the GRLN-R did not appear to constitutively activate the 
Gαs pathway, as seen by the absence of a response to SPA and the lack of an increase in 
basal cAMP accumulation upon receptor expression. This may be a consequence of a 
weaker coupling of the GRLN-R to the Gαs pathway than the Gαi/o and Gαq/11 pathways. 
Also once Gαs is activated it can dissociate from the membrane to the cytosol 
(Wedegaertner et al., 1994; Ransnas et al., 1989; Witte et al., 1999), therefore to evoke a 
further response another G protein must be found before the next G protein cycle can be 
activated. In Chapter 4 the constitutive activation of the Gαi/o pathway through GRLN-R 
activation was only revealed upon inducing receptor expression at a higher doxycycline 
concentration than used in this study (i.e. 25 ng/mL not 6 ng/mL used in this study). Thus 
increasing the GRLN-R expression level may also reveal that the GRLN-R can 
constitutively activate the Gαs pathway, a suggestion that warrants further investigation. 
As the apparent constitutive activity of a GPCR may vary substantially in various systems 
(Seifert and Wenzel-Seifert, 2002) it is impossible to compare the constitutive activities 
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achieved in the Gαq/11, Gαi/o and Gαs pathways. The use of a [35S]GTPγS binding assay 
followed by immunoprecipitation of Gαq, Gαs and Gαo from the reaction mixture using G 
protein specific antiserum could allow a direct comparison of the constitutive activity of 
these pathways, but the variables of G protein expression and relative affinities of the G 
protein antibodies must be taken into account. 
5.4 Summary 
In this study [35S]GTPγS binding studies revealed that the growth hormone secretagogues 
act with a higher efficacy in activation of the Gαi/o pathway than ghrelin, but act with 
similar efficacies in the Gαq pathway, thus for the first time demonstrating functional 
selectivity of the GRLN-R. Furthermore, it has been shown that GRLN-R can couple to 
Gαs, Gαo and Gαq pathways. Certainly, it is possible that GRLN-R may couple to all four G 
protein families as a study by Schwartz’s group has suggested the GRLN-R stimulate 
serum response element-mediated transcriptional activity via the activation of Gα13 (Holst 
et al., 2005). 
Table 5-4 – Potency of ghrelin and the growth hormone secretagogues as measured in the 
[35S]GTPγS binding, inositol phosphate accumulation and cAMP accumulation assays. 
pEC50 ± S.E.M Ligand 
Gαi/o 
[35S]GTPγS 
filtration binding 
assay 
Gαq [35S]GTPγS 
binding assay with 
immunoprecipitation 
step 
Inositol phosphate 
accumulation assay 
(Gαq/11) 
cAMP accumulation 
assay (Gαs) 
Ghrelin 9.19 ± 0.16 9.03 ± 0.13 9.22 ± 0.11 8.78 ± 0.15 
MK-677 9.28 ± 0.24 9.05 ± 0.15 9.43 ± 0.13 8.66 ± 0.21 
GHRP-6 8.01 ± 0.07 7.98 ± 0.23 9.05 ± 0.19 # 7.85 ± 0.19 
L-692,585 7.20 ± 0.03 7.11 ± 0.20 9.24 ± 0.22 † 7.97 ± 0.21 
# GHRP-6 acts with a significantly higher potency in the inositol phosphate accumulation assay 
than in the Gαi/o filtration binding assay (p<0.05), the Gαq/11 binding assay with immunoprecipitation 
step (p<0.05) and the cAMP accumulation assay (p<0.01). 
† L-692,585 acts with a significantly higher potency in the inositol phosphate accumulation assay 
than the Gαi/o filtration binding assay (p<0.01), the Gαq/11 binding assay with immunoprecipitation 
step (p<0.01) and the cAMP accumulation assay (p<0.01). 
Data was compared using a one-way ANOVA with Turkey’s multiple comparison test. Data is 
expressed as the mean ± S.E.M of at least three individual experiments.  
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Table 5-5 – Efficacy of of ghrelin and the growth hormone secretagogues as measured via 
[35S]GTPγS binding, inositol phosphate accumulation and cAMP accumulation assays.  
Emax ± S.E.M Ligand 
Gαi/o 
[35S]GTPγS 
filtration binding 
assay 
Gαq [35S]GTPγS 
binding assay with 
immunoprecipitation 
step 
Inositol phosphate 
accumulation assay 
(Gαq/11) 
cAMP accumulation 
assay (Gαs) 
Ghrelin 98.1 ± 1.9 94.3 ± 4.0 97.5 ± 4.8 93.2 ± 5.0 
MK-677 167.8 ± 8.4# 98.7 ± 4.8 121.4 ± 7.3 85.0 ± 6.6 
GHRP-6 152.7 ± 6.5† 113.2 ± 10.9 99.1 ± 9.5 91.9 ± 7.3 
L-692,585 150.5 ± 8.0‡ 116.5 ± 12.7 92.7 ± 7.9 70.0 ± 5.8 
# MK-677 acts with a significantly higher efficacy in the Gαi/o filtration binding assay than in the 
Gαq/11 binding assay with immunoprecipitation step (p<0.001), the inositol phosphate accumulation 
assay (p<0.01) and the cAMP accumulation assay (p<0.001). 
† GHRP-6 acts with a significantly higher efficacy in the Gαi/o filtration binding assay than measured 
in the inositol phosphate accumulation assay (p<0.05) and the cAMP accumulation assay. 
‡ L-692,585 acts with a significantly higher efficacy in the Gαi/o filtration binding assay than 
measured in the inositol phosphate accumulation assay (p<0.01) and the cAMP accumulation 
assay (p<0.001). L-692,585 also acts with a significantly higher efficacy in the Gαq/11 binding assay 
with immunoprecipitation step than measured in the cAMP accumulation assay (p<0.05). 
Data is expressed as the percentage of the maximum response achieved to ghrelin in each assay 
(mean ± S.E.M). Data was compared using a one-way ANOVA with Turkey’s multiple comparison 
test. Data is expressed as the mean ± S.E.M of at least three individual experiments.
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6 Effect of A204E and I134T mutations on the 
function of the GRLN-R 
6.1 Introduction 
Mutations within GPCR genes may affect receptor function and have been linked to the 
development of a number of human diseases such as: female infertility (Huhtaniemi et al., 
2006); nephrogenic diabetes insipidus (Rosenthal et al., 1992; Van den Ouweland et al., 
1992) retinitis pigmentosa (Kennan et al., 2005) and obesity (Vaisse et al., 1998, Vaisse et 
al., 2000; Sina et al., 1999). The latter involves the melanocortin-4 receptor, in which over 
50 different obesity-associated mutations have been described, most of which are missense 
mutations (point mutations that result in the substitution of one amino acid for another) that 
reduce the ability of the receptor to signal to its endogenous ligand, α-melanocyte-
stimulating hormone (Farooqi et al., 2003; Lubrano-Berthelier et al., 2003; Vaisse et al., 
1998; Vaisse et al., 2000; Nijenhuis et al., 2003).  
As well as affecting receptor pharmacology, mutations within GPCRs can disrupt the 
normal trafficking of receptors to the cell surface as cells employ a quality control system 
in the ER to prevent misfolded membrane proteins from being trafficked to the plasma 
membrane. Any proteins that do not attain their native conformation are retained in the ER 
to undergo several rounds of protein folding. If the native conformation fails to be reached, 
they are unfolded, transported to the cytosol and degraded by the proteasome (Ma & 
Hendershot, 2001).  
 
Four naturally occurring missense mutations of the GRLN-R have been identified that 
result in decreased cell surface expression and distinct pharmacological abnormalities of 
the GRLN-R (Liu et al., 2007, Wang et al., 2004; Holst and Schwartz, 2006; Pantel et al., 
2006). The I134T (I3.43), V160M (V4.42) and F279L (F6.51) mutations are present in the 
third, fourth and sixth transmembrane spanning domains, respectively, whilst the A204E 
mutation is located in the second extracellular loop (Figure 6-1). The results of studies that 
have investigated the effects of these mutations on the GRLN-R are summarised in Table 
6-1. 
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Figure 6-1 – Structure of the GRLN-R identifying the known missense mutations of the 
GRLN-R. Missense mutations of the GRLN-R are shown in red. A cysteine residue in the 
extracellular end of TMIII is predicted to form a disulphide bond with a cysteine residue in ECL2 
(shown as a dotted line). Residues that are predicted to undergo N-linked glycosylation are marked 
with . 
 
Interestingly, the A204E and F279L mutations have been associated with the development 
of a short stature/obese phenotype in vivo (Pantel et al., 2006). Indeed, it has been 
suggested that the development of this phenotype provides evidence that constitutive 
activity of the GRLN-R is important in vivo (Holst & Schwartz, 2006). However, the 
F279L mutation has been described in one study as reducing, but not completely ablating, 
the constitutive activity of the mutated GRLN-R (Liu et al., 2007). Thus the reduced cell-
surface expression of the GRLN-R, caused by these mutations (Liu et al., 2007) may be 
important in the development of the short stature/obese phenotype. To date no studies have 
investigated whether the decreased cell-surface expression of the GRLN-R caused by the 
A204E is due to ER-retention of the receptor. 
The I134T mutation has been shown to ablate the signalling of the GRLN-R to ghrelin, 
whilst having no effect on the constitutive activity of the receptor (Liu et al., 2007). 
However, the effect of this mutation on the signalling to the growth hormone 
secretagogues has not been tested. Indeed as ghrelin and the growth hormone 
secretagogues have overlapping, but not identical binding sites, on the GRLN-R (Holst et 
al., 2009; Feighner et al., 1998), it is possible that the mutated GRLN-R retains its ability 
to signal upon activation by the growth hormone secretagogues. 
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Table 6-1 – Effect of the A204E, F279L, I134T and V160M mutations on the pharmacology of 
the GRLN-R. 
Mutation Effect in vitro Phenotype in 
vivo* 
A204E No effect on ghrelin affinity and efficacy1. Ablated the constitutive 
activity of the GRLN-R1,3,4. May decrease cell surface expression of 
the GRLN-R3,4 
Short stature 
and obese 
phenotype4 
F279L One study showed the F279L mutation ablated receptor constitutive 
activity2, another showed a reduced but nonetheless measurable 
constitutive activity3. One study showed the F279L mutation had no 
affect on ghrelin potency3, whilst another study showed the mutation 
decreased the potency of ghrelin7. The mutation has also been 
reported to decrease the cell surface expression of the GRLN-R3 and 
decrease the specific binding of MK-6776 
Short stature 
and obese 
phenotype5 
I134T Ablates signalling to ghrelin, no effect on the constitutive activity of 
the GRLN-R, decreased cell surface expression3 
Not reported 
V160M Increased ghrelin potency by some 20-fold, reduced the constitutive 
activity of the GRLN-R, decreased cell surface expression 3 
Not reported 
1Holliday et al., 2007, 2Holst et al., 2004, 3Liu et al., 2007,4Pantel et al., 2006, 5Wang et al., 2004, 
6Feighner et al., 1998, 7Holst et al., 2009. * Due to the rarity of these mutations, a direct link 
between the A204E and F279L mutations and the phenotype observed in vivo cannot be 
established. 
 
The aim of this study was to explore the effects of the A204E and I134T mutations on the 
localisation and signalling of the GRLN-R; in particular, to establish whether these 
mutations caused ER-retention of the GRLN-R and to test whether receptor containing the 
I134T mutation retained its ability to signal to the growth hormone secretagogues. 
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6.2 Results 
6.2.1 Construction of a Flp-In™ T-REx™ cell line expressing 
HA-GRLN-R-I134T-eCFP or HA-GRLN-R-A204E-eCFP 
Epitope tags were added to the GRLN-R containing either the A204E or the I134T 
missense mutations, to allow detection of the receptor by immunoblotting and 
epifluorescence microscopy. The 9 amino acid HA tag (YPYNVPDYA), which originates 
from the full length haemagglutinin protein, a glycoprotein required for infectivity of the 
human influenza virus (Wilson et al., 1984), was fused at the N-terminus (directly after the 
initiating methionine residue) and a eCFP reporter molecule at the C-terminus (Figure 6-2). 
The HA tag was added to the mutant receptors rather than a VSV-G tag added to the wild-
type receptor (i.e. the un-mutated GRLN-R tagged at the N-terminus with VSV-G and at 
the C-terminus with eCFP; described in Chapter 4) to aid future studies into the 
dimerisation of the mutated receptors with the wild-type GRLN-R, which would require 
differential tagging of the receptors. 
The HA-GRLN-R-I134T-eCFP and the HA-GRLN-R-A204E-eCFP constructs were 
ligated into pcDNA5 and co-transfected with the Flp-recombinase expression plasmid 
pOG44 into Flp-In™ T-REx™ HEK293 cells. Flp-In™ T-REx™ HEK293 cells 
transfected with the HA-GRLN-R-I134T-eCFP construct (hereafter referred to as GRLN- 
R-I134T cells) or the HA-GRLN-R-A204E-eCFP construct (GRLN-R-A204E cells) were  
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2 - Schematic diagrams of the HA-GRLN-R-I134T-eCFP and HA-GRLN-R-A204E-
eCFP constructs. A. PCR was used to mutate I1343.43 to T1343.43 or B. to mutate A204 to E204. 
Subsequently PCR was used to add a HindIII site and an HA tag at the N terminus as well as to 
add a KpnI restriction site and to remove the STOP codon at the C-terminus of the mutated 
receptors. The resulting PCR products and vector (pECFP-N1) were sequentially digested with 
HindIII and KpnI, before the constructs were ligated into the vector in-frame with eCFP.  
            GRLN-R-I134T    HA        eCFP 
pECFP-N1 
HindIII KpnI NotI 
N C 
A 
            GRLN-R-A204E    HA        eCFP 
pECFP-N1 
HindIII KpnI NotI 
N C 
B 
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Figure 6-3 - Testing doxycycline induction in GRLN-R-I134T and GRLN-R-A204E cells. Cells 
were treated with varying concentrations of doxycycline (0-50 ng/mL) for 16 h. Cells were 
harvested and lysates prepared. As a control lysates were also prepared from parental Flp-In™ T-
REx™ HEK293 cells (marked ‘C’). Samples were resolved using SDS-PAGE followed by western 
blotting using sheep anti-GFP antiserum (which cross-reacts with eCFP). The top panel is the 
resulting western blot of lysates from GRLN-R-I134T cells and the bottom panel from GRLN-R-
A204E cells. Immunoblot is representative of the results from three individual experiments. 
 
tested for the successful integration of the expression cassette into the host cell line. To test 
whether receptor expression could be detected, cells were grown for 16 h in media 
supplemented with increasing concentrations (0-50 ng/mL) of doxycycline; the cells were 
subsequently lysed and the samples analysed by immunoblotting.  
 
In the absence of doxycycline, both the GRLN-R-A204E and GRLN-R-I134T cells 
showed similar protein banding to parental Flp-In™ T-REx™ HEK293 cells, indicating 
that no receptor-specific signals were detected (Figure 6-3). In lysates prepared from 
GRLN-R-I134T cells the addition of doxycycline led to the detection of two receptor 
species; one with a molecular mass of approximately 70 kDa and another with an apparent 
molecular mass of 105 kDa (the mass of the construct is expected to be around 69 kDa). At 
doxycycline concentrations of 6-50 ng/mL, the largest proportion of signal was expressed 
as the 105 kDa form. In contrast, immunoblotting of lysates prepared from GRLN-R-
A204E cells showed that, despite a doxycycline-dependent increase in receptor expression, 
even at the highest doxycycline concentrations tested, the majority of receptor detected 
existed as a species with an apparent molecular mass of 70 kDa. 
 
As Flp-In™ T-REx™ cells ensure integration of the gene occurs at only one locus, protein 
expression becomes solely the property of the gene of interest, thus construction of the cell 
lines expressing the GRLN-R-I134T or the GRLN-R-A204E allowed comparison of the 
pharmacology and localisation of the mutant receptors with the wild-type GRLN-R. As 
treatment with 6 ng/mL doxycycline (16 h) was sufficient to induce expression of the  
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GRLN-R, GRLN-R-I134T and GRLN-R-A204E, this concentration was chosen to induce 
receptor expression in all further studies.   
 
6.2.2 Glycosylation states of the GRLN-R, GRLN-R-I134T and 
GRLN-R-A204E 
Glycosylated membrane proteins change from a high mannose glycosylated state to a 
complex glycosylated state in the medial-trans-Golgi compartment (Sadeghi et al., 1997). 
Addition of complex glycosylation renders protein insensitive to digestion with Endo-β-
acetylglucosamindase H (Endo H) whilst retaining the sensitivity of the protein to peptide-
N4-(acetyl-β-glucosaminyl)-asparagine amidase (PNGaseF). Thus digestion of membrane 
proteins with Endo H and/or PNGaseF has been widely used to determine whether a 
mutant membrane protein resides in the ER-cis-Golgi complex (Sadeghi et al., 1997). To 
determine the glycosylation states of both wild-type and mutated GRLN-R, lysates were 
prepared from doxycycline-treated GRLN-R, GRLN-R-A204E and GRLN-R-I134T cells 
and digested with either PNGaseF or Endo H and, as a control, samples were prepared 
without the addition of enzyme (Figure 6-4). Immunoblotting of these cell lysates with 
anti-GFP antiserum revealed that for both the GRLN-R and the GRLN-R-I134T, in the 
abscence of treatment with PNGaseF or Endo H, a large proportion of total receptor 
existed with a mass of around 105 kDa; although a small proportion of receptor with an 
apparent mass of 70 kDa was also detected. Treatment of the cell lysates with Endo H did 
not reduce the apparent mass of the 105 kDa species, however Endo H reduced the 
apparent mass of the 70 kDa receptor pool to around 50 kDa. Treatment of the cell lysates 
with PNGaseF reduced the mass of both receptor species, resulting in the detection of a 
species with a molecular mass around 50-60 kDa.  
Immunoblotting cell lysates produced from GRLN-R-A204E cells showed that, in the 
absence of treatment with PNGaseF or Endo H, only one receptor specific species with a 
mass of around 70 kDa was detected. This 70 kDa signal was reduced to a mass of around 
50 kDa by treatment with either PNGaseF or Endo H. Interestingly, treatment with 
PNGaseF led to an increase in intensity of the 50 kDa signal (corresponding to 
unglycosylated receptor), compared to that obtained after Endo H treatment. 
The results from these experiments demonstrate that the majority of GRLN-R and GRLN-
R-I134T exist as mature (complex-glycosylated) receptor. In contrast, the largest  
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Figure 6-4 - Effect of deglycosylation with Endo H or PNGaseF on the molecular mass of 
GRLN-R, GRLN-R-I134T and GRLN-R-A204E. GRLN-R. GRLN-R-I134T and GRLN-R-A204E 
cells were incubated in media supplemented, as required, with 6 ng/mL doxycycline (16 h). Cells 
were harvested, lysates prepared and to 30 µg of protein 1 unit (U) of PNGaseF or 1 mU of Endo H 
was added. Samples were digested for 16 h at 4 °C before being resolved by SDS-PAGE followed 
by immunoblotting with sheep anti-GFP antiserum. Immunoblots are representative of the results 
from three individual experiments.      
 
proportion of GRLN-R-A204E exists as immature (high-mannose glycosylated) receptor, 
suggesting that the GRLN-R-A204E is being retained within the pre-trans-Golgi 
compartment. However, the results of the deglycosylation experiments suggest that some 
mature GRLN-R-A204E is formed, as digestion with PNGaseF appeared to lead to an 
increase in the intensity of the species with an apparent mass of 50 kDa (corresponding to 
unglycosylated receptor) compared to that obtained after digestion with Endo H.  
 
6.2.3 Localisation of GRLN-R-I134T and GRLN-R-A204E 
The results of the deglycosylation experiments (Figure 6-4) suggested that the GRLN-R-
A204E might be retained within the ER. Thus the localisation of the wild-type GRLN-R 
and its mutants were examined to test whether the mutations had any effect on the 
receptors’ subcellular distribution. Receptor localisation was visualised by exciting the 
eCFP tag located at the receptor’s C-terminus. In both GRLN-R-I134T and GRLN-R-
A204E cell lines, no fluorescent signal was observed in the absence of doxycycline (Figure 
6-5). In GRLN-R-I134T cells, eCFP expression was detected both at the plasma membrane 
and in vesicles within the cell, a distribution similar to that observed for wild-type GRLN- 
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Figure 6-5 - Epifluorescence microscopy images showing the localisation of the wild-type 
GRLN-R, the GRLN-R-I134T
 
and the GRLN-R-A204E. Wild-type GRLN-R cells (top panel), 
GRLN-R-I134T cells (middle panel) and GRLN-R-A204E cells (bottom panel) were grown on 
coverslipes in media supplemented, where indicated, with 6 ng/mL doxycycline (16 h). Subsquently 
cells were formaldehyde-fixed (3.7 %(v/v) formaldehyde; 10 min; 25 °C) and receptor expression 
viewed by excitation of the C-terminal eCFP tag with 436/12 nm light. In the absence of 
doxycycline, eCFP fluorescence could not be observed. Upon doxycycline induction, in the wild-
type GRLN-R and GRLN-R-I134T cells, eCFP linked to the receptor could be seen both at the 
plasma membrane and in vesicles throughout the cell. In the GRLN-R-A204E cells the eCFP-linked 
receptor appeared to be retained in cytoplasmic regions of the cells. Scale bar width represents 20 
µm. Images are representative of three individual experiments.
- doxycycline  GRLN-R-I134T 
- doxycycline  GRLN-R-A204E 
+ doxycycline 
+ doxycycline 
- doxycycline  GRLN-R + doxycycline 
Kirstie Ann Bennett, 2009  Chapter 6, 195 
R cells (see Chapter 4, Figure 4-6). In contrast, in the GRLN-R-A204E cells, eCFP 
expression appeared to be distributed evenly throughout the inside of the cell. 
To further investigate the subcellular distribution of the receptors, an ER-Tracker™ red 
dye was used to stain the ER and co-localisation with eCFP fluorescence assessed. 
Analysis of GRLN-R, GRLN-R-I134T and GRLN-R-A204E cells revealed weak co-
localisation of the GRLN-R and GRLN-R-I134T with the ER marker, with the eCFP signal 
also detected in punctuate vesicles within the cell that did not co-localise with the ER 
marker. In contrast, the GRLN-R-A204E showed a high degree of co-localisation with the 
ER marker, demonstrating that the receptor variant was trapped within the early secretory 
pathway (Figure 6-6).  
6.2.4 Testing the interaction of GRLN-R, GRLN-R-I134T and 
GRLN-R-A204E with calnexin  
Calnexin is an ER chaperone protein that is involved in ensuring the proper folding of 
many transmembrane glycoproteins (Parodi, 2000), making prolonged interaction of a 
protein with calnexin indicative of protein misfolding. The results of the previous 
experiments had provided evidence that the A204E mutation caused the GRLN-R to be 
retained within the ER, possibly due to protein misfolding. Thus to test whether the 
GRLN-R-A204E associated more stably with calnexin than the GRLN-R or the GRLN-
I134T, a co-immunoprecipitation assay was utilised.  
Lysates from GRLN-R, GRLN-R-A204E and GRLN-R-I134T cells were prepared, 
immunoprecipitated using anti-GFP antiserum and analysed by western blotting. Analysis 
of the total lysates demonstrated that all samples were equally loaded and there was no up-
regulation of calnexin following receptor expression (Figure 6-7).  Analysis of the total 
lysates for the receptor’s eCFP tag showed receptor expression was only observed upon 
induction with 6 ng/mL doxycycline. Despite equal loading of the lysates, the GRLN-R 
and GRLN-R-I134T were expressed at substantially higher levels than the intracellularly 
retained GRLN-A204E.  
Analysis of the immunoprecipitation samples showed that each of the receptors interacted 
with calnexin, although to different extents. When taking into account for the differences 
in receptor expression level, the GRLN-R-A204E appeared to show a more stable 
interaction with calnexin compared to both the GRLN-R and the GRLN-R-I134T whilst 
both the GRLN-R and the GRLN-R-I134T showed similar interactions with calnexin. Thus 
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Figure 6-6 - Co-localisation of GRLN-R, GRLN-R-I134T and GRLN-R-A204E with a marker of 
the ER. In each cell line receptor expression was induced with 6 ng/mL doxycycline (16 h). Cells 
were rinsed with PBS before incubation in a humidified incubator (37 °C; 5 % CO2/ 95 % air) with 1 
µM ER-tracker™ red (20 min). Cells were subsequently formaldehyde-fixed and mounted onto 
microscope slides. The images of receptor (pseudo-coloured green) and ER marker (red) were 
aligned (colour combine column) with overlapping regions shown as a yellow colour. Scale bar 
width equals 20 µm. Images are representative of two individual experiments.
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Figure 6-7 - Interaction of GRLN-R, GRLN-R-I134T and GRLN-R-A204E with the ER 
chaperone protein calnexin. Expression of GRLN-R, GRLN-R-I134T or GRLN-R-A204E was 
induced by the addition of 6 ng/mL doxycycline (16 h) in the respective cell lines. Cells were lysed 
and proteins immunoprecipitated using sheep anti-GFP antiserum. Subsequently, total lysates and 
immunoprecipitated (pulldown) lysates were resolved by SDS-PAGE followed by western blotting 
with either a rabbit anti-GFP antibody or an anti-calnexin antibody. Results shown are from one 
experiment (n =1). 
 
these results are consistent with the previous findings, which suggest that the A204E 
mutation leads to intracellular retention of the GRLN-R.  
6.2.5 Time course of GRLN-R-A204E folding 
Next, to determine whether the GRLN-R-A204E failed to achieve maturation, or whether it  
exhibited slower folding kinetics than the GRLN-R and GRLN-R-I134T to reach its native 
conformation, a time course of induction of protein expression was performed.  
Lysates were prepared from GRLN-R-A204E cells that had been treated with doxycycline 
for 0-72 h, lysates were subsequently deglycosylated (with either Endo H or PNGaseF) and 
analysed by immunoblotting. In the absence of doxycycline, no signal could be detected 
(Figure 6-8), whereas after 9 h induction, a faint 70 kDa signal was detected that was 
reduced to 50 kDa by treatment with Endo H or PNGaseF. The intensity of the signal for 
immature receptor increased as time of doxycycline-induction increased. Interestingly, a 
faint signal for the 105 kDa mature receptor was also detected, although this could 
Pulldown lysates Total lysates 
105 kDa 
75 kDa 
75 kDa calnexin 
GFP 
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Figure 6-8 - Time course of folding of GRLN-R-A204E mutant. Lysates were prepared from 
GRLN-R-A204E cells treated with 1 µg/mL doxycycline for 0 –72 h. Samples were deglycosylated 
for 16 h (4 °C) with 1 mU Endo H or 1 U PNGaseF (as indicated) before being resolved by SDS-
PAGE followed by western blotting with anti-GFP antiserum. The lower panel shows the presence 
of a signal at 105 kDa after overexposure of the blot. Immunoblots representative of an n=1. 
 
only be seen after prolonged exposure of the immunoblot (lower panel of Figure 6-8). 
Treatment with PNGaseF reduced the intensity of 105 kDa band and increased the signal 
for the unglycosylated 50 kDa form. Thus, this demonstrates that some, albeit a small, 
proportion of GRLN-R-A204E protein underwent complex glycosylation. 
6.2.6 Signalling of the GRLN-R-A204E in intact cells 
To test whether mature receptors were being formed and whether these receptors were 
fully functional, an intact cell assay was utilised. As ghrelin is a peptide ligand it is 
expected to be cell-impermeable, as such, any response to ghrelin must be mediated via 
activation of receptors expressed at the plasma membrane. Using an inositol phosphate 
accumulation assay, non-induced control cells showed no response to treatment with 1 µM 
ghrelin or 1 µM of the inverse agonist SPA (Figure 6-9). Upon induction of GRLN-R-
A204E expression, a significant response to ghrelin could be obtained (p<0.001; one-way 
ANOVA with Tukey’s multiple comparison test), demonstrating that some functional 
GRLN-R-A204E was expressed at the plasma membrane. Inducing receptor expression 
had no effect on the level of basal inositol phosphate accumulation compared to non-
induced cells, suggesting that unlike the wild-type GRLN-R, this receptor mutant was not 
0 h 9 h 16 h 72 h 
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Figure 6-9 - Response of GRLN-R-A204E to ghrelin and SPA as measured using an inositol 
phosphate accumulation assay.
 Cells were incubated with 1 µCi/mL [3H]myo-inositol and 
receptor expression induced as required. Prior to the assay media was replaced with Krebs-Ringer 
buffer supplemented with 10 mM lithium chloride to block the breakdown of inositol phosphates into 
myo-inositol. A. Cells were stimulated with 1 µM ghrelin or 1 µM SPA for 30 min (37 °C), as 
indicated. White bars indicate the responses obtained in the absence of receptor expression, whilst 
black bars indicate the responses obtained upon expression of GRLN-R-A204E. After ligand-
stimulation cells were lysed with perchloric acid and [3H]total inositol phosphates isolated from the 
mixture using ion-exchange chromatography. The amount of [3H]total inositol phosphates 
accumulated were measured using liquid scintillation spectrometry (120 s/sample). Data points 
represent the mean ± S.E.M of three independent experiments performed in duplicate. ***p<0.001 
as measured using a one-way ANOVA with Tukey’s multiple comparison test. B. A concentration-
response curve to ghrelin was generated in induced GRLN-R-A204E cells. Data points represent 
the mean ± S.E.M of three independent experiments performed in duplicate.
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constitutively active. This was confirmed by treatment of cells with 1 µM SPA, which had 
no effect on the level of inositol phosphate accumulation in the absence of ghrelin. 
To determine the potency of ghrelin signalling on GRLN-R-A204E at the plasma 
membrane, the inositol phosphate accumulation assay was used to generate a 
concentration-response curve to ghrelin. This demonstrated that the level of inositol 
phosphate accumulation increased in a concentration-dependent manner (Figure 6-9), 
yielding a pEC50 value of 8.93 ± 0.12 a value that was shown to not be significantly 
different (p=0.14) to the wild-type receptor (pEC50 = 9.22 ± 0.11) when compared using an 
unpaired, two-tailed t-test. 
6.2.7 Signalling of the GRLN-R-A204E through the Gαi/o 
pathway 
As the inositol phosphate accumulation assays demonstrated that the GRLN-R-A204E 
retained its ability to signal through activation of the Gαq/11 pathway, the ability of the 
receptor to activate the Gαi/o pathway was tested. The wild-type GRLN-R has been 
described as a promiscuous receptor, able to activate the Gαi/o pathway in response to 
stimulation with ghrelin (Bassil et al., 2007; Esler et al., 2007; Dezaki et al., 2007; 
Chapters 3 and 4).  
Figure 6-10 - Testing the ability of the GRLN-R-A204E to evoke a [35S]GTPγS response 
through activation of Gαi/o pathway. GRLN-R-A204E cells were transfected with Gαo1 and receptor 
expression was induced by the addition of 6 ng/mL doxycycline (16 h)
. 
Membranes were prepared 
and tested for their ability to increase [35S]GTPγS binding in response to stimulation with increasing 
concentrations of ghrelin (20 min; 30 °C). G protein-bound [35S]GTPγS was separated from the 
reaction mixture by rapid filtration through GF/C filters soaked in 1 x PBS and bound  [35S]GTPγS 
measured (for 5 min) using liquid-scintillation spectrometry. 
 
Data points represent the mean ± 
S.E.M of three independent experiments performed in triplicate. 
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Figure 6-11 - Binding of [His[125I]]-ghrelin to membranes prepared from GRLN-R, GRLN-R-
I134T and GRLN-R-A204E cells. GRLN-R, GRLN-R-I134T, and GRLN-R-A204E cells were 
induced with 6 ng/mL doxycycline (16 h); subsequently cells were harvested and membranes 
prepared. Binding of [His[125I]]-ghrelin was determined by addition of a final concentration of 83 pM 
of [His[125I]]ghrelin to 5 µg of cell membranes, ± 1 µM cold ghrelin to label non-specific binding, in a 
final volume of 150 µL. Binding was carried out for 120 min at 4 °C before being terminated by 
rapid filtration through GF/B soaked in 0.5 %(w/v) PEI. Specific binding of [His[125I]]ghrelin to 
membranes from GRLN-R cells and GRLN-R-I134T cells was determined by subtracting total 
[His[125I]]-ghrelin binding from non-specific binding. Data points represent the mean ± S.E.M of 
three independent experiments performed in duplicate. *p<0.05 as compared using a one-way 
ANOVA with Dunnett’s post-hoc test. 
 
GRLN-R-A204E cells were transfected to express Gαo1 and receptor expression was 
induced by the addition of doxycycline. Membranes were prepared and, using a 
[35S]GTPγS binding assay, a concentration-response curve to ghrelin was generated, 
allowing determination of the potency of ghrelin (pEC50 = 8.94 ± 0.44), a value that was 
not significantly different (p=0.63) to that of the wild-type GRLN-R (pEC50 = 9.19 ± 0.16) 
when compared using an unpaired, two-tailed t-test (Figure 6-10). Thus the results from 
both this experiment and the inositol phosphate accumulation experiments demonstrate that 
the A204E mutation does not alter the potency of ghrelin via activation of the Gαq/11 and 
Gαi/o pathway, respectively. Furthermore it demonstrates that, like the wild-type GRLN-R, 
the GRLN-R-A204E is able to promiscuously couple to multiple G protein pathways. 
6.2.8 Binding of [His[125I]]-ghrelin to membranes prepared from 
GRLN-R, GRLN-R-I134T and GRLN-R-A204E cells 
To assess whether the A204E or I134T mutations affect the expression levels of the 
GRLN-R, a radioligand binding assay was utilised. Membranes were prepared from wild-
type GRLN-R, GRLN-R-I134T and GRLN-R-A204E cells and the specific binding of 
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[His[125I]]-ghrelin to the membranes measured. (Figure 6-11). Specific binding of 
[His[125I]]-ghrelin to membranes prepared from GRLN-R-A204E cells was significantly 
lower than in membranes prepared from wild-type GRLN-R cells (p<0.05; one-way 
ANOVA with Dunnett’s post-hoc test). In contrast, the I134T mutation had no significant 
effect on the level of specific [His[125I]]-ghrelin binding compared to the wild-type GRLN-
R, indicating that this mutation did not affect the mutant’s expression level. Moreover, in 
contrast to published data (Liu et al., 2007), this data demonstrates that the I134T mutation 
does not ablate ghrelin binding to the GRLN-R.   
6.2.9 Testing the response to GRLN-R-I134T in an intact cell 
assay 
As the GRLN-R-I134T was shown to be able to bind [His[125I]]-ghrelin (section 6.2.8), the 
ability of the mutant receptor to signal in response to ghrelin was tested using the intact-
cell inositol phosphate assay. In the absence of receptor, no significant (p>0.05; one-way 
ANOVA with Tukey’s multiple comparison test) response of the cells to 1 µM ghrelin or 
to 1 µM SPA was observed (Figure 6-12). Receptor expression led to a significant increase 
(p<0.05) in basal inositol phosphate accumulation, a response around 6.5-fold above that 
measured in the absence of receptor expression. The increase in the basal levels of inositol 
phosphate accumulation was similar to the 6.3-fold increase in inositol phosphate levels 
measured upon expression of the wild-type GRLN-R shown in Chapter 5 (Figure 5-6). 
However, for the GRLN-R-I134T, incubation with 1 µM SPA did not significantly reduce 
the level of inositol phosphate accumulation to that obtained in the absence of receptor 
expression, although the level of inositol phosphate accumulated in the absence of receptor 
expression was not statistically different compared to SPA-treated cells. These results 
suggest that the efficacy and/or affinity of SPA for the GRLN-R may have been lowered 
by the I134T mutation. 
In line with the radioligand binding data (section 6.2.8), a significant response to 1 µM 
ghrelin was obtained in cells expressing GRLN-R-I134T (p<0.001). Moreover, GRLN-R-
I134T responded to ghrelin in a concentration-dependent manner yielding a pEC50 value of 
8.76 ± 0.13 (Figure 6-12). This value was not significantly different (p=0.05) to the 
potency of ghrelin acting at the GRLN-R (pEC50 = 9.22 ± 0.11; Chapter 5; Table 5-3; 
compared using an unpaired, two tail t-test). Taken together, these findings suggest that
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Figure 6-12 - Response of GRLN-R-I134T to ghrelin and SPA as measured using an inositol 
phosphate accumulation assay. Cells were incubated with 1 µCi/mL [3H]myo-inositol and 
receptor expression induced as required. Prior to the assay, media was replaced with Krebs-Ringer 
buffer supplemented with 10 mM lithium chloride to block the breakdown of inositol phosphates into 
myo-inositol. A. Cells were stimulated with 1 µM ghrelin or 1 µM SPA for 30 min (37 °C), as 
indicated. White bars indicate the responses obtained in the absence of receptor expression, whilst 
black bars indicate the responses obtained upon expression of GRLN-R-I134T. After ligand-
stimulation cells were lysed with perchloric acid and [3H]total inositol phosphates isolated from the 
mixture using ion-exchange chromatography. The amount of [3H]total inositol phosphates 
accumulated were measured using liquid scintillation spectrometry (120 s/sample).Data points 
represent the mean ± S.E.M of three independent experiments performed in duplicate. ***p<0.001; 
* p<0.05, as measured using a one-way ANOVA with Tukey’s multiple comparison test. B. A 
concentration-response curve to ghrelin was generated in induced GRLN-R-I134T cells. Data 
points represent the mean ± S.E.M of three independent experiments performed in duplicate.     
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the GRLN-R-I134T was constitutively active, and could signal in response to ghrelin.  
6.2.10 Signalling of GRLN-R-I134T through Gαq/11 and Gαi/o 
pathways 
As the wild-type GRLN-R was shown to signal through the Gαq/11 and Gαi/o pathways, the 
signaling of the GRLN-R-I134T through these pathways was tested using [35S]GTPγS 
binding assays. As the I134T mutation has been shown to ablate the signaling of the 
GRLN-R to ghrelin (Liu et al., 2007), the ability of the GRLN-R-I134T to signal to the 
growth hormone secretagogues was also tested.  
The ability of the GRLN-R-I134T to couple to Gαq/11 can be shown as an increase in 
inositol phosphate accumulation in response to ghrelin. To assess whether a maximally 
effective concentration of either ghrelin or the growth hormone secretagogues could 
increase [35S]GTPγS binding via activation of Gαq, a [35S]GTPγS binding assay with 
immunoprecipitation step was used. Expression of GRLN-R-I134T was induced by the 
addition of doxycycline to GRLN-R-I134T cells transfected with Gαq; subsequently  
Figure 6-13 - Testing the ability of ghrelin and the growth hormone secretagogues to evoke 
a [35S]GTPγS response in GRLN-R-I134T cells transfected to express Gαq. GRLN-R-I134T cells 
were transfected to express Gαq and receptor expression was induced by the addition of 6 ng/mL 
doxycycline (16 h)
. 
Membranes were prepared and tested for their ability to increase [35S]GTPγS 
binding in response to stimulation with 1 µM ghrelin, MK-677, GHRP-6 or L-692,585 (30 min; 37 
°C). Gαq was immunoprecipitated from the reaction mixture using anti-Gαq antiserum and bound 
[35S]GTPγS measured using liquid scintillation spectrometry (5 min/sample). Data points represent 
the mean ± S.E.M of three independent experiments performed in triplicate. **p<0.01 when 
compared to basal using a one-way ANOVA with Dunnett’s post-hoc test. 
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membranes were prepared and stimulated with 1 µM ghrelin, GHRP-6, L-692,585 or MK-
677 and inositol phosphate accumulation was measured (Figure 6-12). Membranes from 
GRLN-R-I134T cells showed significantly increased (p<0.001; one-way ANOVA with 
Dunnett’s post-hoc test) [35S]GTPγS binding in response to incubation with ghrelin and the 
growth hormone secretagogues, compared to membranes from unstimulated GRLN-R-
I134T cells (Figure 6-13) 
Next, to test whether the GRLN-R-I134T could activate the Gαi/o pathway, cells were 
transfected with Gαo1 and the ability to increase [35S]GTPγS binding measured (Figure 6-
14). In the absence of receptor expression, treatment with maximally effective 
concentrations of ghrelin and the growth hormone secretagogues failed to significantly 
increase the levels of [35S]GTPγS binding compared to the absence of ligand (p=0.49; one-
way ANOVA). Upon induction of GRLN-R-I134T expression, ghrelin, GHRP-6, L-
692,585 and MK-677 increased [35S]GTPγS binding in a concentration-dependent manner. 
The potency and efficacy values of ghrelin and the growth hormone secretagogues are 
listed in (Table 6-2).  
Table 6-2 - Potency and efficacy values of ligands acting at GRLN-R-I134T via Gαi/o  
activation, measured using a [35S]GTPγS binding assay.  
Ligand pEC50 ± S.E.M Emax ± S.E.M 
Ghrelin 9.72 ± 0.18 89.6 ± 5.1 
MK-677 9.77 ± 0.22 147.2 ± 10.3 
GHRP-6 7.63 ± 0.17 145.3 ± 8.5 
L-692,585 7.37 ± 0.34 150.4 ± 20.8 
Data is expressed as the mean ± S.E.M of two (MK-677, GHRP-6, L-692,585) or three (ghrelin) 
individual experiments performed in triplicate. Emax is displayed as the maximum response of ligand 
expressed as the percentage of the maximum response achieved by ghrelin. 
 
The potency values obtained for ghrelin acting at the GRLN-R-I134T were compared to 
ghrelin acting at the wild-type GRLN-R (obtained in Chapter 4; Table 4-1) with an 
unpaired, two-tailed t-test. This showed there was no significant difference in the potency 
of ghrelin acting at the wild-type GRLN-R and the GRLN-R-I134T (p=0.09). The 
potencies and efficacies of the growth hormone secretagogues acting at the GRLN-R-
I134T appeared to be similar to those measured at the wild-type GRLN-R (obtained in 
Chapter 4; Table 4-1), however, due to the number of experiments performed (n=2) 
statistical tests could not be used to compare the data.
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Figure 6-14 - Response of the GRLN-R-I134T via activation of the Gαi/o pathway as measured 
using a [35S]GTPγS binding assay. A. Membranes prepared from uninduced GRLN-R-I134T cells 
transfected with Gαo1 were tested for their ability to increase levels of [35S]GTPγS binding in 
response to 1 µM ghrelin, GHRP-6, L-692,585 and MK-677 (20 min; 30 °C). G protein-bound 
[35S]GTPγS was separated from the reaction mixture by rapid filtration through GF/C filters soaked 
in 1 x PBS and bound  [35S]GTPγS measured (for 5 min) using liquid-scintillation spectrometry. 
Data points represent the mean ± S.E.M of three independent experiments performed in triplicate. 
B. Concentration-response curves to ghrelin, GHRP-6, MK-677 and L-692,585 were generated in 
membranes prepared from GRLN-R-I134T cells transfected with Gαo1, in which receptor expression 
had been induced by treatment with doxycycline (6 ng/mL; 16 h). Data points represent the mean ± 
S.E.M of three independent (for ghrelin) or two independent experiments (for GHRP-6, MK-677 and 
L-692,585) performed in triplicate.
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6.2.11 Effect of ghrelin and the growth hormone secretagogues 
on the localisation of GRLN-R-I134T and GRLN-R-A204E  
Finally, as both the GRLN-R-A204E and the GRLN-R-I134T responded to ghrelin the 
effect of ghrelin and the growth hormone secretagogues on the localisation of the receptors 
was tested.  In Chapter 4, epifluorescence microscopy showed that the GRLN-R appeared 
to internalise upon treatment with maximally effective concentrations of ghrelin and the 
growth hormone secretagogues. In contrast, treatment with the inverse agonist SPA was 
shown to trap the GRLN-R at the plasma membrane leading to a loss of punctate vesicles 
within intracellular regions of the cells.  
In the absence of ligand, GRLN-R-A204E was found inside the cell to a large extent, but 
the receptor also showed overlap with the plasma membrane marker wheat germ agglutinin 
(Figure 6-15). The addition of maximally effective concentrations of ghrelin, GHRP-6, 
MK-677, or L-692,585 (1 µM; 30 min) shifted the localisation of the receptor to punctuate 
vesicles within the cell (Figure 6-15). Quantification of the images showed that the 
formation of vesicles was accompanied by a significant decrease of the eCFP fluorescence 
intensity at the plasma membrane for ghrelin and all growth hormone secretagogues 
(p<0.01; one-way ANOVA with Dunnett’s post-hoc test) (Figure 6-16). Surprisingly, the 
addition of the inverse agonist SPA (1 µM; 16 h) also decreased the amount of cell surface 
receptors (p<0.05), although this was not accompanied by the formation of intracellular 
vesicles. 
In the GRLN-R-I134T cells, the addition of maximally effective concentrations of ghrelin 
and the growth hormone secretagogues also increased receptor internalisation from the 
plasma membrane into large punctuate vesicles within the cell (Figure 6-16). 
Quantification of the fluorescent signals showed that there was no significant decrease in 
plasma membrane-localised receptors upon treatment with ghrelin or the growth hormone 
secretagogues compared to the basal condition (Figure 6-17).  The addition of SPA caused 
a significant (p<0.01) redistribution of the GRLN-R-I134T to plasma membrane, 
indicating both that SPA binds to the GRLN-R-I134T and that it acts as an inverse agonist, 
increasing the proportion of GRLN-R-I134T localised at the plasma membrane.
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Figure 6-15 - Localisation of GRLN-R-A204E after treatment with ghrelin, GHRP-6, L-692,585, 
MK-677 or SPA (cont’d overleaf). Receptor was induced as required and treated with a maximally 
effective concentration of agonist (1 µM; 30 min for ghrelin, GHRP-6, L-692,585 and MK-677 and 1 
µM for 16 h for SPA; 37 °C). Cells were formaldehyde-fixed before the plasma membrane was 
stained with WGA-Alexa Fluor®-594 conjugate. Cells were mounted onto coverslips, eCFP 
visualized using 436/12 nm light and the WGA-Alexa Fluor®-594 conjugate visualized at 575/12 
nm. The images of GRLN-R-A204E (pseudo-coloured green) and the plasma membrane (red) 
were aligned (colour combine column) with overlapping regions shown as a yellow colour. Scale 
bar width represents 20 µm. 
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Figure 6-15 (cont’d) - Localisation of GRLN-R-A204E after treatment with ghrelin, GHRP-6, L-
692,585, MK-677 or SPA. Receptor was induced as required and treated with a maximally 
effective concentration of agonist (1 µM; 30 min for ghrelin, GHRP-6, L-692,585 and MK-677 and 1 
µM for 16 h for SPA; 37 °C). Cells were formaldehyde-fixed before the plasma membrane was 
stained with WGA-Alexa Fluor®-594 conjugate. Cells were mounted onto coverslips, eCFP 
visualized using 436/12 nm light and the WGA-Alexa Fluor®-594 conjugate visualized at 575/12 
nm. The images of GRLN-R-A204E (pseudo-coloured green) and the plasma membrane (red) 
were aligned (colour combine column) with overlapping regions shown as a yellow colour. Scale 
bar width represents 20 µm. 
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Figure 6-16 - Localisation of GRLN-R-I134T after treatment with ghrelin, GHRP-6, L-692,585, 
MK-677 or SPA (cont’d overleaf). Receptor was induced as required and treated with a maximally 
effective concentration of agonist (1 µM; 30 min for ghrelin, GHRP-6, L-692,585 and MK-677 and 1 
µM for 16 h for SPA; 37 °C). Cells were formaldehyde-fixed before the plasma membrane was 
stained with WGA-Alexa Fluor®-594 conjugate. Cells were mounted onto coverslips, eCFP 
visualized using 436/12 nm light and the WGA-Alexa Fluor®-594 conjugate visualized at 575/12 
nm. The images of GRLN-R-I134T (pseudo-coloured green) and the plasma membrane (red) were 
aligned (colour combine column) with overlapping regions shown as a yellow colour. Scale bar 
width represents 20 µm. 
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Figure 6-16 (cont’d) – Localisation of GRLN-R-I134T after treatment with ghrelin, GHRP-6, L-
692,585, MK-677 or SPA. Receptor was induced as required and treated with a maximally 
effective concentration of agonist (1 µM; 30 min for ghrelin, GHRP-6, L-692,585 and MK-677 and 1 
µM for 16 h for SPA; 37 °C). Cells were formaldehyde-fixed before the plasma membrane was 
stained with WGA-Alexa Fluor®-594 conjugate. Cells were mounted onto coverslips, eCFP 
visualized using 436/12 nm light and the WGA-Alexa Fluor®-594 conjugate visualized at 575/12 
nm. The images of GRLN-R-I134T (pseudo-coloured green) and the plasma membrane (red) were 
aligned (colour combine column) with overlapping regions shown as a yellow colour. Scale bar 
width represents 20 µm. 
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Figure 6-17 - Proportion of GRLN-R-A204E and GRLN-R-I134T detected at the plasma 
membrane after treatment with ghrelin, the growth hormone secretagogues or the inverse 
agonist SPA. Autoquant software was used to determine the proportion of total eCFP fluorescence 
located at the plasma membrane after treatment with 1 µM ghrelin, GHRP-6, L-692,595 or MK-677 
for 30 min or 1 µM SPA for 16 h (37 °C). Data points represent the mean ± S.E.M of the 
quantification of A. three GRLN-R-A204E cells or B. three GRLN-R-I134T cells. *p<0.05, **p<0.001 
when compared to basal using a one-way ANOVA with Dunnett’s post-hoc test.
B 
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A 
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6.3 Discussion 
Mutations within genes encoding GPCRs may affect receptor function and, for the GRLN-
R, two missense mutations (A204E and F279L) have been associated with the 
development of a short-stature/obese phenotype in vivo (Pantel et al., 2006; Wang et al., 
2004). The aim of this study was to further investigate two missense mutations of the 
GRLN-R, A204E and I134T, which have been reported to have altered pharmacology. 
To aid studies into the effects of missense mutations on the function of the GRLN-R, 
receptors were engineered to contain either the A204E or I134T missense mutations and 
were subsequently tagged at the N-terminus with a HA tag and at the C-terminus with 
eCFP. In Chapter 4 the addition of an N-terminal epitope tag (VSV-G) and a C-terminal 
eCFP tag to the GRLN-R was investigated and shown to have no effect on the 
pharmacology and localisation of the receptor. The addition of a HA tag at the N-terminus 
of the GRLN-R has previously been used to study the pharmacology of the wild-type 
GRLN-R (Liu et al., 2007; Pantel et al., 2006). Importantly, these studies showed that the 
addition of the HA tag to the wild-type receptor did not affect the constitutive activity of 
the receptor (Pantel et al., 2006). Furthermore, the affinity of ghrelin for the GRLN-R was 
similar to the affinity values obtained for the untagged receptor and similar to the affinity 
values reported by Holst et al. (2005).  
Using the HA-GRLN-R-A204E-eCFP and the HA-GRLN-R-I134T-eCFP constructs two 
inducible cell lines were created which proved to be extremely useful for investigating the 
effect of the A204E and I134T mutations on the pharmacology and localisation of the 
GRLN-R. 
6.3.1 The GRLN-R-A204E is partially ER-retained 
Whilst studies investigating the affects of the A204E mutation agree that this mutation 
ablates the constitutive activity of the GRLN-R (Holliday et al., 2007; Liu et al., 2007; 
Pantel et al., 2006), conflicting reports have been published about the effect of the A204E 
mutation on receptor localisation. If the A204E mutation only interferes with constitutive 
activity of the GRLN-R, the receptor would be expected to be plasma membrane 
delineated, as constitutive activity of the receptor has been shown to be a key requirement 
for constitutive endocytosis (Holliday et al., 2007). Indeed the distribution of the GRLN-R-
A204E has been shown to be plasma membrane delineated in a study by Holliday et al. 
(2007). However, in this study, epifluorescence microscopy data showed that the GRLN-
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R-A204E was trapped within the cell, a finding in agreement with that of Pantel et al. 
(2006). Furthermore immunoblotting of lysates prepared from GRLN-R-A204E cells 
revealed that, in contrast to the GRLN-R, the largest proportion of the GRLN-R-A204E 
existed as immature, high mannose glycosylated receptor – a glycosylation state indicative 
of ER retention of a GPCR (Sadeghi et al., 1997). Co-immunoprecipitation assays also 
revealed that, compared to the amount of protein recovered, the GRLN-R-A204E 
interacted more stably with the ER-resident molecular chaperone calnexin than the GRLN-
R. Together, these experiments demonstrated that a large fraction of GRLN-A204E was 
being retained within the ER.  
The insertion or removal of charged amino acids by missense mutations are well known to 
affect protein structure and folding. For example, a single change in the net charge of the 
gonadotrophin releasing hormone receptor (the alteration of a alanine residue, A1293.40, to 
an aspartic acid residue) is sufficient to favour ER retention of the receptor, decreasing the 
amount of receptor available at the cell membrane, leading to the disorder 
hypergonadotropic hypogonadism (Conn et al., 2007). Similarly, the V206D mutation in 
the type 2 vasopressin receptor has been reported to induce ER retention of the receptor 
(Robben et al., 2006), leading to the heritable disorder nephrogenic diabetes insipidus. In 
line with these studies, the A204E mutation in the GRLN-R that introduces a negatively 
charged glutamic acid residue in place of a neutral alanine residue causes ER retention of 
the GRLN-R-A204E. However, in this study, immunoblotting experiments revealed that a 
small proportion of receptor was complex glycosylated as it was insensitive to Endo H, but 
could be digested by PNGaseF. Furthermore, ghrelin was shown to increase the level of 
inositol phosphate accumulation in a concentration-dependent manner in an intact cell 
assay; as ghrelin is membrane-impermeable the observed increase in inositol phosphate 
levels is most likely derived from GRLN-R-A204E localised at the cell-surface membrane. 
Therefore, even though a large proportion of the GRLN-R-A204E was ER retained, these 
data clearly demonstrated that some mature GRLN-R-A204E was expressed at the cell-
surface; a finding in agreement with other groups who have used intact cell inositol 
phosphate accumulation assays to measure activation of the GRLN-R-A204E in response 
to ghrelin (Pantel et al., 2006; Liu et al., 2007; Holliday et al., 2007).  
The difference between the localisation of the GRLN-R-A204E in this study compared to 
that of Holliday et al. (2007) may be due to the methods used to detect the receptor. 
Holliday et al. (2007) used immunocytochemistry with an antibody raised against a FLAG 
epitope tag (added to the N-terminus of the GRLN-R-A204E) to detect the receptor 
expressed in (permeabilised) HEK293 cells, perhaps the structure of the ER-retained 
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receptor was altered in such a way that the antibody was unable to recognise the FLAG 
tag.  
6.3.2 Effect of the A204E mutation on the cell-surface 
expression of the GRLN-R-A204E  
Interestingly, although data from this experiment clearly showed that the GRLN-R-A204E 
was partially ER retained, the data from the epifluorescence microscopy experiments 
seemed to contradict this, showing that the GRLN-R-A204E was expressed at the cell-
surface at a higher level than the wild-type GRLN-R (measured in Chapter 4; Figure 4-8). 
Although it could be interpreted that the A204E mutation increased the level of surface 
expression of the GRLN-R-A204E compared to the wild-type receptor, quantification of 
epifluorescence microscopy images is a crude measurement of cell-surface expression and 
contradicts the findings from the more sensitive binding and immunoblotting experiments. 
Indeed the radioligand binding experiments demonstrated that specific binding of 
[His[125I]]-ghrelin to the GRLN-R-A204E was significantly lower than for the wild-type 
GRLN-R; whilst immunoblotting experiments showed that the majority of the GRLN-R-
A204E existed as an immature form.  
6.3.3 The A204E mutation ablates the constitutive activity of 
the GRLN-R 
The A204E mutation has been described to ablate the constitutive activity of the GRLN-R-
A204E (Holliday et al., 2007; Liu et al., 2007; Pantel et al., 2006). Indeed, in this study the 
GRLN-R-A204E appeared to lack any measurable constitutive activity. The inositol 
phosphate accumulation studies (shown in Figure 6-9) revealed that, in contrast to the 
wild-type GRLN-R, induction of the expression of the GRLN-R-A204E did not alter the 
level of inositol phosphates observed compared to cells lacking receptor expression. In 
addition, incubation of GRLN-R-A204E cells with the inverse agonist SPA had no effect 
on the accumulation of inositol phosphates measured in the absence of ligand treatment. 
However, the results of the epifluorescence microscopy experiments appeared to show an 
inconsistency with the other data.  
In a steady-state situation, the wild-type GRLN-R is localised at the plasma membrane and 
in intracellular vesicles, whilst treatment with the inverse agonist SPA promotes its 
accumulation at the plasma membrane; likely through blocking the constitutive activity, 
and thereby constitutive internalisation, of the GRLN-R (Holliday et al., 2007). As 
treatment of the GRLN-R-A204E cells with SPA had no effect on signalling of the 
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receptor in the inositol phosphate accumulation experiments, SPA was predicted to have 
little effect on the localisation of the GRLN-R-A204E. However, quantification of the 
epifluorescence microscopy experiments (shown in Figure 6-17) showed treatment with 
SPA actually led to a significant reduction in the cell surface expression of the GRLN-R-
A204E.  
The serotonin 5-HT2C receptor is an example of a constitutively active receptor whose 
expression can be down-regulated, both in vitro and in vivo by chronic inverse agonist 
exposure (>24 h) (Devlin et al., 2004). In this study the GRLN-R-A204E was incubated 
with inverse agonist for 16 h. Although 16 h incubation with SPA was shown to increase 
the level of both wild-type GRLN-R and GRLN-R-I134T compared to basal conditions, 
this was likely due to retarding constitutive receptor activity which would trap the receptor 
at the plasma membrane. Thus the down-regulation of the GRLN-R may only become 
apparent in a situation where the receptor lacks any constitutive activity. However, further 
studies are needed to investigate this, as 16 h of inverse agonist exposure may be too short 
a time for receptor down-regulation to occur.   
6.3.4 The GRLN-R-A204E responds to ghrelin with a potency 
similar to that of the GRLN-R 
As many peptide ligands tend to exploit residues in the extracellular end of TM helices and 
in the extracellular domains upon receptor binding (Schwartz et al., 2006), the A204E 
mutation could have affected the binding of ghrelin or any of the growth hormone 
secretagogues. Indeed, another mutation in the second extracellular loop of the GRLN-R 
(E197G) was found to decrease the potency of ghrelin (Holst et al., 2009). However, in this 
study and in keeping with the findings from other studies (Liu et al., 2007; Pantel et al., 
2006), the A204E mutation appeared to have no effect on the signalling of the receptor to 
ghrelin. The GRLN-R-A204E responded to ghrelin in the inositol phosphate accumulation 
assay with a potency (pEC50) that was not statistically different to that obtained by the 
wild-type GRLN-R. Furthermore, the A204E mutation had no effect on the promiscuous 
coupling of the GRLN-R, as in GRLN-R-A204E cells the potency of ghrelin in the Gαi/o 
pathway was also similar to that obtained for the GRLN-R. In addition, maximally 
effective concentrations of ghrelin and the growth hormone secretagogues were all able to 
internalise the GRLN-R-A204E suggesting that the receptor could also bind and signal to 
GHRP-6, MK-677 and L-692,585 at the cell surface.  
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The effect of the A204E mutation on the structure of the GRLN-R has not been determined 
in this or any other study. However, another missense mutation of the GRLN-R, the F279L 
mutation in TMVI, has also been reported to affect the constitutive activity of the GRLN-R 
(Liu et al., 2007; Holst et al., 2004). The F279L mutation occurs in a cluster of amino acids 
in TMVI and TMVII that were shown in mutagenesis studies to be critical in maintaining 
the constitutive activity of the GRLN-R (Holst et al., 2004). Although the A204E mutation 
is distinct from this region and is distinct from residues known to participate in the ghrelin-
binding pocket (Feighner et al., 1998, Holst et al., 2009) the data presented here suggest 
the A204E mutation may alter receptor folding, disrupting the structural domain 
responsible for the constitutive activity of the receptor. The concept of altered receptor 
folding is also supported by the findings that most of the GRLN-R-A204E exists as an 
immature form and that the receptor is partially ER-retained.  
A recent study on the free fatty acid 1 receptor has shown that a glutamic acid to alanine 
mutation at two positions in ECL2 results in constitutive activation of the receptor due to 
the disruption of a ionic-lock formed between the two glutamic acid residues and two 
arginine residues located in the TM domains (TMV and TMVII) (Sum et al., 2009). Thus 
the A204E mutation in the GRLN-R may result in the ability of the glutamic acid to form 
an ionic-lock with residues in the TM domains, ablating the constitutive activity of the 
receptor, although clearly this would need to be further explored. 
Interestingly, in the melanocortin-4 receptor, mutations within the extracellular domain of 
the receptor, which selectively impair the constitutive activity of the receptor, have been 
linked to the development of obesity (Srinivasan et al., 2004). Although it is tempting to 
link this lack of constitutive activity of the GRLN-R-A204E to the obese phenotype 
observed in subjects harbouring the A204E mutation, the results from this study 
demonstrate that the GRLN-R-A204E undergoes a higher degree of ER retention than the 
wild-type GRLN-R. Thus, the observed phenotype may be solely due to lower cell-surface 
expression of GRLN-R-A204E. As the expression of the GRLN-R has been reported to be 
extremely low in vivo (Katugampola et al., 2001), ER retention of the GRLN-R-A204E 
could potentially have a severe impact on receptor signalling. The short/obese phenotype 
has also been observed in subjects displaying the F279L mutation (Wang et al., 2004). In 
one study the F279L mutation was shown to reduce cell-surface expression of the GRLN-
R, whilst reducing, but not completely inhibiting, the constitutive activity of the mutated 
GRLN-R (Liu et al., 2007). Thus, the decreased cell surface expression of the F279L or 
A204E mutants, rather than their reduced/lack of constitutive activity, may be the main 
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determinant for the development of the short/obese phenotype observed in vivo. However, 
this question requires further investigation. 
6.3.5 The GRLN-R-I134T is localised both at the cell-surface 
membrane and in vesicles within the cell 
In contrast to the A204E mutation, the I134T mutation has been reported to ablate the 
response of the GRLN-R to ghrelin whilst having no effect on the constitutive activity of 
the receptor (Liu et al., 2007). As the growth hormone secretagogues have been shown to 
have overlapping but not identical binding sites on the GRLN-R (Feighner et al., 1998; 
Holst et al., 2009), this study sought to investigate the effect of the growth hormone 
secretagogues on the I134T mutant. The I134T mutation causes a change of a non-polar, 
neutral isoleucine residue to a polar, neutral threonine residue. Therefore, although the 
mutation is within the structurally important transmembrane domains, it may not have such 
a pronounced effect on the GRLN-R as the A204E mutation.  
In studies by Liu and colleagues (2007) the I134T mutation was demonstrated to decrease 
the cell-surface expression of the GRLN-R-I134T by around 50 %. In this study the co-
immunoprecipitation experiments appeared to show that the GRLN-R-I134T indeed was 
expressed at a lower level than wild-type GRLN-R. In contrast, radioligand binding studies 
performed in membrane samples revealed that the specific binding of [His[125I]]-ghrelin to 
GRLN-R-I134T was not significantly different to that of the GRLN-R, although the use of 
membrane samples means that, potentially, [His[125I]]-ghrelin may also be binding to 
receptor expressed in the ER. However, immunoblotting experiments indicated that the 
largest proportion of receptor appeared to be mature, complex glycosylated protein, 
indicative of a localisation beyond the cis-Golgi complex. Moreover, epifluorescence 
microscopy data demonstrated that the GRLN-R-I134T was located both at the plasma 
membrane and in small vesicles within the cell, similar to the wild-type GRLN-R. 
However, studies by Liu et al. (2007) suggest that the I134T mutation may decrease the 
cell-surface expression of the GRLN-R-I134T, which needs to be confirmed by intact cell 
binding studies. 
Interestingly, both the GRLN-R-I134T and the wild-type GRLN-R showed weak co-
localisation with a marker of the ER. Moreover, co-immunoprecipitation studies showed 
that both the GRLN-R-I134T and the wild-type GRLN-R interact with calnexin, although 
this interaction was weaker compared to that observed for GRLN-R-A204E. Likely, these 
ER-localised GRLN-R and GRLN-R-I134T represent pools of newly-synthesised receptor 
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that are being folded in the ER. Alternatively, receptor overexpression may saturate the N-
terminal glycosylation and/or protein folding system of the early secretory pathway, 
resulting in intracellular accumulation of these receptors. This could be investigated by 
assessing the interaction of these receptors with calnexin upon combined inhibition of 
protein synthesis (i.e. with cyclohexamide) and proteasomal degradation (i.e. using 
Bortezomib), which would discriminate between a protein that stayed retained within the 
ER and a protein that temporarily resides there whilst being folded.  
6.3.6 The GRLN-R-I134T is constitutively active 
Since the GRLN-R-I134T shows a similar localisation as the wild-type GRLN-R, and the 
vesicular distribution of the wild-type receptor was the result of its constitutive activity, the 
constitutive activity of the GRLN-R-I134T was assessed. Epifluorescence microscopy data 
demonstrated that the inverse agonist SPA caused a significant increase in the amount of 
GRLN-R-I134T located at the plasma membrane, a finding consistent with inhibition of 
the constitutive activity and hence, constitutive internalisation of the GRLN-R-I134T.  
In inositol phosphate accumulation studies, expression of the GRLN-R-I134T increased 
accumulation of inositol phosphates, indicating that GRLN-R-I134T was constitutively 
active, at least in the Gαq/11 pathway. Indeed the increase in inositol phosphate levels upon 
expression of the GRLN-R-I134T was similar to that observed upon expression of the 
wild-type GRLN-R. Interestingly, incubation of the cells with the inverse agonist SPA 
reduced inositol phosphate levels slightly, but did not cause a significant reduction to the 
level observed in the absence of GRLN-R-I134T expression. This suggested that, although 
the receptor was constitutively active, the I134T mutation might reduce the efficacy of 
SPA on the GRLN-R, perhaps by reducing the affinity of SPA for the receptor. 
The results from the inositol phosphate and epifluorescence experiments are in agreement 
with the study by Liu and colleagues, who found that despite conserved inverse agonist 
function, both the efficacy and potency of SPA was reduced at the GRLN-R-I134T (Liu et 
al., 2007). 
6.3.7 The GRLN-R-I134T is activated by ghrelin and growth 
hormone secretagogues 
In contrast to previously published results (Liu et al., 2007), this study has shown that the 
GRLN-R-I134T responded to ghrelin in a concentration-dependent manner. In the inositol 
phosphate accumulation assay this yielded a response with a pEC50 of 8.76 ± 0.13, a 
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response not significantly different to ghrelin activating the wild-type receptor. Thus the 
GRLN-R-I134T, like the wild-type GRLN-R, was capable of activating more than one G 
protein family. Liu et al. (2007) used inositol phosphate experiments conducted in COS-7 
cells to try to measure activation of the GRLN-R-I134T by ghrelin, however, in this study 
inositol phosphate accumulation experiments were performed in HEK293 cells, thus the 
discrepancies between the results of these studies could reflect differences in the folding of 
the GRLN-R-I134T in the two expression systems. Indeed, mutagenesis studies have 
identified several residues that are critical for binding of both ghrelin and the growth 
hormone secretagogues (Feighner et al., 1998; Holst et al., 2009). Although the residue 
I1343.43 was not analysed in these studies, it appears that this residue is too deep within the 
TM domain to be critical for ligand binding, although it cannot be ruled out that alteration 
of this residue causes a disturbance in receptor structure. 
In the Gαi/o pathway the growth hormone secretagogues all acted with potencies and 
efficacies at the GRLN-R-I134T that were not significantly different to that observed upon 
activation of the GRLN-R. Ghrelin and the growth hormone-secretagogues were also 
shown to be able to increase [35S]GTPγS binding through activation of the Gαq/11 pathway, 
but further studies are needed to test whether there were any significant changes in the 
potencies of the growth hormone secretagogues through this pathway. Further evidence 
that ghrelin and the growth hormone secretagogues bind GRLN-R-I134T came from 
epifluoresence microscopy experiments that showed GRLN-R-I134T was internalised 
upon addition of maximally effective concentrations of ghrelin, GHRP-6, L-692,585 and 
MK-677 into large intracellular vesicles. However, quantification of these images showed 
that receptor localisation at the plasma membrane upon agonist treatment was not 
significantly reduced compared to control cells. This suggests that for the GRLN-R-I134T, 
ghrelin and the growth hormone secretagogues have a reduced ability to internalise the 
receptor. However, as semi-quantification of epifluorescence data introduces relatively 
large errors (especially when there is so little receptor co-localised at the plasma membrane 
in basal conditions) whole-cell binding studies or cell surface biotinylation experiments 
will likely allow a more accurate quantification of receptor levels at the plasma membrane 
after treatment with ghrelin, the growth hormone secretagogues or SPA.  
6.3.8 Classification of the A204E and I134T mutations 
A classification scheme to define melanocortin-4 receptor inactivating mutations has been 
proposed in which receptors could be classed in one of five groups (Tao & Segaloff, 2003) 
according to their cell-biological and/or pharmacological effects. These are: defective 
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biosynthesis (class I); impaired trafficking to the cell surface (class II); defective ligand 
binding (class III); defective receptor activation (class IV) or no defects (class V). 
According to this system, the data from this study suggests that the A204E mutation leads 
to both class II and class IV defects, as the receptor is ER-retained (although its partial 
localisation at the plasma membrane makes it not a full class II mutant) and the 
constitutive activity of the receptor is ablated. SPA acting at the GRLN-R-I134T appears to 
be less efficacious in lowering accumulated levels of inositol phosphates upon expression 
of the GRLN-R-I134T compared to the wild-type GRLN-R. Thus the I134T mutation 
could cause a class III (defective ligand binding) and/or a class IV (defective receptor 
activation) mutation, as more studies are needed to determine whether ghrelin and SPA 
bind to the GRLN-R-I134T with the same affinity as the wild-type GRLN-R (which, if 
they did, would rule out a class III mutation).  
6.4 Summary and conclusions 
The results of this study have demonstrated for the first time that the A204E mutation 
causes partial ER retention of the GRLN-R. This may have detrimental effects in vivo as 
the reduced expression of the GRLN-R-A204E and its low level of plasma membrane 
localisation could have a serious impact on receptor function. Moreover, expression of 
mutant GPCRs may interfere with the cell surface expression of their corresponding wild-
type counterparts through their association in the ER and intracellular entrapment of the 
resulting complex (Zhu and Wess, 1998; Brothers et al., 2004; Gehret et al., 2006).  
In contrast to the A204E mutation, the I134T mutation does not cause ER-retention of the 
GRLN-R-I134T, but instead shows a subcellular localisation similar to the wild-type 
GRLN-R. However, the efficacy of the inverse agonist SPA appears reduced by the I134T 
mutation. Interestingly, in the melanocortin-4 receptor the S127L (S3.30) mutation, a 
missense mutation linked to the development of obesity, decreases the potency of α-
melanocyte-stimulating hormone some 30-fold but it has no effect on the constitutive 
activity of this receptor (Govaerts et al., 2005). Thus it will be interesting to see if the 
I134T mutation is linked to the development of disease in vivo.  
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7 Final discussion 
Ghrelin and the GRLN-R have been shown to be involved in a number of physiological 
processes, such as: GH release, sleep regulation, energy homeostasis and appetite 
stimulation. This makes the ghrelin/GRLN-R system an attractive therapeutic target for the 
treatment of disorders such as cachexia, GH deficiency, obesity and ageing (i.e. by 
reversing the natural decline of GH which can lead to frailty and loss of independence). 
Although the GRLN-R has been suggested to couple to multiple G protein pathways 
(Gαq/11, Gαi/o, Gαs and Gα12/13), little is known about the signalling of the GRLN-R to ghrelin 
and the growth hormone secretagogues in all but the Gαq/11 pathway. The aim of this thesis 
was to further investigate the activation of the GRLN-R through the Gαi/o pathway. 
7.1 Ligand-induced activation of the GRLN-R 
In 2005 the growth hormone secretagogues GHRP-6 and L-692,429 were described to act 
as ago-allosteric modulators of the GRLN-R (Holst et al., 2005). Co-administration of the 
growth hormone secretagogues with ghrelin led to an increase in ghrelin’s efficacy (as the 
growth hormone secretagogues acted as co-agonists), whilst L-692,429 and GHRP-6 acted 
either to increase or decrease (respectively) the potency of ghrelin (Holst et al., 2005). As 
the binding sites for ghrelin and the growth hormone secretagogues were known to 
overlap, to describe their results Holst and colleagues developed a necessarily complex 
model that relied on the GRLN-R existing as a homo-dimer (Holst et al., 2005). Ghrelin, 
due to its large size, was predicted to only bind to one protomer leaving the second 
protomer free to bind a growth hormone secretagogue. However, the study by Holst and 
colleagues was not designed to fully investigate allosteric regulation of the GRLN-R and 
thus did not examine any of the hallmarks of an allosteric interaction i.e. that the effect was 
saturable, probe-dependent or that the dissociation kinetics of a radiolabelled version of 
ghrelin was altered by co-administration with GHRP-6 or L-692,429. Nevertheless, up 
until now L-692,429 and GHRP-6 have been universally accepted as allosteric modulators 
of the GRLN-R (May et al., 2007; Leach et al., 2007; Langmead and Christopoulos, 2006). 
In this thesis, the effects of co-administration of ghrelin with either GHRP-6, L-692,585 (a 
commercially available analogue of L-692,429) or MK-677 was measured through 
activation of the Gαi/o pathway. [35S]GTPγS assays were chosen to study activation of the 
Gαi/o pathway to allow measurement of ligand efficacies in a system where fewer 
compounds would reach the maximum system response (Strange, 2008) and to avoid the 
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measurement of other G protein-dependent or independent pathways activated by the 
GRLN-R. Interestingly, in this system, GHRP-6, L-692,585 and MK-677 were shown not 
to be ago-allosteric modulators of the GRLN-R but simple orthosteric ligands.  
Concentration-response curves to ghrelin in the presence of multiple, fixed concentrations 
of the growth hormone secretagogues led to an increase in the efficacy of ghrelin, most 
likely because each of the growth hormone secretagogues tested acted with a significantly 
higher efficacy than ghrelin i.e. they acted as super-agonists. In the reverse experiment 
(where concentration-response curves were generated to the growth hormone 
secretagogues in the presence of varying, fixed concentrations of ghrelin), ghrelin led to a 
concentration-dependent increase in the efficacy of the growth hormone secretagogues at 
low growth hormone secretagogues concentrations, whilst at high concentrations, ghrelin 
had no effect on efficacy.  
In the presence of increasing ghrelin concentrations the growth hormone secretagogues 
showed a trend towards a decreased potency, but this could be due to ghrelin (which acts 
as a partial agonist in regards to the growth hormone secretagogues) competing with the 
growth hormone secretagogues for binding to the GRLN-R. Indeed, fitting the 
experimental data to a modified operational model of allosterism (originally described by 
Leach et al., 2007 and modified by Dr Christopher Langmead at GlaxoSmithKline), 
showed that the data was best fitted to a model which described a competitive, rather than 
an allosteric, interaction. Furthermore, binding studies demonstrated that the dissociation 
of [His[125I]]-ghrelin from the GRLN-R was not altered by administration of the growth 
hormone secretagogues, thus demonstrating a lack of allosterism.  
The model generated by Holst et al (2005) relied on the GRLN-R existing as a homo-
dimer. In this study no attempt was made to determine whether the GRLN-R existed as a 
homo-dimer, although this has been previously described (Jiang et al., 2006; Leung et al., 
2007). This opens up the possibility that the super-agonist effects of the growth hormone 
secretagogues could be due to their ability to bind to both protomers of a GRLN-R homo-
dimer, creating a receptor structure which signals with higher efficacy than that produced 
by binding of ghrelin to one protomer of the dimer. To investigate this further an 
asymmetrical homo-dimer could be formed between a GRLN-R mutated at E1243.33 to 
Q1243.33 (a mutation which has been shown to ablate the binding of ghrelin and the growth 
hormone secretagogues; Feighner et al., 1998; Holst et al., 2009) and a GRLN-R mutated 
in the ERY sequence (i.e. at arginine R1413.50) to inhibit G protein coupling. This would 
result in a receptor that could only signal to ghrelin and the growth hormone secretagogues  
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Figure 7-1 – Use of an asymmetrical homo-dimer to investigate the pharmacology of the 
GRLN-R. A. An asymmetrical homo-dimer could be created to investigate the pharmacology of the 
GRLN-R by mutating E1243.33 (for example, to Q1243.33) in one receptor (to ablate ligand binding; 
dark blue receptor) and mutating the arginine residue (R1413.50) in the ERY sequence to inhibit G 
protein binding to a second receptor (light-blue receptor). Ghrelin and the growth hormone 
secretagogues should only evoke a G protein-mediated response if both the mutated receptors 
come together to form a ‘homo-dimer’. B. In the model by Holst et al. (2005) the growth hormone 
secretagogues were predicted to be able to bind to both protomers of a GRLN-R homo-dimer, 
leading to the receptor signalling with a higher efficacy than that observed for ghrelin (which 
because of its size is predicted to be unable to bind to both protomers simultaneously). The 
asymmetrical homo-dimer could be used to investigate whether the growth hormone 
secretagogues signal with an efficacy equal to that of ghrelin when one protomer of the dimer is 
unable to bind ligand. 
 
if the two mutated receptors formed a ‘homo-dimer’, thus allowing the measurement of 
growth hormone secretagogues efficacy in a system where ligand could only bind to one 
protomer of the dimer (Figure 1-1). It is worth noting that the receptor that is mutated to 
inhibit ligand binding would still be able signal in the absence of ligand as the Q1243.33 
does not affect the constitutive activity of the receptor. Similar approaches have been used 
successfully in the past for other GPCRs (e.g. the metabotropic glutamate receptors; 
Goudet et al., 2005 and the leukotriene B4 receptor; Damian et al., 2008) to investigate 
‘trans’ signalling across dimers. 
A 
B 
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To allow further investigation into the pharmacology of the GRLN-R a Flp-In™ T-REx™ 
HEK293 cell line was created expressing the receptor tagged at the N-terminus with VSV-
G and at the C-terminus with an eCFP fusion protein. Tagging the GRLN-R had no effect 
on the pharmacology or localisation of the receptor and allowed confirmation that the 
GRLN-R was modified by N-linked glycosylation, most likely at two asparagine residues 
at the N-terminus which occur as part of a N-X-S/T motif.  
[35S]GTPγS binding experiments used to measure G protein activation in membranes 
prepared from GRLN-R cells (either transfected with Gαq or Gαo1) revealed that GHRP-6, 
L-692,585 and MK-677 all acted as super-agonists in the Gαi/o pathway but as full agonists 
in the Gαq/11 pathway, thus demonstrating functional selectivity at the GRLN-R. This is the 
first time that functional selectivity at the GRLN-R has been described. This finding could 
potentially have implications in vivo; as the growth hormone secretagogues appear to 
stabilise a receptor conformation that favours coupling to Gαi/o, the efficacy of a response 
could differ from ghrelin depending on the local concentrations of G protein in different 
cells. 
Whole-cell second messenger pathways were also used to measure activation of the Gαq/11 
and Gαi/o pathways. Inositol phosphate accumulation studies demonstrated that ghrelin and 
the growth hormone secretagogues acted with efficacies that were similar to those 
measured in [35S]GTPγS binding assays performed using an immunoprecipitation step to 
separate [35S]GTPγS-bound Gαq from unbound Gαq. However, GHRP-6 and L-692,585 
acted with significantly higher potencies in the inositol phosphate accumulation assays 
than the [35S]GTPγS binding assays, most likely due to response amplification or a 
difference in receptor reserve between these two systems. In contrast to the [35S]GTPγS 
studies, ghrelin and the growth hormone secretagogues failed to induce a response in 
cAMP accumulation assays. Although coupling of the GRLN-R to Gαo1 could be viewed as 
an artefact created by the addition of exogenous G protein, it was demonstrated that 
[35S]GTPγS binding assays were also able to measure a response to ghrelin in the absence 
of exogenous G protein. The [35S]GTPγS filtration binding assay measured a response to 
ghrelin that was sensitive to PTx, confirming coupling of the GRLN-R to the Gαi/o 
pathway. Thus the results were interpreted as reflecting the inability of the GRLN-R to 
couple to Gαi1-3, as inhibition of AC by Gαo1-2 is less potent than by Gαi1-3, although 
previous studies have demonstrated that the GRLN-R can couple to Gαi2 in cells 
endogenously expressing the GRLN-R (Bassil et al., 2007).   
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Although studies in vivo and in cell lines endogenously expressing the GRLN-R have 
suggested that the GRLN-R can couple to Gαs (Kohno et al., 2003; Malagon et al., 2003), 
data from recombinant studies remains contradictory, with some studies supporting Gαs 
coupling (Rossi et al., 2008; Caminos et al., 2005) and others disagreeing with this (Cunha 
and Mayo, 2002; Casanueva et al., 2008). Interestingly, in this thesis ghrelin, GHRP-6, L-
692,585 and MK-677 were all shown to be able to evoke a Gαs response in cAMP 
accumulation assays, with ghrelin and the growth hormone secretagogues displaying 
similar potencies as measured in the [35S]GTPγS binding experiments. However, L-
692,585 acted as a partial agonist with respect to ghrelin, suggesting L-692,585 induces a 
receptor conformation which only weakly couples to the Gαs pathway. 
The results of these studies confirm that the GRLN-R is a promiscuous receptor being able 
to couple to Gαq/11, Gαi/o and Gαs pathways. However, it is clear that further experiments, 
aimed at deducing the specific isoforms within each G protein family the GRLN-R can 
couple, are needed to aid understanding of the pharmacology of the GRLN-R. To achieve 
this [35S]GTPγS binding assays could be performed in membranes prepared from GRLN-R 
cells transfected with a panel of G protein subunits, followed by immunoprecipitation of 
[35S]GTPγS-bound G protein from the reaction mixture. If full concentration-response 
curves to ghrelin and the growth hormone secretagogues were performed then the 
potencies at each of the G proteins could be measured, allowing a rank-order of G protein 
coupling to the GRLN-R to be compiled.  
7.2 Constitutive activity of the GRLN-R    
The expression of GRLN-R in the Flp-In™ T-REx™ HEK293 cell line resulted in the 
HEK293 cells appearing rounded compared to un-induced cells, a response that was 
accompanied by a high level of cell detachment. This effect appeared to be mediated by the 
GRLN-R as reducing the levels of receptor expression led to a reduction in severity of the 
cell-rounding phenotype. In contrast, HEK293 cells expressing the GRLN-R-A204E (a 
mutant receptor that does not display any constitutive activity) did not display the cell-
rounding phenotype (data not shown), supporting the hypothesis that constitutive activity 
was responsible for the changed morphology of the wild-type GRLN-R cells. 
The cell-rounding phenotype has been reported for another constitutively active GPCR, the 
sphingosine 1-phosphate-5 receptor (Niedernberg et al., 2003). It would be interesting to 
investigate whether the phenotype mediated by GRLN-R expression is the result of 
constitutive activation of the Gα12/13 pathway, a pathway that can alter cell morphology i.e. 
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by actin re-organisation (Riobo and Manning, 2005). This could be achieved by over-
expressing Gα13 (to see if this increased the severity of the cell-rounding phenotype) or by 
using small interfering ribonucleic acid (siRNA) to silence Gα13 expression. 
The GRLN-R has been reported to constitutively activate the Gαq/11 pathway (Holliday et 
al., 2007; Holst et al., 2004; Holst et al., 2003) being able to evoke a response that is up to 
50 % of the maximal signal achieved upon ghrelin stimulation (Holst et al., 2003). 
However, it is clear that the constitutive activity of the GRLN-R is not a result of receptor 
over-expression as gene-dosing experiments performed by Holst et al. (2004) showed that, 
at similar expression levels, the related receptor GPR38 remained silent in the absence of 
ligand. 
A doxycycline concentration of 6 ng/mL was deemed optimal to stimulate GRLN-R 
expression in the GRLN-R Flp-In™ T-REx™ cell line, as this was the lowest 
concentration of doxycycline tested that allowed a significant response of the GRLN-R to 
ghrelin to be detected in [35S]GTPγS binding assays. At this expression level constitutive 
activity of the GRLN-R through activation of Gαq could be measured and the constitutive 
activity significantly reduced by addition of the inverse agonist SPA. However, in the Gαi/o 
pathway, although the addition of 6 ng/mL doxycycline led to a significant increase in 
[35S]GTPγS loading, there was no significant decrease in [35S]GTPγS binding levels upon 
addition of the inverse agonist SPA. Thus further experiments are needed to determine 
whether the GRLN-R is less effective at constitutively activating the Gαi/o pathway or 
whether this is just an artefact created by comparing the response of the GRLN-R in two 
different experimental systems (one using immunoprecipitation to recover [35S]GTPγS-G 
protein and another using a filtration step to separate [35S]GTPγS-bound G protein from 
unbound G protein). Indeed, the level of constitutive activity of the GRLN-R measured 
upon addition of exogenous Gαq, Gαo1, Gαs and Gα13 could be compared, using, for example, 
a [35S]GTPγS assay with immunoprecipitation step to establish whether the GRLN-R can 
constitutively activate every G protein pathway to which it is coupled (although the 
variables of G protein expression and relative affinities of the G protein antibodies must be 
taken into account). 
7.3 GRLN-R mutants 
As well as studying the pharmacology of the wild-type GRLN-R, the effect of A204E or 
I134T missense mutations on the localisation and pharmacology of the GRLN-R was 
investigated. The A204E missense mutation occurs in ECL2, whilst the I134T mutation 
Kirstie Ann Bennett, 2009  Chapter 7, 228 
occurs in TM3. Interestingly the A204E mutation (which has been associated with the 
development of an obese/short stature phenotype in vivo) was shown to cause partial 
retention of the GRLN-R within the ER-cis-Golgi complex, whilst receptor expressed at 
the cell-surface was shown to be devoid of any constitutive activity. The lack of 
constitutive activity was in agreement with other studies into the A204E mutation (Pantel 
et al., 2006; Liu et al., 2007; Holliday et al., 2007). Although the A204E mutation has been 
reported in some studies to lower cell-surface expression of the GRLN-R (Pantel et al., 
2006: Liu et al., 2007), this is the first study to provide evidence to suggest this is due to 
partial retention of the receptor within the ER, most probably due to altered receptor 
folding.  
Interestingly, a recent study by Sum et al. (2009) have shown that two glutamic residues in 
ECL2 of the free fatty acid receptor FFA1 form an ionic lock with two arginine residues in 
TMV and TMVII. Mutating the glutamic acid residues to alanine residues results in 
constitutive activation of the FFA1. Thus the A204E mutation may inhibit the constitutive 
activity of the GRLN-R, for example, by forming an ionic lock with a residue within the 
TM domains (such as R2836.45 at the top of TMVI). This could be investigated further by 
introducing point mutations into the TM domains to see if the constitutive activity of the 
GRLN-R could be ablated, for example, by mutating R2836.45 to A2836.45.   
The I134T mutation has been suggested to ablate the response of the GRLN-R to ghrelin, 
however, in this thesis the GRLN-R-I134T was shown to be able to bind [His[125I]]-ghrelin 
and retained the ability to signal to ghrelin and the growth hormone secretagogues in both 
the Gαq/11 and Gαi/o pathways. The efficacy of SPA at the GRLN-R-I134T was shown to be 
reduced in a study by Liu et al. (2007); results of the inositol phosphate accumulation 
experiments appeared to agree with this, as SPA failed to return the inositol phosphate 
levels accumulated upon receptor expression to those seen in the absence of receptor.    
Missense mutations within GPCRs often result in protein misfolding, which commonly 
results in the retention of a misfolded receptor in the ER by molecular chaperones and 
quality control machinery. However, the expression of misfolded GPCRs at the plasma 
membrane can be greatly increased by treatment with chemical or pharmacological 
chaperones (Brown et al., 1996; Sato et al., 1996; Robben et al., 2005). Chemical 
chaperones include osmolytes such as glycerol, DMSO and trimethyl-amine-N-oxide (Sato 
et al., 1996; Tamarappoo et al., 1999; Yang et al., 1999; Song and Chuang, 2001) that may 
stabilise the receptor conformation or trigger a stress response that leads to upregulation of 
chaperone proteins (Welch and Brown, 1996; Diamant et al., 2001). Pharmacological 
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chaperones include non-peptide receptor antagonists that stabilise ER-retained mutated 
protein – as seen for the vasopressin 2 receptor (Morello et al., 2000; Robben et al., 2006). 
Indeed non-peptide antagonists have been used successfully in vivo to relieve nephrogenic 
diabetes insipidus (Bernier et al., 2006) demonstrating that rescuing ER-retained mutated 
GPCRs offers a clinical treatment that may be used to cure a number of debilitating 
diseases. Due to the lack of commercially available non-peptide GRLN-R antagonists the 
effects of pharmacological chaperones in altering GRLN-R-A204E localisation could not 
be investigated. However the effects of chemical chaperones (e.g. DMSO) on the 
localisation of the GRLN-R-A204E warrants further investigation.  
7.4 Conclusion 
This study has led to a fuller understanding of the pharmacology of the GRLN-R, showing 
that the growth hormone secretagogues do not act as allosteric modulators of the GRLN-R, 
although they do act as super-agonists in the Gαi/o pathway (favouring coupling of the 
GRLN-R to Gαi/o). The development of GRLN-R cell lines has provided extremely useful 
tools for studying the GRLN-R and the two mutated receptors (GRLN-R-I134T and 
GRLN-R-A204E) and will enable further investigations into the G protein coupling and 
constitutive activation of the GRLN-R.  
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